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Abstract
Covariate adjustment is common in the analysis of randomised trials, and can increase
statistical power without increasing sample size. Published research on covariate ad-
justment, and guidance for choosing covariates, focusses on trials where individuals
are randomised to treatments. In cluster randomised trials (CRTs) clusters of indi-
viduals are randomised. Valid analyses of CRTs account for the structure imposed by
cluster randomisation. There is limited published research on the effects of covariate
adjustment, or guidance for choosing covariates, in analyses of CRTs.
I summarise existing guidance for choosing covariates in individually randomised trials
and CRTs, and review the methods used to investigate the effects of covariate adjust-
ment. I review the use of adjusted analyses in published CRTs. I use simulation,
analytic methods, and analyses of trial data to investigate the effects of covariate ad-
justment in mixed models. I use these results to form guidance for choosing covariates
in analyses of CRTs.
Guidance to choose covariates a priori and adjust for covariates used to stratify ran-
domisation is also applicable to CRTs. I provide guidance specific to CRTs using
linear and logistic mixed models. Cluster size, the intra-cluster correlations (ICCs) of
the outcome and covariate, and the strength of the relationship between the outcome
and covariate influence the power of adjusted analyses and the precision of treatment
effect estimates. An a priori estimate of the product of cluster size and the ICC of
the outcome can be used to assist choosing covariates. When this product is close
to one, adjusting for a cluster level covariate or a covariate with a negligible ICC
provide similar increases in power. For smaller values of this product, adjusting for a
cluster level covariate gives minimal increases in power. The use of separate within-
cluster and contextual covariate effect parameters may increase power further in some
circumstances.
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Chapter 1
Introduction
Randomised controlled clinical trials are essential for testing the efficacy and effective-
ness of new medical treatments and interventions. Appropriate statistical design and
analysis allows valid and useful conclusions to be made. Including data apart from
treatment assignment and outcome data in the analysis of a trial may make infer-
ence more precise, analysis more efficient, and conclusions more relevant. In a cluster
randomised trial pre-existing groups, termed as clusters, of individuals are randomly
allocated to treatment arms. This introduces additional complexity to the analysis of
the trial and the effects of including other data. This thesis considers the appropriate
and effective use of covariate data in the analysis of cluster randomised trials.
1.1 Randomised controlled trials
In a randomised controlled trial (RCT), individuals are randomly allocated to treat-
ment arms. Outcomes are compared between treatment arms to infer the relative
efficacy or effectiveness of the treatments. The random assignment to treatment arms
ensures there are no systematic differences between individuals in each of the arms at
baseline except treatment assignment itself; there are no confounding variables in the
classical sense, as described by Hauck et al. [1]. A confounding variable is one that is
related to both the outcome and exposure of interest [1]. In an RCT, treatment arm
is independent of other variables, and therefore the analysis of RCTs can be based
on only the outcome data and treatment arm allocation. For example, we could use
a two-sample t-test to compare a normally distributed, continuous outcome variable
between two treatment arms and infer a treatment effect. However, in RCTs other
variables are often measured and can be used in the analysis of the trial.
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1.2 Covariates in randomised controlled trials
A Dictionary of Epidemiology [2] defines a covariate as a “variable that is possibly
predictive of the outcome under study”, and notes that a covariate “may be of direct
interest to the study or may be a confounding variable or effect modifier”. In this thesis
I consider a covariate to be a variable that is possibly correlated with outcome under
study and is independent of treatment arm allocation. Due to randomisation, baseline
characteristics measured or fixed (for example, sex and ethnicity) before randomisation
fit this definition. This could include demographic characteristics and physiological
measurements. Variables measured before randomisation, which may also be measured
as outcomes, are also covariates. A variable such as the size of a cluster (the number
of individuals in the trial in a cluster) may be a covariate if it is assumed that cluster
size is not related to treatment arm (for example, if all individuals are recruited before
randomisation).
Many methods for analysing RCTs allow us to include covariate data. In model based
analyses of trials this can be done by adding covariate variables and parameters to
the linear predictor part of the model. For example, a linear regression model for trial
analysis not including covariates could be
Yi = α+ βXi + i
where Yi is the outcome variable for individual i, Xi is a binary variable indicating
treatment arm allocation for individual i, and the i are individual error terms. In
this model, the parameter β is the unadjusted treatment effect. A set of covariates
Z1, Z2, Z3. . . can be included in the analysis model:
Yi = α+ βXi + γ1Zi1 + γ2Zi2 + γ3Zi3 + . . .+ i
where Zik is the value of covariate Zk for individual i. In this model, the parameter
β is the treatment effect adjusted for the set of covariates. The adjusted treatment
effect parameter represents a treatment effect conditional on values for the covariates.
Adjusting for covariates in the analysis of RCTs can increase the precision of the
treatment effect estimate [3] for some models. That is, the uncertainty associated
with an estimate of treatment effect may be reduced. Adjusting for covariates can
also increase the power of a hypothesis test of no treatment effect: assuming there is a
non-zero treatment effect, the probability of a trial producing a statistically significant
result is increased [4, 5]. In many non-linear models, such as logistic regression, the
unadjusted and adjusted treatment effect parameters are not generally equal [6,7] and
have different interpretations [8]. The effects of covariate adjustment in the analysis
of RCTs are described in Chapter 2.
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Analyses adjusting for covariates are often reported in RCT reports. Reviews indicate
between 25% and 72% of trial reports include an adjusted analysis, depending on what
trials are in the review and how adjusted analyses are counted [9–11]. There is a range
of published guidance on choosing covariates in the analysis of RCTs [12–15], which
will be summarised in Section 2.5.
1.3 Cluster randomised trials
A cluster randomised trial (CRT) is an RCT in which pre-existing groups, termed as
clusters, of individuals are randomly allocated to treatment arms . This is distinct from
individually randomised trials, where individuals themselves are randomly allocated
to treatment arms. For example, clusters may be clinical practices or schools where
the individuals are patients and school children, respectively.
A cluster randomised design is associated with a loss in statistical power and additional
complexity in design and analysis [16]. Therefore, the use of cluster randomisation
must be justified by one or more of several reasons [17]. It may be impractical to
individually randomise. There may be concerns of contamination between individuals
in different treatment arms within the same cluster; for example in the ObaapaVitA
trial geographical clusters were randomised, allowing fieldworkers distributing vitamin
A supplement or placebo capsules to only carry one type at a time [18]. Cluster
randomisation may help compliance with treatment. Routine data may be accessible
at cluster level but not at individual level. The treatment may be most appropriately
applied at cluster level; for example in a trial of a school-based violence prevention
program whole schools were randomised, because all students and staff were necessarily
exposed to the intervention [19].
In a CRT there is additional correlation structure in the data, as individuals within
the same cluster tend to be more alike than individuals in separate clusters. The
intra-cluster correlation coefficient (ICC) quantifies the similarity of a variable for
individuals within the same cluster compared to the whole population. The ICC is
defined generally as the correlation between values of a variable for individuals in the
same cluster [20]. It is assumed that variable values for individuals in different clusters
are independent, and that each pair of individuals in the same cluster have the same
correlation. That is, the observations within a cluster are exchangeable. It is often
assumed that the ICC is the same for all clusters and then the ICC for a variable Y
is [20, 21]:
ρ = corr(Yij , Ykj) =
cov(Yij , Ykj)√
var(Yij)var(Ykj)
where Yij is the value of Y for individual i in cluster j, and i 6= k.
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It is well established that a valid analysis of a CRT must take account of the clustering,
for example by analysing at cluster level, using generalised estimating equations, or
using a mixed effects regression model. These methods are widely described, for
example by Donner & Klar [22] and Eldridge & Kerry [17].
1.4 Covariates in cluster randomised trials
As with individually randomised trials, in CRTs covariates are independent of treat-
ment arm allocation by design. The analysis of a CRT can be based on only outcome
data and treatment arm allocation, plus cluster membership information. A model for
the analysis of a CRT with a continuous outcome variable is the linear mixed effects
model:
Yij = α+ βXj + uj + eij
where uj ∼ N(0, τ2)
eij ∼ N(0, σ2) .
Yi is the outcome variable and Xj is a binary variable indicating treatment arm allo-
cation, for individual i in cluster j. The uj are random cluster effects, and the eij are
independent individual level residuals. The parameter β is the cluster-specific treat-
ment effect. Covariates can be included in this model, just as in a linear regression
model, by adding parameters and variables to the linear predictor:
Yij = α+ βXj + γ1Zij1 + γ2Zij2 + γ3Zij3 + . . .+ uj + eij
Zijk is the value of covariate Zk for individual i in cluster j. The parameters γk are
the effects of the covariates, and β is the cluster-specific treatment effect parameter
adjusted for the covariates.
As with RCTs, adjusting for covariates in the analysis of CRTs can increase precision
of treatment effect estimates, and increase the power of a test of no treatment effect
[16,23,24]. Cluster randomisation, however, adds complexity to the effects of covariate
adjustment. The variance of the outcome variable can be partitioned into variance at
the cluster level and variance at the individual level and both of these can be affected
by covariate adjustment. Covariates themselves can exist at two levels: cluster and
individual. Cluster level covariates describe something about the cluster and are fixed
for individuals in the same cluster. Individual level covariates describe something
about the individual, and may be correlated within clusters themselves having a non-
zero ICC.
Existing published research on the effects of covariate adjustment in CRTs mostly
focuses on the use of linear mixed effects models for continuous outcome data [16,23–
29
26]. Published guidance for choosing covariates in the analysis of CRTs [16, 23–25] is
limited in scope and application. This literature will be explored in Section 3.3.
1.5 Generalised linear models and mixed effects models
Generalised linear models (GLMs) are regression models that can be used to analyse a
number of different types of outcome data including continuous and binary variables.
A GLM has three components:
1. The probability distribution, from the exponential family, of the response vari-
able Y .
2. A linear predictor, η = βX where X is a vector of predictor variables and β is
a vector of parameters.
3. A link function g such that E[Y ] = µ = g−1(η).
Common link functions are linear, log, logit, probit, complementary log-log, and gen-
eralised logistic (g(µ) = log(µθ/(1 − µθ))) link functions. We are interested in the
situation where Y is the outcome of an RCT and there are two predictor variables:
X, a binary variable indicating treatment arm; and Z, a covariate independent of X
by randomisation. To consider covariate adjustment in GLMs we compare treatment
effect parameters and their estimators when using two different linear predictors:
1. η = α∗ + β∗X
2. η = α+ βX + γZ
Linear predictor (1) gives unadjusted models while linear predictor (2) gives models
adjusted for the covariate Z. So β∗ is the unadjusted treatment effect parameter,
while β is the treatment effect parameter adjusted for Z. The effect of adjusting for
a covariate Z on (β∗ − β), the relative precision of treatment effect estimators (βˆ∗
and βˆ), and the power of tests of no treatment effect based on the two models, are
summarised in Chapter 2.
A mixed effects model is a statistical model that includes both fixed and random
effects. Mixed effects models can be used for the analysis of CRTs by including
a random cluster effect. To consider covariate adjustment in mixed effects models
we compare treatment effect parameters and their estimators when using the linear
predictors:
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1. η = α∗ + β∗X + uj
2. η = α+ βX + γZ + uj
The uj are random cluster effects with uj ∼ N(0, τ2). Linear predictor (1) gives un-
adjusted models while linear predictor (2) gives models adjusted for the covariate Z.
β∗ is the unadjusted treatment effect parameter, while β is the treatment effect pa-
rameter adjusted for Z. Both treatment effects are conditional on the random cluster
effect, and so the treatment effects are said to be cluster-specific. Having introduced
RCTs, CRTs, covariates, generalised linear models, and mixed effects models, I can
now outline the aims of this research project and the structure of this thesis.
1.6 Aims
The overall aim of this project is to address gaps in research on the effects of covariate
adjustment in CRTs and produce guidance for choosing covariates in the analysis of
CRTs. The project has three major aims:
1. To review existing knowledge and practice in the choice and handling of covari-
ates in the analysis of CRTs.
2. To review published recommendations on choosing covariates, in the context of
CRTs and identify which advice is applicable in the analysis of CRTs.
3. To develop further guidance for choosing covariates in the analysis of CRTs.
To address the first aim, I review methodological research on the effects of covariate
adjustment in the analysis of individually randomised trials and CRTs. I also sum-
marise published guidance on choosing covariates, and relate this to the methodolog-
ical research. In the context of that literature, I review current practice in covariate
adjustment and choosing covariates in CRTs.
To address the second and third aims, I use data from two published CRTs to in-
vestigate distributions of and relationships between covariates and outcome variables.
Simulation studies are used to investigate the effects of covariate adjustment in CRTs
and evaluate covariate adjustment strategies. The literature reviews, review of current
practice, and exploration of trial data are used to develop the plans for these simula-
tions studies. I also present a short analytic investigation of the effects of covariate
adjustment in linear mixed effects models.
Results of the literature review and simulation studies are then used to identify which
guidance on choosing covariates in individually randomised trials is applicable to
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CRTs. They are also used to produce guidance on choosing covariates that is specific
to the analysis of CRTs. This guidance is relevant for those designing and analysing
CRTs. The work of this project focuses on the analysis of CRTs using linear and
logistic mixed effects models.
1.7 Structure of this thesis
In Chapters 2 to 5 I address the first major aim of the thesis. I review the published
research on adjusted analyses and choosing covariates in individually randomised trials
in Chapter 2, and the equivalent literature for CRTs in Chapter 3. In Chapter 4 I
review the two main methods used to investigate the effects of covariate adjustment.
In Chapter 5 I review the use of adjusted analyses and choosing covariates in a large
sample of published CRT reports.
In Chapters 6 to 10 I address the second and third major aims of the thesis. Chapter
6 contains methods and results of an exploration of data from two published CRTs.
In Chapter 7 I outline the methods and plans for simulation studies on the effects of
covariate adjustment in CRTs, and the results are given in Chapter 8. In Chapter 9 I
present a small analytic investigation of power in adjusted linear mixed effects models.
Guidance for choosing covariates in CRTs is discussed in Chapter 10.
In Chapter 11 I discuss the work in this thesis and identify areas for future research.
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Chapter 2
Adjusted analyses and choosing
covariates in individually
randomised trials
I begin with a review of the published literature on adjusted analyses and choosing
covariates in individually randomised trials. This provides a useful starting point as
there is a large amount of published methodology work which has led to published
guidance for choosing covariates. I move on to the literature concerning CRTs in
Chapter 3.
The effects of covariate adjustment on treatment effect estimates, the precision of
those estimates, and power for generalised linear models are summarised in Section
2.1. The choice of treatment effect estimator, covariates used in randomisation, and
baseline imbalance of covariates are considered in Sections 2.2 to 2.4. This literature
has led to published guidance on choosing covariates in RCTs, which is summarised
in Section 2.5.
2.1 Effects of covariate adjustment in individually
randomised trials
The primary analysis of an RCT typically involves estimating a treatment effect, pro-
viding a measure of precision for that estimate (as a standard error or confidence
interval), and reporting a significance test of no treatment effect. The effects of ad-
justing for covariates on each of these three results can be considered as follows:
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1. The difference between the unadjusted and adjusted treatment effect (Section
2.1.1).
2. The precision of adjusted and unadjusted estimators (Section 2.1.2).
3. The power of tests of no treatment effect based on either the adjusted or unad-
justed models (Section 2.1.3).
I focus on analysis using generalised linear models (GLMs) which were introduced in
Section 1.5. I am interested in the situation where there is an outcome Y and two
predictor variables: X, a binary variable indicating treatment arm; and Z, a covari-
ate. The covariate Z is independent of X by randomisation. To consider covariate
adjustment in GLMs we compare treatment effect parameters and their estimators
when using two different linear predictors:
1. η = α∗ + β∗X
2. η = α+ βX + γZ
Linear predictor (1) leads to an unadjusted estimate of treatment effect, while linear
predictor (2) will provide an estimate of treatment effect adjusted for the covariate Z.
So β∗ is the unadjusted treatment effect parameter, while β is the treatment effect
parameter adjusted for Z. The effect of adjusting for a covariate Z on treatment
effect (β∗ − β), the relative precision of treatment effect estimators (βˆ∗ and βˆ), and
the power of tests of no treatment effect based on the two models, are summarised in
the following sections.
2.1.1 Difference between treatment effects
For GLMs using the linear predictors described above, the unadjusted treatment effect
estimator, βˆ∗, is asymptotically unbiased for the adjusted effect, β, if one of the
following is true [6]:
1. There is no treatment effect, β = 0
2. There is no covariate effect, γ = 0, or the covariate is fixed, var(Z) = 0
3. The link function is linear (g−1(η) = aη+b) or a log link (g−1(η) = c exp(aη)+b)
The first condition establishes that if there is no treatment effect then the adjusted
and unadjusted treatment effect parameters coincide. Therefore, a significance test of
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no treatment effect (where the null hypothesis is H0 : β = β
∗ = 0) is testing the same
null hypothesis when using either the unadjusted or adjusted models.
The second condition shows that if the covariate is not at all prognostic then the
adjusted and unadjusted treatment effect parameters coincide. So not adjusting for a
covariate that is independent of outcome does not bias the treatment effect estimate.
The third condition demonstrates that there is no bias when a linear or log link
function is used, but for some commonly used link functions (such as the logit, probit,
complementary log-log, generalised logistic, and power link functions) the unadjusted
parameter of treatment effect is biased for the adjusted effect parameter [5–7]. The
unadjusted parameter is attenuated (closer to the null value) for “any link function
based on an inverse cumulative distribution function . . . with a log concave density
function” [7] such as the logit, probit and complementary log-log link functions. But
the unadjusted parameter is biased away from the null for the power family of links
(g(µ) = (µa − 1)/a, for 0 < a < 1) [7].
The magnitude of this bias increases with larger covariate effect (increasing magni-
tude of γ) or larger variation of the covariate (increasing var(Z)) [5, 7]. When γ or
var(Z) are close to zero, there is little difference between the unadjusted and adjusted
treatment effect parameters [5,7]. A simulation study by Negassa and Hanley [27] in-
vestigated the effects of omitting a single covariate from a logistic regression. With a
treatment effect with odds ratio 2.0, omitting a single binary covariate with an effect
less than that of the treatment (that is, odds ratio less than 2.0) the percentage change
in estimate of treatment effect when omitting the covariate was less than 5%. As the
effect of the covariate increased, the relative bias increased from 2.9% to more than
20% (for odds ratios from 2.0 to 10.0). When the omitted covariate was continuous
the relative bias was greater than 10% when the effect per unit increase was equal to
the treatment effect and the relative bias increased as the covariate effect increased.
The asymptotic bias, as a result of a link function that is not linear or log, described in
this section may not be considered a true bias. Rather, the unadjusted and adjusted
treatment effects are two distinct treatment effect parameters which are both valid
measures of the effect of treatment. The difference in meaning between the adjusted
and unadjusted parameters is discussed in Section 2.2.
2.1.2 Precision
The precision of two estimators can be compared by their asymptotic relative precision
(ARP). The ARP of an adjusted estimator of treatment effect, βˆ, to the unadjusted
35
estimator of treatment effect, βˆ∗, is defined by [3]
ARP (βˆ to βˆ∗) =
var(βˆ)−1
var(βˆ∗)−1
=
var(βˆ∗)
var(βˆ)
.
This value quantifies the increase or decrease in precision obtained by adjusting for
the covariate. An ARP greater than one indicates that the adjusted estimator has
greater precision.
For linear regression models it can be shown that [3]
ARP (βˆ to βˆ∗) =
1− ρ2XZ
1− ρ2Y Z.X
where ρ2XZ is the square of the simple correlation of the treatment variable and the
covariate and ρ2Y Z.X is the square of the partial correlation of the outcome and the
covariate conditional on the treatment. In an RCT ρ2XZ = 0, since patients are
randomised to treatment arms, and so
ARP (βˆ to βˆ∗) =
1
1− ρ2Y Z.X
≥ 1
Adjusting for a prognostic covariate (a covariate with ρY Z.X 6= 0) increases the preci-
sion of the estimate of treatment effect in a linear regression model, and the stronger
the association between the covariate and the outcome, the greater the increase in
precision [3].
Robinson et al. [5] consider covariate adjustment in generalised linear models with
a binary outcome variable and two binary predictor variables, using seven different
link functions. Considering the results which are applicable to the case of randomised
trials (when the two predictor variables X and Z are independent), for linear and
log link functions ARP (βˆ to βˆ∗) ≥ 1. ARP (βˆ to βˆ∗) = 1 if and only if Z is also
independent of Y . When using linear or log link functions, the adjusted estimate of
treatment effect has greater precision than the unadjusted estimate. However, for
models with logit, probit, log-log, complementary log-log or generalised logistic (with
0 < θ ≤ 1) link functions, ARP (βˆ to βˆ∗) ≤ 1. Again ARP (βˆ to βˆ∗) = 1 if and only if
Z is also independent of Y . This result is also shown for the logistic regression model
by Robinson and Jewell [3]. When using these link functions, the unadjusted estimate
of treatment effect has greater precision than the adjusted estimate, in contrast to the
result for linear and log link functions.
2.1.3 Power
The power of a significance test of no treatment effect is the probability of a sta-
tistically significant result assuming that there is a true treatment effect of a given
size.
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For a GLM with any link function, β = 0 implies that β∗ = 0 (Section 2.1.1). So the
null hypothesis of a test of no treatment effect can always be stated as H0 : β = β
∗ = 0.
As described previously, for linear regression models adjusted and unadjusted treat-
ment effect parameters coincide while the adjusted estimator has greater precision. We
conclude that a test of no treatment effect based on the adjusted model has greater
power than a test based on the unadjusted model [3].
We can compare tests of no treatment effect by their asymptotic relative efficiency
(ARE). Suppose we have a parameter of interest θ and we wish to test θ = θ0. And
we have a statistic T that is a consistent estimator of µT (θ), a monotone function
(at least close to θ = θ0) of θ. A definition of ARE called the Pitman efficiency of
two such statistics T1 and T2 that are asymptotically normally distributed with means
µT1(θ) and µT2(θ) and variances σ
2
T1
and σ2T2 is given by [28]:
ARE(T1 to T2 at θ = θ0) =
[
µ′T1(θ0)
µ′T2(θ0)
]2 [
σ2T2(θ0)
σ2T1(θ0)
]
(2.1)
We can test the null hypothesis β = 0 using the adjusted or unadjusted Wald test
statistics
βˆ√
var(βˆ)
or
βˆ∗√
var(βˆ∗)
which have asymptotic normal distributions with means β/
√
var(βˆ) and β∗/
√
var(βˆ∗)
and variances of one. Substituting the adjusted and unadjusted Wald test statistics
into the definition of ARE in equation 2.1 we obtain the ARE of a test of no treatment
effect based on the adjusted estimator to a test based on the unadjusted estimator [5]:
ARE(βˆ to βˆ∗) =
[
lim
β→0
(
d
dβ
β
)(
d
dβ
β∗
)−1]2 [
lim
β→0
var(βˆ∗|X)
var(βˆ|X)
]
(2.2)
where we are considering β and β∗ as functions of β.
For any link function, ARE(βˆ to βˆ∗) ≥ 1 (shown for binary predictor and outcome
variables by Robinson et al. [5] and generally by Neuhaus [4]). So adjusting for
a covariate independent of treatment allocation increases the power of a test of no
treatment effect when using any GLM. The gain in power as a result of adjusting for
a prognostic covariate increases with the variance of the covariate effect γZ [4].
A simulation study of logistic regression by Negassa and Hanley [27] estimated power
by the proportion of simulated studies in which a hypothesis of no treatment effect
was rejected at the 5% level. For the treatment effect, an odds ratio (OR) of 2.0 was
used throughout. For a binary covariate, with OR=2.0, power was close to 1 when
the covariate was either included or excluded (for sample size 500 or 1000). For a
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sample size of 500 and with a covariate OR=10.0 the power was close to 0.9 with
covariate included but reduced to 0.8 with the covariate omitted. For a sample size
of 1000 the power remained above 0.95 for both covariate included and omitted with
covariate OR=10.0. For a continuous covariate the reduction in power was much more
pronounced. For a sample size of 500 and with covariate OR=10.0 (per unit increase)
the power was close to 0.8 with covariate included but reduced to 0.6 with the covariate
omitted. For a sample size of 1000 the power was close to 1 with covariate included
but less than 0.9 when the covariate was omitted.
A simulation study by Hernandez et al. [29] investigated the effects of omitting a single
binary covariate in a logistic regression. The effect on power was quantified by the
percentage reduction in sample size achieved by adjusting for the covariate (so that
equal power is obtained by the adjusted and unadjusted tests of no treatment effect).
The results of simulations with unadjusted covariate effects of OR=2.0, OR=5.0 and
OR=10.0, and unadjusted treatment effects of OR=1.4 and OR=1.7, are summarised
in Table 2.1. For a larger covariate effect there is a greater reduction in required sample
size. The magnitude of the reduction is smaller when there is a larger treatment effect.
Unadjusted treatment effect
OR=1.4 OR=1.7
Unadjusted covariate effect OR=2.0 3.3% 2.8%
OR=5.0 13.8% 13.5%
OR=30.0 45.5% 43.6%
Table 2.1: Reduction in required sample size for a test of no treatment effect when
adjusting for a covariate in a logistic regression. (Figures from Table 3 of Hernandez
et al. [29])
2.2 Covariate adjustment and model choice
In many GLMs (such as logistic regression) adjusted and unadjusted treatment effect
parameters do not coincide (Section 2.1.1). They are both valid measures of treat-
ment effect, but have different interpretations. The unadjusted treatment effect is a
marginal effect, and can be described as population averaged. It is a measure of the
effect of treatment on the population of patients in the trial. On the other hand, the
adjusted treatment effect is a conditional effect. It is a measure of treatment effect
conditional on a given value of the covariate. Where we include more than one covari-
ate, the treatment effect is conditional on all covariates. As more covariates are added
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to a model the treatment effect being estimated becomes closer to a subject-specific
effect [8].
If the only objective of a trial is a test of no treatment effect, then greater power is
obtained by using an adjusted model (Section 2.1.3). If estimation of a treatment effect
is the primary aim, then the choice between the unadjusted and adjusted treatment
effect depends on what is more appropriate in the context and wider aims of the study.
An adjusted estimate of treatment effect (closer to the subject-specific effect) may be
more relevant to individual patients in a clinical setting, but the unadjusted model
may be more relevant to policy makers interested in effects at population level. This
choice is highlighted by Hauck et al. [8]. Austin et al. [10] recommend that there is
a need for an “informed debate” about the choice between unadjusted and adjusted
treatment effects. Lingsma et al. [30] emphasise the advantage of increasing power
by adjusting for covariates, but the difference in interpretation between estimates still
remains the overbearing consideration [31].
Hauck et al. [8] and Austin et al. [10] also highlight the difficulties in meta-analysis if
only adjusted treatment effects are reported. If the choice of covariates varies between
analyses, the same adjusted effect is not being estimated by each analysis so it may
be inappropriate or misleading to combine them in a meta-analysis. This argument
suggests that presenting an unadjusted estimate of treatment effect, as well as any
adjusted estimate, may be useful for future meta-analyses.
2.3 Covariates and trial design
Simple randomisation ensures balance of covariates between treatment arms over all
randomisations, but in a single trial there may be chance baseline imbalance. Strati-
fying randomisation, or using an adaptive randomisation procedure such as minimisa-
tion, can be used to restrict the extent of imbalance in one or more chosen covariates.
This helps to provide more comparable treatment arms and can improve the efficiency
of the analysis of the trial [32].
The use of restricted randomisation has implications for analyses. Standard errors are
biased upwards [33] and significance tests have non-nominal size [34] when the effect of
a covariate used to balance treatment arms is omitted. Therefore, it is recommended
to adjust for covariates used in restricted randomisation in an adjusted analysis. In
multi-centre and international trials randomisation may be stratified by centre or
country for administrative convenience, and the use of random effects for centre may
be useful under some conditions [35]. However, it may be expected that centre or
country is not related to outcome and so some authors suggest it is not necessary to
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include them as a covariate despite being used in randomisation [12,36].
2.4 Balance of covariates between treatment arms
In an RCT, randomisation ensures that there is no systematic imbalance of covari-
ates between treatment arms. Values of any covariate (measured or unmeasured) are
drawn from the same distribution for all treatment arms. The independence between
treatment arm and covariates ensures that there cannot be any classical confounding
as may be found in observational studies, and allows us to attribute any difference in
outcome to a difference in the effects of the experimental and control treatments.
However, in a single RCT there may be imbalance of a covariate between treatment
arms. This chance imbalance has been used as justification for the inclusion of covari-
ates that are observed to be imbalanced between treatment arms: for example, in 3
out of 39 adjusted analyses reviewed by Austin et al. [37]. However, this justification
is invalid and choosing covariates due to baseline imbalance should be avoided [38–40].
Adjusting for a covariate only when it is significantly imbalanced between treatment
arms leads to type I error lower than the nominal level [41].
Consider the example given by Senn [38] of an RCT with continuous outcome Y and
a continuous covariate Z. Let n0 and n1 be the number of patients in the control and
experimental treatment arms, respectively. Assume Z and Y have a bivariate normal
distribution with known correlation ρ and standard deviations σZ and σY . Let β be
the treatment effect. So in the control arm:
Z, Y ∼ N(µZ , µY , σ2Z , σ2Y , ρ)
And in the experimental treatment arm:
Z, Y ∼ N(µZ , µY + β, σ2X , σ2Y , ρ)
Denote the means of Z and Y in the control and experimental treatment arms by
Z¯0, Y¯0 and Z¯1, Y¯1. Then the standardised difference between treatment arms of the
covariate at baseline is
∆Z =
Z¯1 − Z¯0
σZ
√
1/n0 + 1/n1
and the standardised difference between treatment arms of the outcome variable is
∆Y =
Y¯1 − Y¯0
σY
√
1/n0 + 1/n1
.
These have a joint normal distribution
∆Z ,∆Y ∼ N(0,Λ, 1, 1, ρ)
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where Λ = β/(σY
√
1/n0 + 1/n1). In the analysis of a trial, the value ∆Z would
be used to test baseline balance, while ∆Y would be used in an unadjusted test
of no treatment effect. Under the null hypothesis of no treatment effect (β = 0),
the unconditional distribution of ∆Y is N(0, 1), however conditional on an observed
imbalance of the covariate Z (∆Z = δZ) the distribution of ∆Y is N(ρδZ , 1− ρ2). So,
an unadjusted test of nominal size α of no treatment effect will have conditional (on
an observed distribution of Z) size
φ(α, ρ, δZ) = Φ
[
zα/2 − ρδZ
(1− ρ)2
]
+ 1− Φ
[−zα/2 − ρδZ
(1− ρ)2
]
where zα/2 is a critical value of the standard normal distribution, and Φ is the standard
normal cumulative distribution function. If covariate Z is prognostic, then ρ 6= 0 and
typically φ(α, ρ, δZ) 6= α. That is, an unconditional test of no treatment effect will
typically have non-nominal size conditional on an observed imbalance of a covariate.
For example (given by Senn [38]), let α = 0.05, ρ = 0.73 and δZ = 1.43 as may be
seen in a clinical trial. Then the covariate Z is not considered significantly imbalanced
between treatment arms (P-value of 0.15), but the conditional size of a test of no
treatment effect at the 5% level is in fact 0.09.
The logic of adjusting for only significantly imbalanced covariate suggests that when a
covariate is balanced it does not affect significance tests, but the above example shows
that this is not the case. In general, the imbalance or balance of a covariate is not an
adequate criterion on which to base selection for an adjusted analysis. As Senn [38]
notes, unadjusted analyses take into account chance imbalance of covariates and are
valid in the absence of knowledge about covariates and their distributions.
Further, selecting covariates on the basis of a significant level of imbalance also fails to
recognise some other issues. Only covariates that are observed, reported, and tested
could possibly be found to be imbalanced and hence selected; and imbalance neglects
the size of the effect of a covariate on the outcome.
Note that it is fair to be cautious of unadjusted treatment effect estimates when a
highly prognostic covariate is imbalanced between treatment arms. Altman [42] sug-
gests that it is important to show a baseline comparison table, as general information
and to allow readers to assess for themselves the validity of an unadjusted treatment
effect estimate, taking into account clinical knowledge and common sense as well as
baseline imbalance. This is also included in CONSORT guidelines [43].
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2.5 Choosing covariates in the analysis of individually
randomised trials
It is not necessary to adjust for any covariates not used in restricted randomisation
when estimating the treatment effect in the analysis of an RCT. By design, treatment
arm and any covariate (measured or unmeasured) not used to restrict randomisation
are independent. So an unadjusted estimate of treatment effect is an unbiased esti-
mate of the marginal treatment effect (which may differ from the conditional/adjusted
treatment effect under some models), and a significance test of no treatment effect is
of nominal size [38]. It is recommended that the report of a trial analysis includes
unadjusted results as well adjusted analyses results [9].
However, there are advantages to adjusted analyses. Firstly, including a covariate
will adjust for any chance imbalance of the covariate between treatment arms, and
so adjust for any chance bias of the treatment effect estimate [38, 44]. Secondly, in
some models, such as linear regression, adjusting for a covariate increases the precision
of the treatment effect estimate, although for other models (such as logistic regres-
sion) precision decreases when introducing a covariate. Finally, when using any GLM
adjusting for a covariate increases the power of a significance test of no treatment
effect.
When an adjusted analysis is carried out, the primary motivation for choosing to
include a particular covariate is that it is known to be a prognostic factor [12–15,
38]. Gains in precision and power increase as the effect size of an included covariate
increases. By incorporating highly prognostic factors as covariates, gains in power are
maximised. When the outcome measure of a trial can also be measured at baseline,
it is recommended to adjust for baseline by including it as a covariate as baseline
measures of outcome are often highly prognostic [12,45].
It is widely recommended that the selection of prognostic covariates is done a priori,
on the basis of prior knowledge [13,14]. This may be from previous clinical trials, pilot
studies, observational studies, or wider medical knowledge. However, in some cases
it may not be possible to select highly prognostic covariates prior to the trial, due
to a lack of wider knowledge. In this situation, it is recommended by some authors
that post hoc selection of covariates is appropriate as long as that method is objective
and pre-specified [12]. However, the use of variable selection algorithms may lead to
misestimated standard errors and invalid analysis [14]. Choosing a covariate because
it is observed to be prognostic of outcome in the particular trial data being analysed
is not recommended [13,14].
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Selecting covariates due to an observed baseline imbalance is wholly inappropriate
and can lead to invalid analysis [38]. Therefore, it is recommended throughout the
literature that this practice is avoided [13,14,38].
It is recommended that covariates used to balance randomisation (for example, factors
used to stratify randomisation) are adjusted for in an adjusted analysis [13–15]. Failure
to adjust for covariates used in randomisation leads to incorrect standard errors and
significance tests of non-nominal size [34,35].
The literature offering guidelines and recommendations for choosing covariates in ad-
justed analyses of individually randomised trials is almost universally in agreement
that covariates should be chosen a priori and because they are highly prognostic or
used in randomisation. There is some argument that post hoc selection of covariates
can be justified when there is a lack of previous knowledge, where the method is
pre-specified. Post hoc selection of covariates due to an observed relationship with
outcome, or imbalance between treatment arms should be entirely avoided.
2.6 Conclusion
There is a significant body of published literature on the effects of covariate adjustment
in the analysis of individually randomised trials, summarised for GLMs in Section 2.1.
This work uses analytic methods, simulation studies, and example trial data. Dis-
cussion of other considerations such as interpretation of treatment effect parameters,
covariates used in the design of a trial, and imbalance of covariates has been sum-
marised in Sections 2.2 to 2.4.
Published guidance on choosing covariates in individually randomised trials is broadly
consistent. These recommendations for the selection of covariates are justified by the
statistical literature on the effects of covariate adjustment, parameter interpretation,
baseline balance, and trial design.
In CRTs, the effects of covariate adjustment and considerations for adjusted analyses
are more complex. The literature relevant to adjusted analyses and choosing covariates
in CRTs in particular is looked at in the next chapter.
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Chapter 3
Adjusted analyses and choosing
covariates in cluster randomised
trials: literature review
I now move attention to published literature regarding covariate adjustment in the
analysis of CRTs, which are the focus of this thesis. Firstly, I summarise the known
effects of covariate adjustment in Section 3.1. In Section 3.2, I look at the proposition
of using two covariate effect parameters in adjusted analyses. I summarise published
guidance for choosing covariates in CRTs in Section 3.3.
3.1 Effects of covariate adjustment in cluster
randomised trials
As with individually randomised trials, we are concerned with the effect of adjusting
for a covariate on estimates of treatment effect, precision, and power. I firstly consider
change in estimate of treatment effect, and then precision and power for linear mixed
effects models. Literature concerning repeated measures and cross-sectional designs
with binary outcomes is described in Sections 3.1.3 and 3.1.4.
3.1.1 Change in estimate of treatment effect in linear mixed effects
models
Raab & Butcher [23] consider the change in estimate of treatment effect when adjusting
for covariates in the analysis of CRTs with linear mixed effects models. Consider a
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CRT consisting of J clusters each of m individuals. If no covariate is considered, then
the unadjusted linear mixed effects model is
Yij = α
∗ + β∗Xj + uj + eij (3.1)
where Yij is the outcome for individual i in cluster j and Xj indicates treatment
arm (X = 1 for the experimental arm, X = 0 for the control arm). The uj are
independent cluster random effects with uj ∼ N(0, τ2), and the eij are individual
level residuals with eij ∼ N(0, σ2). The marginal ICC of outcome Y is τ2τ2+σ2 . Now
consider introducing individual level covariates Z1, Z2, . . ., so the mixed effects model
becomes
Yij = α+ βXj + γ1Zij1 + γ2Zij2 + . . .+ uj + eij
with Yij and Xj as before, and Zijk is the covariate value Zk for individual i in cluster
j. These uj are independent random cluster effects with uj ∼ N(0, τ2y|z), and the eij
are individual residuals with eij ∼ N(0, σ2y|z). The difference between the unadjusted
and adjusted treatment effect estimates is
γ1(z¯1E − z¯1C) + γ2(z¯2E − z¯2C) + . . .
where z¯kE and z¯kC are the observed means for covariate Zk in the experimental (E)
and control (C) treatment arms [23]. Note that this is the difference between the
unadjusted and adjusted treatment effect estimates in a particular trial, and is not
the difference between unadjusted and adjusted treatment effect parameters. When a
covariate is at the cluster level, the difference may be large since larger imbalance of
the covariate can occur due to a small numbers of clusters [23]. However, restricted
randomisation can be used to limit imbalance of such covariates between treatment
arms.
3.1.2 Precision and power in linear mixed effects models
Raudenbush [24], Murray [16] and Raab & Butcher [23] consider the analysis of CRTs
with continuous outcome measures, analysed with a linear mixed effects model, and
give some analytic results for the precision of treatment effect estimates. The Optimal
Design software (see Appendix E for reference) allows the user to do power studies
in CRTs, and the software documentation [26] and other papers [46] give supporting
analytic results.
Firstly, I look at analytic results from Raudenbush [24], Murray [16] and Raab &
Butcher [23]. Consider a CRT consisting of J clusters each of m individuals, ran-
domised equally to two treatment arms. If no covariate is considered, then the unad-
justed mixed effects model is as in equation 3.1. The marginal ICC of outcome Y is
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ρ = τ
2
τ2+σ2
. The variance of the estimate of the unadjusted treatment effect parameter
βˆ∗ is then given by [23,24]
var(βˆ∗) =
4∆
J
with ∆ = τ2 +
σ2
m
(3.2)
which can also be written in terms of the marginal ICC, ρ, as [47]
var(βˆ∗) = 4
(τ2 + σ2)(1 + (m− 1)ρ)
mJ
. (3.3)
Now consider introducing an individual level covariate Z, so the mixed effects model
is
Yij = α+ βXj + γZij + uj + eij (3.4)
with Yij and Xj as before, and Zij is the covariate value for individual i in cluster j.
These uj are independent random cluster effects with uj ∼ N(0, τ2y|z), and the eij are
individual residuals with eij ∼ N(0, σ2y|z).
If we assume that the regression coefficient of the covariate is known, then the variance
of the adjusted treatment effect estimate is [23]
4(τ2y|z + σ
2
y|z/m)
J
.
When covariate coefficients are estimated from the data, the variance of the estimate
of the adjusted treatment effect parameter βˆ is [23, 24]
var(βˆ|Z) = 4∆y|z
J
[
1 +
J(z¯..E − z¯..C)2/4
∆y|xSSwz/σ2y|z + SSbz
]
(3.5)
where
∆y|z = τ2y|z +
σ2y|z
m
SSwz =
J∑
j=1
(zij − z¯.j)2
and SSbz =
∑
j∈E
(z¯.j − z¯..E)2 +
∑
j∈C
(z¯.j − z¯..C)2 .
The zij are values of covariate Z for individual i in cluster j. z¯.j is the mean of covariate
Z in cluster j. z¯..E and z¯..C are means of the covariate in the experimental treatment
arm (E) and control treatment arm (C). So, SSwz is the pooled, within-cluster sum
of squares of the covariate, and SSbz is the pooled, between-cluster (within treatment
arm) sum of squares of the covariate.
Comparing equations 3.5 and 3.2 we see that the precision of the estimate of treatment
effect increases most with covariate adjustment when ∆y|z is smaller than ∆, and the
means of the covariate are similar in each treatment arm [23,24]. In CRTs with random
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effects, the total variance of the outcome is reduced by (1− R2yz) when adjusting for
the covariate Z (where R2yz is the correlation between Y and Z) [16]:
(τ2y|z + σ
2
y|z) = (τ
2 + σ2)(1−R2yz)
This reduction in variance is not necessarily divided proportionally between the cluster
level and individual level components of variance. Raab & Butcher [23] state that when
there are “large” clusters it is most important to reduce the cluster level variance to
improve the precision of the estimate of treatment effect by covariate adjustment.
Imbalance of the covariate between treatment arms will decrease the precision of the
treatment effect estimate [23].
3.1.2.1 Optimal Design software
The Optimal Design software (see Appendix E for reference) performs power calcu-
lations for several designs of CRTs. For a two level CRT, the software allows the
inclusion of a cluster level covariate when the outcome is continuous and a linear
mixed effects model is used. The software allows the user to plot a graph of power
against one of the following: cluster size (m); number of clusters (J); ICC of outcome
(ρ); standardised treatment effect (δ); or the proportion of cluster level variation ex-
plained by the covariate (R2). In each case, the remaining parameters and significance
level must be specified by the user.
The software documentation [26] shows how the variance results given above extend
to power calculation. Consider a CRT as described above and the unadjusted linear
mixed effects model as given in equation 3.1. A test of no treatment effect can be
carried out with a nested ANOVA giving an F test statistic, defined as
F =
MStreatment
MScluster
where MStreatment and MScluster are the observed mean squares between treatment
arm and between cluster (within treatment arm), respectively. Using this test statistic
is equivalent to fitting the linear mixed effects model using restricted maximum like-
lihood estimation and using a Wald test [26]. As the number of clusters J increases,
the F statistic converges to the ratio of expected mean squares:
E[MStreatment]
E[MScluster]
=
mτ2 + σ2 +mJβ∗2/4
mτ2 + σ2
= 1 +
mJβ∗2/4
mτ2 + σ2
Under the null hypothesis of no treatment effect (β∗ = 0) this ratio is equal to one.
So under the null hypothesis, the F statistic follows a central F distribution with 1
and J − 2 degrees of freedom (F ∼ F (1, J − 2)). Under the alternative hypothesis
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(β∗ 6= 0) the F statistic follows a non-central F distribution with 1 and J − 2 degrees
of freedom and non-centrality parameter
λ =
β∗2
4(τ2 + σ2/m)/J
.
The non-centrality parameter λ is the ratio of the squared treatment effect (β∗2) and
the variance of the estimate of treatment effect (var(βˆ∗)). The power of a test of no
treatment effect is related to the size of the non-centrality parameter. In order to fa-
cilitate power calculation, the treatment effect β∗ can be replaced by the standardised
effect
δ =
β∗√
τ2 + σ2
.
In terms of the marginal ICC of the outcome (ρ = τ
2
τ2+σ2
) the non-centrality parameter
is
λ =
Jδ2
4(ρ+ (1− ρ)/m) .
Given values for J , m, δ, and ρ, the non-centrality parameter can be calculated,
and hence the power of a test of no treatment effect can be calculated for a chosen
significance level.
Adjusting for a cluster level covariate only, the adjusted linear mixed effects model
is as in equation 3.4 with σ2y|z = σ
2. For a normally distributed covariate Z, the
(expected) variance of the treatment effect estimate is [24]
var(βˆ|Z) = 4∆y|z
J
[
1 +
1
J − 4
]
.
The F statistic for a test of no treatment effect is defined as for the unadjusted model:
F =
MStreatment
MScluster
As the number of clusters increases, the F statistic converges to the ratio of expected
values of mean squares:
E[MStreatment]
E[MSclusters]
= 1 + λz
where
λz =
Jβ2
4(τ2y|z + σ
2/m)
Now under the alternative hypothesis (β 6= 0) the F statistic follows a non-central
F distribution with 1 and J − 3 degrees of freedom and non-centrality parameter λz.
Again, the treatment effect β can be replaced by the standardised effect
δ =
β√
τ2 + σ2
.
We express the conditional cluster level variance by τ2y|z = (1 − R2)τ2, so R2 is the
proportion of cluster level variance explained by the covariate. Then the non-centrality
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parameter can be given by
λz =
Jδ2
4((1−R2)ρ+ (1− ρ)/m) .
Given values for J , m, δ, ρ, and R2 the non-centrality parameter can be calculated,
and hence the power of an adjusted (for a cluster level covariate) test of no treatment
effect can be calculated for a chosen significance level.
Raudenbush at al. [48] use the Optimal Design software to investigate the effect on
power of adjusting for a cluster level covariate in a linear mixed effects model. The
authors note that power in this design depends on the correlation between the cluster
level covariate and the true cluster level mean outcome. This is distinct from the
correlation between the sample cluster level covariate and the sample cluster level
mean outcome.
As an alternative to power of a test, the Optimal Design software also allows calcu-
lation of minimum detectable effect sizes (MDES). The MDES is the smallest true
effect that will give a statistically significant result at a given power and significance
level. Bloom et al. [46] give an expression for the MDES in the analysis of a CRT:
MDES ≈MJ−K
√
ρ(1−R2c)
pi(1− pi)J +
(1− ρ)(1−R2s)
pi(1− pi)mJ
where there are J clusters randomised each including m individuals. A proportion
pi of clusters are randomised to the experimental treatment arm. ρ is the marginal
ICC of the outcome, R2c is the proportion of cluster level variance explained by the
covariates, and R2s is the proportion of subject level variance (within cluster) that is
explained by the included covariates. MJ−K is a factor based on the t distribution
that accounts for degrees of freedom (J −K). When the degrees of freedom exceeds
about 20, M is approximately 2.8 for a two-tailed test with 80% power and a 5%
significance level.
3.1.2.2 Power in linear mixed effects models
Konstantopoulos [25] considers the case of adjusting for q cluster level covariates, and
r individual level cluster-mean centred covariates. As before consider a CRT consist-
ing of J clusters each of m individuals, randomised equally to two treatment arms.
Assume that adjusting for q cluster level covariates reduces cluster level variance by
a proportion R2C , and adjusting for r individual level cluster-mean centred covariates
reduces individual level variance by a proportion R2I . Then for a two-tailed t test of
the null hypothesis of no treatment effect, the power is given by
1−H
[
t(α/2,J−2−q), (J − 2− q), λ
1
2
z
]
+H
[
−t(α/2,J−2−q), (J − 2− q), λ
1
2
z
]
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where tα/2,d is the two-tailed critical value of the t distribution at the α level with
d degrees of freedom, H(x, ν, λ
1
2
z ) is the cumulative distribution function of the non-
central t distribution with ν degrees of freedom and non-centrality parameter λ
1
2
z . The
non-centrality parameter is given by
λ
1
2
z =
√
Jδ
2
√
(1−R2C)ρ+ (1−R2I)(1− ρ)/n
with δ = β
∗√
τ2+σ2
and ρ is the ICC of the outcome (see the Appendix of Konstan-
topoulos [25]). As noted by Konstantopoulos [25], the power can also be computed
using the non-central F distribution with 1 and (J−2−q) degrees of freedom, and the
non-centrality parameter λz. This is equivalent to the result given in the Optimum
Design software documentation [26].
Konstantopoulos [25] uses empirical data from studies in education to further inves-
tigate the effects of covariate adjustment in CRTs. From this empirical investigation,
Konstantopoulos [25] makes several conclusions:
• For an outcome ICC greater than or equal to 0.1 and with individual level
covariates cluster-mean centred, cluster-level covariates typically increase power
more than individual level covariates. (Especially when there are 20 or more
clusters.)
• When individual level covariates are not cluster mean centred (allowing reduc-
tion of individual and cluster level residual variance), they typically increase
power more than cluster level covariates.
• For outcome ICC values smaller than 0.1, individual level covariates typically
increase power more than cluster level covariates (irrespective of any centring).
3.1.3 Repeated measures designs with continuous outcomes
In a repeated measures CRT we obtain outcome data at two or more time points. In
this section we consider the case where there are only two measurements: baseline
(t=0) and follow-up (t=1). The baseline measure of outcome may be used to adjust
the treatment effect by explicitly modelling time effects. That is, the linear predic-
tor of the model includes an effect for time and time by treatment arm interaction.
Baseline measures of outcome are an outcome at time equal to zero. The fixed effect
of interaction between time and treatment arm is the treatment effect of interest. I
now consider models of this type, in both cross-sectional and cohort designs, when a
linear mixed effects model is used for analysis. In a cross-sectional design the subjects
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measured at each time point may not be the same individuals, but in the cohort de-
sign the same individuals are measured at both time points. I will firstly summarise
the work of Murray & Blitstein [47] who consider cross-sectional and cohort designs
separately. Then I will consider the paper of Teerenstra et al. [49] who give the effect
of including baseline measurement of outcome on power (and sample size) in terms of
a single parameter.
Firstly, consider the cross-sectional design and the work of Murray & Blitstein [47].
The adjusted model (which models baseline measurement of outcome as well as follow-
up) is given by
Yijt = α+ δXj + ζt+ βXjt+ uj + vjt + eij
where Yijt is the outcome for individual i in cluster j at time t (where t = 0 at baseline
and t = 1 at follow-up) and Xj indicates treatment arm. The uj are independent
cluster random effects with uj ∼ N(0, σ2c ), the vjt are time by cluster random effects
with vjt ∼ N(0, σ2ct), and the eij are individual residuals with eij ∼ N(0, σ2e). The
correlation between Yijt in the same cluster at different time points is given by
ρc =
σ2c
σ2c + σ
2
ct
which is called the “cluster autocorrelation” [49]. The marginal ICC is given by
ρ =
σ2c + σ
2
ct
σ2c + σ
2
ct + σ
2
e
.
Murray & Blitstein [47] define the “operative ICC” as the ICC that contributes to the
variance of the treatment effect estimate (so it is the adjusted ICC). The operative
ICC is given by
ρop =
σ2ct
σ2ct + σ
2
e
.
The treatment effect β is estimated by the net difference between time by treatment
arm means
(y¯1E − y¯0E)− (y¯1C − y¯0C)
where y¯tE and y¯tC are the means of outcome at time t in the experimental (E) and
control (C) treatment arms. The variance of that effect estimate is [16]
var(βˆ) = 8
σ2ct + σ
2
e/m
J
which can also be expressed in terms of the unadjusted ICC and cluster autocorrela-
tion, or the operative ICC as
var(βˆ) = 8
σ2ρ+mσ2(1− ρ)(1− ρc)
mJ
= 8
(σ2ct + σ
2
e)(1 + (m− 1)ρop)
mJ
(3.6)
where σ2 = σ2c + σ
2
ct + σ
2
e . Comparing equations 3.3 and 3.6, the (τ
2 + σ2) term
is replaced by σ2ct + σ
2
e and the unadjusted ICC ρ is replaced by the operative ICC
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ρop. The expression is multiplied by an additional factor of two, which reflects that
the treatment effect is estimated by the difference between four means rather than
two. The cluster autocorrelation ρc is positive, which means that (σ
2
ct + σ
2
e) < (τ
2 +
σ2) and ρop < ρ. For the adjusted model to give smaller variance of the treatment
effect estimate than the unadjusted model these reductions must be large enough to
overcome the additional factor of two. This occurs if the cluster autocorrelation ρc is
large enough.
Murray & Blitstein [47] also consider the cohort repeated measures design as follows.
Recall that in a cohort design, the same individuals provide outcome data at two
or more time points. The adjusted model (which includes baseline measurement of
outcome) is given by
Yijt = α+ δXj + ζt+ βXjt+ uj + sij + vjt + wijt + eijt
where Yijt is the outcome for individual i in cluster j at time t (where t = 0 at baseline
and t = 1 at follow-up) and Xj indicates treatment arm. There are five random effects:
the uj are cluster random effects with uj ∼ N(0, σ2c ); the sij are random subject effects
with sij ∼ N(0, σ2s); the vjt are time by cluster random effects with vjt ∼ N(0, σ2ct);
the wijt are time by subject random effects with wijt ∼ N(0, σ2st); and the eijt are
residuals with eijt ∼ N(0, σ2e). When there is one measure of each subject at each
time point (as usual) the random effects wijt and eijt cannot be estimated separately.
The correlation between Yijt in the same subject and different time points (within
subject correlation) is
ρs =
σ2s
σ2s + σ
2
st + σ
2
e
which is the “subject autocorrelation”. The operative ICC ρop is then given by
ρop =
σ2ct
σ2ct + σ
2
st + σ
2
e
.
The variance of the treatment effect estimate is [16]
var(βˆ) = 8
σ2ct + (σ
2
st + σ
2
e)/m
J
which can also be expressed in terms of the operative ICC as
var(βˆ) = 8
(σ2ct + σ
2
st + σ
2
e)(1 + (m− 1)ρop)
mJ
. (3.7)
Comparing equations 3.3 and 3.7, the (τ2 +σ2) term is replaced by (σ2ct+σ
2
st+σ
2
e) and
the unadjusted ICC ρ is replaced by the operative ICC ρop. As in the cross-sectional
design, the expression is multiplied by an additional factor of two which reflects that
the treatment effect is estimated by the difference between four means. As the cluster
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and subject autocorrelation (ρc + ρs) are positive, then (σ
2
ct + σ
2
st + σ
2
e) < (τ
2 + σ2)
and ρop < ρ. Again, if the autocorrelations are large enough so that the reductions
are large enough to overcome the factor of two, then the adjusted analysis will give
smaller treatment effect variance than the unadjusted analysis.
Now turn to the work of Teerenstra et al. [49] who consider repeated measures CRTs
with both cohort and cross-sectional design (as well as a mixture of these) together,
and express the effect of including baseline measurement in terms of a single parameter.
The model (which allows inclusion of baseline measurement of outcome) is given by
Yijt = α+ δXj + ζt+ βXjt+ uj + sij + vjt + wijt
where Yijt is the outcome for individual i in cluster j at time t (where t = 0 at baseline
and t = 1 at follow-up)and Xj indicates treatment arm. There are four random
effects: the uj are cluster random effects with uj ∼ N(0, σ2c ); the sij are random
subject effects with sij ∼ N(0, σ2s); the vjt are time by cluster random effects with
vjt ∼ N(0, σ2ct); and the wijt are time by subject random effects with wijt ∼ N(0, σ2st).
This model is the same as that used by Murray & Blitstein [47] for the cohort design,
except now the wijt term includes all time by subject variation (i.e. the eijt have
been subsumed into the wijt term). As before, we have cluster autocorrelation ρc and
subject autocorrelation ρs:
ρc =
σ2c
σ2c + σ
2
ct
and ρs =
σ2s
σ2s + σ
2
st
This model is adequate to describe both cohort and cross-sectional designs. In a cross-
sectional design, ρs = 0 and all sij = 0. With 0 < ρs < 1, the model is for the usual
cohort design.
The variance of the unadjusted treatment effect estimator (that is, only follow-up
outcome is included in the model) is
var(βˆ∗) =
(
1
piC
+
1
piE
)
σ2(1 + (m− 1)ρ)
mJ
(3.8)
where the proportion of clusters in the experimental and control treatment arms are
piE and piC , and σ
2 is the total variance over all subjects over all clusters (σ2 =
σ2c +σ
2
ct+σ
2
s +σ
2
st). The variance of a change-from-baseline treatment effect estimator
(where the outcome variable used is the difference between outcome measured at
follow-up and at baseline) is
var(βˆ∗∗) = 2(1− r)
(
1
piC
+
1
piE
)
σ2(1 + (m− 1)ρ)
mJ
where
r =
σ2c + σ
2
s/m
σ2c + σ
2
ct + (σ
2
s + σ
2
st)/m
=
mρ
1 + (m− 1)ρρc +
1− ρ
1 + (m− 1)ρρs .
53
The expected values of the unadjusted (βˆ∗) and change-from-baseline (βˆ∗∗) treatment
effect estimators are equal, and so are also equal to any combination aβˆ∗+ (1−a)βˆ∗∗.
The combination with smallest variance is when a = r, as shown in the appendix of
Teerenstra et al. [49].
Including baseline measures of outcome (conducting an analysis of covariance (AN-
COVA)) the variance of the treatment effect estimate becomes
var(βˆ) = (1− r2)
(
1
piC
+
1
piE
)
σ2(1 + (m− 1)ρ)
mJ
. (3.9)
From equations 3.8 and 3.9, we can see that the ratio of variances for an adjusted anal-
ysis to an unadjusted analysis is (1− r2). So as r increases, the precision of treatment
effect estimate increases, the power increases and the required sample size decreases.
Note that r is the correlation between a cluster mean at baseline and at follow-up. It
is a weighted average of the cluster autocorrelation and subject autocorrelation, and
so will lie between the two and be at least as large as the smaller.
Now consider comparing the cross-sectional and cohort designs. For a completely
cross-sectional design, there will be no correlation between subjects at baseline and
follow-up conditional on cluster. Therefore the subject autocorrelation will be zero
(ρs = 0). The correlation between cluster means r, now denoted as rcross is then
rcross =
mρ
1 + (m− 1)ρρc ≤ r .
The ratio of required sample size is then given by (equation 8 of Teerenstra et al. [49])
var(βˆcross)
var(βˆcohort)
=
1− r2cross
1− r2
=
(
1 + (1− ρ) ρs
(1 + (n− 1)ρ)(1− r)
)
×
(
1− (1− ρ) ρs
(1 + (n− 1)ρ)(1 + r)
) (3.10)
So the cross-sectional design gives larger variance of treatment effect estimator (or a
larger required sample size for the same variance) than an equivalent cohort design,
although for a large cluster size or small subject autocorrelation the difference is small.
3.1.4 Cross-sectional designs with binary outcomes
Nixon & Thompson [50] investigate the effect on the precision of treatment effect es-
timates when adjusting for baseline in the analysis of repeated cross-sectional CRTs
with binary outcomes. In such a trial there is a binary outcome measured at baseline
and at follow-up, but outcomes are not necessarily measured on the same individuals
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so analyses cannot be adjusted for individual baseline values. Instead, baseline pro-
portions for each cluster can be adjusted for in the analysis. Nixon & Thompson [50]
use simulations to compare the width of confidence intervals for treatment effect esti-
mates between unadjusted and adjusted mixed effects models. The number of clusters
ranged from 10 to 100, and fixed cluster size ranged from 10 to 1000.
When the baseline probabilities were prognostic and there was mild heterogeneity
between clusters (a standard deviation of logit probabilities between clusters of 0.1 at
baseline), simulations showed baseline adjustment making “little difference” [50] to the
estimation of β; mean confidence interval widths were similar between adjusted and
unadjusted models [50]. With extreme heterogeneity of clusters (a standard deviation
of logit probabilities between clusters of 0.5) at baseline or both baseline and follow-
up, then adjusting for baseline proportions improved precision in the estimation of
the treatment effect parameter. Nixon & Thompsons [50] repeated simulation studies
with variable cluster size. The number of clusters was fixed at 30 while the cluster size
was determined by a random variable uniformly distributed between 49.5 and 150.5
and rounded to the nearest integer, to give a range of values around 100 as used in
the fixed cluster size case. These analyses gave similar results to when cluster size
was fixed at 100 [50]. Simulations where baseline is not prognostic of outcome showed
that adjusting for baseline gave less precise estimates when there is a small number of
clusters [50]. To consider the performance of adjusting for baseline proportions when
there is imbalance at baseline, Nixon & Thompson [50] also simulated data sets where
the observed mean of cluster log odds at baseline in the intervention arm is at least√
2 standard errors above the observed mean of cluster log odds at baseline in the
control arm. In this case, baseline adjustment was successful in correcting the chance
bias in the treatment effect estimate [50].
Nixon & Thompson [50] conclude that precision is only markedly increased when ad-
justing for baseline proportions in a repeated cross-sectional CRT when there is a
large cluster size and baseline heterogeneity between clusters. The number of clusters
affects the overall precision but does not appear to influence the effect of baseline ad-
justment. Baseline adjustment successfully adjusts for an observed baseline imbalance
regardless of cluster size or number of clusters.
Austin [51] investigates the power of methods of adjusting for baseline in the analysis
of repeated cross-sectional CRTs with binary outcomes. Austin [51] applies a total of
nine models to simulated trial data. There are three analysis methods used, which
are GEEs, mixed effects models and cluster level linear regression. For each of these,
three different models are used: an unadjusted model, a model adjusted for baseline,
and a model estimating change in response log odds or probability.
55
When the cluster heterogeneity was small the mixed effects model estimating change
in log odds gave consistently lower power for a test of no treatment effect than the
other models. The differences in power increased as the number of clusters or number
of individuals in each cluster increased. Differences in power between the other mod-
els were “negligible” [51]. Any minor difference in power decreased as the number of
clusters or number of individuals in each cluster increased. When the cluster hetero-
geneity was large similar results were seen, except the three unadjusted methods had
“marginally” [51] less power when the number of individuals in each cluster was large.
The differences in power between models was clearer when the cluster autocorrelation
was large. All of these results were essentially identical whether there was a zero or
non-zero secular time effect.
Austin [51] concludes that with exception of mixed effects model estimating change in
log odds, all methods considered had comparable power. However, when the number
of individuals in each cluster is large, methods that did not adjust for baseline had
less power.
3.2 Within-cluster and contextual covariate effect
parameters
Individual level covariates generally have a different value for each individual within a
cluster [52]. An individual level covariate, Zij , can be separated into two components:
a between-cluster component Z¯j (the mean of the covariate in cluster j), and a within-
cluster component (Zij − Z¯j). The literature considered so far describes the case of
using a single variable and single parameter for the effect of a covariate on outcome.
This assumes that effects of the covariates at the individual and cluster level are
identical, which may not be true [52]. Using a single parameter for a variable that has
different effects at the individual level and cluster level leads to misleading estimates
for the effect of the covariate, and biased estimates of residual variance [53].
The mixed effects models used for the analysis of CRTs can easily be adapted to
incorporate separate individual and cluster level covariate effects. For example, Rau-
denbush [24] gives the following modified version of equation 3.4:
Yij = α+ βXj + γWZij + γBZ¯j + uj + eij
= α+ βXj + γW Z¯j + γW (Zij − Z¯j) + γBZ¯j + uj + eij
= α+ βXj + γW (Zij − Z¯j) + (γW + γB)Z¯j + uj + eij
Recall, Yij is the outcome for patient i in cluster j, Xj indicates treatment arm for
cluster j, and uj and eij are random effects (uj ∼ N(0, τ2), eij ∼ N(0, σ2)). Instead of
56
a single covariate effect γ, there are two covariate effects. I will follow the naming con-
vention of Korendijk et al. [54], so γW is the within-cluster coefficient of the covariate
effect and γB is the between-cluster effect. The contextual effect is γC = (γW + γB),
and reflects the regression of cluster mean outcome Y¯j on cluster mean covariate Z¯j .
When the between-cluster effect is zero, the within-cluster and contextual effects are
equal, which is the assumption of the model with a single covariate effect parameter.
Two simulation studies [54,55] have been carried out to investigate the effects of using
separate within-cluster and contextual covariate effect parameters in the analysis of
CRTs with linear mixed effects models.
3.2.1 Bias and precision in linear mixed effects models
Korendijk et al. [54] investigate the effects of ignoring distinct within-cluster and
contextual effects on parameter estimates and their standard error estimates, in the
analysis on CRTs. Korendijk et al. [54] compare a model that includes a within-cluster
covariate effect and a between-cluster covariate effect (the “different-effects” model)
Yij = α+ βXj + γWZij + γBZ¯j + uj + eij
with a model that includes only a single covariate effect (the “ordinary” model)
Yij = α+ βXj + γZij + uj + eij .
In each case, uj are independent cluster random effects with uj ∼ N(0, τ2), and the
eij are individual residuals with eij ∼ N(0, σ2), that are different to the uj and eij in
the previous model.
Cluster size was fixed at 5, with 20 clusters. The ICC of the outcome was fixed at
0.1. The “inequality of covariate effects” (ICE) [54] was defined by the ratio of the
within-cluster effect to the contextual effect:
ICE =
γW
γW + γB
So, with ICE = 1 the between-cluster covariate effect is zero, and the model including
a single covariate effect is correct in assuming a single covariate effect.
Under both analysis models, the treatment effect parameter estimates were unbiased
for all values of the “inequality of covariate effects” and total covariate effect. For
an “inequality of covariate effects” of 0.1, 27.9% of estimated standard errors from
the “ordinary” model were inflated (that is, greater than the 97.5th percentile of
the estimated standard errors from the “different-effects” model). For “inequality
of covariate effects” of 0.333, 3, and 10, the proportion of inflated standard errors
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from model B were 5.7%, 3.1%, and 6.3% respectively. So there was only serious
inflation of estimated standard errors under the “ordinary” model when the within-
cluster covariate effect was particularly small. However, under the “ordinary” model
the coverage of 95% confidence intervals is close to 0.95 under all conditions.
Korendijk et al. [54] conclude that in general, treatment effect estimates and estimated
standard errors are estimated without bias in both models. So it is sufficient to include
a single covariate effect in the analysis model in this regard. However, Korendijk et
al. [54] warn that the parameters associated with random effects (the residual cluster
level and individual level variances) are estimated with bias under the model that
includes only a single covariate effect.
3.2.2 Power in linear mixed effects models
Klar & Darlington [55] consider the analysis of CRTs where the outcome measured at
baseline can be used as a covariate. They assume a cohort repeated measures design,
so the baseline outcomes are from the same individuals as follow-up outcome.
Klar & Darlington [55] consider analysis with the following five linear mixed effects
models:
1. Model 1 including only follow-up outcome data:
Yij = α+ βXj + uj + eij
2. Model 2 using the simplest method of adjusting for baseline, modelling change
in outcome:
Yij − Zij = α+ βXj + uj + eij
3. Model 3 adjusting for baseline measurement of outcome by including a single
covariate effect:
Yij = α+ βXj + γ(Zij − Z¯) + uj + eij
4. Model 4 allowing distinct within-cluster and contextual effects of baseline out-
come on follow-up:
Yij = α+ βXj + γW (Zij − Z¯j) + γC(Z¯j − Z¯) + uj + eij
5. Model 5 modelling change in outcome and allowing distinct within-cluster and
contextual effects of baseline outcome on follow-up:
Yij − Zij = α+ βXj + γW (Zij − Z¯j) + γC(Z¯j − Z¯) + uj + eij
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Note that the variances of the uj and eij are not the same between models. Where
there is a single covariate effect, γ is the effect of baseline outcome on follow-up. In
the models allowing distinct within-cluster and contextual covariate effects, γW is the
within-cluster and γC is the contextual effect of baseline on follow-up.
Klar & Darlington [55] simulated data for CRTs containing 28 clusters with 58 indi-
viduals in each cluster. ICC for both baseline and follow-up measurements of outcome
was 0.03.
Klar & Darlington [55] find that in all models type I error was at the correct level.
Model misspecification does not affect type I error. The power when using Model 4
was “consistently high” [55] for all parameter values compared to other models. Model
5 also gave “consistently high” [55] power and identical results to Model 4 when the
cluster size was fixed. When there was no effect of baseline measurement of outcome
on follow-up (γW = γC = 0), Model 1 gave higher power (similar to models 3, 4 and 5)
while Model 2 gave lower power. When there was a single covariate effect (γW = γC),
models 3, 4 and 5 gave high power. For distinct within-cluster and contextual effects of
baseline on follow-up, Model 4 gave higher power than the other models. The relative
performance of the other models then depended on the combination of parameter
values.
From these results, Klar & Darlington [55] recommend that in CRTs where there is a
baseline measurement of outcome for individuals, Model 4 should be used in analysis
to adjust for baseline. This model allows distinct within-cluster and contextual effects
of baseline outcome on follow-up. Further, use of this model gives estimates of the
within-cluster and contextual effects, which may be of interest to the researchers.
3.3 Choosing covariates in the analysis of CRTs
The selection of covariates in the analysis of CRTs is more complicated because co-
variates exist at both the cluster level and individual level. Further, adjustment for an
individual level covariate can affect the residual variance of the outcome at both the
cluster and individual levels. The choice of actual covariates will depend of the nature
of the trial, but Murray [16] recommends identifying a set of potential covariates that
are related to the outcome measure. Then in a preliminary analysis, examine which
covariates account for individual variation and include these in the analysis. This can
help increase the precision of the estimate of treatment effect [16]. However, Raab &
Butcher [23] propose that the arguments used for individually randomised trials for
specifying covariates a priori are “equally applicable” in the analysis of CRTs.
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Raab & Butcher [23] advise that in the best interests of precision and change in
estimate of treatment effect, trial analysts should identify a set of covariates to include
in analysis that are highly prognostic at the cluster level. Other papers also suggest
that reducing cluster level variation by including cluster level covariates is most useful
[48, 56]. However, adjusting for a cluster level covariate that is not correlated with
outcome compromises power due to the loss of a degree of freedom [25,48], though this
is negligible except when sample size is small [48]. Konstantopoulos [25] recommends
that cluster level covariates should be carefully chosen to balance benefits in precision
with the cost of losing degrees of freedom [25]. Further, Konstantopoulos [25] argues
that both individual and cluster level covariates can be effectively used to improve
power, depending on assumptions, trial design, and variable distributions.
In linear models, adjusting for a baseline measure of outcome (possibly by explic-
itly modelling time) can increase precision and power [47]. Murray [16] states that a
baseline measurement of the outcome is the “single best covariate” to include. How-
ever, from simulation studies of repeated measures CRTs with binary outcomes there
appear to be limited gains in precision or power for including baseline measures of
outcome. Only when there are large cluster sizes and heterogeneity between clusters
at baseline is there an advantage in including baseline [50,51].
Neuhaus & Kalbfleisch [52] give examples where individual level and cluster level
effects of a covariate on outcome are distinct. It is possible to separately model
these cluster and individual level effects of covariates when adjusting. Using a single
covariate effect when cluster and individual effects differ does not bias the treatment
effect estimate or its precision [54]. Using separate covariate effects is recommended
by Korendijk et al. [54] to ensure variance parameter estimates are unbiased. Klar &
Darlington [55] recommend using separate covariate effects, as this can give greater
power for a test of no treatment effect.
Moerbeek [57] compares strategies of recruiting more clusters or measuring, and ad-
justing for, covariates to increase power. When adjusting for a covariate, separate
within-cluster and contextual covariate parameters are used. Moerbeek [57] recom-
mends that when cluster size is small, and the cost to recruit clusters is large, indi-
vidual level covariates should be measured. When cluster level size is large, but cost
to recruit a cluster is small, measuring cluster level covariates is recommended.
3.4 Conclusion
Published research on the effects of covariate adjustment in CRTs is limited, focussing
on linear mixed effects models and a limited number of other designs and analysis
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methods. Notably, there is little work on the effects of covariate adjustment when using
logistic mixed effects models. A small number of authors have considered including
separate within-cluster and contextual covariate effect parameters in linear mixed
effects models. They suggest that in some cases such a model may be preferred to a
model with a single covariate effect parameter. The simulation studies consider only
specific sample sizes and values for ICCs, and the same ICC for a covariate and the
outcome variable.
Existing recommendations for choosing covariates in the analysis of CRTs are limited
in quantity and scope. There is some direct extension of recommendations from in-
dividually randomised trials, such as the general advice of choosing highly prognostic
covariates a priori. However, the issue of choosing covariates in CRTs has rarely been
addressed directly and with consideration for practical usefulness of results.
There exists significant scope for further work on the effects of covariates in CRTs,
and the development of recommendations for choosing covariates in the analysis of
CRTs. In particular, the effects of covariate adjustment when using logistic mixed
effects models warrant investigation. There is also potential further development of
results outlined in this chapter and Chapter 2 into practical recommendations for
researchers undertaking CRTs. The research presented in the later chapters of this
thesis addresses these areas for further investigation. That work is preceded, in the
next chapter, by a review of the analytic and simulation methods that have been used
in previous work to investigate the effects of covariate adjustment in RCTs and CRTs.
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Chapter 4
Methods used to investigate the
effects of covariate adjustment
In this chapter I review the methods used to investigate the effects of covariate ad-
justment in individually randomised and cluster randomised trials in the published
research that was considered in Chapters 2 and 3. The methods can be separated
into two groups: analytic methods, and simulations. Analytic methods involve the
use of mathematical analysis, applying known mathematical and statistical theorems,
to investigate the theoretical effects of covariate adjustment. Simulation, specifically
Monte Carlo simulation, is the generation of large numbers of samples to approxi-
mate sampling distributions under a chosen model. I look at the use of each of these
approaches, and consider how they may be useful in further research.
4.1 Analytic methods
These methods seek to compare parameters and their estimators between an adjusted
model that incorporates a single covariate (independent of treatment arm) and an
unadjusted model that includes only a treatment effect. As described in Chapter 2,
three separate effects of covariate adjustment are of interest:
1. The difference between the unadjusted and adjusted treatment effect - asymp-
totic bias.
2. The precision of adjusted and unadjusted estimators.
3. The power of tests of no treatment effect based on either the adjusted or unad-
justed models.
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Published research has tended to apply analytic methods to each of these separately.
This is expected since the asymptotic bias is a feature of only the parameters defined
by the model. Precision, however, is a property of estimators of those parameters and
power depends on asymptotic properties of both parameters and their estimators.
4.1.1 Difference between treatment effects
Two papers [6, 7] present methods of investigating the effect of omitting a covariate
on treatment effect parameters when using GLMs. Gail et al. [6] identify conditions
where the difference between unadjusted and adjusted treatment effect parameters is
zero and give an approximation for this difference when the covariate effect is close
to zero. Neuhaus & Jewell [7] identify conditions where the asymptotic bias is zero,
but also find conditions that determine the direction of the asymptotic bias. Further,
Neuhaus & Jewell [7] give an expression for the unadjusted treatment effect parameter
in terms of the adjusted treatment effect parameter for a treatment effect parameter
close to zero.
Gail et al. [6] firstly define unadjusted and adjusted models using the conditional
expected value of the outcome variable. The authors consider method of moments
estimators for the model parameters. It follows from these that the treatment effect
parameters coincide if the treatment effect or covariate effect are zero. Gail et al. [6]
then use a second-order Taylor expansion for the unadjusted treatment effect param-
eter to find an approximation for the difference between the unadjusted and adjusted
treatment effect parameters. From this it is shown that the treatment effect parame-
ters coincide if the function linking the linear part of the model to the expected value
of the outcome is linear or exponential. Finally, the authors show that these results
hold for the equivalent GLMs using the maximum likelihood estimation equations.
The details of these methods are given in Appendix C.1.
The method of Neuhaus & Jewell [7] is referred to as a geometric approach and uses
the relationship between the expected value of the outcome in the control treatment
arm and the absolute difference between expected values of the outcome in each treat-
ment arm. Having defined the appropriate GLMs, the authors express the absolute
difference between expected value of the outcome in each treatment arm in terms
of the model parameters. In particular, they consider for the adjusted model the
difference between expected outcome in the treatment arms as a function of the ex-
pected outcome in the control treatment arm. For example, the graphs in Figure 4.1
(page 65) plot the difference between arms (∆) over the expected value in the control
treatment arm (µ0), for three values of the treatment effect parameter (β) for logit,
identity, and log link functions. Averaging this curve with respect to the distribu-
63
tion of the covariate gives a point on that (µ0,∆) plane, which is the expected value
for the outcome in the control arm and absolute difference between arms under the
unadjusted model. Using Jensen’s inequality, the authors show that the unadjusted
and adjusted treatment effect parameters coincide when there is no treatment effect
or the GLM link function is linear or log, but the adjusted treatment effect is greater
in magnitude when using a logistic link. That is, the adjusted log odds ratio will be
further from one. Finally, Neuhaus & Jewell [7] use a first-order Taylor expansion to
give an approximation for the unadjusted treatment effect parameter in terms of the
adjusted treatment effect parameter and covariate distribution. The details of these
methods are given in Appendix C.2.
There are some notable differences between these two papers. Gail et al. [6] rely on a
second order Taylor series approximation to obtain an expression for the unadjusted
treatment effect parameter in term of the adjusted treatment effect parameter. Whilst
this generates legitimate conclusions, it gives little insight into the reason for the
asymptotic bias or the direction of the bias, or to the validity of conclusions where the
Taylor series is not an appropriate approximation. The method of Neuhaus & Jewell
[7], however, does not rely on Taylor series to assess the direction of asymptotic bias
or to establish conditions in which there is no asymptotic bias. This approach gives
conclusions that are valid where the Taylor series approximation may not hold. It also
gives a more intuitive and insightful consideration of the mathematical reason for, and
direction of, an asymptotic bias between the unadjusted and adjusted treatment effect
parameters. Also note that the expression given by Gail et al. [6] for the asymptotic
bias and the expression given by Neuhaus & Jewell [7] are not directly comparable
as they are Taylor series approximations taken at different points (at covariate effect
equal to zero and treatment effect equal to zero, respectively).
For mixed effects models, Raab & Butcher [23] give an expression for the change
in estimate of treatment effect when adjusting for covariates in linear mixed effects
models. This follows from the analysis of covariance estimates of the parameters and
is given in Section 3.1.1.
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Figure 4.1: Difference between expected values of the outcome in each treatment arm,
∆, plotted against the expected value of the outcome in the control treatment arm,
µ0. For treatment effect parameters, β = 1.5, 0.5, 0.05.
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4.1.2 Precision of treatment effect estimate
Robinson & Jewell [3] investigate the effect on the precision of estimates of treatment
effect when adjusting for a binary covariate in a logistic regression model. This work
is then extended to GLMs with a binary outcome by Robinson et al. [5]. They find
conditions on the link function for which there is greater precision under the unad-
justed or adjusted models. The authors express the treatment effect parameters in
terms of conditional probabilities. Using standard likelihood theory results, the vari-
ances for treatment effect estimators are then given in terms of these probabilities
and sample sizes. Using Jensen’s inequality, Robinson et al. [5] show that if the link
function is linear or log, the adjusted model gives greater precision of the treatment
effect estimate. Also, for other link functions such as logit and probit, the adjusted
treatment effect estimator has less precision.
Raudenbush [24], Murray [16] and Raab & Butcher [23] consider the analysis of CRTs
with continuous outcome measures, analysed with a linear mixed effects model, and
give some analytic results for the precision of treatment effect estimates. They give
expressions for the variances of the unadjusted and adjusted treatment effect esti-
mates. Comparing these expressions, they conclude that reducing the residual cluster
level and individual level variances of the outcome through covariate adjustment can
improve the precision.
4.1.3 Power of test of no treatment effect
As described in Section 2.1.3, the power of tests of no treatment effect can be compared
by their asymptotic relative efficiency (ARE). This was introduced in Section 2.1.3.
Recall, we have a parameter of interest θ and we wish to test θ = θ0. We also have a
statistic T that is a consistent estimator of µT (θ), a monotone function (at least close
to θ = θ0) of θ. A definition of ARE called the Pitman efficiency of two such statistics
T1 and T2 that are asymptotically normally distributed with mean µT (θ) and variance
σ2T (θ)is given by [28]:
ARE(T1 to T2 at θ = θ0) =
[
µ′T1(θ0)
µ′T2(θ0)
]2 [
σ2T2(θ0)
σ2T1(θ0)
]
We can test the null hypothesis β = 0 by the adjusted or unadjusted Wald test
statistics
βˆ√
var(βˆ)
or
βˆ∗√
var(βˆ∗)
which have asymptotic normal distributions with means β/
√
var(βˆ) and β∗/
√
var(βˆ∗)
and variances 1.
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Four papers [3–5, 58] evaluate the ARE of tests of no treatment effect based on the
unadjusted and adjusted estimators. There is a progression from specific models to
general classes of model. Begg & Lagakos [58] consider only the logistic regression
model. Robinson & Jewell [3] consider the logistic regression model with a binary
covariate; this method is extended to GLMs with a binary outcome and covariate by
Robinson et al. [5]. The method and results of Neuhaus [4] consider all GLMs.
Robinson et al. [5] express the ARE in terms of the GLM link function and condi-
tional probabilities for the outcome variable. By the Cauchy-Schwarz and Jensen’s
inequalities, they show that the ARE of the adjusted model to the unadjusted model
is greater than or equal to one. That is, the adjusted model is more efficient and has
greater power for a test of no treatment effect. Details of this method are given in
Appendix C.4. Neuhaus [4] use expressions for the estimator variances in terms of
expected value then, by application of the Cauchy-Schwarz inequality, conclude the
same results as Robinson et al. [5] but for all GLMs. Details of this method are given
in Appendix C.5.
The Optimal Design software documentation [26] and Konstantopoulos [25] present
analytic results for the power of unadjusted and adjusted analyses of CRTs using linear
mixed effects models. The Optimal Design software documentation [26] considers
a nested ANOVA, which is equivalent to fitting a linear mixed effects model using
restricted maximum likelihood. Power can be calculated by comparing central and
non-central F distributions. Konstantopoulos [25] has an equivalent approach but in
terms of t distributions. These methods and results are summarised in Section 3.1.2.
4.1.4 Review of analytic methods
There are several strengths to the analytic methods described in this section. The
major advantage is the ability to generate absolute conclusions. Results can be found
that apply to all link functions, or to all values of parameters (such as intercept,
treatment effect, or covariate effect). Such universal conclusions allow us to confidently
use these results without fear of special cases or quirks in particular models; special
cases do of course exist, but they are uncovered by the analytic methods rather than
remaining undiscovered. Analytic methods also allow us to establish necessary and
sufficient conditions for particular results. For example, Gail et al. [6] establish that
there is no asymptotic bias if and only if the link function is linear or log. Therefore,
we can be absolutely confident that under the conditions of the given theorem there
is no asymptotic bias when using these link functions, but that for any other link
function there will be an asymptotic bias. A final advantage of analytic methods is
that they can provide insight into the mathematical workings of models and explicitly
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show the role of any assumptions. For example, the geometric approach of Neuhaus
and Jewell [7] gives some insight into the reasons for asymptotic bias under certain
models.
However, analytic methods have some limitations. Firstly, the methods described here
only consider the straightforward case of adjusting for a single covariate (or vector of
covariates). Extension of these methods to more general cases of adjusting for any
subset of a selection of covariates may not be straightforward at all. The often strong
assumptions on which these analytic methods are based also restricts this approach.
Some results of analytic methods (for example, the expression for the magnitude
of asymptotic bias) rely on approximations such as the second-order Taylor series.
Where the conditions of the approximation do not hold, such as when the parameter
is not close to zero, these results are not reliable. Further, these expressions are
only approximations when we truncate the Taylor series, rather than exact results.
Therefore, such results are quite limited and cannot be immediately generalised to all
situations. Finally, a number of results rely on asymptotic properties of estimators.
In small trials, asymptotic results may not be appropriate and so our conclusions may
not be relevant.
These disadvantages can limit the utility of analytic methods in investigating the
effects of covariate adjustment. If we wish to investigate scenarios where the approxi-
mations, asymptotic results or assumptions used in these methods are not appropriate,
then our analytical methods may well break down. For example, as noted by Neuhaus
& Jewell [7], the integration necessary to evaluate the magnitude of asymptotic bias is
often intractable, so an approximation such as the Taylor series is required. Further,
analytic methods may not be useful if we wish to investigate more complex models
such as introducing further covariates, or compare multiple models or assumptions.
Analytic methods may simply fail to give useful results when more relationships are
introduced. We may also find that the analysis diverges into multiple separate anal-
yses for each combination of relationships between variables, or set of assumptions.
While theoretically analytical results could be found, this multiplicity will not help to
give overall conclusions. Finally, if we wish to investigate a particular policy of covari-
ate adjustment rather than inclusion or exclusion of a single covariate, then analytic
methods are limited.
4.2 Simulation
Simulation studies can be used to investigate the sampling distribution of an estimator
or test statistic. In terms of the effects of covariate adjustment on asymptotic bias,
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precision and efficiency, we wish to investigate the sampling distribution of treatment
effect estimators and related test statistics. Simulation allows us to approximate sam-
pling distributions under chosen conditions (the underlying data generating model)
without requiring analytic investigation.
A simulation is carried out by:
1. Specifying the data generating model.
2. Producing independent data sets from the data generating model.
3. Calculating the estimator or test statistic of interest for each data set.
4. Calculating summary statistics of the sample of the estimator or test statistic,
to estimate true sampling distribution parameters or properties of interest.
With a large number of simulated data sets, the summary statistics are good approxi-
mations to true sampling distribution parameters. We can improve the precision with
which the true parameters are estimated by increasing the number of simulated data
sets.
In the models we are considering, the complete data generating model can be consid-
ered in three parts:
1. The model of outcome on predictor variables (that is, treatment allocation and
covariate).
2. The parameter values for that model.
3. The distribution of covariates and treatment allocation.
One of three methods is used to specify these three factors in each simulation study.
In the first, all three parts are specified analytically and then all data is generated
directly from probability distributions. For example, Negassa & Hanley [27] specify a
logistic model with parameter values. The covariate is binary with equal probability
of either value, or continuous and normally distributed. The expected value of the
outcome is fixed for the control treatment arm at the lower level of the binary covariate
(or mean of the continuous covariate). The second method is to use data from one
or more RCTs for baseline covariate, and possibly treatment allocation, information.
The model and parameter values are then chosen by the investigator, and outcome
data is produced by simulation. For example, Hernandez et al. [59] use baseline data
from seven RCTs in traumatic brain injury. Missing covariate data was imputed,
then outcome data was simulated with a chosen treatment effect. The final option is
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to sample, with replacement, all data from existing trial data, so data are simulated
without reference to a standard distribution. For example, Hernandez et al. [29]
sample with replacement from hypothetical trial data sets. The same method could
be applied to actual trial data.
In any simulation it is important to choose appropriate parameter values and variable
distributions, except where trial data is sampled. Multiple values of a parameter are
typically investigated in any one simulation study, to consider the effect the parameter
value has on outcome, if any at all. Values for parameters and variable distributions
are chosen on the basis of previous knowledge, for example from reviews or meta-
analyses of trials, from particular trials, or on the basis of wider knowledge. When
parameter values are varied, suitable values can be found in the same way. For exam-
ple, Hernandez et al. [29] consider treatment effect values across the range observed
in a published survey of thirteen cardiovascular RCTs. In addition, distributions for
covariates are typically chosen to be common and easy to generate from, so that
standard distributions in software can be used.
An important issue in the simulation studies presented in this section is quantifying
the effect of covariate adjustment. In studies investigating bias some papers give the
unadjusted estimate, which can be compared directly to the adjusted parameter value,
others give the absolute difference between unadjusted and adjusted estimates, while
some give the bias as a percentage. Precision of unadjusted and adjusted estimates is
not compared in the studies in this section. The effect on test efficiency is reported
by some giving the relative efficiency/power of the unadjusted test to the adjusted
test, or by giving only the empirical power of the unadjusted test, or in some cases
by reporting the percentage reduction in required sample size when adjusting for the
covariate.
4.2.1 Simulations used to investigate the effects of covariate
adjustment
A number of papers have used simulation to investigate and quantify the effects of
covariate adjustment on treatment effect, precision and power in GLMs. As an ex-
ample, consider one simulation study of Negassa & Hanley [27]. Data was generated
from the logistic regression model
logit[pr(Y = 1)] = α+ βX + γZ
where Y is a binary outcome variable, X is a binary treatment variable and Z is a
binary covariate. The parameters were chosen to give treatment effect with odds ratio
of 2.0, covariate effect with odds ratio of 2.0, and pr(Y = 1|Z = 0) = 0.4. It was
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also assumed that pr(Z = 1) = pr(Z = 0) = 0.5 and sample size was 500. Analyses
of 10,000 simulated data sets were carried out under the assumptions of the adjusted
model above, and the unadjusted model omitting the covariate Z:
logit[pr(Y = 1)] = α∗ + β∗X .
The simulation estimate of relative asymptotic bias was then calculated by
| ˜ˆβ∗ − ˜ˆβ|
˜ˆ
β
where
˜ˆ
β∗ is the median of the 10,000 estimated unadjusted treatment effect parameters
βˆ∗. And ˜ˆβ is the median of the 10,000 estimated adjusted treatment effect parameters
βˆ. The simulation estimate of power under either the adjusted or unadjusted model
was given by the proportion of simulated data sets that show a significant (at 5%
level) treatment effect.
Five papers have included simulation studies to investigate the effect of covariate ad-
justment on asymptotic bias [6, 7, 27] and test efficiency [27, 29, 59] in GLMs. Gail
et al. [6] simulate the asymptotic bias for a trial with 100 patients. Outcome data
is simulated and analysed for six models. A binary covariate is used with two distri-
butions (one symmetric). Three different treatment effects are considered. Neuhaus
& Jewell [7] consider asymptotic bias in GLMs with logistic, complementary log-log,
and probit link functions. Data for two independent covariates is generated from a
bivariate normal distribution, so this is not strictly a simulation of trial data as one
of these continuous covariates is taking the role of treatment arm. Each data set con-
tains 500 observations. The simulation studies are repeated with 100 observations and
gamma distributed covariates, but results are not given. Neuhaus & Jewell [7] report
the observed unadjusted treatment effect, which can be compared to the unadjusted
treatment parameter. Two values for the effect of the omitted covariate are considered.
Negassa & Hanley [27] report relative asymptotic bias and power for a logistic regres-
sion model. The treatment effect parameter was fixed throughout (OR=2.0) while the
covariate effect was varied (OR between 2.0 and 10.0). Both a binary (with symmetric
distribution) and continuous (normally distributed with mean zero and variances 1.0
and 5.0) covariate are considered. Sample sizes of 500 and 1000 are used. Results are
reported as line graphs of percentage asymptotic bias or power against covariate effect.
Hernandez et al. [29] consider efficiency for a logistic regression model with a binary
covariate. Data is generated by sampling with replacement from hypothetical trial
data sets of 360 patients. Four values for covariate effect are considered (unadjusted
OR=1, 2, 5 and 10) and three values of treatment effect (unadjusted OR=1, 1.4, and
1.7). Outcome incidence and covariate prevalence are also varied with sample size
increased for small values of both, to prevent zeroes in denominators on odds ratios.
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The power of adjusted and unadjusted tests, and percentage reduction in required
sample size when adjusting, are reported for each simulation. Hernandez et al. [59]
consider test efficiency for a logistic regression model. Baseline data is taken from
seven large trials in traumatic brain injury, and outcome data is simulated using a
full model containing seven covariates. Unadjusted analysis (no covariates included)
is compared to three adjusted analyses: the first including a single continuous co-
variate, the second including two more covariates, and the last being the full model.
Results are reported as the percentage reduction in required sample size compared to
the unadjusted analysis.
Simulations have also been used in investigations of the effects of covariate adjustment
in the analysis of CRTs. Nixon & Thompson [50] investigate the effect on the precision
of treatment effect estimates when adjusting for baseline in the analysis of repeated
cross-sectional CRTs with binary outcomes. Austin [51] investigates the power of
methods of adjusting for baseline in the analysis of repeated cross-sectional CRTs
with binary outcomes. Austin [51] applies a total of nine models to simulated trial
data. Two simulation studies [54, 55] have been carried out to investigate the effects
of incorporating separate individual and cluster level covariate effects in the analysis
of CRTs with linear mixed effects models.
4.2.2 Review of simulation methods
Using simulation studies to investigate the effects of covariate adjustment in RCTs
addresses some of the limitations of a purely analytic approach. Conclusions from
simulation studies are not asymptotic results, and do not require particular approxi-
mations. When performing simulation studies, it is straightforward to vary parameter
values, covariate distributions and investigate a variety of effects. It is also easier to
investigate more complex covariate situations, different algorithms for choosing co-
variates, and different analysis methods. Simulation studies also quantify the effects
being investigated, which can be reported in a variety of useful ways (for example,
percentage sample size reduction). The precision of the results provided by simulation
depends on the sample size, or number of repetitions, of the simulation. The precision
of results can be increased by increasing the simulation sample size.
Simulation methods do have some weaknesses. Firstly, a number of features, namely
the model, parameter values, covariate distributions, and sample sizes, must be spec-
ified to generate simulated data. This may be done implicitly by choosing trial data
from which to sample. Conclusions are dependent on these choices and so are not
easily generalisable. No absolute conclusions, or conditions, are found as in some an-
alytic methods. Practically, simulation studies may also be costly to run in terms of
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computation and time. Increasing the number of factors that are varied (for example,
parameter values or distributions of variables) increases the number of separate sim-
ulations to be run. Improving the precision of results also requires large increases in
the number of simulation iterations to be run, increasing the time required.
4.3 Conclusion
Both analytic and simulation methods have been used to investigate the effects of
covariate adjustment in the analysis of individually randomised and cluster randomised
trials. Different analytic methods are used for considering each effect (asymptotic bias,
precision, test efficiency) and models, whereas simulation provides a unified approach
to investigating and quantifying effects. The advantages of an analytic approach lie
in the ability to prove absolute conclusions and theorems, but are limited by relying
on asymptotic results and specific assumptions. Simulation studies can be used where
analytic approaches are unsuitable, and are a more flexible and practical method for
quantifying the effects of covariate adjustment.
Analytic and simulation methods will both be useful in extending the investigation of
the effects of covariate adjustment in the analysis of CRTs. Simulation in particular
provides a powerful tool to investigate the behaviour of mixed effects models under a
variety of assumptions and conditions.
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Chapter 5
Review of the use of covariates
in cluster randomised trials
The aim of this thesis is to provide practical guidance for choosing covariates in the
analysis of CRTs, so a consideration of current practice in adjusted analyses and
choosing covariates in CRTs is important. In this chapter I present some results from
a review of the use of covariates in CRTs using a sample of published reports.
The work reported in this chapter is part of a comprehensive review of the use of
covariates in the design, analysis, and reporting of CRTs [60]. This was carried out
in collaboration with Noah Ivers, Sandra Eldridge, Monica Taljaard, and Stephen
Bremner. The Accepted Author Manuscript of the paper can be found in Appendix
F.
5.1 Aims
The aims of the review included assessing adherence to guidance for the use of co-
variates in randomisation, reporting, and analysis of CRTs. In this chapter I focus
only on results pertaining to the use of covariates in analysis. In particular, I wish to
address the following aims:
1. To assess the prevalence of adjusted analyses reported for CRTs.
2. To investigate the use of cluster level and individual level covariates in adjusted
analyses.
3. To assess adherence to existing guidelines for choosing covariates.
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4. To identify if justification is provided for the choice of covariates.
Previous reviews of the use of covariates have excluded CRTs [9, 11, 12, 37, 61]. A
review of CRTs in primary care [62] described the use of matching or stratification,
and reporting of baseline covariates.
5.2 Methods of the review
Two researchers (Neil Wright and Noah Ivers) independently reviewed all papers. Dis-
crepancies were resolved by discussion. A sample of 15 papers were selected and used
in a pilot. Following this, questions were updated to clarify meaning and terminology.
Only analyses of the primary outcome were considered. To be considered, an analysis
had to include a comparison between treatment arms, by reporting a treatment effect
estimate and standard error or confidence interval, or a P-value. In each CRT report,
only the most emphasised or the first reported adjusted analysis (excluding adjusting
for baseline measure of outcome or covariates used in randomisation) was used for the
purposes of this review. Any method for selecting covariates that used data from the
trial under analysis (for example, baseline balance or covariate selection algorithms)
is a post hoc method.
5.3 Sample of published trial reports used in the review
The sample of 300 CRTs was identified using a published electronic search strategy [63]
implemented in Medline. The sample was previously used by Ivers et al. [64] to review
the impact of the CONSORT extension to CRTs [65] on the reporting and methodology
of CRTs. The following search strategy was used in MEDLINE (reproduced from [64]):
1. randomized controlled trial.pt.
2. animals/
3. humans/
4. 2 NOT (2 AND 3)
5. 1 NOT 4
6. cluster$ adj2 randomi$.tw.
7. ((communit$ adj2 intervention$) OR (communit$ adj2 randomi$)).tw.
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8. group$ randomi$.tw.
9. 6 OR 7 OR 8
10. intervention?.tw.
11. cluster analysis/
12. health promotion/
13. program evaluation/
14. health education/
15. 10 OR 11 OR 12 OR 13 OR 14
16. 9 OR 15
17. 16 AND 5
Titles and abstracts were screened in a random order until the target sample size of
300 was reached. Only main reports of CRTs were included. Pilot and feasibility
studies, protocols, conference proceedings, and secondary analyses were excluded [64].
The sample includes reports of CRTs published between 2000 and 2008 across 150 En-
glish language journals. The journals include general medical journals (for example:
the New England Journal of Medicine (NEJM), the Journal of the American Medical
Association (JAMA), The Lancet, and the British Medical Journal (BMJ)), and vari-
ous specialty journals (for example: the British Journal of Psychiatry, Diabetes Care,
the International Journal of Cancer, and the Journal of Nutrition).
5.4 Use of adjusted analyses
Out of 300 trial reports, 219 (73.0%) included at least one adjusted analysis of the
primary outcome. Of 207 trial reports that reported a baseline measure of the primary
outcome, 155 (74.9%) included an analysis adjusting for a baseline measure of the
outcome. Of 174 trials that used covariates in randomisation, 30 (17.2%) included an
analysis adjusting for all covariates used in randomisation.
There were 140 (46.7%) trials that included an analysis adjusting for covariates other
than baseline measure of outcome or covariates used in randomisation. In 50 reports
published in journals with impact factor (from journal citation reports, ISI Web of
Science, 2009) greater than 10, 22 (44%) included an analysis adjusting for other
covariates, and 118 (47%) out of 250 published in other journals.
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The proportion of trial reports including an analysis adjusting for other covariates by
number of clusters in each treatment arm is given in Table 5.1. The three subgroups
were formed by the lower quartile, upper quartile, and middle half of trials. Seven
trials are not included as the number of clusters was not reported. The proportion of
trial reports including an analysis adjusting for other covariates by overall trial sample
size is given in Table 5.2 (page 77).
Clusters in each treatment arm Number of trials / Relevant trials (%)
Fewer than 5 33/75 (44%)
5-22 71/147 (48%)
Greater than 22 33/71 (46%)
Table 5.1: Proportion of CRT reports that included an analysis adjusting for covari-
ates other than baseline measure of outcome or covariates used in randomisation, by
number of clusters.
Overall trial sample size Number of trials / Relevant trials (%)
Fewer than 100 individuals 13/47 (28%)
101-200 26/54 (48%)
201-300 19/29 (66%)
301-400 10/22 (45%)
401-500 6/19 (32%)
501-600 7/13 (54%)
601-700 5/10 (50%)
701-800 6/10 (60%)
801-900 3/7 (43%)
901-1000 3/7 (43%)
Greater than 1000 individuals 36/67 (54%)
Table 5.2: Proportion of CRT reports that included an analysis adjusting for covariates
other than baseline measure of outcome or covariates used in randomisation, by total
number of individuals in the CRT.
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5.5 Choice of covariates in adjusted analyses
Out of 219 trial reports that included an adjusted analysis, in 93 (42.4%) reports
authors did not describe when covariates had been chosen. In 71 (32.4%) reports
covariates were reportedly chosen a priori, but in 55 (25.1%) reports some or all
covariates were reported to be chosen post hoc. In 73 (33.3%) trial reports, authors
gave some justification for the choice of covariates.
One hundred and forty trial reports included an analysis adjusting for covariates other
than baseline measure of outcome or covariates used in randomisation. Of these, 7
(5.0%) included only cluster level covariates, while 100 (71.4%) adjusted for only
individual level covariates. In 29 (20.7%) analyses both cluster and individual level
covariates were included. In four (2.9%) of the trials it was unclear which level of
covariates had been included.
When included, the number of cluster level covariates ranged from 1 to 8, with a me-
dian of 1. Likewise, the number of individual level covariates included in an adjusted
analysis ranged from 1 to 28, with a median of 3. The distribution of cluster level and
individual level covariates is shown in Figure 5.1 (page 79).
In trials with fewer than five clusters in each treatment arm, the number of individual
level covariates adjusted for ranged from 1 to 14. The range was 1 to 11 covariates
for trials with 5 to 22 clusters per arm and for trials with more than 22 clusters per
arm. The median and range of the number of individual level covariates adjusted for
is given for the total number of individuals in the trial in Table 5.3 (page 80), and a
scatter plot is given in Figure 5.2 (page 79) for trial sample sizes up to 1000.
Two trials with fewer than five clusters in each treatment arm included adjusted for
one and two cluster level covariates. In nineteen trials with 5 to 22 clusters per arm,
the maximum number of cluster level covariates adjusted for was 5. In trials with
greater than 22 clusters per arm, up to 8 cluster level covariates were adjusted for.
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Figure 5.1: Distributions of number of cluster level and individual level covariates
included in adjusted analyses.
Figure 5.2: Number of individual level covariates included in adjusted analyses against
overall trial sample size (excluding trials with sample size greater than 1000).
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Overall trial sample size Number of individual level covariates
Median (min,max)
Fewer than 100 2.5 (2, 14)
101-200 2 (1, 7)
201-300 3 (1, 10)
301-400 4 (1, 10)
401-500 5.5 (2, 11)
501-600 5 (1, 9)
601-700 5 (2, 11)
701-800 2.5 (1, 7)
801-900 3 (3, 7)
901-1000 2 (1, 5)
Greater than 1000 4.5 (2, 28)
Table 5.3: Median (range) of number of individual level covariates (when non-zero)
included in adjusted analyses, by total number of individuals in the trial.
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5.6 Conclusion
Adjusted analyses are common in reports of CRTs. Further, adjusting for covariates
other than baseline measure of outcome and covariates used in randomisation is pre-
sented in almost half of the trial reports in the sample. This compares to 34% of trials
in the review by Austin et al. [37] which excluded CRTs. This covariate adjustment
is observed in CRTs of all sizes and in high impact and other journals. There may
be less use of such adjusted analyses in the very smallest trials. The prevalence of
adjusted analyses, especially those using covariates other than a baseline measure of
outcome, highlights a need for guidance in choosing covariates in CRTs.
Authors of three-quarters of trials reporting a baseline measure of outcome subse-
quently adjust for it, following recommendations. However, less than one fifth adjust
for all covariates used in randomisation. This defies guidance presented in Chapter 2
on adjusting for covariates used in randomisation and can undermine the validity of
conclusions.
Adjusting for individual level covariates is more common than adjusting for cluster
level covariates. In the smallest trials, fewer individual level covariates are typically
adjusted for. Note that we only consider the level at which the covariate is measured,
not necessarily the level at which it was included in a model (for example, individual
level covariates may have been aggregated at cluster level). The potential utility of
adjusting for covariates at each level needs further investigation.
It is often not reported when it was that covariates adjusted for in an analysis were
chosen. This prevents readers from assessing the validity of covariate selection and
analysis methods. Although this occurs less than in the individually randomised trials
included in reviews by Austin et al. [37] and Yu et al. [11]. When this is reported, many
covariates are stated to have been chosen post hoc. This is inappropriate in a primary
analysis of a trial [13,23]. Guidance for choosing covariates in CRTs should emphasise
the importance of choosing covariates a priori, just as for individually randomised
trials.
In this chapter, I have investigated the use of adjusted analyses and choice of covariates
in a wide sample of published CRT reports. With a large proportion of CRTs including
adjusted analyses there is a demand for further guidance on choosing covariates in
CRTs. Additionally, there is a need for emphasis of following existing guidance for
choosing covariates in both individually randomised trials and CRTs.
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Chapter 6
Exploration of empirical trial
data
In this chapter I present analyses of data sets from two CRTs: the OPERA [66, 67]
and FIAT [68, 69] trials. Analyses of data from these example CRTs will allow me
to demonstrate known effects of covariate adjustment, and help to identify areas for
further investigation. The results will be used to inform the design of simulation
studies. The aims of these analyses are:
1. To demonstrate the effects of covariate adjustment on estimated standard error
of treatment effect estimates, and estimates of residual variance.
2. To identify hypotheses to be further investigated through analytic work and
simulations, with respect to the effects of covariate adjustment in the analysis
of CRTs.
3. To provide parameter values and bounds for the simulations of CRT data.
I present estimated ICCs for outcome variables and covariates. I compare results
between unadjusted analyses, and analyses adjusting for covariates or covariates ag-
gregated at cluster level. I also compare results between models including a single
covariate effect parameter and models with separate within-cluster and contextual
covariate effect parameter. In Sections 6.1 and 6.2 I explain the methods used in the
analyses and introduce the two data sets. In Section 6.3 I then present results and
identify areas for further investigation.
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6.1 Methods
6.1.1 Estimating ICCs of outcome variables and covariates
I estimated ICCs for all outcome variables and covariates, giving separate estimates
of the ICC for each treatment arm. For this, I used a user-written (by Dr. Obioha
Ukoumunne) adaptation of the loneway command in Stata which allows negative ICCs
to be estimated. For continuous variables, I also estimated the ICC by fitting linear
mixed effects models using restricted maximum likelihood estimation. The variance
estimates given by the model were then used to calculate the estimated ICC. Therefore,
this estimate of ICC must be non-negative. The linear mixed effects models included
a term for treatment arm, so that a single ICC is estimated for both treatment arms.
For binary variables, I estimated the ICC from a logistic mixed effects model fitted
using maximum likelihood estimation. For binary variables, the ICC on the log odds
scale can be defined by [20]
ρl =
τ2
τ2 + pi2/3
where τ2 is the cluster level variance. The individual level variance is given by the
variance of the logistic distribution, and does not depend on the cluster prevalence.
This definition of the ICC assumes that the binary variable is a dichotomisation of
some underlying continuous variable. This assumption may not be suitable for many
types of binary variable, such as sex or ethnicity. I estimated the ICC of binary
variables using this formula, including the cluster level variance estimate from a logistic
mixed effects model. The ICC on the log odds scale is not directly comparable with
the ICC on the linear scale. Corresponding ICCs depend on the overall prevalence;
some comparison values are given by Eldridge et al. [20]. For binary variables, it is
not possible to define an (common across clusters) ICC on the linear scale when using
a hierarchical model in the presence of a covariate (such as treatment arm) [20].
6.1.2 Effects of covariate adjustment
I compared standard errors and residual variances between models that exclude and
include a single covariate. Linear mixed effects models were used when the outcome
variable was continuous, logistic mixed effects models when it was binary, and Poisson
mixed effects models for count outcomes. The proportion reduction in estimated
standard error of the treatment effect estimate (SE) was calculated as
Proportion reduction of SE =
Unadjusted SE−Adjusted SE
Unadjusted SE
= 1− Adjusted SE
Unadjusted SE
.
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6.1.3 Effects of separate within-cluster and contextual covariate
effect parameters
I compared estimates of treatment effect, standard error, variance, and covariate ef-
fects between models that use a single parameter for covariate effect, and models that
use two parameters for covariate effect. Using this type of model in the analysis of
CRTs was introduced in Chapter 3. Instead of a single covariate effect γ, the linear
predictor of the model includes two covariate effects: γW is the within-cluster coeffi-
cient of the covariate effect; and γC is the contextual covariate effect. For example,
the linear mixed effects model incorporating two parameters for the covariate effect is
Yij = α+ βXj + γW (Zij − Z¯j) + γCZ¯j + uj + eij
where Yij is the outcome for patient i in cluster j, Xj indicates treatment arm for
cluster j, and uj and eij are random effects (uj ∼ N(0, τ2), eij ∼ N(0, σ2)). Z¯j is
the cluster mean of the covariate for cluster j. Models using a single covariate effect
parameter assume that the within-cluster and contextual covariate effect parameters
are equal (γW = γC).
6.2 Introduction of data sets
6.2.1 The OPERA data set
6.2.1.1 The OPERA trial
The OPERA trial [66, 67] was a CRT investigating the effectiveness of exercise in
reducing depression in residents of care homes. The clusters of the individuals in
the trial were residential care homes. The original trial analysis had three co-primary
outcomes defined for three populations: number of depressive symptoms at 12 months
in individuals recruited before randomisation; number of depressive symptoms at six
months in those depressed at baseline; and prevalence of depression in all residents
present at 12 months. Randomisation was stratified by location, and minimised by
type of home and size of home. The allocation ratio was planned to be 1 to 1.5.
Seventy-eight clusters were randomised, 35 to the intervention arm and 43 to the
control arm, with a total of 2,078 eligible residents. 891 residents had usable data at
randomisation and 679 residents were present at 12 months follow-up.
The original analysis of the number of depressive symptoms at 12 months used a linear
mixed effects model. Analysis was adjusted for covariates used in randomisation and
the proportion of residents with moderate to severe cognitive impairment in the home
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at baseline (a cluster level covariate), sex, age at the endpoint, on antidepressants
at baseline, Short Physical Performance Battery (SPPB) at baseline, and baseline
measure of outcome. The analysis of number of depressive symptoms at six months in
those depressed at baseline used a linear mixed effects model, with the same covariates.
The analysis of prevalence of depression in all residents present at 12 months used a
logistic mixed effects model. The same covariates were included for this analysis,
except the baseline measure of outcome was the proportion of residents in the cluster
who were depressed at baseline.
6.2.1.2 OPERA Analysis population
The population I used for investigation was all individuals present at 12 months and
with data for depression status at 12 months, however in each analysis the population
may be reduced due to missing data on outcome or covariates. This data set includes
595 individuals in 78 clusters. Cluster size ranges from one to 17.
6.2.1.3 OPERA Outcome variables
In my analysis, I considered two continuous individual level outcome variables, plus
dichotomised versions of these outcome to give two binary outcome variables. The
first continuous outcome is an individual’s score on the Geriatric Depression Scale
(GDS score). This outcome is dichotomised to give the binary covariate depression
status. Generally, a GDS score of 5 or greater is indicative of depression. This binary
variable is also used in the original trial analyses.
The second continuous outcome is an individual’s score on the Mini Mental State
Examination, which I call the cognitive function score or CF score. This outcome is
dichotomised to give the binary variable normal cognitive function. A CF score of
25 or greater is considered normal cognitive function. These outcome variables are
summarised in Table 6.1 (page 86).
6.2.1.4 OPERA Covariates
Four types of covariates were investigated in this analysis: outcome variables mea-
sured at baseline; cluster level covariates used in randomisation; other cluster level
covariates; and other individual level covariates. The covariates are summarised in
Table 6.2 (page 86). Age at baseline was used as a covariate in the analysis presented
in this chapter, although the original analysis of the trial used age at endpoint.
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Outcome variable Type Notes
GDS score Continuous 0[best] - 15[worst]
Cognitive function score (CF score) Continuous 0[worst] - 30[best]
Depression status Binary GDS score ≥ 5
Normal cognitive function Binary CF score ≥ 25
Table 6.1: OPERA data set outcome variables.
Covariate Type Notes
Outcome variables measured at baseline:
GDS score at baseline Continuous 0[best] - 15[worst]
Cognitive function score at baseline Continuous 0[worst] - 30[best]
Depression status at baseline Binary GDS score ≥ 5
Normal cognitive function at baseline Binary CF score ≥ 25
Cluster level covariates used in randomisation:
Location of home Binary
Size of home (> 32 beds) Binary
Other cluster level covariates:
Proportion depressed in home pre randomisation Continuous
Mean CF score in home pre randomisation Continuous
Other individual level covariates:
Age at baseline Continuous
Sex Binary
Table 6.2: OPERA data set covariates.
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6.2.2 The FIAT data set
6.2.2.1 The FIAT trial
The FIAT trial [68,69] was a CRT investigating the effectiveness of financial incentives
to improve adherence to anti-psychotic depot medication over a one year intervention
period. The clusters in the trial were mental health teams operating in the community,
with their patients being the individuals in the trial population. The primary outcome
of the trial was adherence level, defined as the percentage of depots administered out of
the total number scheduled. Secondary outcomes included clinical improvements and
the number of hospital admissions. Randomisation was stratified by the deprivation
level of the area in which the health teams operated (categorised as either high or low,
and based on data from the mental illness needs index score). Seventy-three clusters
were randomised, with a total of 141 patients.
The analysis of the primary outcome used a linear mixed effects model, with a ran-
dom effect for health teams. Data were used from all patients who had at least four
months of complete data during the baseline and follow-up periods. The original pri-
mary analysis adjusted for MINI (Mental Illness Needs Index) score, average number
of weeks between depots according to treatment cycle, and baseline measure of the
outcome variable. Data from 123 patients, in 62 clusters were included in the primary
analysis of the trial.
6.2.2.2 FIAT Analysis population
The population used in my analysis was all patients randomised, however in each
analysis the population may be reduced due to missing data on outcome or covariates.
The full data set includes 141 individuals in 73 clusters. Cluster size ranges from one
to seven. Thirty five clusters contain only one individual, and twenty two contain two
individuals.
6.2.2.3 FIAT Outcome variables
In my analysis I considered seven outcome variables, of which four are continuous, one
is binary, and two are count data. Adherence (the percentage of depots administered
out of the total number scheduled) is a continuous variable, which is dichotomised to
give a binary covariate achieved at least 95% adherence. Slippage is the percentage of
the prescribed time interval that expired before the depot is taken, and is bounded at
0 and 100 percent. The mean slippage during the intervention period is a continuous
87
outcome variable. Clinical improvement is measured by the Clinical Global Impression
Scale, giving continuous outcome CGI score. Quality of life is rated by the DIALOG
scale, giving the outcome quality of life. The number of psychiatric hospital admis-
sions and the number of involuntary hospital admissions are the two count outcome
variables. These outcome variables are summarised in Table 6.3 (page 89).
6.2.2.4 FIAT Covariates
Four types of covariates were included in my analysis: outcome variables measured at
baseline; the (binary) cluster level covariate used to stratify randomisation; and other
individual level covariates. These include continuous, binary, categorical, and count
data types. The covariates are summarised in Table 6.4 (page 89).
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Outcome variable Type Notes
Adherence Continuous Percentage of pre-
scribed depots ad-
ministered
Achieved at least 95% adherence Binary Adherence ≥ 95%
Slippage Continuous
CGI score Continuous
Quality of life Continuous
Number of psychiatric hospital admissions Count
Number of involuntary hospital admissions Count
Table 6.3: FIAT data set outcome variables.
Covariate Type Notes
Outcome variables measured at baseline:
Adherence Continuous Percentage of depots
administered
Achieved at least 95% adherence Binary Adherence ≥ 95%
Slippage Continuous
Quality of life Continuous
Number of psychiatric hospital admissions Count
Number of involuntary hospital admissions Count
Cluster level covariate used in randomisation:
MINI score category Binary
Other individual level covariates:
Age Continuous
Years of formal education Continuous
Number of years since illness diagnosed Continuous
Average treatment cycle during baseline Continuous
Sex Binary
Has children Binary
Table 6.4: FIAT data set covariates.
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6.3 Results
In this section, I firstly present estimated ICCs of the variables in each data set,
and then compare results of unadjusted analyses and analyses adjusting for single
covariates. Comparison of results using a single or separate covariate effect parameters
are at the end of this section.
6.3.1 Estimated ICCs of outcome variables and covariates
The number of observations and estimated ICCs for outcome variables are given in
Table 6.5 (page 91) for the OPERA data set, and Table 6.7 (page 92) for the FIAT
data set.
In OPERA, GDS score outcome has an estimated ICC very close to zero. The estimate
ICC for cognitive function score outcome is heterogeneous between treatment arms,
with an estimated common ICC close to 0.05. Normal cognitive function appears to
have quite different ICCs in each treatment arm, however there is a large amount of
uncertainty in such estimates of ICCs.
In FIAT, the ANOVA ICC estimates for adherence and achieved at least 95% adherence
show heterogeneity between treatment arms. Where a common ICC is assumed, the
estimated ICC is large for adherence. There is also a difference between estimated
ICCs in each treatment arm for slippage, and when a common ICC is assumed it is
estimated to be very close to zero.
Estimated ICCs for covariates in the OPERA data set are given in Table 6.6 (page
91), and for the FIAT data set in Table 6.8 (page 93). ICC estimates range from close
to zero, to large ICCs (∼ 0.5). In the OPERA data set, some covariates show a high
degree of heterogeneity of ICC between treatment arms. In the FIAT data set most
covariates have similar estimated ICCs between arms
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Outcome variable Number of observations Estimated ICC (ANOVA) Estimated ICC (model)
in experimental arm in control arm
GDS score 595 −0.0249 0.0049 <0.0001
Cognitive function (CF) score 549 0.0906 0.0258 0.0544
Depression status (binary) 595 −0.0050 0.0322 0.0152†
Normal cognitive function (binary) 549 0.1067 0.0192 0.1193†
Table 6.5: Estimated ICCs of outcome variables in the OPERA data set. From random effects ANOVA for each treatment arm, and from mixed
effects model assuming common ICC across arms. († ICC estimated from logistic mixed effects model is on logistic scale.)
Covariate Number of observations Estimated ICC (ANOVA) Estimated ICC (model)
in experimental arm in control arm
Outcomes measured at baseline:
GDS Score at baseline 585 0.0865 −0.0567 0.0221
Cognitive function score at baseline 571 0.0696 0.0522 0.0561
Depression status at baseline (binary) 585 0.1105 −0.0570 0.0374†
Normal cognitive function at baseline (binary) 571 0.0148 −0.0013 0.0139†
Other individual level covariates:
Age at baseline 593 0.1231 0.1715 0.1527
Sex (binary) 595 0.0733 0.0065 0.0378†
Table 6.6: Estimated ICCs of covariates in the OPERA data set. From random effects ANOVA for each treatment arm, and from mixed effects
model assuming common ICC across arms. († ICC estimated from logistic mixed effects model is on logistic scale.)
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Outcome variable Number of observations Estimated ICC (ANOVA) Estimated ICC (model)
in experimental arm in control arm
Adherence 131 −0.0819 0.5975 0.3463
Achieved at least 95% adherence (binary) 131 −0.0401 0.6183 0.0479†
Slippage (mean during intervention) 131 0.1490 −0.0399 <0.0001
Quality of Life 88 −0.0200 −0.0803 <0.0001
CGI score 107 0.3077 0.3409 0.2771
Number of hospital admissions (psychiatric) 138 0.3026 0.2644 0.0739
Number of hospital admissions (involuntary) 141 0.6202 0.2712 0.5203
Table 6.7: Estimated ICCs of outcome variables in FIAT data set. From random effects ANOVA for each treatment arm, and from mixed effects
model assuming common ICC across arms. († ICC estimated from logistic mixed effects model is on logistic scale.)
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Covariate Number of observations Estimated ICC (ANOVA) Estimated ICC (model)
in experimental arm in control arm
Outcomes measured at baseline:
Adherence at baseline 127 0.1299 0.1916 0.1455
Achieved at least 95% adherence at baseline (binary) 127 −0.0112 −0.2012 0.1943†
Slippage (mean during baseline) 127 −0.0226 −0.0184 <0.0001
Quality of Life at baseline 85 0.1045 0.4409 0.2970
Number of hospital admissions (psychiatric) at baseline 138 0.2963 0.8109 0.5271
Number of hospital admissions (involuntary) at baseline 138 0.7366 −0.4266 0.4698
Individual level covariates:
Age 141 0.1655 0.1537 0.1309
Years of formal education 112 0.1000 0.2054 0.1862
Number of years since illness diagnosed 127 0.3936 −0.0548 0.1805
Average treatment cycle during baseline 127 0.0071 −0.3439 0.0170
Sex (binary) 141 −0.2397 −0.0651 <0.0001†
Has children (binary) 138 0.1482 0.2723 0.2378†
Table 6.8: Estimated ICCs of covariates in FIAT data set. From random effects ANOVA for each treatment arm, and from mixed effects model
assuming common ICC across arms. († ICC estimated from logistic mixed effects model is on logistic scale.)
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6.3.2 Effects of covariate adjustment on the estimated standard
error of treatment effect estimates
6.3.2.1 Continuous outcome variables with very small ICCs
Table 6.9 (page 95) presents estimated standard errors and variances for unadjusted
and adjusted analyses of GDS score (OPERA), which has an estimated ICC very close
to zero. Adjusting for baseline measure of outcome shows the largest reduction (24%)
in estimated standard error of the treatment effect estimate. This is accompanied
by a reduction in the estimated individual level variance, but an increase in the esti-
mated cluster level variance of the outcome. An increase in cluster level variance is
unexpected, however this may be explained by the nature of fitting a mixed effects
model. The estimated unadjusted cluster level variance is very close to zero (estimate
less than 0.00005) and these variances are constrained to be non-negative. The in-
crease then may be an artefact of fitting a model with a particularly small cluster
level variance.
Adjusting for depression status at baseline (a dichotomised baseline measure of out-
come) reduces the estimated standard error of the treatment effect estimate by 17%.
When either of these covariates is cluster aggregated, the reduction in standard error
when adjusting is much smaller (and further reduced when using a log odds summary
of depression status).
Other covariates do not have a marked effect on the estimated standard error of the
treatment effect estimate or on the estimated variances of the outcome, except the
covariate sex when aggregated at cluster level by log odds. Here, there is an increase in
the estimated individual level variance of the outcome and an increase in the standard
error of the estimated treatment effect of 8%.
Table 6.10 (page 97) summarises the effects of adjusting for single covariates in an
analysis of quality of life (FIAT), which has estimated ICC very close to zero. Ad-
justing for a baseline measure of outcome reduces the standard error of the treatment
effect estimate by eighty percent, which is not achieved when adjusting for this co-
variate summarised at cluster level (two percent reduction). Adjusting for psychiatric
hospital admissions at baseline reduces the standard error by almost five percent;
when the covariate is summarised at cluster level, the reduction in standard error is
almost four percent.
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Cluster level Individual level
SE of effect estimate Proportion variance of outcome variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted Unadjusted Adjusted
GDS score at baseline 585 0.2756 0.2099 0.2386 <0.0001 0.0120 11.0940 6.3220
→ Cluster aggregated 585 0.2756 0.2707 0.0177 <0.0001 <0.0001 11.0940 10.6764
Depression status at baseline 585 0.2756 0.2286 0.1706 <0.0001 <0.0001 11.0940 7.6314
→ Cluster aggregated (proportion) 585 0.2756 0.2716 0.0146 <0.0001 <0.0001 11.0940 10.7676
→ Cluster aggregated (log odds) 585 0.2756 0.2743 0.0048 <0.0001 <0.0001 11.0940 10.7778
Centre 595 0.2733 0.2773 −0.0147 <0.0001 <0.0001 11.0972 11.0635
Size 595 0.2733 0.2732 0.0003 <0.0001 <0.0001 11.0972 11.0891
Proportion depressed in home at baseline 595 0.2733 0.2709 0.0085 <0.0001 <0.0001 11.0972 10.8797
Continued on next page.
Table 6.9: Example of the effects of adjusting for a single covariate in a linear mixed effects model, using OPERA data set. Outcome variable is
GDS score. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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Cluster level Individual level
SE of effect estimate Proportion variance of outcome variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted Unadjusted Adjusted
Mean CF score in home at baseline 595 0.2733 0.2755 −0.0082 <0.0001 <0.0001 11.0972 11.0826
Age 593 0.2731 0.2731 0.0002 <0.0001 <0.0001 11.0501 11.0437
→ Cluster aggregated (mean) 593 0.2731 0.2726 0.0020 <0.0001 <0.0001 11.0501 10.9954
Sex 595 0.2733 0.2733 <0.0001 <0.0001 <0.0001 11.0972 11.0810
→ Cluster aggregated (proportion) 595 0.2733 0.2745 −0.0043 <0.0001 <0.0001 11.0972 11.0968
→ Cluster aggregated (log odds) 595 0.2733 0.2960 −0.0832 <0.0001 <0.0001 11.0972 11.1703
Table 6.9: Example of the effects of adjusting for a single covariate in a linear mixed effects model, using OPERA data set. Outcome variable is
GDS score. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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Cluster level Individual level
SE of effect estimate Proportion variance of outcome variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted Unadjusted Adjusted
Quality of Life at baseline 60 0.2413 0.2214 0.0827 <0.0001 <0.0001 0.8116 0.6158
→ Cluster aggregated (mean) 60 0.2413 0.2367 0.0191 <0.0001 <0.0001 0.8116 0.6793
Age 88 0.1906 0.1933 −0.0142 <0.0001 <0.0001 0.7397 0.7386
→ Cluster aggregated (mean) 88 0.1906 0.1941 −0.0187 <0.0001 <0.0001 0.7397 0.7347
Achieved 95% adherence 84 0.1861 0.1825 0.0189 <0.0001 <0.0001 0.6676 0.6426
→ Cluster aggregated (proportion) 84 0.1861 0.1859 0.0008 <0.0001 <0.0001 0.6676 0.6664
→ Cluster aggregated (log odds) 8 0.8197 0.9561 −0.1664 <0.0001 <0.0001 1.0078 0.9141
MINI score category 88 0.1906 0.1926 −0.0108 <0.0001 <0.0001 0.7397 0.7379
Psychiatric hospital admissions at baseline 88 0.1906 0.1814 0.0484 <0.0001 <0.0001 0.7397 0.6685
→ Cluster aggregated (mean) 88 0.1906 0.1834 0.0378 <0.0001 <0.0001 0.7397 0.6833
Table 6.10: Example of the effects of adjusting for a single covariate in a linear mixed effects model, using FIAT data set. Outcome variable is
quality of life. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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6.3.2.2 Continuous outcome variables with larger ICCs
The effects of adjusting for single covariates in an analysis of cognitive function score
(OPERA) (ICC = 0.05) are given in Table 6.11 (page 99). Adjusting for baseline
measure of outcome shows the largest reduction in estimated standard error of the
treatment effect estimate of 48%. With this there is a large reduction in both the
cluster and individual level variance estimates. Adjusting for baseline measure of
outcome aggregated at cluster level gives a smaller reduction in standard error (20%),
with a larger reduction of cluster level variance (to almost zero) but a much smaller
reduction of individual level variance. There is a 15% reduction in standard error when
adjusting for mean CF score (of home) at baseline, with a large reduction in cluster
level variance. Adjusting for sex aggregated at cluster level by log odds increases the
estimated standard error by 12%, and increases cluster level variance of the outcome.
Table 6.12 (page 101) summarises the effects of adjusting for single covariates in an
analysis of CGI score (FIAT), which has an ICC of approximately 0.3. Adjusting
for a baseline measure of quality of life slightly inflates the standard error of the
treatment effect estimate, and only reduces cluster and individual level variances very
slightly. An increase in standard error is not expected when there is a reduction
in residual variances, however here there are only small changes and the increase
in standard error may be explained by the reduction in degrees of freedom caused
by adding the covariate to the model. This inflation is larger when the covariate is
summarised at cluster level, and there is an increase in the adjusted individual level
variance estimate compared to the unadjusted estimate. A similar pattern is seen for
the covariate years of formal education. Adjusting for achieved at least 95% adherence
reduces the standard error of treatment effect estimate, more so when summarised by
cluster proportion. An increase in the individual level variance of outcome is offset by
a reduction of the cluster level variance.
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Cluster level Individual level
SE of effect estimate Proportion variance of outcome variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted Unadjusted Adjusted
Cognitive function score at baseline 533 0.6962 0.3595 0.4837 2.6655 0.4250 43.6222 13.7126
→ Cluster aggregated 533 0.6962 0.5552 0.2025 2.6655 <0.0001 43.6222 39.5394
Normal cognitive function at baseline 533 0.6962 0.5605 0.1949 2.6655 1.6257 43.6222 29.0360
→ Cluster aggregated (proportion) 533 0.6962 0.5691 0.1825 2.6655 <0.0001 43.6222 43.0253
→ Cluster aggregated (log odds) 533 0.6962 0.6320 0.0923 2.6655 0.2219 43.6222 43.0903
Centre 549 0.6788 0.6704 0.0123 2.3233 1.9783 44.2811 44.3278
Size 549 0.6788 0.6741 0.0069 2.3233 2.2195 44.2811 44.2278
Proportion depressed in home at baseline 549 0.6788 0.6693 0.0139 2.3233 2.0878 44.2811 44.2923
Mean CF score in home at baseline 549 0.6788 0.5732 0.1556 2.3233 0.0770 44.2811 43.7581
Continued on next page.
Table 6.11: Example of the effects of adjusting for a single covariate in a linear mixed effects model, using OPERA data set. Outcome variable is
cognitive function score. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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Cluster level Individual level
SE of effect estimate Proportion variance of outcome variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted Unadjusted Adjusted
Age 548 0.6804 0.6920 −0.0170 2.3467 2.7243 44.3446 43.5540
→ Cluster aggregated 548 0.6804 0.6796 0.0013 2.3467 2.3181 44.3446 44.3611
Sex 549 0.6788 0.6808 −0.0030 2.3233 2.4953 44.2811 43.2876
→ Cluster aggregated (proportion) 549 0.6788 0.6798 −0.0015 2.3233 2.3180 44.2811 44.2538
→ Cluster aggregated (log odds) 549 0.6788 0.7595 −0.1190 2.3233 2.7519 44.2811 44.5047
Table 6.11: Example of the effects of adjusting for a single covariate in a linear mixed effects model, using OPERA data set. Outcome variable is
cognitive function score. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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Cluster level Individual level
SE of effect estimate Proportion variance of outcome variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted Unadjusted Adjusted
Quality of Life at baseline 67 0.3795 0.3898 −0.0270 0.4352 0.4079 1.4585 1.4331
→ Cluster aggregated (mean) 67 0.3795 0.4020 −0.0593 0.4352 0.3772 1.4585 1.4943
Years of formal education 87 0.3001 0.3017 −0.0053 0.0723 0.0912 1.7692 1.6886
→ Cluster aggregated (mean) 87 0.3001 0.3075 −0.0249 0.0723 0.1579 1.7692 1.5845
Ahieved 95% adherence at baseline 102 0.3312 0.3241 0.0213 0.5190 0.4473 1.5438 1.5779
→ Cluster aggregated (proportion) 102 0.3312 0.3156 0.0469 0.5190 0.3806 1.5438 1.5833
→ Cluster aggregated (log odds) 8 0.6346 0.6614 −0.0422 0.0000 0.0000 0.6042 0.4375
Sex 107 0.3254 0.3217 0.0116 0.5361 0.5342 1.5793 1.5228
→ Cluster aggregated (proportion) 107 0.3254 0.3209 0.0139 0.5361 0.4973 1.5793 1.5830
→ Cluster aggregated (log odds) 50 0.5452 0.5478 −0.0047 0.5125 0.5272 1.6862 1.6706
Table 6.12: Example of the effects of adjusting for a single covariate in a linear mixed effects model, using FIAT data set. Outcome variable is CGI
score. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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6.3.2.3 Binary outcome variable with small ICC
Table 6.13 (page 103) summarises the effects of adjusting for single covariates in
an analysis of the binary outcome depression status (OPERA), which has an ICC
on the logistic scale close to 0.02. The estimated standard error of the treatment
effect estimate increases by around 20% when adjusting for either depression status
at baseline or GDS score at baseline. Estimated cluster level variance also increases
when adjusting for these covariates. This reflects what would be expected in a logistic
regression model, where adjusting for a covariate correlated with outcome will increase
the standard error of the estimated treatment effect.
Adjusting for depression status or GDS score measured at baseline when aggregated
at cluster level reduces the cluster level variance to close to zero, but only marginally
reduces the estimated standard error.
Adjusting for other covariates marginally changes the estimated standard error of the
treatment effect estimate. As with the continuous outcome variables, adjusting for
sex aggregated at cluster level by log odds increases the estimated standard error.
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Cluster level
SE of effect estimate Proportion variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted
Depression status at baseline 585 0.1738 0.2102 −0.2090 0.0377 0.1092
→ Cluster aggregated (proportion) 585 0.1738 0.1687 0.0294 0.0377 <0.0001
→ Cluster aggregated (log odds) 585 0.1738 0.1705 0.0194 0.0377 <0.0001
GDS score at baseline 585 0.1738 0.2095 −0.2053 0.0377 0.0582
→ Cluster aggregated 585 0.1738 0.1695 0.0248 0.0377 <0.0001
Centre 595 0.1750 0.1774 −0.0137 0.0509 0.0504
Size 595 0.1750 0.1751 −0.0005 0.0509 0.0511
Proportion depressed in home at baseline 595 0.1750 0.1682 0.0392 0.0509 <0.0001
Continued on next page.
Table 6.13: Example of the effects of adjusting for a single covariate in a logistic mixed effects model, using OPERA data set. Outcome variable is
depression status. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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Continued from previous page.
Cluster level
SE of effect estimate Proportion variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted
Mean CF score in home at baseline 595 0.1750 0.1719 0.0179 0.0509 0.0238
Age 593 0.1763 0.1717 0.0261 0.0563 0.0294
→ Cluster aggregated 593 0.1763 0.1689 0.0420 0.0563 0.0116
Sex 595 0.1750 0.1750 0.0002 0.0509 0.0501
→ Cluster aggregated (proportion) 595 0.1750 0.1756 −0.0033 0.0509 0.0500
→ Cluster aggregated (log odds) 595 0.1750 0.1915 −0.0940 0.0509 0.0609
Table 6.13: Example of the effects of adjusting for a single covariate in a logistic mixed effects model, using OPERA data set. Outcome variable is
depression status. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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6.3.2.4 Binary outcome variable with larger ICC
The effects of adjusting for a single covariate when analysing the outcome normal cog-
nitive function with a logistic mixed effects model are summarised in Table 6.14 (page
106). As with the analysis of depression status, adjusting for the baseline measures of
outcome increases the estimated standard error of the treatment effect estimate (by
24.6% and 37.7%), while also increasing the estimated cluster level variance. Also as
before, adjusting for cluster aggregated baseline measures of outcome decreases the
estimated standard error of the treatment effect estimate and estimated cluster level
variance of the outcome.
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Cluster level
SE of effect estimate Proportion variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted
Normal cognitive function at baseline 533 0.2728 0.3400 −0.2461 0.4275 0.6049
→ Cluster aggregated (proportion) 533 0.2728 0.2259 0.1719 0.4275 0.0297
→ Cluster aggregated (log odds) 533 0.2728 0.2345 0.1406 0.4275 0.0262
Cognitive function score at baseline 533 0.2728 0.3756 −0.3769 0.4275 0.6836
→ Cluster aggregated (mean) 533 0.2728 0.2229 0.1829 0.4275 0.0000
Centre 549 0.2745 0.2750 −0.0019 0.4455 0.4358
Size 549 0.2745 0.2745 −0.0001 0.4455 0.4456
Proportion depressed in home at baseline 549 0.2745 0.2746 −0.0006 0.4455 0.4416
Continued on next page.
Table 6.14: Example of the effects of adjusting for a single covariate in a logistic mixed effects model, using OPERA data set. Outcome variable is
normal cognitive function status. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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Cluster level
SE of effect estimate Proportion variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted
Mean CF score in home at baseline 549 0.2745 0.2680 0.0236 0.4455 0.3739
Age 548 0.2741 0.2794 −0.0192 0.4427 0.4831
→ Cluster aggregated (mean) 548 0.2741 0.2737 0.0017 0.4427 0.4346
Sex 549 0.2745 0.2773 −0.0104 0.4455 0.4555
→ Cluster aggregated (proportion) 549 0.2745 0.2734 0.0038 0.4455 0.4328
→ Cluster aggregated (log odds) 549 0.2745 0.2994 −0.0910 0.4455 0.4618
Table 6.14: Example of the effects of adjusting for a single covariate in a logistic mixed effects model, using OPERA data set. Outcome variable is
normal cognitive function status. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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6.3.2.5 Count outcome variable (Number of involuntary hospital
admissions)
The outcome number of involuntary hospital visits is a count outcome, but when
treated as continuous variable had a large estimated ICC of 0.52. Table 6.15 (page
109) summarises the effects of adjusting for some single covariates in an analysis of
number of involuntary hospital visits using a Poisson mixed effects model. Adjusting
for a baseline measure of outcome reduces the standard error of the treatment effect
estimate by 14%, and by 15% when the covariate is summarised by cluster mean.
The estimated cluster level variance is reduced in each case. Adjusting for number
of psychiatric hospital admissions at baseline, or age, also shows a notable reduction
in the standard error, which is slightly larger when the covariate is summarised by
cluster mean. Adjusting for sex as an individual level covariate inflates the standard
error and the cluster level variance of outcome, but decreases the standard error when
summarised by cluster proportion.
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Cluster level
SE of effect estimate Proportion variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted
Number of involuntary hospital admissions at baseline 138 0.6571 0.5627 0.1437 3.3418 1.8327
→ Cluster aggregated (mean) 138 0.6571 0.5560 0.1539 3.3418 1.7671
Number of psychiatric hospital admissions at baseline 138 0.6571 0.6110 0.0703 3.3418 2.6192
→ Cluster aggregated (mean) 138 0.6571 0.6095 0.0725 3.3418 2.6324
Quality of Life at baseline 85 0.7252 0.7523 −0.0374 2.0160 2.0482
→ Cluster aggregated (mean) 85 0.7252 0.7685 −0.0597 2.0160 2.0047
Age 141 0.6575 0.6001 0.0872 3.4130 2.5769
→ Cluster aggregated (mean) 141 0.6575 0.5982 0.0901 3.4130 2.4497
Continued on next page.
Table 6.15: Example of the effects of adjusting for a single covariate in a Poisson mixed effects model, using FIAT data set. Outcome variable is
number of involuntary hospital visits. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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Cluster level
SE of effect estimate Proportion variance of outcome
Covariate adjusted for Sample size Unadjusted Adjusted reduction of SE Unadjusted Adjusted
Number of years since illness diagnosed 127 0.7510 0.7572 −0.0083 3.9284 4.0071
→ Cluster aggregated (mean) 127 0.7510 0.7499 0.0015 3.9284 3.8855
Sex 141 0.6575 0.6908 −0.0506 3.4130 3.9042
→ Cluster aggregated (proportion) 141 0.6575 0.6430 0.0220 3.4130 3.1202
→ Cluster aggregated (log odds) 68 1.1990 1.1845 0.0121 0.0031 0.0043
MINI score category 141 0.6575 0.6257 0.0484 3.4130 2.8766
Table 6.15: Example of the effects of adjusting for a single covariate in a Poisson mixed effects model, using FIAT data set. Outcome variable is
number of involuntary hospital visits. (Variances are as estimated in fitting the mixed effects models. SE = Estimated standard error.)
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6.3.3 Effects of using separate within-cluster and contextual
covariate effect parameters
Tables 6.16 and 6.17 (page 112) compare estimated standard errors of treatment effect
of two linear mixed effects analyses: one using a single parameter for the effect of a
covariate; and the other using two parameters for covariate effect and separating the
covariate into cluster means and individual residuals. Between these two approaches,
there is little difference in estimated standard errors for any of the covariates. In some
cases there is a marked difference between the contextual and within-cluster covariate
effect (for example, with GDS score at baseline, and cognitive function score as the
outcome), but less than 2% decrease in estimated standard error.
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SE of treatment effect Proportion Estimates of covariate effects
Covariate adjusted for Sample size Single CE Separate CEs reduction of SE Single Contextual Within-cluster
GDS score at baseline 585 0.2099 0.2079 0.0091 0.6783 0.5345 0.7015
Cognitive function score at baseline 571 0.2784 0.2826 -0.0149 0.0408 0.0629 0.0358
Depression status at baseline 585 0.2286 0.2282 0.0016 3.7241 2.9405 3.8637
Normal cognitive function at baseline
Age 593 0.2731 0.2725 0.0019 0.0103 0.0598 -0.0066
Sex 595 0.2733 0.2742 -0.0036 -0.2997 -0.1159 -0.3353
Table 6.16: Example of the effects of adjusting for a single covariate using either a single covariate effect parameter, or separate within-cluster and
contextual covariate effect parameters. Outcome variable is GDS score.
SE of treatment effect Proportion Estimates of covariate effects
Covariate adjusted for Sample size Single CE Separate CEs reduction of SE Single Contextual Within-cluster
GDS score at baseline 543 0.6800 0.6715 0.0125 0.1310 0.5445 0.0797
Cognitive function score at baseline 533 0.3595 0.3641 -0.0128 0.9263 0.9503 0.9214
Depression status at baseline 543 0.6806 0.6792 0.0020 1.2691 2.4918 1.1119
Normal cognitive function at baseline
Age 548 0.6920 0.6794 0.0182 -0.0955 0.0183 -0.1239
Sex 549 0.6808 0.6794 0.0021 2.1838 1.1283 2.3442
Table 6.17: Example of the effects of adjusting for a single covariate using either a single covariate effect parameter, or separate within-cluster and
contextual covariate effect parameters. Outcome variable is cognitive function score.
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6.4 Conclusion
The results presented in this chapter demonstrate some effects of covariate adjustment
in linear and logistic mixed effects models already described in published research.
Some results are less clearly related to known effects and suggest areas for further
careful investigation of the effects of covariate adjustment in the analysis of CRTs.
Where a continuous outcome variable has a particularly small ICC, it appears that
reducing cluster variance may not be important in reducing the estimated standard
error of treatment effect. For example, we observe cases where there is reduced stan-
dard error despite an increase in cluster level variance. The reduction in standard
error when adjusting for an individual level covariate is smaller when the covariate
is aggregated to the cluster level. However, when the outcome variable has a large
ICC, there is less difference between adjusting for a cluster aggregated covariate or
the individual level covariate itself.
For binary outcomes analysed with a logistic mixed effects model, we observe an
increase in the standard error of treatment effect estimate when adjusting for a co-
variate. This is what occurs for logistic regression models (as described in Chapter
2), so we might also expect an increase in power due to a larger estimated treatment
effect. However, when adjusting for cluster aggregated covariates, we observe a re-
duction in the estimated standard error of treatment effect estimates. Further, where
the outcome variable has a larger ICC this effect appears to be greater. The effect of
adjusting for individual or cluster level covariates in a logistic mixed effects model on
treatment effect estimates, standard error, and power warrant further investigation.
For a variety of outcome variables and covariates, we see little increase in precision by
using a separate covariate effects model compared to a single covariate effect model.
Only where there is a large difference between the within cluster and contextual co-
variate effects does there appear to be an advantage, which supports the results of
Korendijk et al. [54]. This comparison needs to be extended beyond standard error
to also consider power and investigate if there are any conditions under which there
is a clear advantage in using the more complex model.
The following chapters of this thesis investigate the effects of covariate adjustment in
CRTs, including the areas highlighted by these analyses.
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Chapter 7
Simulation study methods
Simulation has widely been used to investigate the effects of covariate adjustment in
a variety of situations, as discussed in Chapters 2, 3 and 4. In this chapter I describe
the simulation methods I used to investigate the effects of covariate adjustment in the
analysis of CRTs using mixed effects models. Monte Carlo simulation allows us to
estimate quantities such as power, type I error, bias, coverage, and the distributions
of model based standard error and empirical standard error.
In simulation studies, data are firstly generated according to a known model, then
the data are analysed with the methods of interest. The model used to generate
data, including its parameter values, and the model used to analyse the data must be
specified [70]. In the next section, I outline the parameter values chosen to be used
to generate simulation data. In Section 7.2 I describe the data generating models
and how remaining parameter values were calculated. In Section 7.4 I describe the
models used to analyse the simulated data. Details of the software used to carry
out simulations are given in Section 7.5. A description of how presented results are
calculated is given in Section 7.6.
7.1 Parameter values
In this section I describe the parameter values I chose to initially investigate in sim-
ulation studies. In particular these are: cluster size; number of clusters; marginal
ICCs; marginal prevalence; difference between treatment arms (treatment effect); and
covariate effect. These are sufficient to fully specify the models that are outlined in
Section 7.2. The necessary values for the parameters in the linear predictor part of
the data generating models can be deduced given values for these parameters. How
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they are calculated is also described in Section 7.2.
7.1.1 Cluster size and number of clusters
Initial investigation used fixed cluster sizes of 30 (with 20 clusters per treatment arm)
and five (with 60 clusters per treatment arm).
7.1.2 ICCs, variance parameters, and prevalence
For continuous outcome variables and covariates, I assumed a marginal normal distri-
bution. A standard normal distribution was used, as any normally distributed variable
can be rescaled to a standard normal as follows:
X ∼ N(µ, σ2) =⇒ X − µ
σ
∼ N(0, 1)
Therefore, the total variance of continuous variables was fixed at one and specifying a
marginal ICC implicitly specified the marginal cluster level and individual level vari-
ances. Note that while these marginal parameters are fixed, the residual variances will
vary as the distribution or effect of any covariate in the model varies. The calculation
of residual variance parameters is described in Section 7.2.
For binary variables, expected value and variance are not independent parameters.
Instead, I specified marginal expected values (which is the marginal prevalence) in
the control treatment arm. The values initially used were 0.5 (giving the maximum
variation of a binary variable) and 0.1.
Marginal ICCs were chosen to be 0.0005, 0.005, 0.05, and 0.1 for each variable. Cluster
level covariates, where the ICC is one, were also used. For binary variables, these ICCs
were used on the outcome scale, and the equivalent ICC on the linear predictor scale
of the data generating model were calculated as necessary.
7.1.3 Treatment effect
Treatment effect was specified by the difference between expected values in each treat-
ment arm. Given cluster size, number of clusters, and marginal distribution of the out-
come variable I calculated the minimum detectable treatment effect. This is achieved
by solving sample size formulae for the treatment effect. For continuous outcome
variables, I used the following sample size formula:
N =
2(zα/2 + zβ)
2(1 + (m− 1)ICCY )
∆2
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Where N is the number of individuals in each treatment arm, m is the cluster size,
ICCY is the outcome ICC, and ∆ is the difference in means between treatment arms.
The size of the significance test is α and required power is 1 − β. From this the
minimum detectable effect is:
∆ =
(
2(zα/2 + zβ)
2(1 + (m− 1)ICCY )
N
) 1
2
This gives two solutions of the same magnitude, one positive and one negative. I used
only the positive treatment effect, as the two are equivalent (by recoding the treatment
arm variable). For binary outcomes, I used the following sample size formula:
N =
(zα/2 + zβ)
2 × [Π1(1−Π1) + Π0(1−Π0)]× (1 + (m− 1)ICCY )
∆2
Where Π1 and Π0 are the prevalence in each treatment arm and ∆ = Π1 − Π0. This
gives the minimum detectable effect as:
∆ =
−B ± (B2 − 4AC) 12
2A
−Π0
where
A = N(1 + (m− 1)ICCY )−1 + (zα/2 + zβ)2
B = −2N(1 + (m− 1)ICCY )−1Π0 − (zα/2 + zβ)2
C = N(1 + (m− 1)ICCY )−1Π20 − (zα/2 + zβ)2Π0(1−Π0) .
This gives two solutions, one negative and one positive, which have different magnitude
if the prevalence is not 0.5. I used the positive treatment effect. In the simulations, I
used treatment effects equal to this minimum detectable effect, simulating a sufficiently
well powered trial. I also used a treatment effect of zero so that type I error could be
estimated.
7.1.4 Covariate effect
Covariate effect was specified by the value of the covariate effect parameter in the linear
predictor of each model. The magnitude of this parameter is bounded, since residual
variance parameters must be non-negative. Equivalently, the correlation between
an outcome variable and a covariate at each level is bounded by -1 and 1. The
bounds of the covariate effect parameter under each model are given in Section 7.2.
I used covariate effect parameters equal to 0, 0.25, 0.5, 0.75, and 0.95 times the
maximum positive covariate effect. This covers a wide range of the possible values for
the covariate effect parameter.
Some models used different values for separate covariate effects at the cluster and
individual levels. The ratios of the between-cluster to the within-cluster covariate
effect parameter used were: 2, 1, 0, -0.5, and -0.66. These values are equivalent to
“inequality of covariate effects” [54] of 0.333, 0.5, 1, 2, and 3.
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7.2 Data generating models
In this section I outline the models used to generate data. I also give details of how
model parameter values were calculated, given the parameters outlined in Section 7.1.
7.2.1 Generating continuous outcome and continuous covariate data
The outcome data generating model when both the outcome and covariate are con-
tinuous was a linear mixed effects model. The individual level covariate was also
generated with a linear mixed effects model. The model was:
Yij = α+ βXj + γZij + uj + eij (7.1)
where
uj ∼ N(0, τ2)
eij ∼ N(0, σ2)
The covariate data generating model was:
Zij = aj + bij
aj ∼ N(0, τ2z )
bij ∼ N(0, σ2z)
In this model both the outcome Y and covariate Z have normal distributions, and
there is a linear relationship between outcome and covariate. Xj is the treatment arm
variable, equal to zero for half of the clusters (the control arm) and one for the other
half of the clusters (the experimental treatment arm).
Collecting the cluster level and individual level random effects in equation 7.1, the
model for the outcome data can be written as:
Yij = α+ βXj + (γaj + uj)︸ ︷︷ ︸
Cluster level random effect
+ (γbij + eij)︸ ︷︷ ︸
Individual level random effect
(7.2)
Since aj and uj are independent and normally distributed, their sum is also normally
distributed:
(γaj + uj) ∼ N(0, γ2τ2z + τ2)
Similarly, the sum of bij and eij is normally distributed:
(γbij + eij) ∼ N(0, γ2σ2z + σ2)
So the between-cluster and within-cluster variance components of the outcome Y are
(γ2τ2z + τ
2) and (γ2σ2z + σ
2), respectively. Therefore, the marginal within treatment
arm ICC of the outcome Y in terms of the model parameters is
ICCY =
γ2τ2z + τ
2
γ2(τ2z + σ
2
z) + τ
2 + σ2
. (7.3)
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The marginal ICC of the covariate Z is
ICCZ =
τ2z
τ2z + σ
2
z
. (7.4)
Any normally distributed variable can be rescaled to have variance of one, so both the
outcome and covariate were scaled in this way. This standardised the treatment and
covariate effect parameter values, and imposes the following restrictions:
γ2(τ2z + σ
2
z) + τ
2 + σ2 = 1 (7.5)
τ2z + σ
2
z = 1 (7.6)
Given a value for the marginal ICC of the outcome (ICCY ), the between-cluster and
within-cluster variance components are determined implicitly (by equations 7.3 and
7.5):
Marginal between-cluster variance of Y = γ2τ2z + τ
2 = ICCY (7.7)
Marginal within-cluster variance of Y = γ2σ2z + σ
2 = 1− ICCY (7.8)
Similarly, given a value for the marginal ICC of the covariate (ICCZ) the between-
cluster and within-cluster variance components are chosen implicitly (by equations 7.4
and 7.6):
Marginal between-cluster variance of Z = τ2z = ICCZ
Marginal within-cluster variance of Z = σ2z = 1− ICCZ
These complete the relationships necessary to calculate the remaining parameter val-
ues, given the marginal ICCs for outcome and covariate, and the covariate effect.
In summary, given values for ICCY , ICCZ , and γ, the remaining parameters values
were calculated in the following steps:
1. τ2z = ICCZ
2. σ2z = 1− ICCZ
3. τ2 = ICCY − γ2τ2z (Using equation 7.7.)
4. σ2 = (1− ICCY )− γ2σ2z (Using equation 7.8.)
Additionally, by setting α = 0, the outcome has expected value zero in the control
treatment arm (E[Yij |Xj = 0] = 0), and expected value β in the experimental treat-
ment arm (E[Yij |Xj = 1] = β).
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Note that the adjusted variance components (τ2 and σ2) must be non-negative, which
restricts the values that the covariate effect parameter γ can take:
0 ≤ τ2 = ICCY − γ2τ2z ⇒ γ2 ≤
ICCY
τ2z
=
ICCY
ICCZ
and 0 ≤ σ2 = (1− ICCY )− γ2σ2z ⇒ γ2 ≤
1− ICCY
σ2z
=
1− ICCY
1− ICCZ
So the value of the covariate effect parameter γ is restricted by the inequality:
|γ| ≤ min
{√
ICCY
ICCZ
,
√
1− ICCY
1− ICCZ
}
The value of covariate effect parameters in simulation is chosen as a factor of the
maximum possible value for the covariate effect paramter. Call this factor the covariate
effect factor (CEF), then if ICCZ ≤ ICCY ,
γ = CEF×
√
1− ICCY
1− ICCZ .
The covariate effect parameter γ is related to the individual level correlation between
the outcome and covariate, ri, by
γ = ri
sd(γbij + eij)
sd(bij)
= ri
√
1− ICCY
1− ICCZ
∴ CEF = ri
So if ICCZ ≤ ICCY , then the covariate effect factor is equal to the individual level
correlation between the outcome and covariate.
If ICCZ ≥ ICCY , then
γ = CEF×
√
ICCY
ICCZ
γ = rc
sd(γaj + uj)
sd(aj)
= rc
√
ICCY
ICCZ
∴ CEF = rc .
where rc is the cluster level correlation between the outcome and covariate. So if
ICCZ ≥ ICCY , then the covariate effect factor is equal to the cluster level correlation
between the outcome and covariate.
7.2.2 Generating binary outcome and continuous covariate data
When using logistic mixed effects models, I wished to generate data with given values
for the marginal proportion and marginal ICC in the control arm. However, it is
not as straightforward to calculate model parameter values as for linear mixed effects
models. In Section 7.2.2.1 I describe approaches for generating binary outcome data
that were considered but not used. In Section 7.2.2.2 I describe the data generating
model that was used in simulations.
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7.2.2.1 Methods not used
The logistic mixed effects model is used to analyse binary outcome data from CRTs,
and is the analysis method I am investigating. However, the logistic relationship
between the linear predictor and outcome variable make it difficult to fix the marginal
outcome distribution. Consider the logistic mixed effects model
Yij ∼ Bernoulli(pij)
logit(pij) = ηij = α+ βXj + γZij + uj
where
uj ∼ N(0, τ2) .
The model for the continuous covariate is as in Section 7.2.1. Under this model, the
marginal expected value of the binary outcome in the control arm is:
E[Yij |Xj = 0] = E[pij |Xj = 0] = E[logit−1(α+ γZij + uj)]
And the ICC within the control treatment arm on the scale of the outcome variable
can be defined by:
ICC =
var(E[Yij |Xj = 0, uj ])
var(Yij |Xj = 0)
The variances and expected values in these equations do not generally have a closed
algebraic form, so cannot be rearranged to provide expressions for parameter values.
There is no straightforward algebraic way to calculate model parameter values to
ensure that the marginal distribution of the outcome is fixed.
Linear approximations using Taylor series have been used to simplify the relationship
between the outcome variable and the linear predictor in logistic regression models,
for example by Gail et al. [6] and Neuhaus & Jewell [7]. The Taylor series expansion
of ηij(pij) at pij = Π is:
ηij = logit(Π) +
pij −Π
Π(1−Π) + ...
From this we can obtain an approximate expression for pij in terms of ηij and Π,
which is linear:
pij ≈ Π + Π(1−Π)(ηij − logit(Π))
Using this linear approximation the marginal expected value of Y and the marginal
ICC of outcome in the control arm are given by:
E[Yij |Xj = 0] = E[pij |Xj = 0] = E[Π + Π(1−Π)(ηij − logit(Π))|Xj = 0]
= Π + Π(1−Π)(E[ηij |Xj = 0]− logit(Π))
= Π + Π(1−Π)(α− logit(Π))
ICCY = Π(1−Π)(γ2τ2z + τ2)
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This would allow us to calculate parameter values given values for E[Yij ] and ICCY .
However, the linear approximation is poor as we move away from pij = Π. Further,
it does not take into account the contribution of the individual level variance of the
covariate to the expected value or the ICC of the outcome.
I considered an extension of this approach: using piecewise linear approximations to
the logistic function, so that the approximation does not diverge from the function as
we move away from pij = Π. For example, a piecewise linear approximation could be:
pij =

0 ηij < −2
1
2 +
η
4 −2 ≤ ηij ≤ 2
1 ηij > 2
This uses the Taylor series linear approximation of ηij (as above) at pij =
1
2 between
η = −2 and η = 2. For η < −2 and η > 2, this approximation takes the values of the
limits of pij as η → −∞ and η →∞, respectively. However, using this approximation
we again have expressions for the marginal expected values and ICC of the outcome
which cannot be easily used to calculate parameter values. For example, the expected
value of the outcome in the control treatment arm is:
E[Yij |Xj = 0] = E[pij |Xj = 0]
=
(
1
2
+
E[ηij |Xj = 0]
4
)
× Pr(−2 < η < 2) + Pr(η > 2)
=
(
1
2
+
α
4
)(
Φ
(
2− α√
τ2 + σ2
)
− Φ
( −2− α√
τ2 + σ2
))
+
(
1− Φ
(
2− α√
τ2 + σ2
))
Instead of the logistic model, a probit mixed effects model could instead be used to
generate binary outcome data in simulation studies of CRTs. The probit mixed effects
model to use would be:
Yij ∼ Bernoulli(pij)
Φ−1(pij) = ηij = α+ γZij + uj
uj ∼ N(0, τ2)
where the continuous covariate is as before, and Φ−1 is the inverse cumulative normal
distribution function. The marginal expected value of the outcome in the control arm
is given by:
E[Yij |Xj = 0] = E[pij |Xj = 0] = E[Φ(ηij)|Xj = 0]
= E[Φ(α+ γZij + uj)]
= Φ
(
α√
1 + γ2(τ2z + σ
2
z) + τ
2
)
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This expression for the marginal expected value of the outcome can be rearranged to
give an expression for parameter values. The ICC of the outcome variable also has a
straightforward relationship with the ICC on the scale of the linear predictor, which
is given in equation 7.12. The probit mixed effects model forms the basis of the latent
variable approach used in simulations and described in the next section.
7.2.2.2 Latent variable approach
A binary variable can be generated by dichotomising a latent continuous variable [70].
This is the method I used to generate binary outcome data, and the details of my
method are described in this section.
Firstly, a continuous latent outcome variable was generated with a linear mixed effects
model:
Y ∗ij = α+ βXj + γZij + uj + eij
where
uj ∼ N(0, τ2)
eij ∼ N(0, σ2)
The continuous covariate Z was generated using:
Zij = aj + bij
aj ∼ N(0, τ2z )
bij ∼ N(0, σ2z)
Then binary outcome Y was then generated as
Yij =
{
1 if Y ∗ij > 0
0 otherwise
A binary outcome generated from dichotomising a continuous latent variable in this
way is equivalent to a probit mixed effects model formulation [71].
Given this model, the marginal expected value of Y in the control treatment arm is
E[Yij |Xj = 0] = Pr(Yij = 1|Xj = 0) = Pr(Y ∗ij > 0|Xj = 0)
= Pr(α+ γZij + uj + eij > 0)
= Φ
(
α√
γ2(τ2z + σ
2
z) + τ
2 + σ2
) (7.9)
and in the experimental treatment arm is
E[Yij |Xj = 1] = Pr(Yij = 1|Xj = 1) = Pr(Y ∗ij > 0|Xj = 1)
= Pr(α+ β + γZij + uj + eij > 0)
= Φ
(
α+ β√
γ2(τ2z + σ
2
z) + τ
2 + σ2
)
.
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Where Φ is the Cumulative Distribution Function of the standard normal distribution.
So the difference in expected value of the outcome between treatment arms is:
∆ = E[Yij |Xj = 1]− E[Yij |Xj = 0]
= Φ
(
α+ β√
γ2(τ2z + σ
2
z) + τ
2 + σ2
)
− Φ
(
α√
γ2(τ2z + σ
2
z) + τ
2 + σ2
)
(7.10)
The marginal ICC of the outcome in the control treatment arm on the scale of the
latent outcome variable is [71]
ICCY ∗ =
γ2τ2z + τ
2
γ2(τ2z + σ
2
z) + τ
2 + σ2
(7.11)
The marginal ICC of the outcome in the control treatment arm (ICCY ) is related to
the ICC of the latent outcome variable (ICCY ∗) by:
ICCY =
Φ2
(
Φ−1(Π0),Φ−1(Π0), ICCY ∗
)−Π20
Π0(1−Π0) (7.12)
Where Π0 is the prevalence of the outcome in the control treatment arm, and Φ2 is
the bivariate normal cumulative distribution function.
By restricting the individual level variance of Y ∗ to be one
γ2σ2z + σ
2 = 1 (7.13)
the marginal distribution of Y is given by a probit mixed effects model.
These complete the relationships necessary to calculate remaining parameter values,
given the marginal ICCs for outcome and covariate, and the covariate effect. In
summary, given values for ICCY , ICCZ , γ, Π0, and ∆, I calculated other parameter
values as follows:
1. τ2z = ICCZ
2. σ2z = 1− ICCZ
3. σ2 = 1− γ2σ2z (Using equation 7.13.)
4. Obtain ICCY ∗ from ICCY using equation 7.12 and a numerical method (see
Appendix D).
5. τ2 = ICCY ∗1−ICCY ∗ − γ
2τ2z (Using equation 7.11.)
6. α = Φ−1(Π0)
√
γ2τ2z + τ
2 + 1 (Using equation 7.9.)
7. β = Φ−1 (Π0 + ∆)×
√
γ2τ2z + τ
2 + 1− α (Using equation 7.10.)
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Note that the adjusted variance components (τ2 and σ2) must be non-negative, which
restricts the values that the covariate effect parameter γ can take:
0 ≤ τ2 = (ICCY ∗ − 1)γ
2τ2z + ICCY ∗
1− ICCY ∗
⇒ γ2 ≤ ICCY ∗
(1− ICCY ∗)τ2z
=
ICCY ∗
(1− ICCY ∗)ICCZ
and 0 ≤ σ2 = 1− γ2σ2z
⇒ γ2 ≤ 1
σ2z
=
1
1− ICCZ
So the value of the covariate effect parameter γ is restricted by the inequality:
|γ| ≤ min
{√
ICCY ∗
(1− ICCY ∗)ICCZ ,
√
1
1− ICCZ
}
7.2.3 Generating continuous outcome and binary covariate data
The outcome data generating model when the outcome was continuous and the co-
variate was binary was a linear mixed effects model. The model was:
Yij = α+ βXj + γZij + uj + eij
where
uj ∼ N(0, τ2)
eij ∼ N(0, σ2)
The covariate was generated using a Probit mixed effects model:
Zij ∼ Bernoulli(pij)
Φ−1(pij) = αz + bj
bj ∼ N(0, τ2z )
The expected value of the covariate Z is
E[Zij ] = Pr(Zij = 1) = Φ
(
αz√
τ2z + 1
)
(7.14)
The ICC of the covariate is
ICCZ =
Φ2
(
Φ−1(ΠZ),Φ−1(ΠZ), ICCZ∗
)−Π2z
ΠZ(1−ΠZ) (7.15)
where ICCZ∗ is the covariate ICC on the scale of the linear predictor:
ICCZ∗ =
τ2z
τ2z + 1
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The marginal expected values and ICC (within treatment arm) of Yij
E[Yij |Xj = 0] = α+ γΠZ
E[Yij |Xj = 1] = α+ γΠZ + β
ICCY =
γ2 × ICCZ ×ΠZ(1−ΠZ) + τ2
γ2 ×ΠZ(1−ΠZ) + τ2 + σ2
Total variance of outcome restricted to be one:
γ2 ×ΠZ(1−ΠZ) + τ2 + σ2 = 1
In summary, given values for ICCY , ICCZ , ΠZ , and γ, the remaining parameters
values were calculated in the following steps:
1. Obtain ICCZ∗ from ICCZ using equation 7.15 and a numerical method (see
Appendix D).
2. τ2z =
ICCZ∗
1−ICCZ∗
3. αz = Φ
−1(Πz)
√
τ2z + 1
4. τ2 = ICCY − γ2 × ICCZ ×ΠZ(1−ΠZ)
5. σ2 = (1− ICCY )− γ2 × (1− ICCZ)×ΠZ(1−ΠZ)
Additionally, by setting α = −γΠZ , the outcome has mean zero in the control treat-
ment arm (E[Yij |Xj = 0] = 0), and mean β in the experimental treatment arm
(E[Yij |Xj = 1] = β).
The adjusted variance components (τ2 and σ2) must be non-negative, which restricts
the values that the treatment effect parameter γ can take:
0 ≤ τ2 = ICCY − γ2 × ICCZ ×ΠZ(1−ΠZ)
⇒ γ2 ≤ ICCY
ICCZ ×ΠZ(1−ΠZ)
and 0 ≤ σ2 = (1− ICCY )− (1− ICCZ)× γ2 ×ΠZ(1−ΠZ)
⇒ γ2 ≤ 1− ICCY
(1− ICCZ)×ΠZ(1−ΠZ)
So the value of the covariate effect parameter γ is restricted by the inequality:
|γ| ≤ min
{√
ICCY
ICCZ ×ΠZ(1−ΠZ) ,
√
1− ICCY
(1− ICCZ)×ΠZ(1−ΠZ)
}
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7.2.4 Generating binary outcome and binary covariate data
The outcome data when both the outcome and covariate are binary was generated
using the latent variable approach previously described. The individual level covariate
was also generated with a probit mixed effects model. The outcome model was:
Y ∗ij = α+ βXj + γZij + uj + eij
where
uj ∼ N(0, τ2)
eij ∼ N(0, σ2)
The covariate was generated using a probit mixed effects model:
Zij ∼ Bernoulli(pij)
Φ−1(pij) = αz + bj
bj ∼ N(0, τ2z )
The expected value of the covariate Z is
E[Zij ] = Pr(Zij = 1) = Φ
(
αz√
τ2z + 1
)
(7.16)
The ICC of the covariate is
ICCZ =
Φ2
(
Φ−1(ΠZ),Φ−1(ΠZ), ICCZ∗
)−Π2z
ΠZ(1−ΠZ) (7.17)
where ICCZ∗ is the covariate ICC on the scale of the linear predictor:
ICCZ∗ =
τ2z
τ2z + 1
Then binary outcome Y was generated as
Yij =
{
1 if Y ∗ij > 0
0 otherwise
Given this model, the marginal expected value of Y in the control treatment arm is
E[Yij |Xj = 0] = Pr(Yij = 1|Xj = 0)
= Pr(Y ∗ij > 0|Xj = 0)
= Pr(α+ γZij + uj + eij > 0)
= ΠZ × Φ
(
α+ γ√
τ2 + σ2
)
+ (1−ΠZ)× Φ
(
α√
τ2 + σ2
)
and in the experimental treatment arm is
E[Yij |Xj = 1] = Pr(Yij = 1|Xj = 1)
= Pr(Y ∗ij > 0|Xj = 1)
= Pr(α+ β + γZij + uj + eij > 0)
= ΠZ × Φ
(
α+ β + γ√
τ2 + σ2
)
+ (1−ΠZ)× Φ
(
α+ β√
τ2 + σ2
)
.
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So the difference in expected value of the outcome between treatment arms is:
∆ = E[Yij |Xj = 1]− E[Yij |Xj = 0]
= ΠZ × Φ
(
α+ β + γ√
τ2 + σ2
)
+ (1−ΠZ)× Φ
(
α+ β√
τ2 + σ2
)
−ΠZ × Φ
(
α+ γ√
τ2 + σ2
)
− (1−ΠZ)× Φ
(
α
τ2 + σ2
) (7.18)
The marginal ICC of the outcome (in the control treatment arm) on the scale of the
latent outcome variable is
ICCY ∗ =
γ2 × ICCZ ×ΠZ(1−ΠZ) + τ2
γ2 ×ΠZ(1−ΠZ) + τ2 + σ2
The marginal ICC of the outcome (in the control treatment arm) is related to the ICC
of the latent outcome variable by:
ICCY =
Φ2
(
Φ−1(Π0),Φ−1(Π0), ICCY ∗
)−Π20
Π0(1−Π0) (7.19)
By restricting the individual level variance of Y ∗ to be one
σ2 + γ2 × (1− ICCZ)×ΠZ(1−ΠZ) = 1
the marginal distribution of Y is given by a probit mixed effects model.
In summary, given values for ICC0, ΠY , ICCZ , ΠZ , γ, and δ, I calculated other
parameter values as follows:
1. Obtain ICCZ∗ from ICCZ using equation 7.17 and a numerical method (see
Appendix D).
2. τ2z =
ICCZ∗
1−ICCZ∗
3. αz = Φ
−1(Πz)
√
τ2z + 1
4. Obtain ICCY ∗ from ICCY using equation 7.19 and a numerical method (see
Appendix D).
5. σ2 = 1− γ2 × (1− ICCZ)×ΠZ(1−ΠZ)
6. τ2 = ICCY ∗1−ICCY ∗ − γ
2 × ICCZ ×ΠZ(1−ΠZ)
7. Solve for α using numerical method (see Appendix D):
Π0 = ΠZ × Φ
(
α+ γ√
τ2 + σ2
)
+ (1−ΠZ)× Φ
(
α√
τ2 + σ2
)
8. Solve equation 7.18 for β using numerical method (see Appendix D).
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The adjusted variance components (τ2 and σ2) must be non-negative, which restricts
the values that the covariate effect parameter γ can take:
0 ≤ τ2 = ICCY ∗
1− ICCY ∗ − γ
2 × ICCZ ×ΠZ(1−ΠZ)
⇒ γ2 ≤ ICCY ∗
(1− ICCY ∗)× ICCZ ×ΠZ(1−ΠZ)
and 0 ≤ σ2 = 1− γ2 × (1− ICCZ)×ΠZ(1−ΠZ)
⇒ γ2 ≤ 1
(1− ICCZ)×ΠZ(1−ΠZ)
So the value of the covariate effect parameter γ is restricted by the inequality:
|γ| ≤ min
{√
ICCY ∗
(1− ICCY ∗)× ICCZ ×ΠZ(1−ΠZ) ,
√
1
(1− ICCZ)×ΠZ(1−ΠZ)
}
7.2.5 Generating cluster level covariate data
For cluster level continuous covariates, the methods described above were used with
ICC equal to one. For cluster level binary covariates, the following model was used to
generate the covariate Z:
Zj ∼ Bernoulli(Πz)
Then for continuous outcomes, given values for ICCY , ΠZ , and γ, the residual variance
parameter values were calculated as:
1. τ2 = ICCY − γ2 ×ΠZ(1−ΠZ)
2. σ2 = 1− ICCY
For binary outcomes, given values for ICCY , ΠY , ΠZ , γ, and δ, I calculated other
parameter values as follows:
1. Obtain ICCY ∗ from ICCY using equation 7.19 and a numerical method (see
Appendix D).
2. σ2 = 1
3. τ2 = ICCY ∗1−ICCY ∗ − γ
2 ×ΠZ(1−ΠZ)
4. Solve for α using numerical method (see Appendix D):
ΠY = ΠZ × Φ
(
α+ γ√
τ2 + σ2
)
+ (1−ΠZ)× Φ
(
α√
τ2 + σ2
)
5. Solve equation 7.18 for β using numerical method (see Appendix D).
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7.2.6 Separate individual and cluster level covariate effects
In the previous section, a single parameter is used to include the covariate in the data
generating model for the outcome. We also wish to investigate the performance of
analysis models when the covariate has different effects on the outcome at cluster and
individual levels.
7.2.6.1 Continuous outcome and continuous covariate
The outcome data generating model when both the outcome and covariate are con-
tinuous was a linear mixed effects model. The individual level covariate was also
generated with a linear mixed effects model. The model was:
Yij = α+ βXj + γbaj + γwZij + uj + eij
where
uj ∼ N(0, τ2)
eij ∼ N(0, σ2) .
The covariate data generating model was:
Zij = aj + bij
aj ∼ N(0, τ2z )
bij ∼ N(0, σ2z)
Given this model, the between cluster variance of the outcome Y is
(γ2b + γ
2
w)τ
2
z + τ
2
and the within cluster variance of the outcome Y is
γ2wσ
2
z + σ
2 .
Therefore, the marginal ICC of the outcome Y is
ICCY =
(γ2b + γ
2
w)τ
2
z + τ
2
(γ2b + γ
2
w)τ
2
z + τ
2 + γ2wσ
2
z + σ
2
. (7.20)
So, given values for ICCY , ICCZ , γw, and γb the remaining parameters values were
calculated in the following steps:
1. τ2z = ICCZ
2. σ2z = 1− ICCZ
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3. τ2 = ICCY − (γ2b + γ2w)τ2z
4. σ2 = (1− ICCY )− γ2wσ2z
The adjusted variance components (τ2 and σ2) must be non-negative, which restricts
the values that the covariate effect parameters γw and γb can take:
0 ≤ τ2 = ICCY − (γ2b + γ2w)τ2z ⇒ (γ2b + γ2w) ≤
ICCY
τ2z
=
ICCY
ICCZ
and 0 ≤ σ2 = (1− ICCY )− γ2wσ2z ⇒ γ2w ≤
1− ICCY
σ2z
=
1− ICCY
1− ICCZ
7.3 Covariate used to stratify randomisation
To simulate the use of a continuous covariate to stratify randomisation, the cluster
mean of the continuous covariate was used. This was dichotomised, with a cut-off of
zero, to create two strata. Within each strata, half of the clusters were allocated to
the experimental treatment arm and half were allocated to the control treatment arm.
7.4 Data analysis models
Where the outcome variable was continuous, a linear mixed effects model was used to
analyse the simulated CRT data. Where the outcome variable was binary, a logistic
mixed effects model was used. Linear mixed effects models were fitted using the Stata
13 command mixed, and using Restricted Maximum Likelihood (REML). Logistic
mixed effects models were fitted using the Stata 13 command melogit which uses
maximum likelihood (ML).
In each simulation, two or three analysis were to be compared. For example, the
comparison is often between an unadjusted model and a model adjusted for a covariate.
For each simulated data set, both analysis method were applied as per the “moderately
independent” strategy described by Burton et al. [70].
7.4.1 Testing balance of covariates
Simulations were used to investigate the validity of adjusting for a covariate only if it
is imbalanced between treatment arms. A two sample t test of cluster means was used
to test imbalance. If the P-value of this test was less than the specified α level, then
an adjusted mixed effects model was used. Otherwise, the covariate was not used in
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the analysis model. The values of α used were 0, 0.005, 0.1, and 1. With α equal to
zero, an adjusted analysis is never used, so this is equivalent to an a priori choice of
the unadjusted model. With α equal to one, an adjusted analysis is always used, so
this is equivalent to an a priori choice to adjusted for the covariate.
7.4.2 Testing fixed treatment effects in mixed effects models
There are known issues with testing fixed effects in mixed effects models using a
Wald test when there are a small number of clusters, due to the use of asymptotic
approximations [72]. Alternative approaches include comparing the Wald statistic to a
t-distribution and using a degrees of freedom correction, and using empirical sandwich
estimates of standard error [72–75].
I calculated P-values for testing treatment effect parameters using REML estimates
and the usual Wald test (comparing the Wald statistic to a normal distribution).
Using REML estimates, rather than ML, gives less inflated type I errors [73]. I also
avoid simulation of CRTs with a very small number fo clusters per treatment arm, to
minimise this error.
7.5 Simulation in Stata
I carried out simulation studies using Stata version 13 (see Appendix E for reference).
Stata is a powerful and flexible statistical software package, which allows program-
ming of simulations and analysis and presentation of results. Although Stata has a
simulation command, I did not use this as it did not provide enough flexibility. Sim-
ulations were instead written directly using loops and the Stata postfile commands,
as described by Feiveson [76]. The seed for the Stata pseudorandom number generator
was set at the start of each set of simulations. Seeds were chosen as recommended by
Stata’s guidance [77] and recorded so that simulations could be reproduced.
The number of iterations used in simulations was 5000 for linear mixed effects models
and 500 for logistic mixed effects models. Therefore, with a linear mixed effects model
an estimated type I error of 5% would have a Monte Carlo standard error of approx-
imately 0.3%, and an estimated power of 80% would have a Monte Carlo standard
error of approximately 0.6%. With a logistic mixed effects model, an estimated type
I error of 5% would have a Monte Carlo standard error of approximately 1%, and an
estimated power of 80% would have a Monte Carlo standard error of approximately
1.8%.
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The Stata command simsum [78] was used to produce results where possible. Given
the simulation sample of treatment effect estimates and standard errors, this com-
mand was used to calculate empirical standard error, and estimates of power and
relative error of model-based standard errors, and Monte Carlo standard errors of
these estimates.
I used the multiple processor version of Stata on high performance computing cluster.
This allowed the simulations to be completed faster than if the processing was done
on a desktop computer with fewer processors.
7.6 Presentation of results
Estimates of power, standard error, and relative error of model-based standard errors
were produced using the Stata command simsum [78]. Using this command, power
is calculated as the proportion of Monte Carlo samples where there is a significant
treatment effect. The Monte Carlo standard error of power is calculated as√
P (1− P )
n
where P is the estimate of power and n is the number of Monto Carlo samples.
The standard errors given in the results are the empirical standard error of the treat-
ment effect estimate, which is the standard deviation of the treatment effect estimates
in the Monte Carlo sample [78]. Using the simsum command, the Monte Carlo stan-
dard error of empirical standard error is calculated as√
V/2(n− 1)
where V is the sample variance of the estimates of the treatment effect parameter,
and n is the number of Monte Carlo samples.
Using simsum, the relative error of model-based standard errors are calculated as
s¯
Empirical Standard Error
− 1
where s¯ is the quadratic mean (or root mean square) of the standard errors produced
by the Stata mixed effects model commands. The Monte Carlo standard error of
relative error is calculated as
(s¯/
√
V )
√
Vs2/(4ns¯
4) + 1/2(n− 1)
where Vs2 is the sample variance of the square of the standard errors produced by the
Stata.
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The estimated relative asymptotic bias of treatment effect estimates were calculated
as
β¯ − β¯∗
β¯∗
where β¯ is the mean of estimates of the adjusted treatment effect parameter, and β¯∗
is the mean of estimates of the unadjusted treatment effect parameter.
For linear mixed effects models, power calculated using a non-central F-distribution
is also presented. This is calculated as
Ftail(1, J − 3, λ, invF (1, J − 3, 0.95)) (7.21)
where
λ =
1
4
β2J
(
ICCY − γ2ICCZ + 1− ICCY − γ
2(1− ICCZ)
m
)−1
.
J is the number of clusters in the CRT. m is the number of individuals in each
cluster. β is the treatment effect parameter. invF (d1, d2, x) is the inverse cumulative
F distribution function, with degrees of freedom d1 and d2. Ftail(d1, d2, λ, x) is the
reverse cumulative (or upper tail) non-central F distribution function, with degrees of
freedom d1 and d2, and non-centrality parameter λ.
7.7 Conclusion
In this chapter I have described the methods used to conduct the simulation studies
to investigate the effects of covariate adjustment in CRTs. In the following chapter I
present results from the simulation studies.
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Chapter 8
Simulation study results
In this chapter I present results from simulation studies investigating the effects of
covariate adjustment in the analysis of CRTs using mixed effects models. The methods
used for simulations have been outlined in Chapter 7.
Estimated type I errors and relative errors for analyses adjusting for a covariate only
when it is imbalanced at baseline are presented in Section 8.1. This will allow us
to assess the application of guidance to not adjust for a covariate only because it is
observed to be imbalanced at baseline [13,14,38] to CRTs.
Estimated type I errors and relative errors of model-based standard errors for analyses
adjusting for covariates used to stratify randomisation are given in Section 8.2. This
will allow us to assess the relevance of guidance to adjust for covariates used to stratify
randomisation [13–15] to CRTs.
Results of simulations investigating the effects of covariate adjustment when using
linear mixed effects models are given in Section 8.3. For the use of logistic mixed
effects models results are given in Section 8.4.
Results for models using separate within-cluster and contextual covariate effect pa-
rameters are given in Section 8.5. These extend previous simulation studies on the
same issue [54,55].
Some results of adjusting for a covariate aggregated at cluster level are presented in
Section 8.6.
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8.1 Adjusting for a covariate imbalanced at baseline
Estimated type I errors and estimated relative error of model-based standard errors
(for a treatment effect of zero) for analyses adjusting for a covariate only when imbal-
anced between treatment arms are presented in Tables 8.1 and 8.2 (page 137). These
are for CRTs with 50 clusters in each treatment arm and 30 individuals in each cluster.
The test for imbalance was a t-test of cluster means of the continuous covariate.
When unadjusted analyses were always used (by using a test of balance at significance
level of zero) or adjusted analyses always used (by using a test of balance at significance
level of one), type I error was close to the nominal 5%. When a significance level of
0.05 or 0.1 was used to test for baseline imbalance, standard errors of treatment effect
estimates were overestimated and type I error was reduced.
Results for an outcome with an ICC of 0.005 and an individual level covariate with an
ICC of 0.005 are presented in Table 8.1 (page 137). For significance levels of 0.05 and
0.1 the smallest estimated type I errors were 1.4% and 0.8%, respectively. In these
cases the relative error of the model-based standard errors were 14.8% and 24.8%.
Estimated type I errors are shown in Figure 8.1 (page 136).
Results for an outcome with an ICC of 0.1 and a cluster level covariate are presented
in Table 8.2 (page 137). For significance levels of 0.05 and 0.1 the smallest estimated
type I errors were 2.8% and 1.9%, respectively. In these cases the relative error of the
model-based standard errors were 9.2% and 15.5%. Estimated type I errors are shown
in Figure 8.2 (page 136).
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Figure 8.1: Estimated type I error of linear mixed effects model analysis, adjusting for
a covariate when a test of balance of covariate is significant. 50 clusters per treatment
arm, cluster size of 30. Outcome ICC = 0.005. Covariate ICC = 0.005. Data from
Table 8.1.
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Figure 8.2: Estimated type I error of linear mixed effects model analysis, adjusting for
a covariate when a test of balance of covariate is significant. 50 clusters per treatment
arm, cluster size of 30. Outcome ICC = 0.1. Cluster level covariate. Data from Table
8.1.
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Estimated Relative Error of SE % (MCSE) Estimated Type I Error % (MCSE)
Covariate Effect Parameter α = 0 α = 0.05 α = 0.1 α = 1 α = 0 α = 0.05 α = 0.1 α = 1
0.00 2.3 (1.0) 2.3 (1.0) 2.3 (1.0) 2.3 (1.0) 4.8 (0.3) 4.8 (0.3) 4.8 (0.3) 4.8 (0.3)
0.25 1.3 (1.0) 2.3 (1.0) 2.6 (1.0) 1.6 (1.0) 4.6 (0.3) 4.4 (0.3) 4.4 (0.3) 4.6 (0.3)
0.50 1.5 (1.0) 4.5 (1.1) 5.9 (1.1) 2.0 (1.0) 5.0 (0.3) 4.4 (0.3) 4.1 (0.3) 4.9 (0.3)
0.75 0.3 (1.0) 7.2 (1.1) 10.7 (1.1) -0.5 (1.0) 5.0 (0.3) 3.4 (0.3) 3.0 (0.2) 5.3 (0.3)
0.95 1.3 (1.0) 14.8 (1.2) 24.8 (1.3) 1.5 (1.0) 4.7 (0.3) 1.4 (0.2) 0.8 (0.1) 4.7 (0.3)
Table 8.1: Estimated relative error and estimated type I error of linear mixed effects model analysis, adjusting for a covariate when test of balance
of covariate is significant at a level of α. 50 clusters per treatment arm, cluster size of 30. Outcome ICC = 0.005. Covariate ICC = 0.005.
Estimated Relative Error of SE % (MCSE) Estimated Type I Error % (MCSE)
Covariate Effect Parameter α = 0 α = 0.05 α = 0.1 α = 1 α = 0 α = 0.05 α = 0.1 α = 1
0.00 0.5 (1.0) 0.6 (1.0) 0.7 (1.0) 0.7 (1.0) 5.5 (0.3) 5.5 (0.3) 5.4 (0.3) 5.2 (0.3)
0.08 0.3 (1.0) 0.9 (1.0) 1.1 (1.0) 0.0 (1.0) 5.2 (0.3) 5.0 (0.3) 5.0 (0.3) 5.2 (0.3)
0.16 -1.1 (1.0) 0.7 (1.0) 1.9 (1.0) -1.1 (1.0) 5.8 (0.3) 5.3 (0.3) 5.0 (0.3) 5.4 (0.3)
0.24 -2.6 (1.0) 2.3 (1.0) 5.7 (1.1) -1.7 (1.0) 5.9 (0.3) 4.5 (0.3) 3.8 (0.3) 5.5 (0.3)
0.30 0.7 (1.0) 9.2 (1.1) 15.5 (1.2) -0.8 (1.0) 4.7 (0.3) 2.8 (0.2) 1.9 (0.2) 5.5 (0.3)
Table 8.2: Estimated relative error and estimated type I error of linear mixed effects model analysis, adjusting for a covariate when test of balance
of covariate is significant at a level of α. 50 clusters per treatment arm, cluster size of 30. Outcome ICC = 0.1. Cluster level covariate..
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8.2 Adjusting for covariates used to stratify
randomisation
Estimated type I errors and estimated relative errors of model-based standard errors
(for a treatment effect of zero) are presented in Tables 8.3 to 8.5 (pages 141 to 143)
for unadjusted and adjusted linear mixed effects model analyses, where the covariate
has been used to stratify randomisation. The simulated CRTs had 50 clusters in each
treatment arm and 30 individuals in each cluster.
Analyses adjusted for the covariate used to stratify randomisation had close to nominal
estimated type I error, and estimated relative error up to 6%. Some deviation from
nominal type I error and misestimation of standard error is expected due to the small
number of clusters, as described in Section 7.4.2.
Analyses using an unadjusted linear mixed effects model produced lower than nominal
type I error and overestimated standard error of treatment effect estimates in several
scenarios. For a cluster level covariate (Table 8.3, page 141), estimated relative error
reached up to 34%, with estimated type I error as low as 0.9%, for an outcome with
an ICC of 0.1 (see Figure 8.3, page 139). For a covariate with an ICC of 0.005 (Table
8.4, page 142), estimated relative error reached up to 56%, with estimated type I error
as low as 0.1%, for an outcome with an ICC of 0.005 (see Figure 8.4, page 139). For
a covariate with an ICC of 0.1 (Table 8.5, page 143), estimated relative error reached
up to 55%, with estimated type I error as low as 0.4%, for an outcome with an ICC
of 0.1 (see Figure 8.5, 140).
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Figure 8.3: Estimated type I error of linear mixed effects model analysis, unadjusted
and adjusted for a covariate used to stratify randomisation. 50 clusters per treatment
arm, cluster size of 30. Outcome ICC = 0.1. Cluster level covariate. Data from Table
8.3.
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Figure 8.4: Estimated type I error of linear mixed effects model analysis, unadjusted
and adjusted for a covariate used to stratify randomisation. 50 clusters per treatment
arm, cluster size of 30. Outcome ICC = 0.005. Covariate ICC = 0.005. Data from
Table 8.4.
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Figure 8.5: Estimated type I error of linear mixed effects model analysis, unadjusted
and adjusted for a covariate used to stratify randomisation. 50 clusters per treatment
arm, cluster size of 30. Outcome ICC = 0.1. Covariate ICC = 0.1. Data from Table
8.5.
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Estimated Relative Error of SE % (MCSE) Estimated Type I Error % (MCSE)
Outcome ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted
0.0005 0.00 (0.000) 6.2 (1.7) 6.3 (1.7) 3.9 (0.4) 3.9 (0.4)
0.0005 0.25 (0.006) 3.5 (1.6) 3.3 (1.6) 4.1 (0.4) 4.3 (0.5)
0.0005 0.50 (0.011) 3.1 (1.6) 3.3 (1.6) 4.5 (0.5) 4.6 (0.5)
0.0005 0.75 (0.017) 5.5 (1.7) 5.6 (1.7) 3.9 (0.4) 3.9 (0.4)
0.0005 0.95 (0.021) 2.4 (1.6) 2.1 (1.6) 4.9 (0.5) 5.1 (0.5)
0.005 0.00 (0.000) 0.8 (1.6) 1.1 (1.6) 5.8 (0.5) 5.6 (0.5)
0.005 0.25 (0.018) 4.1 (1.7) 3.9 (1.7) 4.3 (0.5) 4.4 (0.5)
0.005 0.50 (0.035) 2.3 (1.6) 1.8 (1.6) 4.8 (0.5) 4.6 (0.5)
0.005 0.75 (0.053) 7.6 (1.7) 5.5 (1.7) 3.8 (0.4) 4.0 (0.4)
0.005 0.95 (0.067) 4.1 (1.7) 2.1 (1.6) 4.6 (0.5) 5.0 (0.5)
0.05 0.00 (0.000) 1.7 (1.6) 1.5 (1.6) 5.6 (0.5) 5.5 (0.5)
0.05 0.25 (0.056) 1.4 (1.6) -0.1 (1.6) 5.6 (0.5) 6.1 (0.5)
0.05 0.50 (0.112) 8.4 (1.7) 3.2 (1.7) 4.0 (0.4) 4.8 (0.5)
0.05 0.75 (0.168) 15.6 (1.9) 2.1 (1.6) 2.9 (0.4) 5.4 (0.5)
0.05 0.95 (0.212) 29.3 (2.1) 3.6 (1.7) 1.7 (0.3) 4.5 (0.5)
0.1 0.00 (0.000) 0.8 (1.6) 1.1 (1.6) 5.9 (0.5) 6.1 (0.5)
0.1 0.25 (0.079) -0.1 (1.6) -1.8 (1.6) 5.6 (0.5) 6.1 (0.5)
0.1 0.50 (0.158) 7.2 (1.7) 0.1 (1.6) 3.9 (0.4) 5.5 (0.5)
0.1 0.75 (0.237) 17.7 (1.9) 0.6 (1.6) 3.0 (0.4) 5.8 (0.5)
0.1 0.95 (0.300) 34.4 (2.2) 1.7 (1.6) 0.9 (0.2) 5.2 (0.5)
Table 8.3: Estimated relative error and type I error of linear mixed effects model analysis, unadjusted and adjusted for a covariate used to stratify
randomisation. 50 clusters per treatment arm, cluster size of 30. Cluster level covariate.
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Estimated Relative Error of SE % (MCSE) Estimated Type I Error % (MCSE)
Outcome ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted
0.0005 0.00 (0.000) 5.6 (1.1) 5.6 (1.1) 4.1 (0.3) 4.2 (0.3)
0.0005 0.25 (0.079) 5.2 (1.1) 4.9 (1.1) 4.1 (0.3) 4.0 (0.3)
0.0005 0.50 (0.158) 3.8 (1.0) 3.1 (1.0) 4.1 (0.3) 4.3 (0.3)
0.0005 0.75 (0.237) 6.2 (1.1) 4.1 (1.0) 4.0 (0.3) 4.4 (0.3)
0.0005 0.95 (0.300) 6.8 (1.1) 3.8 (1.0) 4.0 (0.3) 4.5 (0.3)
0.005 0.00 (0.000) 3.9 (1.0) 3.9 (1.0) 4.5 (0.3) 4.6 (0.3)
0.005 0.25 (0.250) 5.5 (1.1) 3.6 (1.0) 4.7 (0.3) 5.0 (0.3)
0.005 0.50 (0.500) 11.8 (1.1) 2.2 (1.0) 3.0 (0.2) 5.0 (0.3)
0.005 0.75 (0.750) 29.4 (1.3) 3.1 (1.0) 1.2 (0.2) 4.7 (0.3)
0.005 0.95 (0.950) 55.9 (1.6) 2.7 (1.0) 0.1 (0.1) 4.7 (0.3)
0.05 0.00 (0.000) 0.8 (1.0) 0.8 (1.0) 5.7 (0.3) 5.7 (0.3)
0.05 0.25 (0.244) 0.9 (1.0) 0.1 (1.0) 5.6 (0.3) 5.9 (0.3)
0.05 0.50 (0.489) 4.5 (1.1) 0.8 (1.0) 4.6 (0.3) 5.1 (0.3)
0.05 0.75 (0.733) 9.4 (1.1) 0.5 (1.0) 3.9 (0.3) 5.8 (0.3)
0.05 0.95 (0.928) 17.4 (1.2) 0.4 (1.0) 3.0 (0.2) 5.8 (0.3)
0.1 0.00 (0.000) -0.9 (1.0) -0.9 (1.0) 6.2 (0.3) 6.2 (0.3)
0.1 0.25 (0.238) 0.2 (1.0) -0.2 (1.0) 5.5 (0.3) 5.6 (0.3)
0.1 0.50 (0.476) 2.2 (1.0) -0.2 (1.0) 5.1 (0.3) 5.4 (0.3)
0.1 0.75 (0.713) 5.2 (1.1) -0.5 (1.0) 4.6 (0.3) 5.9 (0.3)
0.1 0.95 (0.904) 7.8 (1.1) -1.1 (1.0) 4.4 (0.3) 6.3 (0.3)
Table 8.4: Estimated relative error and type I error of linear mixed effects model analysis, unadjusted and adjusted for a covariate used to stratify
randomisation. 50 clusters per treatment arm, cluster size of 30. Covariate ICC = 0.005.
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Estimated Relative Error of SE % (MCSE) Estimated Type I Error % (MCSE)
Outcome ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted
0.0005 0.00 (0.000) 3.5 (1.0) 3.6 (1.0) 4.5 (0.3) 4.4 (0.3)
0.0005 0.25 (0.018) 4.9 (1.1) 5.0 (1.1) 4.4 (0.3) 4.5 (0.3)
0.0005 0.50 (0.035) 4.9 (1.1) 4.9 (1.1) 4.1 (0.3) 4.1 (0.3)
0.0005 0.75 (0.053) 4.6 (1.1) 4.5 (1.1) 4.4 (0.3) 4.4 (0.3)
0.0005 0.95 (0.067) 3.1 (1.0) 2.8 (1.0) 4.6 (0.3) 4.8 (0.3)
0.005 0.00 (0.000) 1.7 (1.0) 1.7 (1.0) 5.4 (0.3) 5.5 (0.3)
0.005 0.25 (0.056) 2.6 (1.0) 2.3 (1.0) 4.9 (0.3) 5.0 (0.3)
0.005 0.50 (0.112) 3.6 (1.0) 2.3 (1.0) 4.4 (0.3) 4.7 (0.3)
0.005 0.75 (0.168) 6.3 (1.1) 4.0 (1.0) 3.8 (0.3) 4.6 (0.3)
0.005 0.95 (0.212) 7.0 (1.1) 3.9 (1.0) 4.0 (0.3) 4.8 (0.3)
0.05 0.00 (0.000) 1.4 (1.0) 1.4 (1.0) 5.6 (0.3) 5.5 (0.3)
0.05 0.25 (0.177) 2.0 (1.0) 0.0 (1.0) 5.1 (0.3) 5.7 (0.3)
0.05 0.50 (0.354) 7.3 (1.1) 0.3 (1.0) 4.1 (0.3) 5.4 (0.3)
0.05 0.75 (0.530) 18.2 (1.2) -0.4 (1.0) 2.8 (0.2) 5.7 (0.3)
0.05 0.95 (0.672) 36.8 (1.4) -0.4 (1.0) 1.1 (0.1) 5.4 (0.3)
0.1 0.00 (0.000) -0.7 (1.0) -0.8 (1.0) 5.9 (0.3) 6.0 (0.3)
0.1 0.25 (0.250) 2.7 (1.0) 1.0 (1.0) 5.3 (0.3) 5.9 (0.3)
0.1 0.50 (0.500) 10.7 (1.1) 0.9 (1.0) 3.6 (0.3) 5.5 (0.3)
0.1 0.75 (0.750) 22.8 (1.2) -0.1 (1.0) 2.0 (0.2) 5.7 (0.3)
0.1 0.95 (0.950) 55.0 (1.6) 0.7 (1.0) 0.4 (0.1) 5.5 (0.3)
Table 8.5: Estimated relative error and type I error of linear mixed effects model analysis, unadjusted and adjusted for a covariate used to stratify
randomisation. 50 clusters per treatment arm, cluster size of 30. Covariate ICC = 0.1.
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8.3 Effects of covariate adjustment in linear mixed
effects models
In this section I present empirical standard errors and estimated power from simula-
tions of unadjusted and adjusted linear mixed effects model analyses.
In all situations, adjusting for a covariate with no effect on the outcome did not signif-
icantly change the estimated power of the analysis or the standard error of estimated
treatment effect. As covariate effect increased, estimated power of adjusted analyses
increased and empirical standard errors from adjusted analyses became smaller.
Empirical standard errors and estimated power from simulations of unadjusted and
adjusted linear mixed effects model analyses are presented in Tables 8.6 to 8.9, for
simulated CRTs with a cluster size of 30 and 20 clusters in each treatment arm. The
tables also present the power of the adjusted analyses as calculated using equation
7.21.
Results for an outcome with an ICC of 0.0005 are presented in Table 8.6 (page 146).
Adjusting for a covariate with an ICC of 0.0005 increased estimated power to a max-
imum of 100% from 78% (see Figure 8.6, page 145), reducing standard error from
0.058 to 0.018. Adjusting for a covariate with an ICC of 0.05 did not significantly
increase estimated power or reduce empirical standard error for any size of covariate
effect. Adjusting for a cluster level covariate also did not increase estimated power or
reduce empirical standard error for any size of covariate effect.
144
70
80
90
10
0
Es
tim
at
ed
 P
ow
er
 (%
)
0.00 0.25 0.50 0.75 0.95
Covariate Effect Parameter
Unadjusted Adjusted for covariate
Figure 8.6: Estimated power when using a linear mixed effects model, unadjusted and
adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome ICC
= 0.0005. Covariate ICC = 0.0005. Treatment effect parameter = 0.163. Data from
Table 8.6.
145
Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.0005 0.00 (0.000) 0.059 (0.001) 0.059 (0.001) 78.6 (0.6) 78.6 (0.6) 77.9
0.0005 0.25 (0.250) 0.058 (0.001) 0.056 (0.001) 78.0 (0.6) 80.6 (0.6) 80.4
0.0005 0.50 (0.500) 0.059 (0.001) 0.051 (0.001) 77.6 (0.6) 88.3 (0.5) 88.3
0.0005 0.75 (0.750) 0.059 (0.001) 0.039 (<0.001) 77.1 (0.6) 98.5 (0.2) 98.5
0.0005 0.95 (0.950) 0.058 (0.001) 0.018 (<0.001) 77.6 (0.6) 100.0 - 100.0
0.1 0.00 (0.000) 0.058 (0.001) 0.058 (0.001) 76.8 (0.6) 76.8 (0.6) 77.9
0.1 0.25 (0.018) 0.058 (0.001) 0.058 (0.001) 77.8 (0.6) 77.7 (0.6) 77.9
0.1 0.50 (0.035) 0.058 (0.001) 0.058 (0.001) 77.7 (0.6) 77.7 (0.6) 78.1
0.1 0.75 (0.053) 0.058 (0.001) 0.057 (0.001) 77.5 (0.6) 77.2 (0.6) 78.3
0.1 0.95 (0.067) 0.059 (0.001) 0.059 (0.001) 76.6 (0.6) 77.0 (0.6) 78.6
1 0.00 (0.000) 0.058 (0.001) 0.059 (0.001) 77.6 (0.6) 76.4 (0.6) 77.9
1 0.25 (0.006) 0.058 (0.001) 0.059 (0.001) 78.6 (0.6) 77.2 (0.6) 77.9
1 0.50 (0.011) 0.058 (0.001) 0.059 (0.001) 77.9 (0.6) 76.6 (0.6) 78.0
1 0.75 (0.017) 0.058 (0.001) 0.059 (0.001) 77.5 (0.6) 77.2 (0.6) 78.2
1 0.95 (0.021) 0.058 (0.001) 0.058 (0.001) 77.4 (0.6) 77.2 (0.6) 78.4
Table 8.6: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 20 clusters per
treatment arm, cluster size 30. Outcome ICC = 0.0005. Treatment effect parameter = 0.163. (CEF = Covariate Effect Factor. MCSE = Monte
Carlo Standard Error.)
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Results for an outcome with an ICC of 0.005 are presented in Table 8.7 (page 149).
Adjusting for a covariate with an ICC of 0.0005 or an ICC of 0.005 increased estimated
power to a maximum of 100% (see Figures 8.7 and 8.8, page 148). Adjusting for a
covariate with an ICC of 0.0005 reduced empirical standard error from 0.062 to 0.028,
and adjusting for a covariate with an ICC of 0.005 reduced empirical standard error
from 0.061 to 0.019. Adjusting for a covariate with an ICC of 0.1 increased estimated
power to a maximum of 84% from 79% (see Figure 8.9, page 148), reducing empirical
standard error from 0.063 to 0.058.
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Figure 8.7: Estimated power when using a linear mixed effects model, unadjusted and
adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome ICC
= 0.005. Covariate ICC = 0.0005. Treatment effect parameter = 0.173. Data from
Table 8.7.
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Figure 8.8: Estimated power when using a linear mixed effects model, unadjusted and
adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome ICC
= 0.005. Covariate ICC = 0.005. Treatment effect parameter = 0.173. Data from
Table 8.7.
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Figure 8.9: Estimated power when using a linear mixed effects model, unadjusted and
adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome ICC
= 0.005. Covariate ICC = 0.1. Treatment effect parameter = 0.173. Data from Table
8.7.
148
Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.0005 0.00 (0.000) 0.060 (0.001) 0.060 (0.001) 79.5 (0.6) 79.6 (0.6) 77.9
0.0005 0.25 (0.249) 0.063 (0.001) 0.061 (0.001) 77.9 (0.6) 80.1 (0.6) 80.1
0.0005 0.50 (0.499) 0.062 (0.001) 0.054 (0.001) 79.8 (0.6) 88.8 (0.4) 87.1
0.0005 0.75 (0.748) 0.061 (0.001) 0.044 (<0.001) 79.2 (0.6) 97.2 (0.2) 97.0
0.0005 0.95 (0.948) 0.062 (0.001) 0.028 (<0.001) 78.6 (0.6) 100.0 - 100.0
0.005 0.00 (0.000) 0.063 (0.001) 0.063 (0.001) 78.8 (0.6) 78.7 (0.6) 77.9
0.005 0.25 (0.250) 0.062 (0.001) 0.060 (0.001) 79.1 (0.6) 81.9 (0.5) 80.4
0.005 0.50 (0.500) 0.062 (0.001) 0.053 (0.001) 78.9 (0.6) 89.1 (0.4) 88.3
0.005 0.75 (0.750) 0.061 (0.001) 0.041 (<0.001) 79.5 (0.6) 98.9 (0.2) 98.5
0.005 0.95 (0.950) 0.061 (0.001) 0.019 (<0.001) 79.4 (0.6) 100.0 - 100.0
Continued on next page.
Table 8.7: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 20 clusters per
treatment arm, cluster size of 30. Outcome ICC = 0.005. Treatment effect parameter = 0.173. (CEF = Covariate Effect Factor. MCSE = Monte
Carlo Standard Error.)
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.1 0.00 (0.000) 0.061 (0.001) 0.061 (0.001) 79.0 (0.6) 79.0 (0.6) 77.9
0.1 0.25 (0.056) 0.061 (0.001) 0.060 (0.001) 79.8 (0.6) 80.2 (0.6) 78.3
0.1 0.50 (0.112) 0.061 (0.001) 0.060 (0.001) 80.2 (0.6) 81.4 (0.6) 79.6
0.1 0.75 (0.168) 0.061 (0.001) 0.058 (0.001) 78.2 (0.6) 82.0 (0.5) 81.8
0.1 0.95 (0.212) 0.063 (0.001) 0.058 (0.001) 78.9 (0.6) 83.9 (0.5) 84.3
1 0.00 (0.000) 0.062 (0.001) 0.063 (0.001) 79.0 (0.6) 78.2 (0.6) 77.9
1 0.25 (0.018) 0.062 (0.001) 0.063 (0.001) 78.6 (0.6) 77.7 (0.6) 78.2
1 0.50 (0.035) 0.062 (0.001) 0.062 (0.001) 78.0 (0.6) 77.8 (0.6) 79.2
1 0.75 (0.053) 0.062 (0.001) 0.061 (0.001) 77.4 (0.6) 79.5 (0.6) 80.9
1 0.95 (0.067) 0.061 (0.001) 0.058 (0.001) 79.1 (0.6) 82.0 (0.5) 82.8
Table 8.7: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 20 clusters per
treatment arm, cluster size of 30. Outcome ICC = 0.005. Treatment effect parameter = 0.173. (CEF = Covariate Effect Factor. MCSE = Monte
Carlo Standard Error.)
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Results for an outcome with an ICC of 0.05 are presented in Table 8.8 (page 153).
Adjusting for a covariate with an ICC of 0.0005 increased estimated power to a max-
imum of 93% from 81% (see Figure 8.10). Adjusting for a covariate with an ICC of
0.05 increased estimated power to a maximum of 100% from 80% (see Figure 8.11,
page 152), reducing empirical standard error from 0.091 to 0.028. Adjusting for a
cluster level covariate increased estimated power to a maximum of 98% from 80% (see
Figure 8.12, page 152), reducing empirical standard error from 0.090 to 0.060.
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Figure 8.10: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome
ICC = 0.05. Covariate ICC = 0.0005. Treatment effect parameter = 0.253. Data
from Table 8.8.
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Figure 8.11: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome
ICC = 0.05. Covariate ICC = 0.05. Treatment effect parameter = 0.253. Data from
Table 8.8.
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Figure 8.12: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome
ICC = 0.05. Covariate ICC = 0.1. Treatment effect parameter = 0.253. Data from
Table 8.8.
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.0005 0.00 (0.000) 0.093 (0.001) 0.093 (0.001) 79.3 (0.6) 79.4 (0.6) 77.9
0.0005 0.25 (0.244) 0.091 (0.001) 0.089 (0.001) 79.5 (0.6) 80.3 (0.6) 78.9
0.0005 0.50 (0.487) 0.089 (0.001) 0.085 (0.001) 80.4 (0.6) 83.7 (0.5) 81.9
0.0005 0.75 (0.731) 0.090 (0.001) 0.079 (0.001) 80.5 (0.6) 89.2 (0.4) 87.1
0.0005 0.95 (0.926) 0.091 (0.001) 0.073 (0.001) 80.5 (0.6) 93.2 (0.4) 92.5
0.05 0.00 (0.000) 0.092 (0.001) 0.092 (0.001) 79.6 (0.6) 79.6 (0.6) 77.9
0.05 0.25 (0.250) 0.091 (0.001) 0.089 (0.001) 79.5 (0.6) 81.9 (0.5) 80.4
0.05 0.50 (0.500) 0.091 (0.001) 0.079 (0.001) 79.8 (0.6) 89.7 (0.4) 88.3
0.05 0.75 (0.750) 0.090 (0.001) 0.059 (0.001) 79.3 (0.6) 98.7 (0.2) 98.5
0.05 0.95 (0.950) 0.091 (0.001) 0.028 (<0.001) 79.5 (0.6) 100.0 - 100.0
Continued on next page.
Table 8.8: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 20 clusters per
treatment arm, cluster size of 30. Outcome ICC = 0.05. Treatment effect parameter = 0.253. (CEF=Covariate Effect Factor. MCSE=Monte Carlo
Standard Error.)
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.1 0.00 (0.000) 0.091 (0.001) 0.091 (0.001) 79.1 (0.6) 79.1 (0.6) 77.9
0.1 0.25 (0.177) 0.090 (0.001) 0.087 (0.001) 78.9 (0.6) 81.4 (0.5) 79.9
0.1 0.50 (0.354) 0.089 (0.001) 0.080 (0.001) 80.0 (0.6) 88.1 (0.5) 86.2
0.1 0.75 (0.530) 0.090 (0.001) 0.067 (0.001) 79.0 (0.6) 96.1 (0.3) 95.6
0.1 0.95 (0.672) 0.090 (0.001) 0.049 (<0.001) 79.5 (0.6) 99.9 (<0.1) 99.9
1 0.00 (0.000) 0.091 (0.001) 0.092 (0.001) 79.1 (0.6) 78.4 (0.6) 77.9
1 0.25 (0.056) 0.090 (0.001) 0.090 (0.001) 79.9 (0.6) 80.8 (0.6) 79.4
1 0.50 (0.112) 0.089 (0.001) 0.084 (0.001) 80.3 (0.6) 85.2 (0.5) 84.2
1 0.75 (0.168) 0.090 (0.001) 0.074 (0.001) 79.7 (0.6) 92.0 (0.4) 92.1
1 0.95 (0.212) 0.090 (0.001) 0.060 (0.001) 79.6 (0.6) 98.4 (0.2) 98.3
Table 8.8: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 20 clusters per
treatment arm, cluster size of 30. Outcome ICC = 0.05. Treatment effect parameter = 0.253. (CEF=Covariate Effect Factor. MCSE=Monte Carlo
Standard Error.)
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Results for an outcome with an ICC of 0.1 are presented in Table 8.9 (page 157).
Adjusting for a covariate with an ICC of 0.0005 increased estimated power to a max-
imum of 88% from 80% (see Figure 8.13). Adjusting for a covariate with an ICC
of 0.1 increased estimated power to a maximum of 100% from 80% (see Figure 8.14,
page 156), reducing empirical standard error from 0.113 to 0.036. Adjusting for a
cluster level covariate increased estimated power to a maximum of 99.9% from 79%
(see Figure 8.15, page 156).
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Figure 8.13: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome
ICC = 0.1. Covariate ICC = 0.0005. Treatment effect parameter = 0.31943. Data
from Table 8.9.
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Figure 8.14: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome
ICC = 0.1. Covariate ICC = 0.1. Treatment effect parameter = 0.319. Data from
Table 8.9.
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Figure 8.15: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Outcome
ICC = 0.1. Cluster level covariate. Treatment effect parameter = 0.319. Data from
Table 8.9.
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.0005 0.00 (0.000) 0.113 (0.001) 0.113 (0.001) 80.1 (0.6) 80.2 (0.6) 77.9
0.0005 0.25 (0.237) 0.113 (0.001) 0.112 (0.001) 80.1 (0.6) 80.4 (0.6) 78.5
0.0005 0.50 (0.474) 0.112 (0.001) 0.109 (0.001) 80.3 (0.6) 82.4 (0.5) 80.3
0.0005 0.75 (0.712) 0.114 (0.001) 0.107 (0.001) 80.2 (0.6) 85.0 (0.5) 83.3
0.0005 0.95 (0.901) 0.113 (0.001) 0.101 (0.001) 79.9 (0.6) 88.2 (0.5) 86.7
0.1 0.00 (0.000) 0.112 (0.001) 0.112 (0.001) 79.4 (0.6) 79.2 (0.6) 77.9
0.1 0.25 (0.250) 0.113 (0.001) 0.110 (0.001) 80.3 (0.6) 82.7 (0.5) 80.4
0.1 0.50 (0.500) 0.115 (0.001) 0.098 (0.001) 79.5 (0.6) 89.9 (0.4) 88.3
0.1 0.75 (0.750) 0.115 (0.001) 0.076 (0.001) 80.0 (0.6) 98.9 (0.2) 98.5
0.1 0.95 (0.950) 0.113 (0.001) 0.036 (<0.001) 80.3 (0.6) 100.0 - 100.0
1 0.00 (0.000) 0.113 (0.001) 0.115 (0.001) 80.9 (0.6) 79.9 (0.6) 77.9
1 0.25 (0.079) 0.115 (0.001) 0.113 (0.001) 79.9 (0.6) 80.6 (0.6) 79.8
1 0.50 (0.158) 0.114 (0.001) 0.103 (0.001) 80.1 (0.6) 87.1 (0.5) 85.9
1 0.75 (0.237) 0.114 (0.001) 0.087 (0.001) 79.5 (0.6) 95.4 (0.3) 95.2
1 0.95 (0.300) 0.114 (0.001) 0.064 (0.001) 79.3 (0.6) 99.9 (<0.1) 99.9
Table 8.9: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 20 clusters per
treatment arm, cluster size of 30. Outcome ICC = 0.1. Treatment effect parameter = 0.319. (CEF=Covariate Effect Factor. MCSE=Monte Carlo
Standard Error.)
157
Tables 8.10 to 8.13 present empirical standard error and estimated power under un-
adjusted and adjusted analyses for simulated CRTs with 60 clusters in each treatment
arm and a cluster size of five.
Results for an outcome with an ICC of 0.0005 are presented in Table 8.10 (page
159). Adjusting for a covariate with an ICC of 0.0005 increased estimated power to
a maximum of 100% from 79% (see Figure 8.16), reducing empirical standard error
from 0.082 to 0.026. Adjusting for a covariate with an ICC of 0.05 or a cluster level
covariate did not significantly increase estimated power or reduce empirical standard
error. Power calculated from the formula suggest that these would increase power by
less than 1%.
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Figure 8.16: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.0005. Covariate ICC = 0.0005. Treatment effect parameter = 0.229. Data
from Table 8.10.
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.0005 0.00 (0.000) 0.081 (0.001) 0.081 (0.001) 79.5 (0.6) 79.6 (0.6) 79.3
0.0005 0.25 (0.250) 0.082 (0.001) 0.080 (0.001) 78.2 (0.6) 80.6 (0.6) 81.9
0.0005 0.50 (0.500) 0.081 (0.001) 0.070 (0.001) 78.9 (0.6) 89.1 (0.4) 89.4
0.0005 0.75 (0.750) 0.083 (0.001) 0.054 (0.001) 79.5 (0.6) 98.9 (0.1) 98.7
0.0005 0.95 (0.950) 0.082 (0.001) 0.026 (<0.001) 79.0 (0.6) 100.0 - 100.0
0.1 0.00 (0.000) 0.083 (0.001) 0.084 (0.001) 78.4 (0.6) 78.3 (0.6) 79.3
0.1 0.25 (0.018) 0.081 (0.001) 0.081 (0.001) 78.7 (0.6) 78.7 (0.6) 79.4
0.1 0.50 (0.035) 0.082 (0.001) 0.082 (0.001) 78.4 (0.6) 78.5 (0.6) 79.4
0.1 0.75 (0.053) 0.081 (0.001) 0.081 (0.001) 79.5 (0.6) 79.4 (0.6) 79.5
0.1 0.95 (0.067) 0.081 (0.001) 0.081 (0.001) 79.1 (0.6) 79.2 (0.6) 79.6
1 0.00 (0.000) 0.083 (0.001) 0.083 (0.001) 79.4 (0.6) 79.3 (0.6) 79.3
1 0.25 (0.006) 0.081 (0.001) 0.082 (0.001) 78.8 (0.6) 78.1 (0.6) 79.4
1 0.50 (0.011) 0.083 (0.001) 0.083 (0.001) 77.8 (0.6) 77.9 (0.6) 79.4
1 0.75 (0.017) 0.081 (0.001) 0.081 (0.001) 78.2 (0.6) 77.5 (0.6) 79.4
1 0.95 (0.021) 0.082 (0.001) 0.083 (0.001) 79.3 (0.6) 79.0 (0.6) 79.4
Table 8.10: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 60 clusters per
treatment arm, cluster size of 5. Outcome ICC = 0.0005. Treatment effect parameter = 0.229. (CEF=Covariate Effect Factor. MCSE=Monte
Carlo Standard Error.)
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Results for an outcome with an ICC of 0.005 are presented in Table 8.11 (page 162).
Adjusting for a covariate with an ICC of 0.0005 increased estimated power to a max-
imum of 100% from 80% (see Figure 8.17), reducing empirical standard error from
0.082 to 0.029. Adjusting for a covariate with an ICC of 0.005 increased estimated
power to a maximum of 100% from 79% (see Figure 8.18, page 161), reducing stan-
dard error from 0.081 to 0.026. Adjusting for a covariate with an ICC of 0.1 increased
estimated power to a maximum of 83% (see Figure 8.19, page 161).
70
80
90
10
0
Es
tim
at
ed
 P
ow
er
 (%
)
0.00 0.25 0.50 0.75 0.95
Covariate Effect Parameter
Unadjusted Adjusted for covariate
Figure 8.17: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.005. Covariate ICC = 0.0005. Treatment effect parameter = 0.231. Data
from Table 8.11.
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Figure 8.18: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.005. Covariate ICC = 0.005. Treatment effect parameter = 0.231. Data
from Table 8.11.
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Figure 8.19: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.005. Covariate ICC = 0.1. Treatment effect parameter = 0.231. Data from
Table 8.11.
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.0005 0.00 (0.000) 0.083 (0.001) 0.083 (0.001) 79.4 (0.6) 79.4 (0.6) 79.3
0.0005 0.25 (0.249) 0.082 (0.001) 0.080 (0.001) 79.2 (0.6) 81.5 (0.5) 81.8
0.0005 0.50 (0.499) 0.083 (0.001) 0.071 (0.001) 78.8 (0.6) 88.8 (0.4) 89.2
0.0005 0.75 (0.748) 0.084 (0.001) 0.056 (0.001) 78.8 (0.6) 98.5 (0.2) 98.5
0.0005 0.95 (0.948) 0.082 (0.001) 0.029 (<0.001) 79.8 (0.6) 100.0 - 100.0
0.005 0.00 (0.000) 0.082 (0.001) 0.082 (0.001) 78.4 (0.6) 78.4 (0.6) 79.3
0.005 0.25 (0.250) 0.082 (0.001) 0.080 (0.001) 79.3 (0.6) 82.1 (0.5) 81.9
0.005 0.50 (0.500) 0.082 (0.001) 0.071 (0.001) 78.9 (0.6) 89.1 (0.4) 89.4
0.005 0.75 (0.750) 0.082 (0.001) 0.054 (0.001) 78.4 (0.6) 98.5 (0.2) 98.7
0.005 0.95 (0.950) 0.081 (0.001) 0.026 (<0.001) 79.4 (0.6) 100.0 - 100.0
Continued on next page.
Table 8.11: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 60 clusters per
treatment arm, cluster size of 5. Outcome ICC = 0.005. Treatment effect parameter = 0.231. (CEF=Covariate Effect Factor. MCSE=Monte Carlo
Standard Error.)
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.1 0.00 (0.000) 0.083 (0.001) 0.083 (0.001) 78.3 (0.6) 78.3 (0.6) 79.3
0.1 0.25 (0.056) 0.083 (0.001) 0.083 (0.001) 78.8 (0.6) 79.2 (0.6) 79.5
0.1 0.50 (0.112) 0.083 (0.001) 0.083 (0.001) 79.2 (0.6) 79.2 (0.6) 80.0
0.1 0.75 (0.168) 0.082 (0.001) 0.080 (0.001) 78.8 (0.6) 79.7 (0.6) 80.9
0.1 0.95 (0.212) 0.083 (0.001) 0.080 (0.001) 79.9 (0.6) 82.6 (0.5) 81.8
1 0.00 (0.000) 0.081 (0.001) 0.082 (0.001) 78.6 (0.6) 78.4 (0.6) 79.3
1 0.25 (0.018) 0.084 (0.001) 0.084 (0.001) 78.2 (0.6) 77.6 (0.6) 79.4
1 0.50 (0.035) 0.083 (0.001) 0.083 (0.001) 78.3 (0.6) 78.2 (0.6) 79.6
1 0.75 (0.053) 0.083 (0.001) 0.082 (0.001) 78.4 (0.6) 78.7 (0.6) 79.9
1 0.95 (0.067) 0.083 (0.001) 0.082 (0.001) 79.1 (0.6) 79.4 (0.6) 80.2
Table 8.11: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 60 clusters per
treatment arm, cluster size of 5. Outcome ICC = 0.005. Treatment effect parameter = 0.231. (CEF=Covariate Effect Factor. MCSE=Monte Carlo
Standard Error.)
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Results for an outcome with an ICC of 0.05 are presented in table 8.12 (page 166). Ad-
justing for a covariate with an ICC of 0.0005 increased estimated power to a maximum
of 100% from 79% (see Figure 8.20), reducing empirical standard error from 0.091 to
0.047. Adjusting for a covariate with an ICC of 0.05 increased estimated power to a
maximum of 100% from 81%, reducing empirical standard error from 0.090 to 0.028.
Adjusting for a cluster level covariate increased estimated power to a maximum of 86%
(see Figure 8.21, page 165), reducing empirical standard error from 0.091 to 0.082.
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Figure 8.20: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.05. Covariate ICC = 0.0005. Treatment effect parameter = 0.251. Data
from Table 8.12.
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Figure 8.21: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.05. Cluster level covariate. Treatment effect parameter = 0.251. Data from
Table 8.12.
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.0005 0.00 (0.000) 0.090 (0.001) 0.090 (0.001) 79.5 (0.6) 79.4 (0.6) 79.3
0.0005 0.25 (0.244) 0.090 (0.001) 0.087 (0.001) 80.6 (0.6) 82.7 (0.5) 81.3
0.0005 0.50 (0.487) 0.091 (0.001) 0.081 (0.001) 80.8 (0.6) 87.4 (0.5) 87.4
0.0005 0.75 (0.731) 0.090 (0.001) 0.067 (0.001) 79.2 (0.6) 96.0 (0.3) 96.2
0.0005 0.95 (0.926) 0.091 (0.001) 0.047 (<0.001) 78.8 (0.6) 100.0 - 99.9
0.05 0.00 (0.000) 0.089 (0.001) 0.090 (0.001) 79.6 (0.6) 79.4 (0.6) 79.3
0.05 0.25 (0.250) 0.089 (0.001) 0.086 (0.001) 79.7 (0.6) 82.1 (0.5) 81.9
0.05 0.50 (0.500) 0.088 (0.001) 0.077 (0.001) 81.4 (0.6) 90.4 (0.4) 89.4
0.05 0.75 (0.750) 0.089 (0.001) 0.059 (0.001) 79.9 (0.6) 99.0 (0.1) 98.7
0.05 0.95 (0.950) 0.090 (0.001) 0.028 (<0.001) 80.6 (0.6) 100.0 - 100.0
Continued on next page.
Table 8.12: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 60 clusters per
treatment arm, cluster size of 5. Outcome ICC = 0.05. Treatment effect parameter = 0.251. (CEF = Covariate Effect Factor. MCSE = Monte
Carlo Standard Error.)
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Continued from previous page.
Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.1 0.00 (0.000) 0.090 (0.001) 0.090 (0.001) 79.7 (0.6) 79.5 (0.6) 79.3
0.1 0.25 (0.177) 0.089 (0.001) 0.088 (0.001) 80.6 (0.6) 81.5 (0.5) 80.8
0.1 0.50 (0.354) 0.089 (0.001) 0.083 (0.001) 78.8 (0.6) 85.1 (0.5) 85.2
0.1 0.75 (0.530) 0.091 (0.001) 0.074 (0.001) 79.9 (0.6) 92.4 (0.4) 92.4
0.1 0.95 (0.672) 0.089 (0.001) 0.061 (0.001) 80.0 (0.6) 98.1 (0.2) 98.1
1 0.00 (0.000) 0.090 (0.001) 0.091 (0.001) 80.0 (0.6) 79.5 (0.6) 79.3
1 0.25 (0.056) 0.090 (0.001) 0.090 (0.001) 80.0 (0.6) 80.5 (0.6) 79.9
1 0.50 (0.112) 0.089 (0.001) 0.087 (0.001) 79.4 (0.6) 81.2 (0.6) 81.4
1 0.75 (0.168) 0.088 (0.001) 0.084 (0.001) 79.5 (0.6) 84.0 (0.5) 84.1
1 0.95 (0.212) 0.091 (0.001) 0.082 (0.001) 79.5 (0.6) 86.1 (0.5) 86.9
Table 8.12: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 60 clusters per
treatment arm, cluster size of 5. Outcome ICC = 0.05. Treatment effect parameter = 0.251. (CEF = Covariate Effect Factor. MCSE = Monte
Carlo Standard Error.)
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Results for an outcome with an ICC of 0.1 are presented in Table 8.13 (page 170).
Adjusting for a covariate with an ICC of 0.0005 increased estimated power to a max-
imum of 99% from 80% (see Figure 8.22). Adjusting for covariate with an ICC of
0.1 increased estimated power to maximum of 100% from 81% (see Figure 8.23, page
169), reducing empirical standard error from 0.096 to 0.03. Adjusting for a cluster
level covariate increased estimated power to a maximum of 92% from 81% (see Figure
8.24, page 169), reducing empirical standard error from 0.096 to 0.080.
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Figure 8.22: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.1. Covariate ICC = 0.0005. Treatment effect parameter = 0.2706589. Data
from Table 8.13.
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Figure 8.23: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.1. Covariate ICC = 0.1. Treatment effect parameter = 0.2706589. Data
from Table 8.13.
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Figure 8.24: Estimated power when using a linear mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Outcome
ICC = 0.1. Cluster level covariate. Treatment effect parameter = 0.2706589. Data
from Table 8.13.
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Empirical SE (MCSE) Estimated Power % (MCSE) Power %
Covariate ICC CEF (parameter) Unadjusted Adjusted Unadjusted Adjusted From Formula
0.0005 0.00 (0.000) 0.097 (0.001) 0.097 (0.001) 80.3 (0.6) 80.2 (0.6) 79.3
0.0005 0.25 (0.237) 0.096 (0.001) 0.094 (0.001) 80.3 (0.6) 81.8 (0.5) 81.0
0.0005 0.50 (0.474) 0.098 (0.001) 0.090 (0.001) 80.1 (0.6) 85.8 (0.5) 85.9
0.0005 0.75 (0.712) 0.096 (0.001) 0.077 (0.001) 79.6 (0.6) 93.7 (0.3) 93.6
0.0005 0.95 (0.901) 0.096 (0.001) 0.062 (0.001) 79.6 (0.6) 99.3 (0.1) 99.0
0.1 0.00 (0.000) 0.096 (0.001) 0.096 (0.001) 79.5 (0.6) 79.5 (0.6) 79.3
0.1 0.25 (0.250) 0.096 (0.001) 0.094 (0.001) 80.3 (0.6) 82.8 (0.5) 81.9
0.1 0.50 (0.500) 0.096 (0.001) 0.084 (0.001) 80.2 (0.6) 89.7 (0.4) 89.4
0.1 0.75 (0.750) 0.096 (0.001) 0.063 (0.001) 79.2 (0.6) 98.9 (0.1) 98.7
0.1 0.95 (0.950) 0.097 (0.001) 0.030 (<0.001) 81.0 (0.6) 100.0 - 100.0
1 0.00 (0.000) 0.097 (0.001) 0.098 (0.001) 80.6 (0.6) 80.3 (0.6) 79.3
1 0.25 (0.079) 0.096 (0.001) 0.096 (0.001) 80.4 (0.6) 81.0 (0.6) 80.2
1 0.50 (0.158) 0.096 (0.001) 0.093 (0.001) 79.5 (0.6) 82.7 (0.5) 82.9
1 0.75 (0.237) 0.098 (0.001) 0.087 (0.001) 79.1 (0.6) 86.7 (0.5) 87.5
1 0.95 (0.300) 0.096 (0.001) 0.080 (0.001) 80.9 (0.6) 92.4 (0.4) 92.1
Table 8.13: Estimated standard error and power, and power calculated from formula, when using a linear mixed effects model. 60 clusters per
treatment arm, cluster size of 5. Outcome ICC = 0.1. Treatment effect parameter = 0.271. (CEF = Covariate Effect Factor. MCSE = Monte Carlo
Standard Error.)
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Overall, adjusting for a covariate with the same ICC as the outcome increased esti-
mated power to a maximum of 100%. For an outcome with an ICC of 0.005, adjusting
for a covariate with an ICC of 0.0005 also increased estimated power to a maximum
of 100%.
With a cluster size of five, adjusting for a covariate with smaller ICC than the outcome
generally increased estimated power more than adjusting for a cluster level covariate.
With a cluster size of 30, this was true for outcomes with an ICC less than or equal to
0.005. However, for an outcome with an ICC of 0.05 or 0.1, adjusting for a cluster level
covariate increased estimated power more than adjusting for a covariate with an ICC
of 0.0005. Adjusting for a cluster level covariate was most beneficial for increasing
estimated power and reducing empirical standard error when the outcome ICC was
larger, and with larger cluster size. The patterns observed when the covariate effect
is largest are also seen for smaller covariate effects.
8.4 Effects of covariate adjustment in logistic mixed
effects models
In this section I present empirical standard errors and estimated power from simula-
tions of unadjusted and adjusted logistic mixed effects model analyses.
In all situations, adjusting for a covariate with no effect on the outcome did not
significantly change the estimated power of the analysis or the empirical standard
error of estimated treatment effect. As covariate effect increased, estimated power of
adjusted analyses increased.
Adjusting for an individual level covariate typically increased the empirical standard
error of the treatment effect estimate. For example, for a CRT with 20 clusters per
treatment arm and a cluster size of 30, for an outcome with an ICC of 0.05 and
expected value in the control treatment arm of 0.1, adjusting for a covariate with an
ICC of 0.05 increased empirical standard error to a maximum of 0.778 from 0.319
(see Table 8.16, page 180, and Figure 8.25, page 172). Adjusting for a cluster level
covariate, however, only reduced the empirical standard error. For example, for a
CRT with 20 clusters per treatment arm and a cluster size of 30, for an outcome with
an ICC of 0.05 and expected value in the control treatment arm of 0.1, adjusting for a
cluster level covariate decreased empirical standard error to a minimum of 0.204 from
0.304 (see Table 8.16, page 180, and Figure 8.26, page 172).
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Figure 8.25: Empirical standard error from adjusted logistic mixed effects model anal-
ysis. 20 clusters per treatment arm, cluster size of 30. Expected value of outcome in
control arm = 0.1. Outcome ICC = 0.05. Covariate ICC = 0.05. Data from Table
8.16.
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Figure 8.26: Empirical standard error from adjusted logistic mixed effects model anal-
ysis. 20 clusters per treatment arm, cluster size of 30. Expected value of outcome in
control arm = 0.1. Outcome ICC = 0.05. Cluster level covariate. Data from Table
8.16.
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As discussed in Section 2.2 with regard to individually randomised trials, adjusted and
unadjusted treatment effect parameters do not coincide when using logistic regression
models. Both are valid measures of treatment effect, but have different interpretations.
The unadjusted treatment effect is a marginal effect, while the adjusted treatment
effect is a conditional effect. In these results I present the estimated relative asymptotic
bias, which is the estimated difference between the adjusted treatment effect estimate
and the unadjusted treatment effect parameter.
Estimated relative asymptotic bias was close to zero when adjusting for a cluster level
covariate. When adjusting for an individual level covariate, the estimated relative
asymptotic bias increased as the covariate effect increased. Although, when adjusting
for a covariate that does not notably increase power, the estimates of relative asymp-
totic bias are small. For example, for a CRT with 60 clusters per treatment arm and
a cluster size of five, for an outcome with an ICC of 0.0005 and expected value in the
control treatment arm of 0.5, when adjusting for a covariate with an ICC of 0.0005
estimated relative asymptotic bias reached as high as 278% (see Table 8.21, page 195,
and Figure 8.27).
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Figure 8.27: Estimated relative asymptotic bias from adjusted logistic mixed effects
model analysis. 60 clusters per treatment arm, cluster size of 5. Expected value of
outcome in control arm = 0.5. Outcome ICC = 0.0005. Covariate ICC = 0.0005.
Data from Table 8.21
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Results for simulated CRTs with 20 clusters in each treatment arm and a cluster size
of 30 are presented in Tables 8.14 to 8.19.
Results for an outcome with an ICC of 0.0005, and an expected value of the outcome
in the control arm of 0.1, are presented in Table 8.14 (page 175). Adjusting for a
covariate with an ICC of 0.0005 increased estimated power to a maximum of 100%
from 78% (see Figure 8.28). In this case, standard error increased from 0.183 to 0.350
and the estimated relative asymptotic bias was 212.4. Adjusting for a covariate with
an ICC of 0.1, or a cluster level covariate, did not significantly change the estimated
power or empirical standard error.
70
80
90
10
0
Es
tim
at
ed
 P
ow
er
 (%
)
0.00 0.25 0.50 0.75 0.95
Covariate Effect Parameter
Unadjusted Adjusted for covariate
Figure 8.28: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.0005. Covariate ICC =
0.0005. Difference between treatment arms = 0.054. Data from Table 8.14.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.177 (0.006) 0.178 (0.006) 82.0 (1.7) 81.8 (1.7) 0.1
0.0005 0.25 (0.250) 0.189 (0.006) 0.190 (0.006) 74.4 (2.0) 77.8 (1.9) 3.0
0.0005 0.50 (0.500) 0.174 (0.006) 0.189 (0.006) 78.8 (1.8) 83.0 (1.7) 13.5
0.0005 0.75 (0.750) 0.181 (0.006) 0.225 (0.007) 77.4 (1.9) 88.8 (1.4) 49.4
0.0005 0.95 (0.950) 0.183 (0.006) 0.350 (0.011) 78.2 (1.8) 99.8 (0.2) 212.4
0.1 0.00 (0.000) 0.179 (0.006) 0.179 (0.006) 81.6 (1.7) 81.4 (1.7) 0.0
0.1 0.25 (0.030) 0.189 (0.006) 0.189 (0.006) 76.0 (1.9) 76.8 (1.9) 0.1
0.1 0.50 (0.060) 0.175 (0.006) 0.177 (0.006) 80.2 (1.8) 80.4 (1.8) 0.0
0.1 0.75 (0.091) 0.182 (0.006) 0.181 (0.006) 78.2 (1.8) 79.6 (1.8) 0.5
0.1 0.95 (0.115) 0.184 (0.006) 0.183 (0.006) 76.6 (1.9) 77.8 (1.9) 0.3
1 0.00 (0.000) 0.178 (0.006) 0.181 (0.006) 77.4 (1.9) 77.0 (1.9) 0.3
1 0.25 (0.010) 0.176 (0.006) 0.180 (0.006) 77.8 (1.9) 76.6 (1.9) 0.3
1 0.50 (0.019) 0.180 (0.006) 0.184 (0.006) 77.6 (1.9) 76.6 (1.9) 0.0
1 0.75 (0.029) 0.175 (0.006) 0.178 (0.006) 81.0 (1.8) 80.6 (1.8) −0.1
1 0.95 (0.036) 0.176 (0.006) 0.179 (0.006) 78.2 (1.8) 78.4 (1.8) −0.1
Table 8.14: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.1 in the control treatment arm. 10 clusters per treatment arm, cluster size 30. Outcome ICC =0.0005. Difference between treatment
arms = 0.054. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.0005, and an expected value of the outcome
in the control arm of 0.5, are presented in Table 8.15 (page 177). Adjusting for a
covariate with an ICC of 0.0005 increased estimated power to a maximum of 100%
from 79% (see Figure 8.29). Empirical standard error increased from 0.111 to 0.239,
and the estimated relative asymptotic bias was 259%. Adjusting for a covariate with
an ICC of 0.1, or a cluster level covariate, did not significantly change the estimated
power or empirical standard error.
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Figure 8.29: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.0005. Covariate ICC =
0.0005. Difference between treatment arms = 0.081. Data from Table 8.15.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.116 (0.004) 0.117 (0.004) 78.0 (1.9) 77.4 (1.9) 0.1
0.0005 0.25 (0.250) 0.115 (0.004) 0.118 (0.004) 78.8 (1.8) 80.2 (1.8) 4.4
0.0005 0.50 (0.500) 0.115 (0.004) 0.127 (0.004) 80.2 (1.8) 83.4 (1.7) 18.3
0.0005 0.75 (0.750) 0.115 (0.004) 0.150 (0.005) 80.8 (1.8) 95.6 (0.9) 63.8
0.0005 0.95 (0.950) 0.111 (0.004) 0.239 (0.008) 79.0 (1.8) 100.0 - 259.4
0.1 0.00 (0.000) 0.118 (0.004) 0.117 (0.004) 75.2 (1.9) 74.8 (1.9) 0.2
0.1 0.25 (0.022) 0.114 (0.004) 0.114 (0.004) 79.0 (1.8) 78.6 (1.8) 0.1
0.1 0.50 (0.044) 0.121 (0.004) 0.121 (0.004) 76.6 (1.9) 75.8 (1.9) 0.2
0.1 0.75 (0.066) 0.118 (0.004) 0.119 (0.004) 77.0 (1.9) 77.0 (1.9) 0.7
0.1 0.95 (0.084) 0.121 (0.004) 0.121 (0.004) 78.4 (1.8) 78.2 (1.8) 0.6
1 0.00 (0.000) 0.122 (0.004) 0.124 (0.004) 75.6 (1.9) 74.4 (2.0) −0.1
1 0.25 (0.007) 0.119 (0.004) 0.120 (0.004) 76.2 (1.9) 76.6 (1.9) 0.3
1 0.50 (0.014) 0.114 (0.004) 0.117 (0.004) 80.8 (1.8) 79.0 (1.8) 0.2
1 0.75 (0.021) 0.118 (0.004) 0.119 (0.004) 76.0 (1.9) 75.0 (1.9) −0.1
1 0.95 (0.027) 0.119 (0.004) 0.120 (0.004) 78.2 (1.8) 77.6 (1.9) −0.1
Table 8.15: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.5 in the control treatment arm. 20 clusters per treatment arm, cluster size 30. Outcome ICC = 0.0005. Difference between treatment
arms = 0.081. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.05, and an expected value of 0.1 in the control
treatment arm, are presented in Table 8.16 (page 180). Adjusting for a covariate
with an ICC of 0.0005 increased estimated power to a maximum of 87% from 79%
(see Figure 8.30). Empirical standard error increased from 0.280 to 0.794, and the
estimated relative asymptotic bias was 219%. Adjusting for a covariate with an ICC
of 0.05 increased estimated power to a maximum of 94% from 77% achieved with
the unadjusted analysis (see Figure 8.31, 179). In this case, empirical standard error
increased from 0.319 to 0.778, and the estimated relative asymptotic bias was 214%.
Adjusting for a covariate with an ICC of 0.1 increased estimated power to a maximum
of 99.8% from 81%. Empirical standard error increased from 0.288 to 0.598, and the
estimated relative asymptotic bias was 216%. Adjusting for a cluster level covariate
increased estimated power to a maximum of 99% from 77% (see Figure 8.32, page
179). Here, empirical standard error reduced from 0.304 to 0.204.
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Figure 8.30: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.05. Covariate ICC = 0.0005.
Difference between treatment arms = 0.088. Data from Table 8.16.
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Figure 8.31: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.05. Covariate ICC = 0.05.
Difference between treatment arms = 0.088. Data from Table 8.16.
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Figure 8.32: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.05. Cluster level covariate.
Difference between treatment arms = 0.088. Data from Table 8.16.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.289 (0.009) 0.290 (0.009) 80.8 (1.8) 81.2 (1.7) 0.1
0.0005 0.25 (0.250) 0.290 (0.009) 0.297 (0.009) 77.4 (1.9) 76.8 (1.9) 3.2
0.0005 0.50 (0.500) 0.291 (0.009) 0.328 (0.010) 78.4 (1.8) 78.8 (1.8) 14.1
0.0005 0.75 (0.750) 0.311 (0.010) 0.439 (0.014) 78.6 (1.8) 82.0 (1.7) 47.7
0.0005 0.95 (0.950) 0.280 (0.009) 0.794 (0.025) 79.4 (1.8) 88.6 (1.4) 219.3
0.05 0.00 (0.000) 0.320 (0.010) 0.321 (0.010) 77.2 (1.9) 77.2 (1.9) 0.2
0.05 0.25 (0.256) 0.306 (0.010) 0.311 (0.010) 78.0 (1.9) 80.2 (1.8) 2.9
0.05 0.50 (0.513) 0.301 (0.010) 0.321 (0.010) 78.4 (1.8) 84.4 (1.6) 14.1
0.05 0.75 (0.769) 0.300 (0.009) 0.388 (0.012) 77.8 (1.9) 88.8 (1.4) 49.2
0.05 0.95 (0.975) 0.319 (0.010) 0.778 (0.025) 76.6 (1.9) 94.0 (1.1) 214.0
Continued on next page.
Table 8.16: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.1 in the control treatment arm. 20 clusters per treatment arm, cluster size 30. Outcome ICC = 0.05. Difference between treatment arms
= 0.088. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Continued from previous page.
Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.1 0.00 (0.000) 0.295 (0.009) 0.296 (0.009) 79.6 (1.8) 79.8 (1.8) 0.2
0.1 0.25 (0.264) 0.306 (0.010) 0.310 (0.010) 80.2 (1.8) 81.6 (1.7) 2.7
0.1 0.50 (0.527) 0.297 (0.009) 0.306 (0.010) 77.4 (1.9) 84.4 (1.6) 13.9
0.1 0.75 (0.791) 0.289 (0.009) 0.356 (0.011) 78.6 (1.8) 92.8 (1.2) 47.7
0.1 0.95 (1.001) 0.288 (0.009) 0.598 (0.019) 81.0 (1.8) 99.8 (0.2) 216.1
1 0.00 (0.000) 0.309 (0.010) 0.316 (0.010) 78.2 (1.8) 77.4 (1.9) 0.0
1 0.25 (0.097) 0.312 (0.010) 0.310 (0.010) 80.6 (1.8) 81.4 (1.7) 0.6
1 0.50 (0.195) 0.276 (0.009) 0.265 (0.008) 78.2 (1.8) 84.0 (1.6) 0.8
1 0.75 (0.292) 0.291 (0.009) 0.239 (0.008) 79.4 (1.8) 92.4 (1.2) 0.7
1 0.95 (0.370) 0.304 (0.010) 0.204 (0.006) 77.4 (1.9) 98.6 (0.5) 1.1
Table 8.16: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.1 in the control treatment arm. 20 clusters per treatment arm, cluster size 30. Outcome ICC = 0.05. Difference between treatment arms
= 0.088. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.05, and an expected value of 0.5 in the control
treatment arm, are presented in Table 8.17 (page 184). Adjusting for a covariate with
an ICC of 0.0005 increased estimated power to a maximum of 91% from 83% (see
Figure 8.33), while empirical standard error increased from 0.194 to 0.602. Adjusting
for a covariate with an ICC of 0.05 increased estimated power to a maximum of 99%
from 82% (see Figure 8.34, page 183). Empirical standard error increased from 0.191
to 0.461, and estimated relative asymptotic bias was 252%. Adjusting for a covariate
with an ICC of 0.1 increased estimated power to a maximum of 100% from 77%.
Adjusting for a cluster level covariate increased estimated power to a maximum of
98% from 82% (see Figure 8.35, page 183). Here, empirical standard error reduced
from 0.188 to 0.132.
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Figure 8.33: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.05. Covariate ICC = 0.0005.
Difference between treatment arms = 0.125. Data from Table 8.17.
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Figure 8.34: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.05. Covariate ICC = 0.05.
Difference between treatment arms = 0.125. Data from Table 8.17.
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Figure 8.35: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.05. Cluster level covariate.
Difference between treatment arms = 0.125. Data from Table 8.17.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.199 (0.006) 0.199 (0.006) 82.4 (1.7) 82.6 (1.7) 0.1
0.0005 0.25 (0.250) 0.192 (0.006) 0.198 (0.006) 79.6 (1.8) 79.8 (1.8) 3.8
0.0005 0.50 (0.500) 0.194 (0.006) 0.224 (0.007) 82.0 (1.7) 84.0 (1.6) 18.7
0.0005 0.75 (0.750) 0.200 (0.006) 0.295 (0.009) 79.0 (1.8) 83.0 (1.7) 61.0
0.0005 0.95 (0.950) 0.194 (0.006) 0.602 (0.019) 83.2 (1.7) 91.0 (1.3) 257.4
0.05 0.00 (0.000) 0.194 (0.006) 0.194 (0.006) 81.4 (1.7) 81.6 (1.7) 0.1
0.05 0.25 (0.256) 0.192 (0.006) 0.195 (0.006) 79.4 (1.8) 79.0 (1.8) 4.0
0.05 0.50 (0.513) 0.198 (0.006) 0.212 (0.007) 81.0 (1.8) 86.6 (1.5) 20.0
0.05 0.75 (0.769) 0.181 (0.006) 0.234 (0.007) 82.8 (1.7) 95.2 (1.0) 61.7
0.05 0.95 (0.975) 0.191 (0.006) 0.461 (0.015) 81.6 (1.7) 99.4 (0.3) 251.6
Continued on next page.
Table 8.17: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.5 in the control treatment arm. 20 clusters per treatment arm, cluster size 30. Outcome ICC = 0.05. Difference between treatment arms
= 0.125. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Continued from previous page.
Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.1 0.00 (0.000) 0.206 (0.007) 0.206 (0.007) 79.6 (1.8) 79.2 (1.8) 0.1
0.1 0.25 (0.231) 0.197 (0.006) 0.197 (0.006) 79.8 (1.8) 82.0 (1.7) 3.2
0.1 0.50 (0.461) 0.195 (0.006) 0.199 (0.006) 78.8 (1.8) 88.2 (1.4) 13.9
0.1 0.75 (0.692) 0.198 (0.006) 0.204 (0.006) 79.8 (1.8) 96.6 (0.8) 38.9
0.1 0.95 (0.877) 0.196 (0.006) 0.196 (0.006) 76.8 (1.9) 100.0 - 99.2
1 0.00 (0.000) 0.200 (0.006) 0.202 (0.006) 82.0 (1.7) 81.4 (1.7) −0.2
1 0.25 (0.073) 0.199 (0.006) 0.194 (0.006) 81.0 (1.8) 81.8 (1.7) −0.2
1 0.50 (0.146) 0.186 (0.006) 0.176 (0.006) 79.8 (1.8) 86.6 (1.5) 0.2
1 0.75 (0.219) 0.192 (0.006) 0.157 (0.005) 78.6 (1.8) 94.4 (1.0) −0.4
1 0.95 (0.277) 0.188 (0.006) 0.132 (0.004) 82.4 (1.7) 98.0 (0.6) 0.3
Table 8.17: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.5 in the control treatment arm. 20 clusters per treatment arm, cluster size 30. Outcome ICC = 0.05. Difference between treatment arms
= 0.125. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.1, and an expected value of 0.1 in the control
treatment arm, are presented in Table 8.18 (page 188). Adjusting for a covariate with
an ICC of 0.0005 increased estimated power to a maximum of 89% from 81% (see
Figure 8.36), while empirical standard error increased from 0.386 to 1.136. Adjusting
for a covariate with an ICC of 0.1 increased estimated power to a maximum of 93%
from 81% (see Figure 8.37, page 187). Empirical standard error increased from 0.381
to 1.024, and estimated relative asymptotic bias was 215%. Adjusting for a cluster
level covariate increased estimated power to a maximum of 100% from 81% (see Figure
8.38, page 187). Here, empirical standard error reduced from 0.188 to 0.132.
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Figure 8.36: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.1. Covariate ICC = 0.0005.
Difference between treatment arms = 0.115. Data from Table 8.18.
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Figure 8.37: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.1. Covariate ICC = 0.1.
Difference between treatment arms = 0.115. Data from Table 8.18.
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Figure 8.38: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.1. Cluster level covariate.
Difference between treatment arms = 0.115. Data from Table 8.18.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.396 (0.013) 0.397 (0.013) 78.2 (1.8) 78.4 (1.8) 0.1
0.0005 0.25 (0.250) 0.386 (0.012) 0.396 (0.013) 81.6 (1.7) 81.8 (1.7) 3.1
0.0005 0.50 (0.500) 0.398 (0.013) 0.444 (0.014) 79.2 (1.8) 80.8 (1.8) 14.5
0.0005 0.75 (0.750) 0.395 (0.013) 0.573 (0.018) 79.0 (1.8) 80.4 (1.8) 50.2
0.0005 0.95 (0.950) 0.386 (0.012) 1.136 (0.036) 80.6 (1.8) 88.8 (1.4) 218.2
0.1 0.00 (0.000) 0.379 (0.012) 0.379 (0.012) 79.8 (1.8) 79.8 (1.8) 0.1
0.1 0.25 (0.264) 0.391 (0.012) 0.401 (0.013) 79.2 (1.8) 79.2 (1.8) 2.8
0.1 0.50 (0.527) 0.382 (0.012) 0.417 (0.013) 80.6 (1.8) 83.6 (1.7) 14.2
0.1 0.75 (0.791) 0.382 (0.012) 0.502 (0.016) 76.2 (1.9) 86.6 (1.5) 48.9
0.1 0.95 (1.001) 0.381 (0.012) 1.024 (0.032) 80.8 (1.8) 93.4 (1.1) 214.6
1 0.00 (0.000) 0.395 (0.012) 0.402 (0.013) 78.0 (1.9) 78.4 (1.8) −0.1
1 0.25 (0.141) 0.384 (0.012) 0.375 (0.012) 79.4 (1.8) 83.2 (1.7) 0.2
1 0.50 (0.283) 0.376 (0.012) 0.340 (0.011) 81.8 (1.7) 88.6 (1.4) −0.6
1 0.75 (0.424) 0.385 (0.012) 0.298 (0.009) 80.0 (1.8) 96.4 (0.8) −1.4
1 0.95 (0.537) 0.377 (0.012) 0.221 (0.007) 81.2 (1.7) 100.0 - 0.3
Table 8.18: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.1 in the control treatment arm. 20 clusters per treatment arm, cluster size 30. Outcome ICC = 0.1. Difference between treatment arms
= 0.115. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.1, and an expected value of 0.5 in the control
treatment arm, are presented in Table 8.19 (page 191). Adjusting for a covariate with
an ICC of 0.0005 increased estimated power to a maximum of 89% from 83% (see
Figure 8.39), while empirical standard error increased from 0.253 to 0.828. Adjusting
for a covariate with an ICC of 0.1 increased estimated power to a maximum of 99%
from 79% (see Figure 8.40, page 190). Empirical standard error increased from 0.261
to 0.602, and estimated relative asymptotic bias was 258%. Adjusting for a cluster
level covariate increased estimated power to a maximum of 100% from 83% (see Figure
8.41, page 190). Here, empirical standard error reduced from 0.271 to 0.146.
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Figure 8.39: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.1. Covariate ICC = 0.0005.
Difference between treatment arms = 0.156. Data from Table 8.19.
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Figure 8.40: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.1. Covariate ICC = 0.1.
Difference between treatment arms = 0.156. Data from Table 8.19.
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Figure 8.41: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 20 clusters per treatment arm, cluster size 30. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.1. Cluster level covariate.
Difference between treatment arms = 0.156. Data from Table 8.19.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.248 (0.008) 0.248 (0.008) 80.0 (1.8) 80.0 (1.8) 0.1
0.0005 0.25 (0.250) 0.262 (0.008) 0.271 (0.009) 82.8 (1.7) 82.6 (1.7) 3.9
0.0005 0.50 (0.500) 0.255 (0.008) 0.299 (0.009) 80.6 (1.8) 82.2 (1.7) 18.6
0.0005 0.75 (0.750) 0.268 (0.008) 0.393 (0.012) 79.8 (1.8) 84.8 (1.6) 59.6
0.0005 0.95 (0.950) 0.253 (0.008) 0.828 (0.026) 82.6 (1.7) 89.4 (1.4) 253.7
0.1 0.00 (0.000) 0.248 (0.008) 0.248 (0.008) 82.0 (1.7) 82.0 (1.7) 0.1
0.1 0.25 (0.264) 0.263 (0.008) 0.271 (0.009) 82.4 (1.7) 83.8 (1.6) 4.0
0.1 0.50 (0.527) 0.247 (0.008) 0.271 (0.009) 78.2 (1.8) 85.6 (1.6) 17.7
0.1 0.75 (0.791) 0.260 (0.008) 0.316 (0.010) 82.6 (1.7) 95.6 (0.9) 59.4
0.1 0.95 (1.001) 0.261 (0.008) 0.602 (0.019) 79.4 (1.8) 99.2 (0.4) 257.9
1 0.00 (0.000) 0.253 (0.008) 0.257 (0.008) 83.6 (1.7) 84.0 (1.6) 0.1
1 0.25 (0.108) 0.251 (0.008) 0.255 (0.008) 81.0 (1.8) 80.2 (1.8) 0.0
1 0.50 (0.215) 0.249 (0.008) 0.229 (0.007) 82.0 (1.7) 89.4 (1.4) 0.0
1 0.75 (0.323) 0.264 (0.008) 0.201 (0.006) 79.6 (1.8) 95.6 (0.9) −1.2
1 0.95 (0.409) 0.271 (0.009) 0.146 (0.005) 82.8 (1.7) 100.0 - −0.6
Table 8.19: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.5 in the control treatment arm. 20 clusters per treatment arm, cluster size 30. Outcome ICC = 0.1. Difference between treatment arms
= 0.156. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Empirical standard error and estimated power under unadjusted and adjusted analyses
are presented in Tables 8.20 to 8.25 (pages 193 to 209) for simulated CRTs with 60
clusters in each treatment arm and a cluster size of five. The tables also present the
estimated relative asymptotic bias.
Results for an outcome with an ICC of 0.0005, and an expected value of the outcome
in the control arm of 0.1, are presented in Table 8.20 (page 193). Adjusting for a
covariate with ICC of 0.0005 increased estimated power to a maximum of 99% from
77% achieved with the unadjusted model (see Figure 8.42). In this case, empirical
standard error increased from 0.268 to 0.718, and the estimate relative asymptotic
bias was 241%. Adjusting for a covariate with ICC of 0.05 or 1 did not significantly
increase estimated power from the unadjusted analysis.
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Figure 8.42: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.0005. Covariate ICC =
0.0005. Difference between treatment arms = 0.079. Data from Table 8.20.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.230 (0.007) 0.230 (0.007) 82.8 (1.7) 82.6 (1.7) 0.2
0.0005 0.25 (0.250) 0.265 (0.008) 0.267 (0.008) 77.4 (1.9) 79.0 (1.8) 3.1
0.0005 0.50 (0.500) 0.258 (0.008) 0.283 (0.009) 80.2 (1.8) 82.6 (1.7) 14.8
0.0005 0.75 (0.750) 0.254 (0.008) 0.318 (0.010) 79.4 (1.8) 93.6 (1.1) 50.7
0.0005 0.95 (0.950) 0.268 (0.008) 0.718 (0.023) 77.0 (1.9) 99.4 (0.3) 241.4
0.1 0.00 (0.000) 0.251 (0.008) 0.252 (0.008) 81.4 (1.7) 80.8 (1.8) 0.2
0.1 0.25 (0.030) 0.262 (0.008) 0.263 (0.008) 76.6 (1.9) 77.0 (1.9) 0.3
0.1 0.50 (0.060) 0.255 (0.008) 0.255 (0.008) 79.6 (1.8) 79.8 (1.8) 0.4
0.1 0.75 (0.091) 0.259 (0.008) 0.260 (0.008) 79.8 (1.8) 80.6 (1.8) 0.6
0.1 0.95 (0.115) 0.258 (0.008) 0.261 (0.008) 76.0 (1.9) 75.8 (1.9) 0.8
1 0.00 (0.000) 0.249 (0.008) 0.251 (0.008) 78.6 (1.8) 78.8 (1.8) 0.2
1 0.25 (0.010) 0.237 (0.007) 0.237 (0.008) 81.2 (1.7) 80.6 (1.8) −0.2
1 0.50 (0.019) 0.263 (0.008) 0.265 (0.008) 75.8 (1.9) 75.2 (1.9) 0.1
1 0.75 (0.029) 0.258 (0.008) 0.257 (0.008) 79.2 (1.8) 79.6 (1.8) 0.4
1 0.95 (0.036) 0.261 (0.008) 0.263 (0.008) 76.8 (1.91) 75.8 (1.93) 0.1
Table 8.20: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.1 in the control treatment arm. 60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.0005. Difference between treatment
arms = 0.079. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.0005, and an expected value of the outcome
in the control arm of 0.5, are presented in Table 8.21 (page 195). Adjusting for a
covariate with ICC of 0.0005 increased estimated power to a maximum of 100% from
81% achieved with the unadjusted model (see Figure 8.43). In this case, empirical
standard error increased from 0.168 to 0.380, and the estimated relative asymptotic
bias was 278%. Adjusting for a covariate with ICC of 0.05 or 1 did not significantly
increase estimated power from the unadjusted analysis.
70
80
90
10
0
Es
tim
at
ed
 P
ow
er
 (%
)
0.00 0.25 0.50 0.75 0.95
Covariate Effect Parameter
Unadjusted Adjusted for covariate
Figure 8.43: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.0005. Covariate ICC =
0.0005. Difference between treatment arms = 0.079. Data from Table 8.21.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.167 (0.005) 0.168 (0.005) 81.6 (1.7) 80.8 (1.8) 0.2
0.0005 0.25 (0.250) 0.176 (0.006) 0.181 (0.006) 77.0 (1.9) 78.0 (1.9) 3.8
0.0005 0.50 (0.500) 0.159 (0.005) 0.175 (0.006) 81.6 (1.7) 85.8 (1.6) 19.4
0.0005 0.75 (0.750) 0.167 (0.005) 0.220 (0.007) 80.8 (1.8) 93.0 (1.1) 60.7
0.0005 0.95 (0.950) 0.168 (0.005) 0.380 (0.012) 81.4 (1.7) 100.0 (0.00) 278.3
0.1 0.00 (0.000) 0.172 (0.005) 0.172 (0.005) 78.6 (1.8) 78.6 (1.8) 0.2
0.1 0.25 (0.022) 0.165 (0.005) 0.165 (0.005) 77.2 (1.9) 77.4 (1.9) 0.0
0.1 0.50 (0.044) 0.171 (0.005) 0.172 (0.005) 75.8 (1.9) 75.2 (1.9) 0.3
0.1 0.75 (0.066) 0.170 (0.005) 0.170 (0.005) 81.4 (1.7) 81.4 (1.7) 0.4
0.1 0.95 (0.084) 0.161 (0.005) 0.162 (0.005) 78.6 (1.8) 78.8 (1.8) 0.3
1 0.00 (0.000) 0.164 (0.005) 0.164 (0.005) 80.8 (1.8) 80.4 (1.8) 0.1
1 0.25 (0.007) 0.172 (0.005) 0.174 (0.006) 79.4 (1.8) 78.8 (1.8) 0.6
1 0.50 (0.014) 0.173 (0.005) 0.175 (0.006) 77.6 (1.9) 77.2 (1.9) 0.0
1 0.75 (0.021) 0.170 (0.005) 0.170 (0.005) 77.0 (1.9) 76.2 (1.9) −0.1
1 0.95 (0.027) 0.179 (0.006) 0.178 (0.006) 78.6 (1.8) 78.6 (1.8) 0.2
Table 8.21: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.5 in the control treatment arm. 60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.0005. Difference between treatment
arms = 0.113. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.05, and an expected value of the outcome
in the control arm of 0.1, are presented in Table 8.22 (page 198). Adjusting for a
covariate with ICC of 0.0005 increased power to a maximum of 93% from 78% achieved
with the unadjusted model (see Figure 8.44). Empirical standard error increase from
0.287 to 0.884, and the estimated relative asymptotic bias was 235%. Adjusting for a
covariate with ICC of 0.05 increased estimated power to a maximum of 97% from 78%
achieved with the unadjusted model (see Figure 8.45, page 197). In this case, empirical
standard error increased from 0.309 to 0.855, and the estimated relative asymptotic
bias was 233%. Adjusting for a cluster level covariate increased estimated power to
a maximum of 85% from 76% achieved with the unadjusted model (see Figure 8.46,
197), and empirical standard error decreased from 0.293 to 0.267.
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Figure 8.44: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.05. Covariate ICC = 0.0005.
Difference between treatment arms = 0.087. Data from Table 8.22.
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Figure 8.45: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.05. Covariate ICC = 0.05.
Difference between treatment arms = 0.087. Data from Table 8.22.
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Figure 8.46: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.05. Cluster level covariate.
Difference between treatment arms = 0.087. Data from Table 8.22.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.284 (0.009) 0.284 (0.009) 81.6 (1.7) 81.0 (1.8) 0.1
0.0005 0.25 (0.250) 0.291 (0.009) 0.296 (0.009) 79.0 (1.8) 81.0 (1.8) 3.2
0.0005 0.50 (0.500) 0.294 (0.009) 0.328 (0.010) 76.8 (1.9) 79.4 (1.8) 14.8
0.0005 0.75 (0.750) 0.283 (0.009) 0.384 (0.012) 80.8 (1.8) 89.0 (1.4) 52.6
0.0005 0.95 (0.950) 0.287 (0.009) 0.884 (0.028) 77.8 (1.9) 93.4 (1.1) 234.8
0.05 0.00 (0.000) 0.307 (0.010) 0.307 (0.010) 78.2 (1.8) 78.6 (1.8) 0.2
0.05 0.25 (0.256) 0.296 (0.009) 0.302 (0.010) 84.8 (1.6) 84.8 (1.6) 2.9
0.05 0.50 (0.513) 0.287 (0.009) 0.319 (0.010) 77.8 (1.9) 82.8 (1.7) 16.7
0.05 0.75 (0.769) 0.293 (0.009) 0.379 (0.012) 77.4 (1.9) 88.2 (1.4) 50.9
0.05 0.95 (0.975) 0.309 (0.010) 0.855 (0.027) 78.2 (1.8) 97.4 (0.7) 232.5
Continued on next page.
Table 8.22: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.1 in the control treatment arm. 60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.05. Difference between treatment arms
= 0.087. (CEF = Covariate Effect Factor. MCSE=Monte Carlo Standard Error.)
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Continued from previous page.
Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.1 0.00 (0.000) 0.302 (0.010) 0.303 (0.010) 77.0 (1.9) 77.0 (1.9) 0.3
0.1 0.25 (0.264) 0.286 (0.009) 0.293 (0.009) 82.2 (1.7) 82.4 (1.7) 2.9
0.1 0.50 (0.527) 0.283 (0.009) 0.301 (0.010) 80.6 (1.8) 86.4 (1.5) 15.5
0.1 0.75 (0.791) 0.288 (0.009) 0.364 (0.012) 79.6 (1.8) 92.4 (1.2) 51.3
0.1 0.95 (1.001) 0.299 (0.009) 0.869 (0.027) 80.2 (1.8) 97.6 (0.7) 247.4
1 0.00 (0.000) 0.276 (0.009) 0.278 (0.009) 80.2 (1.8) 79.2 (1.8) −0.1
1 0.25 (0.097) 0.302 (0.010) 0.301 (0.010) 74.0 (2.0) 75.2 (1.9) 0.0
1 0.50 (0.195) 0.283 (0.009) 0.276 (0.009) 80.0 (1.8) 83.0 (1.7) 0.4
1 0.75 (0.292) 0.302 (0.010) 0.296 (0.009) 79.2 (1.8) 82.6 (1.7) −0.6
1 0.95 (0.370) 0.293 (0.009) 0.267 (0.008) 76.4 (1.9) 84.8 (1.6) 0.9
Table 8.22: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.1 in the control treatment arm. 60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.05. Difference between treatment arms
= 0.087. (CEF = Covariate Effect Factor. MCSE=Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.05, and an expected value of the outcome
in the control arm of 0.5, are presented in Table 8.23 (page 202). Adjusting for
a covariate with ICC of 0.0005 increased estimated power to a maximum of 98%
from 83% achieved with the unadjusted model (see Figure 8.47, page). Empirical
standard error increased from 0.197 to 0.545, and the estimated realtive asymptotic
bias was 257%. Adjusting for a covariate with ICC of 0.05 increased estimated power
to a maximum of 100% from 80% achieved with the unadjusted model (see Figure
8.48, page 201). In this case, empirical standard error increased from 0.188 to 0.469,
and the estimated relative asymptotic bias was 265%. Adjusting for a cluster level
covariate increased estimated power to a maximum of 86% from 83% achieved with
the unadjusted model ((see Figure 8.49, page 201)), and empirical standard error
decreased from 0.200 to 0.185.
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Figure 8.47: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.05. Covariate ICC = 0.0005.
Difference between treatment arms = 0.123. Data from Table 8.23.
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Figure 8.48: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.05. Covariate ICC = 0.05.
Difference between treatment arms = 0.123. Data from Table 8.23.
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Figure 8.49: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.05. Cluster level covariate.
Difference between treatment arms = 0.123. Data from Table 8.23.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.189 (0.006) 0.190 (0.006) 80.0 (1.8) 79.8 (1.8) 0.2
0.0005 0.25 (0.250) 0.182 (0.006) 0.184 (0.006) 80.2 (1.8) 81.8 (1.7) 4.5
0.0005 0.50 (0.500) 0.196 (0.006) 0.220 (0.007) 79.6 (1.8) 82.8 (1.7) 18.9
0.0005 0.75 (0.750) 0.191 (0.006) 0.264 (0.008) 79.2 (1.8) 91.0 (1.3) 61.5
0.0005 0.95 (0.950) 0.197 (0.006) 0.545 (0.017) 82.6 (1.7) 98.0 (0.6) 256.7
0.05 0.00 (0.000) 0.183 (0.006) 0.183 (0.006) 82.0 (1.7) 81.2 (1.7) 0.1
0.05 0.25 (0.256) 0.193 (0.006) 0.198 (0.006) 75.6 (1.9) 77.2 (1.9) 4.6
0.05 0.50 (0.513) 0.189 (0.006) 0.204 (0.006) 82.2 (1.7) 86.8 (1.5) 19.2
0.05 0.75 (0.769) 0.197 (0.006) 0.248 (0.008) 80.8 (1.8) 96.0 (0.9) 60.9
0.05 0.95 (0.975) 0.188 (0.006) 0.469 (0.015) 80.0 (1.8) 99.8 (0.2) 265.4
Continued on next page.
Table 8.23: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.5 in the control treatment arm. 60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.05. Difference between treatment arms
= 0.123. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Continued from previous page.
Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.1 0.00 (0.000) 0.195 (0.006) 0.196 (0.006) 79.8 (1.8) 79.8 (1.8) 0.1
0.1 0.25 (0.231) 0.191 (0.006) 0.195 (0.006) 78.0 (1.9) 79.8 (1.8) 3.2
0.1 0.50 (0.461) 0.190 (0.006) 0.201 (0.006) 75.0 (1.9) 83.8 (1.6) 14.1
0.1 0.75 (0.692) 0.191 (0.006) 0.217 (0.007) 79.2 (1.8) 93.2 (1.1) 40.5
0.1 0.95 (0.877) 0.193 (0.006) 0.273 (0.009) 80.8 (1.8) 98.4 (0.6) 96.6
1 0.00 (0.000) 0.187 (0.006) 0.189 (0.006) 82.4 (1.7) 82.2 (1.7) 0.1
1 0.25 (0.073) 0.198 (0.006) 0.196 (0.006) 77.6 (1.9) 79.8 (1.8) 0.2
1 0.50 (0.146) 0.187 (0.006) 0.183 (0.006) 79.6 (1.8) 83.6 (1.7) 0.0
1 0.75 (0.219) 0.189 (0.006) 0.180 (0.006) 78.8 (1.8) 81.6 (1.7) 0.0
1 0.95 (0.277) 0.200 (0.006) 0.185 (0.006) 82.6 (1.7) 86.2 (1.5) 1.5
Table 8.23: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.5 in the control treatment arm. 60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.05. Difference between treatment arms
= 0.123. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.1, and an expected value of 0.1 in the control
treatment arm, are presented in Table 8.24 (page 206). Adjusting for a covariate with
an ICC of 0.0005 increased estimated power to a maximum of 88% from 74% (see
Figure 8.50), while empirical standard error increased from 0.353 to 1.118. Adjusting
for a covariate with an ICC of 0.1 increased estimated power to a maximum of 95%
from 80% (see Figure 8.51, page 205). Empirical standard error increased from 0.326
to 1.037, and estimated relative asymptotic bias was 242%. Adjusting for a cluster
level covariate increased estimated power to a maximum of 92% from 80% (see Figure
8.52, page 205). Here, empirical standard error reduced from 0.341 to 0.280.
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Figure 8.50: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.1. Covariate ICC = 0.0005.
Difference between treatment arms = 0.095. Data from Table 8.24.
204
70
80
90
10
0
Es
tim
at
ed
 P
ow
er
 (%
)
0.00 0.26 0.53 0.79 1.00
Covariate Effect Parameter
Unadjusted Adjusted for covariate
Figure 8.51: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.1. Covariate ICC = 0.1.
Difference between treatment arms = 0.095. Data from Table 8.24.
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Figure 8.52: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.1. Cluster level covariate.
Difference between treatment arms = 0.095. Data from Table 8.24.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.330 (0.010) 0.332 (0.011) 83.0 (1.7) 82.2 (1.7) 0.4
0.0005 0.25 (0.250) 0.315 (0.010) 0.322 (0.010) 79.6 (1.8) 79.2 (1.8) 3.1
0.0005 0.50 (0.500) 0.329 (0.010) 0.367 (0.012) 78.8 (1.8) 82.0 (1.7) 16.2
0.0005 0.75 (0.750) 0.330 (0.010) 0.483 (0.015) 77.2 (1.9) 83.6 (1.7) 53.9
0.0005 0.95 (0.950) 0.353 (0.011) 1.118 (0.035) 74.4 (2.0) 88.0 (1.5) 239.1
0.1 0.00 (0.000) 0.310 (0.010) 0.311 (0.010) 81.8 (1.7) 82.0 (1.7) 0.2
0.1 0.25 (0.264) 0.355 (0.011) 0.365 (0.012) 77.6 (1.9) 78.6 (1.8) 3.9
0.1 0.50 (0.527) 0.338 (0.011) 0.377 (0.012) 78.4 (1.8) 84.2 (1.6) 17.6
0.1 0.75 (0.791) 0.323 (0.010) 0.418 (0.013) 79.8 (1.8) 90.2 (1.3) 51.2
0.1 0.95 (1.001) 0.326 (0.010) 1.037 (0.033) 80.4 (1.8) 95.4 (0.9) 241.7
1 0.00 (0.000) 0.348 (0.011) 0.352 (0.011) 82.2 (1.7) 81.8 (1.7) −0.1
1 0.25 (0.141) 0.336 (0.011) 0.331 (0.010) 78.0 (1.9) 78.6 (1.8) −0.1
1 0.50 (0.283) 0.322 (0.010) 0.315 (0.010) 78.0 (1.9) 80.0 (1.8) 0.0
1 0.75 (0.424) 0.334 (0.011) 0.295 (0.009) 79.6 (1.8) 88.2 (1.4) −0.3
1 0.95 (0.537) 0.341 (0.011) 0.280 (0.009) 79.6 (1.8) 91.6 (1.2) 1.5
Table 8.24: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.1 in the control treatment arm. 60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.1. Difference between treatment arms
= 0.095. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Results for an outcome with an ICC of 0.1, and an expected value of 0.5 in the control
treatment arm, are presented in Table 8.25 (page 209). Adjusting for a covariate with
an ICC of 0.0005 increased estimated power to a maximum of 96% from 80% (see
Figure 8.53), while empirical standard error increased from 0.215 to 0.692. Adjusting
for a covariate with an ICC of 0.1 increased estimated power to a maximum of 99%
from 80% (see Figure 8.54, page 208). Empirical standard error increased from 0.210
to 0.583, and estimated relative asymptotic bias was 268%. Adjusting for a cluster
level covariate increased estimated power to a maximum of 94% from 83% (see Figure
8.55, page 208). Here, empirical standard error reduced from 0.212 to 0.180.
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Figure 8.53: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.1. Covariate ICC = 0.0005.
Difference between treatment arms = 0.133. Data from Table 8.25.
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Figure 8.54: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.5. Outcome ICC = 0.1. Covariate ICC = 0.1.
Difference between treatment arms = 0.133. Data from Table 8.25.
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Figure 8.55: Estimated power when using a logistic mixed effects model, unadjusted
and adjusted for a covariate. 60 clusters per treatment arm, cluster size 5. Expected
value of outcome in control arm = 0.1. Outcome ICC = 0.5. Cluster level covariate.
Difference between treatment arms = 0.133. Data from Table 8.25.
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Empirical SE (MCSE) Estimated Power % (MCSE) Estimated Relative
Covariate ICC CEF (Parameter) Unadjusted Adjusted Unadjusted Adjusted Asymptotic Bias %
0.0005 0.00 (0.000) 0.214 (0.007) 0.214 (0.007) 79.0 (1.8) 78.4 (1.8) 0.1
0.0005 0.25 (0.250) 0.225 (0.007) 0.231 (0.007) 75.8 (1.9) 76.0 (1.9) 3.4
0.0005 0.50 (0.500) 0.224 (0.007) 0.260 (0.008) 79.4 (1.8) 83.4 (1.7) 19.2
0.0005 0.75 (0.750) 0.222 (0.007) 0.327 (0.010) 79.2 (1.8) 89.2 (1.4) 61.1
0.0005 0.95 (0.950) 0.215 (0.007) 0.692 (0.022) 79.6 (1.8) 96.0 (0.9) 268.1
0.1 0.00 (0.000) 0.216 (0.007) 0.217 (0.007) 81.2 (1.7) 80.8 (1.8) 0.3
0.1 0.25 (0.264) 0.233 (0.007) 0.240 (0.008) 77.2 (1.9) 77.2 (1.9) 4.4
0.1 0.50 (0.527) 0.213 (0.007) 0.237 (0.007) 80.2 (1.8) 88.0 (1.5) 18.4
0.1 0.75 (0.791) 0.222 (0.007) 0.294 (0.009) 79.6 (1.8) 94.0 (1.1) 61.3
0.1 0.95 (1.001) 0.210 (0.007) 0.583 (0.018) 80.0 (1.8) 99.2 (0.4) 268.2
1 0.00 (0.000) 0.219 (0.007) 0.219 (0.007) 80.6 (1.8) 81.2 (1.7) 0.0
1 0.25 (0.108) 0.203 (0.006) 0.202 (0.006) 79.8 (1.8) 79.6 (1.8) −0.4
1 0.50 (0.215) 0.219 (0.007) 0.209 (0.007) 79.6 (1.8) 83.8 (1.6) 0.5
1 0.75 (0.323) 0.222 (0.007) 0.196 (0.006) 79.6 (1.8) 88.4 (1.4) −0.3
1 0.95 (0.409) 0.212 (0.007) 0.180 (0.006) 82.8 (1.7) 94.0 (1.1) 1.8
Table 8.25: Empirical standard error, estimated power, and asymptotic bias, when using a logistic mixed effects model for an outcome with expected
value of 0.5 in the control treatment arm. 60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.1. Difference between treatment arms
= 0.133. (CEF = Covariate Effect Factor. MCSE = Monte Carlo Standard Error.)
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Overall, with a cluster size of five, adjusting for a covariate with the same ICC as
the outcome increased estimated power most notably. However, with a cluster size of
30 and an outcome with an ICC of 0.05 or 0.1 adjusting for a cluster level covariate
often increased power as much as or more than adjusting for a covariate with an ICC
of 0.05 or 0.1. For an outcome with an ICC of 0.0005, adjusting for a covariate with
an ICC of 0.05 or a cluster level covariate, did not significantly increased estimated
power. With a cluster size of five and an outcome with an ICC of 0.05, adjusting for
a covariate with a very small ICC increased estimated power more than adjusting for
a cluster level covariate. But with a cluster size of 30, adjusting for a cluster level
covariate increased estimated power more than adjusting for a covariate with an ICC
of 0.0005.
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8.5 Models using separate within-cluster and contextual
covariate effect parameters
Tables 8.26 to 8.31 give estimated power when using a linear mixed effects model
and adjusting for a covariate using a single covariate effect parameter, or separate
within-cluster and contextual covariate effect parameters.
Tables 8.26 to 8.28 present results for simulated CRTs with a cluster size of 30 and
20 clusters in each treatment arm.
For an outcome with an ICC of 0.0005 (Table 8.26, page 212) estimated power was
not significantly greater using separate covariate effect parameters for any scenarios
simulated. In fact, for all scenarios estimated power was slightly reduced when using
separate covariate effect parameters.
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Estimated Power % (MCSE)
Covariate ICC CEF RCE (γw, γb) Adjusted Separate Effects
0.0005 0.75 -0.67 (0.335, -0.224) 82.3 (0.5) 81.0 (0.6)
0.0005 0.95 -0.67 (0.425, -0.283) 86.0 (0.5) 84.7 (0.5)
0.05 0.75 -0.67 (0.034, -0.022) 77.4 (0.6) 76.3 (0.6)
0.05 0.95 -0.67 (0.042, -0.028) 77.6 (0.6) 76.6 (0.6)
0.1 0.75 -0.67 (0.024, -0.016) 77.7 (0.6) 76.9 (0.6)
0.1 0.95 -0.67 (0.030, -0.020) 76.6 (0.6) 75.8 (0.6)
0.0005 0.75 -0.50 (0.335, -0.168) 82.5 (0.5) 81.7 (0.5)
0.0005 0.95 -0.50 (0.425, -0.212) 85.2 (0.5) 84.6 (0.5)
0.05 0.75 -0.50 (0.034, -0.017) 77.2 (0.6) 76.8 (0.6)
0.05 0.95 -0.50 (0.042, -0.021) 77.4 (0.6) 76.2 (0.6)
0.1 0.75 -0.50 (0.024, -0.012) 77.2 (0.6) 76.2 (0.6)
0.1 0.95 -0.50 (0.030, -0.015) 77.7 (0.6) 76.8 (0.6)
0.0005 0.75 0.00 (0.335, 0.000) 82.2 (0.5) 81.1 (0.6)
0.0005 0.95 0.00 (0.425, 0.000) 85.5 (0.5) 84.3 (0.5)
0.05 0.75 0.00 (0.034, 0.000) 76.8 (0.6) 75.9 (0.6)
0.05 0.95 0.00 (0.042, 0.000) 78.3 (0.6) 77.2 (0.6)
0.1 0.75 0.00 (0.024, 0.000) 78.4 (0.6) 77.1 (0.6)
0.1 0.95 0.00 (0.030, 0.000) 77.2 (0.6) 76.4 (0.6)
0.0005 0.75 1.00 (0.335, 0.335) 82.7 (0.5) 81.7 (0.5)
0.0005 0.95 1.00 (0.425, 0.425) 85.3 (0.5) 84.2 (0.5)
0.05 0.75 1.00 (0.034, 0.034) 76.5 (0.6) 75.4 (0.6)
0.05 0.95 1.00 (0.042, 0.042) 78.0 (0.6) 77.4 (0.6)
0.1 0.75 1.00 (0.024, 0.024) 77.1 (0.6) 75.9 (0.6)
0.1 0.95 1.00 (0.030, 0.030) 77.0 (0.6) 75.9 (0.6)
0.0005 0.75 2.00 (0.335, 0.671) 82.2 (0.5) 81.0 (0.6)
0.0005 0.95 2.00 (0.425, 0.850) 85.1 (0.5) 84.1 (0.5)
0.05 0.75 2.00 (0.034, 0.067) 77.6 (0.6) 76.8 (0.6)
0.05 0.95 2.00 (0.042, 0.085) 77.6 (0.6) 76.9 (0.6)
0.1 0.75 2.00 (0.024, 0.047) 77.7 (0.6) 76.8 (0.6)
0.1 0.95 2.00 (0.030, 0.060) 77.7 (0.6) 77.0 (0.6)
Table 8.26: Estimated power with a linear mixed effects model using a single covariate
effect parameter (Adjusted) or separate covariate effects (Separate Effects). 20 clusters
per treatment arm, cluster size 30. Outcome ICC = 0.0005. (CEF = Covariate Effect
Factor. RCE = Ratio of Covariate Effects. MCSE = Monte Carlo Standard Error.)
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For an outcome with an ICC of 0.05 (Table 8.27, page 215), estimated power was
greater using separate covariate effect parameters when the covariate had an ICC of
0.05 or 0.1, and the between-cluster covariate effect parameter was equal to or twice
the size of the within-cluster covariate effect parameter. Otherwise, estimated power
was reduced when using separate covariate effect parameters. The greatest increase in
power was from 87% to 97% for a covariate with an ICC of 0.1 and when the between-
cluster covariate effect was twice the magnitude of the within-cluster covariate effect,
as shown in Figure 8.57 (page 214).
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Figure 8.56: Estimated power with linear mixed effects models using a single covariate
effect parameter or separate covariate effect parameters. 10 clusters per treatment
arm, cluster size 30. Outcome ICC = 0.05. Covariate ICC = 0.05. Data from Table
8.27.
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Figure 8.57: Estimated power with linear mixed effects models using a single covariate
effect parameter or separate covariate effect parameters. 10 clusters per treatment
arm, cluster size 30. Outcome ICC = 0.05. Covariate ICC = 0.1. Data from Table
8.27.
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Estimated Power % (MCSE)
Covariate ICC CEF RCE (γw, γb) Adjusted Separate Effects
0.0005 0.75 -0.67 (0.731, -0.487) 87.6 (0.5) 86.8 (0.5)
0.0005 0.95 -0.67 (0.926, -0.617) 93.4 (0.4) 92.7 (0.4)
0.05 0.75 -0.67 (0.335, -0.224) 81.8 (0.5) 81.6 (0.5)
0.05 0.95 -0.67 (0.425, -0.283) 82.3 (0.5) 82.6 (0.5)
0.1 0.75 -0.67 (0.237, -0.158) 80.8 (0.6) 80.7 (0.6)
0.1 0.95 -0.67 (0.300, -0.200) 81.9 (0.5) 81.9 (0.5)
0.0005 0.75 -0.50 (0.731, -0.366) 88.2 (0.5) 87.5 (0.5)
0.0005 0.95 -0.50 (0.926, -0.463) 92.9 (0.4) 92.0 (0.4)
0.05 0.75 -0.50 (0.335, -0.168) 83.1 (0.5) 82.6 (0.5)
0.05 0.95 -0.50 (0.425, -0.212) 84.7 (0.5) 84.5 (0.5)
0.1 0.75 -0.50 (0.237, -0.119) 82.4 (0.5) 81.9 (0.5)
0.1 0.95 -0.50 (0.300, -0.150) 82.7 (0.5) 82.4 (0.5)
0.0005 0.75 0.00 (0.731, 0.000) 88.5 (0.5) 87.2 (0.5)
0.0005 0.95 0.00 (0.926, 0.000) 93.4 (0.4) 92.7 (0.4)
0.05 0.75 0.00 (0.335, 0.000) 83.7 (0.5) 82.9 (0.5)
0.05 0.95 0.00 (0.425, 0.000) 87.0 (0.5) 86.0 (0.5)
0.1 0.75 0.00 (0.237, 0.000) 83.3 (0.5) 82.2 (0.5)
0.1 0.95 0.00 (0.300, 0.000) 84.8 (0.5) 84.0 (0.5)
0.0005 0.75 1.00 (0.731, 0.731) 90.0 (0.4) 89.2 (0.4)
0.0005 0.95 1.00 (0.926, 0.926) 93.5 (0.3) 92.8 (0.4)
0.05 0.75 1.00 (0.335, 0.335) 83.8 (0.5) 84.9 (0.5)
0.05 0.95 1.00 (0.425, 0.425) 86.8 (0.5) 89.2 (0.4)
0.1 0.75 1.00 (0.237, 0.237) 82.7 (0.5) 83.2 (0.5)
0.1 0.95 1.00 (0.300, 0.300) 86.1 (0.5) 88.1 (0.5)
0.0005 0.75 2.00 (0.731, 1.462) 88.3 (0.5) 87.5 (0.5)
0.0005 0.95 2.00 (0.926, 1.852) 93.7 (0.3) 93.2 (0.4)
0.05 0.75 2.00 (0.335, 0.671) 84.3 (0.5) 89.9 (0.4)
0.05 0.95 2.00 (0.425, 0.850) 87.4 (0.5) 96.0 (0.3)
0.1 0.75 2.00 (0.237, 0.474) 84.3 (0.5) 90.6 (0.4)
0.1 0.95 2.00 (0.300, 0.601) 86.5 (0.5) 96.6 (0.3)
Table 8.27: Estimated Power with linear mixed effects model using a single covariate
effect parameter (Adjusted) and separate covariate effects models (Separate effects).
20 clusters per treatment arm, cluster size 30. Outcome ICC = 0.05. (CEF = Covari-
ate Effect Factor. RCE = Ratio of Covariate Effects. MCSE = Monte Carlo Standard
Error.)
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For an outcome with an ICC of 0.1 (Table 8.28, page 218), estimated power was
greater using separate covariate effect parameters when the covariate had an ICC of
0.05 or 0.1, and the between-cluster covariate effect parameter was equal to or twice
the size of the within-cluster covariate effect parameter. In some other cases, power
was marginally higher when using separate covariate effect parameters. The greatest
increase in power was from 88% to 96% for a covariate with an ICC of 0.1 and when
the between-cluster covariate effect was twice the magnitude of the within-cluster
covariate effect.
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Figure 8.58: Estimated power with linear mixed effects models using a single covariate
effect parameter or separate covariate effect parameters. 10 clusters per treatment
arm, cluster size 30. Outcome ICC = 0.1. Covariate ICC = 0.05. Data from Table
8.28.
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Figure 8.59: Estimated power with linear mixed effects models using a single covariate
effect parameter or separate covariate effect parameters. 10 clusters per treatment
arm, cluster size 30. Outcome ICC = 0.1. Covariate ICC = 0.1. Data from Table
8.28.
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Estimated Power % (MCSE)
Covariate ICC CEF RCE (γw, γb) Adjusted Separate Effects
0.0005 0.75 -0.67 (0.712, -0.474) 85.2 (0.5) 84.4 (0.5)
0.0005 0.95 -0.67 (0.901, -0.601) 88.4 (0.5) 87.8 (0.5)
0.05 0.75 -0.67 (0.474, -0.316) 82.6 (0.5) 82.4 (0.5)
0.05 0.95 -0.67 (0.601, -0.401) 83.8 (0.5) 84.6 (0.5)
0.1 0.75 -0.67 (0.335, -0.224) 81.8 (0.5) 81.5 (0.5)
0.1 0.95 -0.67 (0.425, -0.283) 82.5 (0.5) 83.5 (0.5)
0.0005 0.75 -0.50 (0.712, -0.356) 84.3 (0.5) 83.7 (0.5)
0.0005 0.95 -0.50 (0.901, -0.451) 88.2 (0.5) 87.5 (0.5)
0.05 0.75 -0.50 (0.474, -0.237) 84.4 (0.5) 83.9 (0.5)
0.05 0.95 -0.50 (0.601, -0.300) 85.4 (0.5) 85.5 (0.5)
0.1 0.75 -0.50 (0.335, -0.168) 82.6 (0.5) 82.0 (0.5)
0.1 0.95 -0.50 (0.425, -0.212) 83.6 (0.5) 84.0 (0.5)
0.0005 0.75 0.00 (0.712, 0.000) 85.2 (0.5) 84.4 (0.5)
0.0005 0.95 0.00 (0.901, 0.000) 88.4 (0.5) 87.4 (0.5)
0.05 0.75 0.00 (0.474, 0.000) 85.3 (0.5) 84.3 (0.5)
0.05 0.95 0.00 (0.601, 0.000) 88.2 (0.5) 87.4 (0.5)
0.1 0.75 0.00 (0.335, 0.000) 84.0 (0.5) 83.2 (0.5)
0.1 0.95 0.00 (0.425, 0.000) 87.0 (0.5) 86.3 (0.5)
0.0005 0.75 1.00 (0.712, 0.712) 85.9 (0.5) 85.2 (0.5)
0.0005 0.95 1.00 (0.901, 0.901) 87.6 (0.5) 86.8 (0.5)
0.05 0.75 1.00 (0.474, 0.474) 85.4 (0.5) 86.6 (0.5)
0.05 0.95 1.00 (0.601, 0.601) 88.9 (0.4) 91.0 (0.4)
0.1 0.75 1.00 (0.335, 0.335) 84.5 (0.5) 85.7 (0.5)
0.1 0.95 1.00 (0.425, 0.425) 87.5 (0.5) 90.3 (0.4)
0.0005 0.75 2.00 (0.712, 1.423) 86.4 (0.5) 85.6 (0.5)
0.0005 0.95 2.00 (0.901, 1.803) 87.5 (0.5) 86.4 (0.5)
0.05 0.75 2.00 (0.474, 0.949) 85.8 (0.5) 92.5 (0.4)
0.05 0.95 2.00 (0.601, 1.202) 89.4 (0.4) 98.4 (0.2)
0.1 0.75 2.00 (0.335, 0.671) 83.9 (0.5) 93.1 (0.4)
0.1 0.95 2.00 (0.425, 0.850) 88.1 (0.5) 99.1 (0.1)
Table 8.28: Estimated Power with a linear mixed effects model using a single covariate
effect parameter (Adjusted) or separate covariate effects models (Separate effects). 20
clusters per treatment arm, cluster size 30. Outcome ICC = 0.1. (CEF = Covariate
Effect Factor. RCE = Ratio of Covariate Effects. MCSE = Monte Carlo Standard
Error.)
218
Tables 8.29 to 8.31 present results for simulated CRTs with a cluster size of 5 and 60
clusters in each treatment arm.
For an outcome with an ICC of 0.0005 (Table 8.29, page 220), estimated power was
marginally smaller in all scenarios when using a linear mixed effects model with sep-
arate within-cluster and contextual covariate effect parameters.
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Estimated Power % (MCSE)
Covariate ICC CEF RCE (γw, γb) Adjusted Separate Effects
0.0005 0.75 -0.67 (0.335, -0.224) 83.0 (0.5) 82.8 (0.5)
0.0005 0.95 -0.67 (0.425, -0.283) 85.8 (0.5) 85.7 (0.5)
0.05 0.75 -0.67 (0.034, -0.022) 78.3 (0.6) 78.4 (0.6)
0.05 0.95 -0.67 (0.042, -0.028) 79.3 (0.6) 79.2 (0.6)
0.1 0.75 -0.67 (0.024, -0.016) 78.8 (0.6) 78.4 (0.6)
0.1 0.95 -0.67 (0.030, -0.020) 77.7 (0.6) 77.6 (0.6)
0.0005 0.75 -0.50 (0.335, -0.168) 82.7 (0.5) 82.6 (0.5)
0.0005 0.95 -0.50 (0.425, -0.212) 85.1 (0.5) 84.8 (0.5)
0.05 0.75 -0.50 (0.034, -0.017) 78.1 (0.6) 77.8 (0.6)
0.05 0.95 -0.50 (0.042, -0.021) 78.9 (0.6) 78.3 (0.6)
0.1 0.75 -0.50 (0.024, -0.012) 80.1 (0.6) 79.9 (0.6)
0.1 0.95 -0.50 (0.030, -0.015) 78.5 (0.6) 78.4 (0.6)
0.0005 0.75 0.00 (0.335, 0.000) 83.7 (0.5) 83.4 (0.5)
0.0005 0.95 0.00 (0.425, 0.000) 86.0 (0.5) 85.6 (0.5)
0.05 0.75 0.00 (0.034, 0.000) 79.4 (0.6) 78.9 (0.6)
0.05 0.95 0.00 (0.042, 0.000) 79.5 (0.6) 79.1 (0.6)
0.1 0.75 0.00 (0.024, 0.000) 78.5 (0.6) 78.4 (0.6)
0.1 0.95 0.00 (0.030, 0.000) 78.2 (0.6) 77.9 (0.6)
0.0005 0.75 1.00 (0.335, 0.335) 83.8 (0.5) 83.5 (0.5)
0.0005 0.95 1.00 (0.425, 0.425) 86.0 (0.5) 85.7 (0.5)
0.05 0.75 1.00 (0.034, 0.034) 78.8 (0.6) 78.6 (0.6)
0.05 0.95 1.00 (0.042, 0.042) 78.7 (0.6) 78.5 (0.6)
0.1 0.75 1.00 (0.024, 0.024) 78.4 (0.6) 78.6 (0.6)
0.1 0.95 1.00 (0.030, 0.030) 77.9 (0.6) 77.7 (0.6)
0.0005 0.75 2.00 (0.335, 0.671) 83.8 (0.5) 83.3 (0.5)
0.0005 0.95 2.00 (0.425, 0.850) 85.9 (0.5) 85.6 (0.5)
0.05 0.75 2.00 (0.034, 0.067) 78.0 (0.6) 78.0 (0.6)
0.05 0.95 2.00 (0.042, 0.085) 78.6 (0.6) 78.8 (0.6)
0.1 0.75 2.00 (0.024, 0.047) 78.4 (0.6) 78.3 (0.6)
0.1 0.95 2.00 (0.030, 0.060) 78.8 (0.6) 78.6 (0.6)
Table 8.29: Estimated Power with a linear mixed effects model using a single covariate
effect parameter (Adjusted) or separate covariate effects (Separate Effects). 60 clusters
per treatment arm, cluster size 5. Outcome ICC = 0.0005. (CEF=Covariate Effect
Factor. RCE=Ratio of Covariate Effects. MCSE=Monte Carlo Standard Error.)
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For an outcome with an ICC of 0.05 or 0.1 (Tables 8.30 and 8.31, pages 224 and
225), estimated power was marginally greater when using separate covariate effect
parameters when the covariate had an ICC of 0.05 or 0.1, and the between-cluster
covariate effect parameter was twice the magnitude of the within-cluster covariate
effect parameter. Otherwise, estimated power was similar or marginally reduced using
separate covariate effect parameters.
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Figure 8.60: Estimated power with linear mixed effects models using a single covariate
effect parameter or separate covariate effect parameters. 60 clusters per treatment
arm, cluster size 5. Outcome ICC = 0.05. Covariate ICC = 0.05. Data from Table
8.30.
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Figure 8.61: Estimated power with linear mixed effects models using a single covariate
effect parameter or separate covariate effect parameters. 60 clusters per treatment
arm, cluster size 5. Outcome ICC = 0.05. Covariate ICC = 0.1. Data from Table
8.30.
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Figure 8.62: Estimated power with linear mixed effects models using a single covariate
effect parameter or separate covariate effect parameters. 60 clusters per treatment
arm, cluster size 5. Outcome ICC = 0.1. Covariate ICC = 0.05. Data from Table
8.31.
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Figure 8.63: Estimated power with linear mixed effects models using a single covariate
effect parameter or separate covariate effect parameters. 60 clusters per treatment
arm, cluster size 5. Outcome ICC = 0.1. Covariate ICC = 0.1. Data from Table 8.31.
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Estimated Power % (MCSE)
Covariate ICC CEF RCE (γw, γb) Adjusted Separate effects
0.0005 0.75 -0.67 (0.731, -0.487) 96.9 (0.2) 96.8 (0.2)
0.0005 0.95 -0.67 (0.926, -0.617) 99.9 (<0.1) 99.9 (<0.1)
0.05 0.75 -0.67 (0.335, -0.224) 83.8 (0.5) 83.7 (0.5)
0.05 0.95 -0.67 (0.425, -0.283) 85.7 (0.5) 85.5 (0.5)
0.1 0.75 -0.67 (0.237, -0.158) 81.5 (0.5) 81.4 (0.5)
0.1 0.95 -0.67 (0.300, -0.200) 82.0 (0.5) 81.9 (0.5)
0.0005 0.75 -0.50 (0.731, -0.366) 96.2 (0.3) 96.1 (0.3)
0.0005 0.95 -0.50 (0.926, -0.463) 99.9 (<0.1) 99.9 (<0.1)
0.05 0.75 -0.50 (0.335, -0.168) 83.9 (0.5) 83.7 (0.5)
0.05 0.95 -0.50 (0.425, -0.212) 86.2 (0.5) 86.2 (0.5)
0.1 0.75 -0.50 (0.237, -0.119) 81.7 (0.5) 81.8 (0.5)
0.1 0.95 -0.50 (0.300, -0.150) 83.2 (0.5) 82.9 (0.5)
0.0005 0.75 0.00 (0.731, 0.000) 96.1 (0.3) 95.9 (0.3)
0.0005 0.95 0.00 (0.926, 0.000) 100.0 - 100.0 -
0.05 0.75 0.00 (0.335, 0.000) 84.6 (0.5) 84.2 (0.5)
0.05 0.95 0.00 (0.425, 0.000) 87.1 (0.5) 86.8 (0.5)
0.1 0.75 0.00 (0.237, 0.000) 81.9 (0.5) 81.7 (0.5)
0.1 0.95 0.00 (0.300, 0.000) 83.5 (0.5) 83.2 (0.5)
0.0005 0.75 1.00 (0.731, 0.731) 96.5 (0.3) 96.5 (0.3)
0.0005 0.95 1.00 (0.926, 0.926) 99.9 (0.1) 99.9 (<0.1)
0.05 0.75 1.00 (0.335, 0.335) 84.1 (0.5) 84.0 (0.5)
0.05 0.95 1.00 (0.425, 0.425) 87.2 (0.5) 87.4 (0.5)
0.1 0.75 1.00 (0.237, 0.237) 82.6 (0.5) 82.6 (0.5)
0.1 0.95 1.00 (0.300, 0.300) 84.2 (0.5) 84.1 (0.5)
0.0005 0.75 2.00 (0.731, 1.462) 96.6 (0.3) 96.4 (0.3)
0.0005 0.95 2.00 (0.926, 1.852) 100.0 - 100.0 -
0.05 0.75 2.00 (0.335, 0.671) 84.9 (0.5) 85.4 (0.5)
0.05 0.95 2.00 (0.425, 0.850) 87.7 (0.5) 88.1 (0.5)
0.1 0.75 2.00 (0.237, 0.474) 83.4 (0.5) 83.9 (0.5)
0.1 0.95 2.00 (0.300, 0.601) 84.6 (0.5) 85.3 (0.5)
Table 8.30: Estimated Power with linear mixed effects model using a single covariate
effect parameter (Adjusted) and separate covariate effects models (Separate effects).
60 clusters per treatment arm, cluster size 5. Outcome ICC = 0.05. (CEF=Covariate
Effect Factor. RCE=Ratio of Covariate Effects. MCSE=Monte Carlo Standard Er-
ror.)
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Estimated Power % (MCSE)
Covariate ICC CEF RCE (γw, γb) Adjusted Separate Effects
0.0005 0.75 -0.67 (0.712, -0.474) 94.1 (0.3) 94.0 (0.3)
0.0005 0.95 -0.67 (0.901, -0.601) 99.0 (0.1) 98.9 (0.1)
0.05 0.75 -0.67 (0.474, -0.316) 85.7 (0.5) 85.5 (0.5)
0.05 0.95 -0.67 (0.601, -0.401) 90.6 (0.4) 90.5 (0.4)
0.1 0.75 -0.67 (0.335, -0.224) 82.7 (0.5) 83.0 (0.5)
0.1 0.95 -0.67 (0.425, -0.283) 85.8 (0.5) 85.9 (0.5)
0.0005 0.75 -0.50 (0.712, -0.356) 93.9 (0.3) 93.6 (0.3)
0.0005 0.95 -0.50 (0.901, -0.451) 99.1 (0.1) 99.0 (0.1)
0.05 0.75 -0.50 (0.474, -0.237) 86.1 (0.5) 85.9 (0.5)
0.05 0.95 -0.50 (0.601, -0.300) 90.6 (0.4) 90.7 (0.4)
0.1 0.75 -0.50 (0.335, -0.168) 83.9 (0.5) 83.9 (0.5)
0.1 0.95 -0.50 (0.425, -0.212) 85.7 (0.5) 85.5 (0.5)
0.0005 0.75 0.00 (0.712, 0.000) 93.9 (0.3) 93.8 (0.3)
0.0005 0.95 0.00 (0.901, 0.000) 98.9 (0.1) 98.9 (0.1)
0.05 0.75 0.00 (0.474, 0.000) 87.1 (0.5) 87.1 (0.5)
0.05 0.95 0.00 (0.601, 0.000) 93.0 (0.4) 92.8 (0.4)
0.1 0.75 0.00 (0.335, 0.000) 84.9 (0.5) 84.7 (0.5)
0.1 0.95 0.00 (0.425, 0.000) 86.5 (0.5) 86.4 (0.5)
0.0005 0.75 1.00 (0.712, 0.712) 93.7 (0.3) 93.7 (0.3)
0.0005 0.95 1.00 (0.901, 0.901) 99.1 (0.1) 99.0 (0.1)
0.05 0.75 1.00 (0.474, 0.474) 87.7 (0.5) 87.6 (0.5)
0.05 0.95 1.00 (0.601, 0.601) 92.1 (0.4) 91.9 (0.4)
0.1 0.75 1.00 (0.335, 0.335) 84.9 (0.5) 84.8 (0.5)
0.1 0.95 1.00 (0.425, 0.425) 87.2 (0.5) 87.5 (0.5)
0.0005 0.75 2.00 (0.712, 1.423) 93.6 (0.3) 93.6 (0.3)
0.0005 0.95 2.00 (0.901, 1.803) 99.0 (0.1) 98.8 (0.2)
0.05 0.75 2.00 (0.474, 0.949) 88.5 (0.5) 89.4 (0.4)
0.05 0.95 2.00 (0.601, 1.202) 92.6 (0.4) 93.7 (0.3)
0.1 0.75 2.00 (0.335, 0.671) 84.8 (0.5) 86.5 (0.5)
0.1 0.95 2.00 (0.425, 0.850) 88.9 (0.4) 90.8 (0.4)
Table 8.31: Estimated Power with a linear mixed effects model using a single covariate
effect parameter (Adjusted) or separate covariate effects models (Separate effects). 60
clusters per treatment arm, cluster size 5. Outcome ICC = 0.1. (CEF=Covariate Ef-
fect Factor. RCE=Ratio of Covariate Effects. MCSE=Monte Carlo Standard Error.)
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8.6 Adjusting for cluster aggregated covariates
The cluster mean of an individual level covariate, rather than the covariate itself,
could be adjusted for in a mixed effects model. In many of the simulations conducted,
standard error was misestimated and estimated type I error was below the nominal
level for this method of analysis. Some examples of estimated relative error of standard
errors and estimate type I errors, from linear mixed effects model, are presented in
Tables 8.32 and 8.33.
For a cluster size of five (Table 8.32, page 227), estimated type I error was as low as
0% for outcomes and covariates with ICCs of 0.0005, 0.5, and 0.1. Estimated relative
error was as high as 186%, 161%, and 133% for outcomes and covariates with ICCs
of 0.005, 0.05, and 0.1, respectively.
For a cluster size of 30 (Table 8.33, page 228), estimated type I error was as low
as 0%, 0.1%, and 0.2% for outcomes and covariates with ICCs of 0.0005, 0.5, and
0.1, respectively. Estimated relative error was as high as 212%, 97%, and 51% for
outcomes and covariates with ICCs of 0.005, 0.05, and 0.1, respectively.
Estimated relative errors increase, and type I errors decrease, as the effect of the
covariate increases. There is greater misestimation of standard error when the outcome
has a smaller ICCs. When the ICCs are 0.05 or 0.1, there is greater misestimation of
standard error when the cluster size is smaller.
I undertook some simulations to further investigate this issue. Adjusting for a covari-
ate that was generated at the cluster level did not lead to misestimation of standard
errors. Adjusting for the true cluster means of an individual level covariate, that is
that cluster level part of the generated covariate, plus an independent random error
also did not lead to misestimation of standard errors. Some scenarios were also sim-
ulated using the R software (see Appendix E) to confirm that these results were not
unique to Stata.
My investigations to date have not revealed the underlying cause for misestimation of
the standard error of treatment effect, and estimated type I error below the nominal
level, when adjusting for the cluster mean of a covariate. Further investigation of the
cause of this problem is ongoing.
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Outcome ICC Covariate ICC Covariate Effect Parameter Estimated Relative Error of SE % (MCSE) Estimated Type I Error % (MCSE)
0.0005 0.0005 0.00 3.3 (1.0) 4.3 (0.3)
0.0005 0.0005 0.25 3.5 (1.0) 4.4 (0.3)
0.0005 0.0005 0.50 13.4 (1.1) 3.1 (0.2)
0.0005 0.0005 0.75 43.2 (1.4) 0.5 (0.1)
0.0005 0.0005 0.95 186.3 (2.9) 0.0 -
0.05 0.05 0.00 0.0 (1.0) 5.0 (0.3)
0.05 0.05 0.25 1.8 (1.0) 4.8 (0.3)
0.05 0.05 0.50 4.3 (1.0) 4.6 (0.3)
0.05 0.05 0.75 28.8 (1.3) 1.4 (0.2)
0.05 0.05 0.95 161.3 (2.6) 0.0 -
0.1 0.1 0.00 0.3 (1.0) 5.1 (0.3)
0.1 0.1 0.25 -0.6 (1.0) 5.2 (0.3)
0.1 0.1 0.50 0.0 (1.0) 5.6 (0.3)
0.1 0.1 0.75 19.6 (1.2) 2.1 (0.2)
0.1 0.1 0.95 133.1 (2.3) 0.0 -
Table 8.32: Estimated relative error and type I error when using a linear mixed effects model, adjusted for a covariate aggregated by cluster mean.
Cluster size of five.
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Outcome ICC Covariate ICC Covariate Effect Parameter Estimated Relative Error of SE % (MCSE) Estimated Type I Error % (MCSE)
0.0005 0.0005 0.00 3.2 (1.0) 4.2 (0.3)
0.0005 0.0005 0.25 6.3 (1.1) 4.3 (0.3)
0.0005 0.0005 0.50 14.5 (1.1) 2.2 (0.2)
0.0005 0.0005 0.75 47.0 (1.5) 0.4 (0.1)
0.0005 0.0005 0.95 212.3 (3.1) 0.0 -
0.05 0.05 0.00 -1.9 (1.0) 5.4 (0.3)
0.05 0.05 0.25 -1.2 (1.0) 5.4 (0.3)
0.05 0.05 0.50 -0.9 (1.0) 5.7 (0.3)
0.05 0.05 0.75 2.6 (1.0) 5.3 (0.3)
0.05 0.05 0.95 96.9 (2.0) 0.1 -
0.1 0.1 0.00 1.2 (1.0) 5.2 (0.3)
0.1 0.1 0.25 0.4 (1.0) 6.4 (0.3)
0.1 0.1 0.50 0.4 (1.0) 5.7 (0.3)
0.1 0.1 0.75 -1.4 (1.0) 5.8 (0.3)
0.1 0.1 0.95 51.3 (1.5) 0.2 (0.1)
Table 8.33: Estimated relative error and type I error when using a linear mixed effects model, adjusted for a covariate aggregated by cluster mean.
Cluster size of 30.
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8.7 Conclusion
In this chapter I have presented results from simulation studies investigating the effects
of covariate adjustment in the analysis of CRTs using mixed effects models.
Standard errors of treatment effect estimates were overestimated and estimated type
I error was below the nominal level when adjusting for a covariate only when it is
imbalanced at baseline. Standard errors were also overestimated and type I error was
also below the nominal level when a covariate was used to stratify randomisation, but
was not adjusted for in the analysis model.
In analyses using a linear mixed effects model, adjusting for a covariate with the same
ICC as the outcome increased estimated power to a maximum of 100%. With a cluster
size of five, adjusting for a covariate with a smaller ICC than the outcome generally
increased estimated power more than adjusting for a cluster level covariate. However,
with a cluster size of 30 and an outcome with an ICC of 0.05 or 0.1, adjusting for a
cluster level covariate increased estimated power more than adjusting for a covariate
with an ICC of 0.0005.
In analyses using a logistic mixed effects model with a cluster size of five, adjusting
for a covariate with the same ICC as the outcome increased estimated power most
notably. However, with a cluster size of 30 and an outcome with an ICC of 0.05 or 0.1
adjusting for a cluster level covariate often increased power as much. For an outcome
with an ICC of 0.0005, adjusting for a covariate with an ICC of 0.05 or a cluster level
covariate, did not significantly increase estimated power. With a cluster size of five
and an outcome with an ICC of 0.05, adjusting for a covariate with a very small ICC
increased estimated power more than adjusting for a cluster level covariate. But with
a cluster size of 30, adjusting for a cluster level covariate increased estimated power
more than adjusting for a covariate with an ICC of 0.0005.
In some circumstances, models using separate within-cluster and contextual covariate
effect parameters gave greater power and precision than models with a single covariate
effect paramter. However, under most scenarios models using separate or a single
covariate effect parameter gave similar standard errors and power.
These results will be used in Chapter 10, along with an analytic investigation presented
in the next chapter, to develop guidance for choosing covariates in the analysis of
CRTs.
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Chapter 9
Analytic investigation of power
in adjusted linear mixed effects
models
The results in Section 8.3 demonstrate that the ICC of the outcome, the ICC of the
covariate, and cluster size all influence the potential increase in power when adjusting
for a covariate. The estimates of power from simulations are consistent with power as
calculated using a non-central F distribution 7.21. In this section, I use this method
of estimating power to further investigate the effect of these parameters on the power
of an adjusted analysis.
Recall the linear mixed effects model used for an adjusted analysis of a CRT:
Yij = α+ βXj + γZij + uj + eij
Yij is the outcome for individual i in cluster j and Xj indicates treatment arm (X = 1
for the experimental arm, X = 0 for the control arm). The uj are independent cluster
random effects with uj ∼ N(0, τ2), and the eij are individual level residuals with
eij ∼ N(0, σ2). The power of the adjusted test of treatment effect can be calculated
as
Ftail(1, J − 3, λ, invF (1, J − 3, 0.95))
where
λ =
β2J
4(τ2 + σ2/m)
.
J is the number of clusters in the CRT. m is the number of individuals in each
cluster. β is the treatment effect parameter. invF (d1, d2, x) is the inverse cumulative
F distribution function, with degrees of freedom d1 and d2. Ftail(d1, d2, λ, x) is the
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reverse cumulative (or upper tail) non-central F distribution function, with degrees of
freedom d1 and d2, and non-centrality parameter λ.
Firstly, scale outcome variable Y and covariate Z to both have variance of one:
γ2τ2z + τ
2 + γ2σz2 + σ2 = 1
τ2z + σ
2
z = 1
Then we can relate the covariate effect and variance parameters in the model to the
marginal ICCs of the outcome (ICCY ) and covariate (ICCZ) as follows:
γ2τ2z + τ
2 = ICCY
γ2σ2z + σ
2 = 1− ICCY
τ2z = ICCZ
σ2z = 1− ICCZ
The non-centrality parameter λ can then be written as
λ =
1
4
β2J
(
ICCY − γ2ICCZ + 1− ICCY − γ
2(1− ICCZ)
m
)−1
.
A larger value of λ gives greater power for the adjusted analysis. Choosing covariates
that will increase power the most depends on γ but also cluster size (m), the ICC of
outcome (ICCY ), and the ICC of covariate (ICCZ). In particular, we want smallest
value of
1
4
β2Jλ−1 = ICCY − γ2ICCZ + 1− ICCY − γ
2(1− ICCZ)
m
.
Note that γ is covariate effect parameter when the total variances of the outcome and
the covariate are both one. To consider the relationship between the outcome and
covariate, it would be more useful to consider the linear correlation between them at
the cluster and individual levels.
9.1 Comparing a cluster level, an individual level, and
an unclustered covariate
I now consider three particular values for ICCZ . If the covariate has the same marginal
ICC as the outcome, then ICCZ = ICCY . For a cluster level covariate, ICCZ = 1. A
covariate for which there is no clustering effect has ICCZ = 0.
If ICCZ = ICCY then:
1
4
β2Jλ−1 = ICCY (1− γ2) + (1− ICCY )(1− γ
2)
m
= ICCY (1− r2) + (1− ICCY )(1− r
2)
m
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where r is the linear correlation between the outcome Y and covariate Z. Since
ICCZ = ICCY , this is the same correlation at cluster and individual level.
If ICCZ = 1, that is Z is a cluster level covariate, then:
1
4
β2Jλ−1 = ICCY − γ2 + 1− ICCY
m
= ICCY (1− r2c ) +
(1− ICCY )
m
Where rc is the linear correlation between the covariate and true cluster means of the
outcome variable.
If ICCZ = 0 then:
1
4
β2Jλ−1 = ICCY +
(1− ICCY )− γ2
m
= ICCY +
(1− ICCY )(1− r2i )
m
Where ri is the linear correlation between the covariate and individual level component
of the outcome variable.
Firstly, compare adjusting for a cluster level covariate (ICCZ = 1) and adjusting for
individual level covariate with same ICC as outcome (ICCZ = ICCY ). Adjusting for
either one covariate will give same power when:
ICCY (1− r2) + (1− ICCY )(1− r
2)
m
= ICCY (1− r2c ) +
(1− ICCY )
m
⇐⇒ r2 (ICCY (m− 1) + 1) = r2c ×m× ICCY
⇐⇒ r2
(
1 +
1
m
(
1
ICCY
− 1
))
= r2c
where r is the linear correlation between the outcome and the covariate with the same
ICC, and rc is the linear correlation between the cluster level covariate and true cluster
means of the outcome variable. Where ICCY (=ICCZ) is small, this equation can be
approximated as:
r2
(
1 +
1
ICCY ×m
)
≈ r2c
For a large value of (ICCY ×m), 1ICCY ×m ≈ 0 so we have r2 ≈ r2c .
As (ICCY ×m)→ 0, 1ICCY ×m →∞ so
r2
(
1 +
1
ICCY ×m
)
> r2c
Therefore, for a large value of the product of cluster size and the ICC of the outcome,
there is similar power adjusting for a covariate with the same ICC as the outcome
or adjusting for a cluster level covariate. For a small value of the product of cluster
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size and the ICC of the outcome, adjusting for the individual level covariate will give
greater power.
Secondly, consider adjusting for either an individual level covariate with same ICC as
outcome (ICCZ = ICCY ) or an individual level covariate with no clustering (ICCZ =
0). Adjusting for either one covariate will give same power when:
ICCY (1− r2) + (1− ICCY )(1− r
2)
m
= ICCY +
(1− ICCY )(1− r2i )
m
⇐⇒ r2 (ICCY (m− 1) + 1) = r2i × (1− ICCY )
⇐⇒ r2
(
1 +m
(
ICCY
1− ICCY
))
= r2i
Where ICCY (=ICCZ) is small, this equation can be approximated as:
r2 (1 + ICCY ×m) ≈ r2i
Therefore, for a small value of the product of cluster size and the ICC of the outcome,
there is similar power adjusting for a covariate with the same ICC as the outcome or
an unclustered covariate. For a large value of the product of cluster size and the ICC
of the outcome, adjusting for the covariate with the same ICC as the outcome will
give greater power.
Finally, consider adjusting for either an individual level covariate with no clustering
(ICCZ = 0) or a cluster level covariate (ICCZ = 1). Adjusting for either one covariate
will give the same power if:
ICCY (1− r2c ) +
(1− ICCY )
m
= ICCY +
(1− ICCY )(1− r2i )
m
⇐⇒ r2c =
1
m
(
1
ICCY
− 1
)
r2i
Again, where ICCY is small, this is approximately:
r2c ≈
r2i
ICCY ×m
If the individual level covariate with no clustering and the cluster level covariate have
the same correlation with the outcome variable at the individual and cluster level,
respectively, (ri = rc), then adjusting for either covariate will give the same power if:
1 = (m+ 1)× ICCY ≈ m× ICCY
If the product of ICC and cluster size is less than one, then adjusting for an unclustered
covariate will give greater power than adjusting for a cluster level covariate with
the same correlation with the outcome (albeit at the cluster level, rather than the
individual level). If the product of ICC and cluster size is greater than one, then
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adjusting for a cluster level covariate will give greater power than adjusting for an
unclustered covariate that had same correlation with the outcome (at the individual
level, rather than the cluster level).
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Chapter 10
Choosing covariates in cluster
randomised trials
In this chapter I address the second and third major aims of this thesis, namely:
2. To review published recommendations on choosing covariates, in the context of
CRTs and identify which advice is applicable in the analysis of CRTs.
3. To develop further guidance for choosing covariates in the analysis of CRTs.
To do this I use the simulation results presented in Chapter 8 and the analytic work
in Chapter 9. In Section 10.1 I consider existing guidance for choosing covariates in
individually randomised trials, and discuss their relevance to CRTs in the light of
simulation results. I discuss further recommendations specific to the analysis of CRTs
in Section 10.2. In Section 10.3 I present a consolidated list of guidance for choosing
covariates in the analysis of CRTs using linear and logistic mixed effects models.
10.1 Recommendations from individually randomised
trial literature
A number of the recommendations for choosing covariates in individually randomised
trials, which are described in Chapter 2, may be equally applicable to CRTs. I now
consider several recommendations in turn, and review their validity for CRTs. I draw
on the literature introduced in Chapter 3 and the results presented in Chapter 8.
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10.1.1 Choosing covariates a priori
Previously published guidance [13,14] that covariates to be adjusted for in a primary
analysis of a trial should be chosen a priori is not specific to individually randomised
trials. Raab & Butcher [23] argue that guidance for choosing covariates a priori
also applies to planning primary analyses of CRTs. The following section discusses
adjusting for a covariate due to an imbalance at baseline, but otherwise this thesis
does not include any empirical evidence to support guidance to choose covariates a
priori. Future investigation could possibly use simulations to investigate the validity
of choosing covariates post hoc, for example using covariate selection algorithms or
choosing covariates observed to be highly correlated with the outcome in the trial
data, in the analysis of CRTs.
10.1.2 Adjusting for covariates significantly imbalanced between
treatment arms
Adjusting for a covariate that is chosen post hoc because it is significantly imbalanced
at baseline leads to overestimation of the standard errors of treatment effect estimates
and type I error below the nominal level, as demonstrated in Section 8.1. This is
evident for both individual and cluster level covariates. The same result is seen in the
analysis of individually randomised trials [38, 39]. Therefore, guidance to not adjust
for covariates due to an observed baseline imbalance is equally applicable to CRTs.
10.1.3 Covariates used in randomisation
The results in Section 8.2 show that failure to adjust for a covariate used to stratify
randomisation leads to overestimation of the standard errors of treatment effect es-
timates and type I errors below the nominal level. This is demonstrated for cluster
level covariates and individual level covariates aggregated to the cluster level. As in
the analysis of individually randomised trials [13], to ensure a valid analysis models
should be adjusted for covariates used to stratify randomisation.
10.1.4 Adjusting for a baseline measure of the outcome
The results in Section 8.3 and Chapter 9 show that the greatest increases in statistical
power, and reductions in standard error for linear mixed effects models, are achieved
when adjusting for a covariate with a high correlation with the outcome and the
same ICC as the outcome. Baseline measures of an outcome variable are often highly
236
correlated with the outcome measured at follow-up. Further, we may reasonably
expect that a baseline measure of the outcome variable will often have a similar ICC
to the outcome measure at follow-up since it is the same variable being measured on
the same sample. For example, in the OPERA and FIAT data sets used in Chapter
6 several outcome variables have similar ICCs at baseline and at follow-up. However,
in some trials it may be expected that the ICC of the outcome will change notably
between baseline and follow-up. In this case the guidance described later in Section
10.2 may be more useful. Broadly, though, the results presented in this thesis support
guidance to adjust for a baseline measure of the outcome variable, where available, in
the analysis of CRTs.
This concludes consideration of general guidance for choosing covariates in the anal-
ysis of individually randomised trials, and how they apply to the analysis of CRTs.
In summary, guidance to choose covariates to be adjusted for a priori, adjust for co-
variates used to stratify randomisation, and adjust for a baseline measure of outcome
where available is also applicable to the analysis of CRTs.
10.2 Recommendations for cluster randomised trials
I now consider how the results presented in Chapters 8 and 9 can be used provide
further guidance for choosing covariates in the analysis of CRTs. These observations
and results are specific to the analysis of CRTs.
10.2.1 Choosing covariates when using a linear mixed effects model
The results of simulations given in Section 8.3 and the work outlined in Chapter 9
are consistent, and show how the ICC of the outcome variable, the ICC of a covari-
ate, and cluster size will influence the precision and power achieved in an adjusted
analysis using a linear mixed effects model. Most relevant to the issue of choosing
covariates in the analysis of CRTs is to identify under what conditions adjusting for
particular covariates will most increase statistical power and precision of treatment
effect estimates.
The work given in Chapter 9 identifies the product of the cluster size and the ICC
of the outcome variable as a useful quantity to reveal what covariates may be most
useful to increase precision and power. Alternatively, this product may be used to
identify types of covariate where adjusting will have little or no effect in increasing
precision or power. In general, if this product is close to one, then adjusting for either
a covariate with an ICC of zero or a cluster level covariate (where the correlations
237
with the outcome at the individual and cluster level, respectively, are equal) will give
similar power. For smaller values of this product, adjusting for a covariate with a
similar or smaller ICC than the outcome will increase power and precision more than
adjusting for a cluster level covariate or covariate with a larger ICC. For a larger
value of this product, adjusting for a covariate with a similar or larger ICC than the
outcome, such as cluster level covariates, will increase power and precision the most.
Although some authors have argued that cluster level covariates are most useful to
improve precision of treatment effect estimates and power [23,48,56], this work shows
that this is not necessarily true, as also demonstrated by Konstantopoulos [25]. This
work goes further than Konstantopoulos [25] by showing how the ICC of the outcome
and cluster size can be combined to be useful for choosing covariates in the analysis
of CRTs.
10.2.2 Choosing covariates when using a logistic mixed effects
model
In the analysis of a binary outcome using a logistic mixed effects model, adjusting for
a cluster level covariate can increase precision and power. The adjusted treatment
effect coincides with the unadjusted cluster specific treatment effect.
However, adjusting for an individual level covariate can increase power but reduce the
precision of the estimate of treatment effect. The adjusted treatment effect in this
case is conditional on the covariate, and is larger in magnitude than the unadjusted
treatment effect. The greater the effect of the covariate on the outcome, the larger this
difference is. This is equivalent to the known effect when adjusting for a covariate in
the analysis of an individually randomised trial using a logistic regression model [5–7].
As with linear models, the ICC of the outcome and cluster size are useful to determine
increases in power achievable by covariate with different ICCs. The expected value of
the binary outcome, which is directly related to the variability of the outcome, has
little effect on these considerations. When the product of cluster size and ICC of the
outcome is large, similar increases in power are achieved when adjusting for a cluster
level covariate or a covariate with the same ICC as the outcome. However, adjusting
for a cluster level covariate also increases precision and does not alter the treatment
effect that is being estimated. When the product of cluster size and ICC is small, a
greater increase in power, but reduction in precision, can be achieved adjusting for a
covariate with a similar or smaller ICC than the outcome.
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10.2.3 Using separate cluster level and individual level covariate
effects
The results given in Section 8.5 identify conditions where greater power and precision is
achieved by using a model with separate within-cluster and contextual covariate effect
parameters. Using a model with separate within-cluster and contextual covariate
effect parameters can achieve greater power than a model with a single covariate
effect parameter when there is a large difference between the two covariate effects,
the overall effect of the covariate is large, the ICCs of the outcome and covariate
are not too small, and the cluster size is not small. The precise conditions for these
parameters to ensure greater power are not evident from this work, and would benefit
from further investigation. However, these results suggest that for a cluster size of 30
the outcome and covariate should have ICCs of at least 0.05, and the between-cluster
effect should be at least the same magnitude as the within-cluster effect (and so the
contextual effect should be twice the magnitude of the within-cluster effect). For a
cluster size of five, results suggest that there is minimal increase in power by using
separate covariate effects for ICCs up to 0.1 and a between-cluster covariate effect up
to twice the magnitude of the within-cluster covariate effect.
If there is a priori belief that the above conditions are fulfilled, then it may be bene-
ficial to use a linear mixed effects model with separate within-cluster and contextual
covariate effect parameters. A model with separate covariate effects may also be use-
ful if the estimates of the covariate effects are of interest themselves, or if we require
unbiased estimates of residual random effects [55].
10.2.4 Adjusting for cluster aggregated covariates
The results in Section 8.6 show that adjusting for an individual level covariate using
only the cluster aggregated means may lead to misestimation of the standard error of
the treatment effect estimate and type I error below the nominal level. This occurs
particularly when cluster size and the ICCs of the outcome and covariate are small.
Investigation so far has not found the underlying cause of this misestimation, and this
would benefit from further investigation.
10.2.5 Choosing covariates in practice
The guidance presented in this thesis assumes some knowledge about the distribu-
tions of, and relationships between, outcome variables and covariates. However, when
planning the analysis of CRTs, the true ICCs of the outcome and covariates, and
239
correlations between the outcome and covariates, are not known. The same issue is
present in the planning of analyses of individually randomised trials. The true correla-
tion between the outcome and covariates will not be known, but prognostic covariates
can be identified using prior knowledge, and this is the recommended practice [13,14].
Similarly, estimates of ICCs and correlations may be obtained from prior knowledge,
for example from previous CRTs, other studies, or from a pilot trial. The CONSORT
extension to CRTs [65] states that an estimated ICC (or coefficient of variation) should
be reported for each primary outcome, providing a source of estimated ICCs for out-
come variables. Reporting of ICCs for covariates in addition to this, for example in
supplementary material or a database, may be valuable for those planning analyses of
CRTs in the future.
10.3 Guidance for choosing covariates in the analysis of
cluster randomised trials
1. Covariate adjustment can increase the power of an analysis of a CRT without
a need to increase either the number of clusters or the number of individuals in
the trial.
2. As for individually randomised trials, covariates to be adjusted for in the analysis
of a CRT should be chosen a priori.
3. Neither individual level nor cluster level covariates should be adjusted for only
because they are observed to be significantly imbalanced between treatment
arms.
4. Covariates used to stratify randomisation should be used in a valid adjusted
analysis.
5. Overall, adjusting for covariates that are highly correlated with the outcome
variable will increase power most substantially.
6. Adjusting for a covariate with the same ICC as the outcome has the potential
to increase power more than adjusting for a covariate with a different ICC.
7. A baseline measure of the outcome variable, where available, is likely to have a
high correlation with the outcome measured at follow-up and a similar ICC. It
may be particularly beneficial to adjust for a baseline measure of the outcome
variable where available.
8. When the product of cluster size and the ICC of the outcome variable is close to
one, power is similar when adjusting for a cluster level covariate or a covariate
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with an ICC close to zero and similar correlation with the outcome.
9. When the product of cluster size and the ICC of the outcome variable is large,
adjusting for a covariate with an ICC similar to or greater than the ICC of the
outcome should be preferred in order to increase power most notably.
10. When the product of cluster size and the ICC of the outcome variable is smaller,
adjusting for a covariate with an ICC similar to or smaller than the ICC of the
outcome should be preferred in order to increase power most notably.
11. If the product of cluster size and outcome ICC is small, adjusting for cluster
level covariates can only increase statistical power marginally.
12. When using a logistic mixed effects model, adjusting for an individual level
covariate changes the treatment effect being estimated. However, adjusting for
a cluster level covariate does not change the treatment effect being estimated.
13. When using a logistic mixed effects model, adjusting for an individual level
covariate will typically increase the standard error of the treatment effect esti-
mate. However, adjusting for a cluster level covariate will typically decrease the
standard error of the treatment effect estimate.
14. If there is a priori belief that within-cluster and contextual covariate effect
parameters differ substantially, the ICCs of the outcome and covariate are not
too small, and the cluster size is not small, then using separate within-cluster
and contextual covariate parameters may increase power further.
10.4 Conclusion
In this chapter I have directly addressed the question of how to choose covariates
in the analysis of CRTs using linear and logistic mixed effects models. I used the
simulation results in Chapter 8 and the analytic work presented in Chapter 9 to
inform recommendations. Several of the guidelines for choosing covariates that were
developed for individually randomised trials are also applicable to CRTs. I have
produced guidance specific to the analysis of CRTs. In Section 10.3 I provide a
summary of guidance, intended to be of practical use to those planning analyses of
CRTs.
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Chapter 11
Discussion and conclusion
Adjusting for covariates is common in primary analyses of CRTs, and can increase
the statistical power of analysis without the need to increase the number of clusters
or number of individuals in the trial. However, investigation of the effects of covariate
adjustment and guidance for choosing covariates in the analysis of CRTs has been
limited. This thesis addresses that gap in knowledge and guidance.
The three major aims of this project were:
1. To review existing knowledge and practice in the choice and handling of covari-
ates in the analysis of CRTs.
2. To review published recommendations on choosing covariates, in the context of
CRTs and identify which advice is applicable in the analysis of CRTs.
3. To develop further guidance for choosing covariates in the analysis of CRTs.
The first of these aims was addressed by a review of literature in Chapters 2 and 3,
and by a review of CRTs which was described in Chapter 5. The review of literature
for individually randomised trials identified extensive methodological research on the
effects of covariate adjustment and consistent published guidance for choosing covari-
ates. However, published research specific to the analysis of CRTs was found to be
limited. The review of a large sample of CRT reports showed that adjusted analyses
are common in CRTs, but there is very little reporting on how covariates are chosen.
The review also showed poor adherence to some existing guidance, which is also the
case in the results of previous reviews of individually randomised trials.
The second and third aims were addressed in Chapter 10, drawing on the results given
in Chapters 8 and 9. Simulations were used to investigate the effects of covariate
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adjustment in linear and logistic mixed effects models. The validity of adjusting for
a covariate only when imbalanced at baseline, and adjusting for a covariate used to
stratify randomisation, were also investigated. The use of separate within-cluster and
contextual covariate effect parameters was also considered. An analytic investigation
of power in adjusted linear mixed effects models extended the inquiry. These results
were firstly used to review guidance for choosing covariates developed for individually
randomised trials, in the context of the analysis of CRTs. The results were then used
to review and extend guidance for choosing covariates that is specific to CRTs.
11.1 Contribution of this thesis to the field of research
There is extensive published research on the effects of covariate adjustment in the
analysis of individually randomised trials, and there is clear guidance for choosing co-
variates in these trials. However, previously published work on the effects of covariate
adjustment in CRTs is limited, focussing on linear mixed effects models and a limited
number of other designs and analysis methods. In particular, there is minimal pub-
lished work on the effects of covariate adjustment when using logistic mixed effects
models.
This thesis presents work investigating the effects of covariate adjustment when using
linear and logistic mixed effects in the analysis of CRTs with continuous or binary
outcomes. The simulations for both linear and logistic mixed effects models are more
extensive than those in previously published work.
This thesis also included a small analytic investigation of power in adjusted linear
mixed effects models. This used the calculation for power described by Spybrook et
al. [26] and Raudenbush et al. [48], but sought to produce some insight of practical
use to researchers planning analyses of CRTs. I identified the product of cluster size
and ICC of the outcome variable as a useful method for choosing covariates in the
analysis of a CRT using mixed effects models.
A small number of authors have previously considered the use of separate within-
cluster and contextual covariate effect parameters in linear mixed effects models
[4, 54, 55]. The simulations presented in this thesis are more extensive than those in
previously published work. In particular, I investigated a variety of values for ICCs,
outcome variables and covariates with different ICCs from each other, and greater va-
riety in the ratio of the within-cluster and contextual covariate effects than in previous
investigations of power.
In Section 8.6, this thesis also highlighted a need for further investigation into the
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effects of adjusting for an individual level covariate aggregated by cluster mean. In
particular, I identified incorrect estimation of the standard error of treatment effect
estimates when fitting such adjusted models.
The issue of choosing covariates in CRTs has rarely been addressed directly in pre-
viously published work, with little consideration for practical usefulness of results. I
have shown that guidance for choosing covariates that was developed for individually
randomised trials is also applicable to the analysis of CRTs. The guidance published
by, for example, the European Medicines Agency [13] and the International Confer-
ence on Harmonization [15] should be equally heeded by researchers in the analysis of
CRTs.
I have also used the simulation and analytic results presented in the thesis to produce
guidance that is specific to CRTs, as given in Section 10.3. Although papers by, for
example, Raab & Butcher [23], Raudenbush et al. [48], and Konstantopoulos [25] have
partly addressed this question, consolidated guidance for choosing covariates in the
analysis of CRTs has not been published to date.
11.2 Limitations of this work
In this thesis, I only considered the use of logistic and linear mixed effects models for
the analysis of CRTs. However, other methods of analysis for CRTs such as generalised
estimating equations are not considered. Additionally, analyses of count, categorical,
and time-to-event outcomes have also not been considered. The work of this thesis
is also limited to CRTs in which all clusters contain the same number of individuals,
and there is an equal number of clusters in each treatment arm.
11.3 Further Work
There must be further investigation into the cause of incorrect estimation of standard
error, and reduced type I error, under some conditions when adjusting for individual
level covariates aggregated by cluster mean in mixed effects models. Appropriate
methods for adjusting for covariates aggregated at the cluster level could then be
developed.
CRTs with count, categorical, or time-to-event outcome variables are outside the scope
of this work, but would benefit from similar investigation. In particular, it would be
important to establish which of the guidance presented in this thesis is also applicable,
or where further considerations must be taken into account. An investigation for
244
analysis of CRTs using generalised estimating equations would also be valuable.
This work could also be extended for application to CRTs with variable cluster size.
If most clusters have the same size, and a minority of clusters have different sizes, it
may be adequate to use the modal cluster size in place of cluster size for calculating
the product of ICC and cluster size, to inform choice of covariates. Where cluster size
is variable but in a narrow range, the utility of mean or median cluster size in the
same way could be explored. If cluster size is widely variable then these findings may
be of limited use.
An analytic investigation into the use of separate within-cluster and contextual co-
variate effect parameters would be valuable. In particular, it would be useful to
identify precise conditions under which using separate within-cluster and contextual
covariate effect parameters would give greater power than using a single covariate ef-
fect parameter. Additionally, an empirical investigation into the differences between
within-cluster and contextual covariate effects that are found in practice would help
to put that work into context.
11.4 Final remarks
This thesis has presented an investigation into the effects of covariate adjustment, in
order to produce guidance for choosing covariates in the analysis of CRTs. I hope
that the results and recommendations given in this thesis can be of some use to those
planning analyses of CRTs. I also hope this work can institute further investigation
of the use of covariates in the analysis of CRTs.
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Appendix A
Glossary
Asymptotic bias
The difference between the treatment effect parameter in an adjusted model and the
parameter in the unadjusted model (as per Gail et al. [6]).
Asymptotic relative efficiency (ARE)
Used to compare the efficiency of tests of no treatment effect. Suppose we have a
parameter of interest θ and we wish to test θ = θ0. And we have a statistic T that is
a consistent estimator of µT (θ), a monotone function (at least close to θ = θ0) of θ.
A definition of ARE called the Pitman efficiency of two such statistics T1 and T2 that
are asymptotically normally distributed with means µT1(θ) and µT2(θ) and variances
σ2T1 and σ
2
T2
is given by [28]:
ARE(T1 to T2 at θ = θ0) =
[
µ′T1(θ0)
µ′T2(θ0)
]2 [
σ2T2(θ0)
σ2T1(θ0)
]
Asymptotic relative precision (ARP)
The asymptotic relative precision (ARP) of an estimator αˆ to an estimator βˆ of a
parameter is the ratio of the inverse of their variances:
ARP (αˆ to βˆ) =
var(αˆ)−1
var(βˆ)−1
=
var(βˆ)
var(αˆ)
Bias
The expected difference between an estimator of a parameter and the true value of
the parameter.
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Binary (variable)
A random variable that can take one of two possible values, often zero or one.
Concave/convex (function)
A continuous function is convex if the value of the function at the midpoint of any
interval is less than the mean of the values of the function at the ends of the interval.
Equivalently, if the function has second derivative then it is convex if and only if that
second derivative is greater than or equal to zero. A function f is concave if −f is
convex.
Confounder / confounding
A variable Z is a confounder of the relationship between exposure X and outcome
Y if it is associated with exposure X and with outcome Y but is not on the causal
pathway between X and Y .
Continuous (variable)
A random variable that can take any value between its minimum and maximum values.
Covariate
In this thesis, concerning randomised controlled trials, a covariate is a variable that
is possibly related to the outcome variable and is independent of treatment arm allo-
cation by randomisation.
Empirical standard error
The standard deviation of treatment effect estimates in a Monte Carlo sample.
Exchangeable
Random variables are exchangeable if any permutation of the variables has the same
covariance structure.
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Generalised linear model (GLM)
Generalised linear models (GLMs) are regression models that can be used to analyse a
number of different types of outcome data including continuous and binary variables.
A GLM has three components:
1. The probability distribution, from the exponential family, of the response vari-
able Y .
2. A linear predictor, η = βX where X is a vector of predictor variables and β is
a vector of parameters.
3. A link function g such that E[Y ] = µ = g−1(η).
Common link functions are linear, log, logit, probit, complementary log-log, and gen-
eralised logistic (g(µ) = log(µθ/(1− µθ))) link functions.
Independence
Two random variables are independent if and only if their joint cumulative distribution
function is the product of their cumulative distribution functions.
Individually randomised trial
A randomised trial in which individuals are randomised to treatment arms. The
randomisation unit (individuals) is the same as the unit of analysis (individuals)
Jensen’s inequality
If f is a convex function and X is a random variable, then
E[f(X)] ≥ g(E[X]) .
If f is a concave function, then
E[f(X)] ≤ g(E[X]) .
Likelihood
The probability of an observed outcome given values for parameters.
Likelihood ratio test
A statistical test using the ratio of likelihoods, used to compare the fit of two models.
Linear predictor
A linear combination of parameters and predictor variables.
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Link function
The function that relates the expected value of the outcome to the linear predictor in
a generalised linear model.
Maximum likelihood estimator (MLE)
The value of the paramter than maximises the likelihood.
Minkowski’s inequality
If p > 1 then: (
n∑
k=1
(ak + bk)
p
)1/p
≤
(
n∑
k=1
apk
)1/p
+
(
n∑
k=1
bpk
)1/p
If p < 1, p 6= 0, then:(
n∑
k=1
(ak + bk)
p
)1/p
≥
(
n∑
k=1
apk
)1/p
+
(
n∑
k=1
bpk
)1/p
Monte Carlo standard error
The estimated standard error of parameter estimates produced by Monte Carlo
simulation.
Parameter
An, often unknown, value that describes a characteristic of the population or relation-
ship between variables.
Power
The probability that a statistical test correct rejects the null hypothesis.
Precision
The inverse of the variance of an estimator.
Relative error of model-based standard error
A comparison of the mean model-based standard error and the empirical standard
error:
s¯
Empirical Standard Error
− 1
where s¯ is a mean of the model-based standard errors in a Monte Carlo sample.
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Taylor series expansion
The Taylor series expansion of a real function f(x) at x = a is:
f(x) = f(a) + f ′(a)(x− a) + f
′′(a)
2!
(x− a)2 + f
(3)(a)
3!
(x− a)3 + . . .
Variance
The expected value of the square of the difference between a random variable and the
expected value of the random variable. Equal to the square of the standard deviation.
Wald test
A significance test of a value of a parameter. The Wald statistic for an estimator θˆ of
the parameter θ0,
θˆ − θ0
se(θˆ)
is compared to the standard normal distribution, or a t distribution.
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Appendix B
Notation
General
Greek letters, e.g.ξ, η Parameters
Hatted letters, e.g. βˆ Estimators of parameters
Capital letters, e.g. X, Y Random variables
Bold letters, e.g. v, A Vectors and matrices
pr(.), P (.) Probability
X¯ Mean of X
E[X] Expected value of X
V ar(X) Variance of X
σ Standard deviation parameter
σ2 Variance parameter
Ω Covariance matrix
η Linear predictor for GLM
g(η) Link function for GLM
g−1(η) = h(η) Inverse link function for GLM
Individually randomised parallel group trials
Y Outcome variable
X Binary treatment arm variable
Z Covariate
α Intercept parameter
β Treatment effect parameter, adjusted
β∗ Treatment effect parameter, unadjusted
γ Covariate effect parameter
ψ = γZ Covariate effect
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Cluster randomised trials
Y Outcome variable
X Binary treatment arm variable
Z Covariate
α Intercept parameter
β Treatment effect parameter, adjusted
β∗ Treatment effect parameter, unadjusted
γ Covariate effect parameter
γW Within-cluster covariate effect parameter
γC Contextual covariate effect parameter
uj Cluster random effects
eij Individual residuals
τ2 Cluster level variance
σ2 Individual level variance
τ2Y |Z Residual cluster level variance of Y
σ2Y |Z Residual individual level variance of Y
aj Cluster level random effect of covariate
bij Individual level random effect of covariate
τ2z Cluster level variance of Z
σ2z Individual level variance of Z
ICCY , ICCZ Intra-cluster correlation coefficient of Y , Z
J , indexed by j Number of clusters
m, indexed by i Cluster size
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Appendix C
Details of literature on effects of
covariate adjustment in
individually randomised trials
C.1 Approach of Gail et al. using moments
In this section I present details of the work of Gail et al. [6].
Gail et al. [6] first define adjusted and unadjusted models for the expectation of the
outcome, as follows: Let Y be an outcome variable, X a binary variable identifying
treatment arm (taking value 1 with probability p) and Z a covariate (which may
be a vector of covariates, although most results are derived as if it is a scalar). By
randomisation, X and Z are independent. Assume that E(Z) = 0 and E(Z2) = σ2
(or where Z is a vector use Ω for the covariance matrix).
Firstly, consider the model that includes a covariate effect. Assume the conditional
expectation of Y given X and Z satisfies
E(Y |X,Z) = h(α+ βX + γZ) = h(η) = g−1(η)
where h(.) is a known function. So β is the treatment effect parameter adjusted for
the covariate Z. Given this model, we have the following moments:
E(Y ) = E{h(α+ βX + γZ)}
E(XY ) = E{Xh(α+ βX + γZ)}
E(ZY ) = E{Zh(α+ βX + γZ)}
(C.1)
If these are N observations (i.e. patients in the trial) then the method of moment
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estimators for the parameters (αˆ, βˆ, γˆ) are the solutions to:
N−1
∑
yi = N
−1∑h(αˆ+ βˆxi + γˆzi)
N−1
∑
xiyi = N
−1∑xih(αˆ+ βˆxi + γˆzi)
N−1
∑
ziyi = N
−1∑ zih(αˆ+ βˆxi + γˆzi)
(C.2)
Now consider the unadjusted model, that does not include a covariate effect. So it is
assumed instead that the conditional expectation of Y given X and Z satisfies
E(Y |X,Z) = E(Y |X) = h(α∗ + β∗X) = h(η∗) = g−1(η∗)
where h(.) is a known function. So β∗ is the unadjusted treatment effect parameter.
Given this model, we have the moments:
E(Y ) = E{h(α∗ + β∗X)}
E(XY ) = E{Xh(α∗ + β∗X)}
(C.3)
Then the method of moments estimators of the unadjusted parameters (αˆ∗, βˆ∗) would
be the solutions to:
N−1
∑
yi = N
−1∑h(αˆ∗ + βˆ∗xi)
N−1
∑
xiyi = N
−1∑xih(αˆ∗ + βˆ∗xi) (C.4)
Now we can define the asymptotic bias of the unadjusted treatment effect by the
difference between the unadjusted and adjusted treatment effect parameters: δ =
β∗ − β.
The following Theorem C.1 shows from the methods of moments equations that there
is no asymptotic bias if at least one of three conditions hold: there is no treatment
effect, there is no covariate effect or the covariate does not vary.
Theorem C.1 (Corollary 1 of Gail et al. [6]).
Given the models and definitions defined above. The adjusted and unadjusted pa-
rameters of treatment effect coincide (δ = 0) if β = 0 or γ = 0 or if Z does not vary
(σ2 = 0).
Proof. If γ = 0 then equations(C.3 are immediately identical to equations C.1. If
β = 0 then ξ1 = ξ0 so β
∗ = 0 = β. If Z does not vary then equations C.3 and C.1 are
identical with β∗ = β and α∗ = α+ γZ.
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Define the following expected values of the outcome Y conditional on treatment arm:
ξ1 = E(Y |X = 1) = EZ(h(α+ β + γZ))
and ξ0 = E(Y |X = 0) = EZ(h(α+ γZ))
We can then express the unadjusted parameters (α∗ and β∗) in terms of the adjusted
parameters (α, β and γ) by equating equations C.3 with the first two equations of
C.1:
α∗ = h−1(ξ0)
β∗ = h−1(ξ1)− h−1(ξ0)
(C.5)
We require h(η) to have the unique inverse h−1 that is well defined at ξ1 and ξ0.
By a second order Taylor expansion of the expression of the unadjusted treatment
effect parameter β∗ given in equations C.5, Gail et al. [6] give an approximate ex-
pression for the asymptotic bias, for a covariate effect close to zero. This is shown in
Theorem C.2. From this expression, it is shown that there is no asymptotic bias if the
function of the linear predictor giving the expected value of the outcome (the function
h(.) is linear or exponential (Theorem C.3). Finally, in Theorem C.4 it is shown that
using a GLM and maximum likelihood estimators gives the same results.
Theorem C.2 (Theorem 2 of Gail et al. [6]).
Given the conditions of Theorem C.1 and also assume h′(.) and h′′(.) exist, h−1 is not
singular at h(α + β) and h(α), and ξ1 and ξ0 are well approximated, for γ close to
zero, by the second-order Taylor series:
ξ1 = EZ(h(α+ β + γZ)) = h(α+ β) +
1
2γ
′Ωγ(α+ β)
ξ0 = EZ(h(α+ γZ)) = h(α) +
1
2γ
′Ωγ(α)
Then, for γ close to zero, the asymptotic bias of the unadjusted treatment effect is
δ = 12γ
′Ωγ
{
h′′(α+ β)
h′(α+ β)
− h
′′(α)
h′(α)
}
.
Proof. This is obtained from the second-order Taylor expansion of β∗ in equation
C.5.
Theorem C.3 (Theorem 5 of Gail et al. [6]).
Assuming the same conditions as Theorems C.1 and C.2 (and β, γ and σ2 are non-
zero), the adjusted and unadjusted parameters of treatment effect coincide (δ = 0) if
and only if h(η) = aη + b or h(η) = ceaη+b + d.
Proof.
δ = 0
⇔ h
′′(α+ β)
h′(α+ β)
− h
′′(α)
h′(α)
= 0
⇔ h
′′(α+ β)
h′(α+ β)
=
h′′(α)
h′(α)
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for arbitrary values of α and β. So δ = 0 if and only if the function h
′′(.)
h′(.) is constant.
h′′(.)
h′(.) = 0 if and only if h(η) = aη+b by integrating or differentiating twice.
h′′(.)
h′(.) = a 6=
0 if and only if h(η) = ceaη+b + d as the general solution to the differential equation
h′′(η)− ah′(η) = 0.
Theorem C.4 (Theorem 6 of Gail et al. [6]).
Consider the GLM defined by
E(Y |X,Z) = g−1(η) = h(η) ,
η = α+ βX + γZ
and Y follows a distribution in the exponential family, so that β is the treatment effect
adjusted for the covariate Z. Also consider an alternative GLM with linear predictor
η∗ = α∗ + β∗X
so that β∗ is the unadjusted treatment effect. Assume θ′(α∗ + β∗) and θ′(α∗) do not
vanish, where θ is the canonical parameter of the distribution of Y (regarded as a
function of the linear predictor). Then the solutions for α∗ and β∗ are given by the
equations in C.5, and the results of Theorems C.1, C.2 and C.3 also apply to these
parameters.
Proof. Recall the log likelihood for a distribution in the exponential family is
l(θ; y) =
yθ − b(θ)
a(ψ)
+ c(y, ψ)
Assume a(ψ) is known, as maximum likelihood estimates of a(ψ) are asymptotically
independent of the estimates of α, β and γ. Also recall
E(Y |X,Z) = g−1(η) = h(η) = b′(θ)
and regard the canonical parameter θ as a function of the linear predictor η.
Under the adjusted GLM, the maximum likelihood equations for N observations are
N∑
i=1
θ′(ηi) (yi − h(ηi)) =0
N∑
i=1
θ′(ηi)xi (yi − h(ηi)) =0
N∑
i=1
θ′(ηi)zi (yi − h(ηi)) =0
(C.6)
Multiplied by N−1, equations C.6 converge to
E
[
θ′(η)(Y − h(η))] = 0 ,
E
[
θ′(η)X(Y − h(η))] = 0 ,
E
[
θ′(η)Z(Y − h(η))] = 0 .
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Similarly, under the unadjusted GLM, the maximum likelihood equations converge to
E
[
θ′(η∗)(Y − h(η∗))] = 0 , E [θ′(η∗)X(Y − h(η∗))] = 0 .
For p as the probability of being assigned to the active treatment arm, these equations
are equivalent to
pθ′(α∗ + β∗)ξ1 + (1− p)θ′(α∗)ξ0 = pθ′(α∗ + β∗)h(α∗ + β∗) + (1− p)θ′(α∗)h(α∗)
pθ′(α∗ + β∗)ξ1 = pθ′(α∗ + β∗)h(α∗ + β∗)
If θ′(α∗ + β∗) and θ′(α∗) do not vanish, then the solutions to these equations are
exactly as given in equations C.5. So, the results of Theorems C.1, C.2 and C.3 also
apply to these parameters.
C.2 Geometric approach of Neuhaus & Jewell
In this section I present details of the work of Neuhaus & Jewell [7].
Let Y be an outcome variable, X a binary variable identifying treatment arm (taking
value 1 with probability p = 12) and Z a covariate (here, we consider Z as one-
dimensional but the methods generalise to Z as a multi-dimensional vector). By
randomisation, X and Z are independent. Assume that E(Z) = µZ and var(Z) = σ
2
Z .
Consider the GLM that includes the covariate, defined by
E(Y |X,Z) = g−1(η) = h(η) ,
η = α+ βX + γZ
and Y follows a distribution in the exponential family. So β is the adjusted treatment
effect parameter. Assume the link function g is strictly monotone increasing and
differentiable. For convenience, define the covariate effect ψ = γZ so E(ψ) = γµZ
and var(ψ) = γ2σ2Z .
The ‘geometric’ method of Neuhaus & Jewell [7] is based on the relationship between:
(1) the expected value of the outcome in the control treatment arm, denoted by µ0, and
(2) the absolute difference between expected values of the outcome in each treatment
arm, denoted by ∆ = µ1 − µ0. So, formally, we have
µk = E(Y |X = k, ψ) = g−1{α+ βk + ψ} for k = 0, 1
and ∆ = µ1 − µ0 .
As per Neuhaus & Jewell [7], we can express ∆(ψ) in terms of µ0(ψ) and β:
∆(ψ) = µ1 − µ0 = g−1{α+ β + ψ} − µ0(ψ)
= g−1{g(µ0(ψ)) + β} − µ0(ψ)
(C.7)
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Then the adjusted treatment effect parameter is β = g(µ1)− g(µ0).
Under this adjusted GLM, the expected value of the outcome in each treatment arm,
µ0 and µ1, varies for different values of the covariate effect, ψ. For example, suppose
we use a logistic regression model with a treatment effect parameter of 1.3 and in-
tercept parameter of -1. Figure C.1a shows the expected value of outcome in each
treatment arm (µ1 and µ0) plotted against the covariate effect. Figure C.1b shows the
same plot but using an identity link function (and same parameter values). Finally,
Figure C.1c shows the same plot but using a log link function. In each of the plots, the
horizontal difference between the two curves is constant, as the treatment effect pa-
rameter is constant and acts on the same scale as the covariate effect (the scale of the
linear predictor). The vertical difference between the curves is the absolute difference
between expected values of the outcome in each treatment arm, ∆. We can see that
for logistic regression, this difference varies for different values of the covariate effect.
For the identity link function, the difference is constant for all values of the covariate
effect. And for a log link function the difference is proportional to the expected value
of the outcome in the control arm.
We can instead plot this absolute difference ∆ against the expected value of the
outcome in the control treatment arm µ0, as described by Neuhaus & Jewell [7].
The shape of this curve depends on the link function used in the GLM and the
value of the treatment effect parameter. Link function g is assumed increasing, so
g−1 is also an increasing function and the (µ0,∆) curves are nested as β increases
(∂∆∂β > 0 for β > 0). Figure C.2a shows such curves for the logit link function and
treatment effect parameter values of 1.5, 0.5 and 0.05. Figures C.2b and C.2c show
such curves for the identity and log link function (and the same treatment effect
parameter values).
Now consider omitting the covariate Z, so we use the same GLM except with linear
predictor
η∗ = α∗ + β∗X
so that β∗ is the unadjusted treatment effect parameter. Averaging with respect to ψ
(i.e. averaging over the distribution of the omitted covariate Z) gives
Eψ[Y |X = 1]− Eψ[Y |X = 0] = Eψ[µ1]− Eψ[µ0]
and so β∗ = g(µ∗1) − g(µ∗0) with µ∗k = Eψ[µk(ψ)]. We can average over the marginal
density of Z since X and Z are independent by design.
Averaging equation C.7 with respect to ψ gives ∆∗ = Eψ[∆] = µ∗1 − µ∗0. The point
(µ∗0,∆∗) in the (µ0,∆) plane is found, then, by averaging the (µ0,∆) curve with
respect to the distribution of ψ. Here, µ∗0 is the expected value of the outcome in the
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control treatment arm under the unadjusted model, and ∆∗ is the absolute difference
between expected values of the outcome in each treatment arm under the unadjusted
model. For example, assuming again a treatment effect parameter of 1.3 and intercept
parameter of -1, and also assume that the covariate Z is binary (taking value 1 with
probability 3/4) with effect parameter of 1.6. Figure C.3 shows the (µ0,∆) curves and
(µ∗0,∆∗) points in this case when using either a logistic, identity or log link function.
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Figure C.1: Expected value of outcome in each treatment arm (µ1 and µ0) plotted
over covariate effect ψ (with treatment effect parameter of 1.3 and intercept parameter
of -1).
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Figure C.2: Difference between expected values of the outcome in each treatment arm,
∆, plotted against the expected value of the outcome in the control treatment arm,
µ0. For treatment effect parameters, β = 1.5, 0.5, 0.05.
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(c) With log link function
Figure C.3: Difference between expected values of the outcome in each treatment arm,
∆, plotted against the expected value of the outcome in the control treatment arm, µ0.
And the point (µ∗0,∆∗), which is these expected values averaged over the distribution
of the binary covariate Z (taking value 1 with probability 3/4) with effect parameter
of 1.6. For treatment effect parameter, β = 1.3.
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The following two lemmas, theorem and corollary find how the direction of the asymp-
totic bias depends on properties of the link function used in the GLM. Lemma C.5
shows that the curve that passes through the point (∆∗, µ∗0) is given by the unadjusted
treatment effect parameter β∗. Thus, the position of the averaged absolute treatment
difference ∆∗, relative to the curve given by the adjusted model will determine the
direction of the asymptotic bias. Lemma C.6 shows by Jensen’s inequality that the
concavity of the (µ0,∆) curve determines the position of the point (µ
∗
0,∆
∗) with re-
spect to the curve, and thus the direction of the asymptotic bias. Theorem C.7 then
relates the direction of asymptotic bias directly to the concavity of a function defined
via link function. Corollary C.8 gives the direction of asymptotic bias for linear, log
and logit link functions.
Lemma C.5.
The curve (µ0,∆) (with β = β0) passes through the point (µ
∗
0,∆
∗) if and only if
β0 = β
∗.
Proof. By the monotonicity of g and the continuity of g−1, there exists a curve
(µ0,∆) of the form of equation C.7 which passes through (µ
∗
0,∆
∗) for some β = β0.
To find β0, substitute ∆ = ∆
∗ and µ0 = µ∗0 into equation C.7:
∆∗ = g−1{g(µ∗0) + β0} − µ∗0
⇔ µ∗1 − µ∗0 = g−1{g(µ∗1)− β∗ + β0} − µ∗0
⇔ g(µ∗1) = g(µ∗1)− β∗ + β0
⇔ β0 = β∗
So the curve (µ0,∆) (with β = β0) passes through the point (µ
∗
0,∆
∗) if and only if
β0 = β
∗.
Lemma C.6.
If the curve (µ0,∆) is concave, convex or linear then β
∗ ≤ β, β∗ ≥ β or β∗ = β
respectively. If the curve (µ0,∆) is strictly concave or convex then β
∗ = β if and only
if γ = 0 or var(Z) = 0.
Proof. By Lemma C.5, the position of the point (µ∗0,∆∗) compared to the curve
(µ0,∆) will tell us the relationship between β and β
∗.
By Jensen’s inequality, if ∆(µ0) is a concave function, then
∆[Eψ(µ0)] ≥ Eψ[∆]
and so
∆[µ∗0] ≥ ∆∗ .
And so the point (µ∗0,∆∗) lies below the curve (µ0,∆), and since ∆ is an increasing
function of β we have β ≥ β∗.
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Similarly if ∆(µ0) is a convex function then β ≤ β∗, and if ∆(µ0) is linear then β = β∗
If ∆(µ0) is strictly concave or convex, then β = β
∗ if and only if µ0 does not vary,
that is if and only if γ = 0 or var(Z) = 0.
Theorem C.7.
If β = 0 then β∗ = β = 0, otherwise if F (t) = −1/g′(t) is strictly convex, concave or
linear then |β∗| < |β|, |β∗| > |β| or β∗ = β respectively.
Proof. By evaluating derivatives of ∆
∂2∆
∂µ20
=
g′′(µ0)(g′[g−1{g(µ0) + β}])2 − {g′(µ0)}2g′′[g−1{g(µ0) + β}]
(g′[g−1{g(µ0) + β}])3 .
If β = 0 then this second derivative is zero and the ∆(µ0) curve is linear, so β
∗ = β = 0.
Let f(t) = g′′(t)/(g′(t))2, then
∂2∆
∂µ20
=
{g′(µ0)}2{g′(µ1)}2{f(µ0)− f(µ1)}
{g′(µ1)}3 .
Link function g is an increasing function, so the denominator and {g′(µ0)}2{g′(µ1)}2
will be positive. Hence, for β > 0, ∆ will be strictly concave, convex or linear if
f is increasing, decreasing or constant respectively. Function f will be increasing,
decreasing or constant if F (t) is convex, concave or linear, respectively. Where F (t)
is
F (t) =
∫ t
−∞
f(u)du =
−1
g′(t)
.
For β < 0, the concavity or convexity of ∆ will be reversed. So by Lemma C.6, if F (t)
is convex, concave or linear then |β∗| < |β|, |β∗| > |β| or β∗ = β respectively.
Corollary C.8.
The adjusted and unadjusted parameters of treatment effect coincide (β = β∗) if g is
a linear or log link. If g is the logistic link then β ≥ β∗.
Proof. If g(t) = at + b then g′(t) = a and so F (t) = −1/a, then by Theorem C.7
β = β∗. If g(t) = c log(at+ b) + d then g′(t) = acat+b and so F (t) =
−1
c t+
−b
ac , then by
Theorem C.7 β = β∗.
If g(t) = log
(
t
1−t
)
then F (t) = t2 − t and ∂2F
∂t2
= 2 > 0. Then by Theorem C.7
|β∗| < |β|.
Neuhaus & Jewell [7] also give an approximate expression for the unadjusted treatment
effect parameter in terms of the adjusted treatment effect parameter, for adjusted
treatment effect parameter close to zero. This is given in Theorem C.9
Theorem C.9.
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For β close to zero, β∗ is approximately independent of X and
β∗ ≈ βH ′(β) = βg′(E[g−1(ψ)])E[1/g′(g−1(ψ))]
where H(β) is the function of β that gives β∗: H(β) = g(µ∗1)− g(µ∗0) = β∗.
Proof. This is given by the first-order Taylor expansion of β∗ = g(µ∗1) − g(µ∗0) =
H(β).
C.3 Approach of Robinson et al. for precision with
binary outcomes and covariates
In this section I present details of the work of Robinson et al. [5] on precision with
binary outcomes and covariates.
Let Y be a binary outcome variable, X a binary variable identifying treatment arm
and Z a binary covariate. By randomisation, X and Z are independent. Consider the
GLM defined by
E(Y |X,Z) = g−1(η) = h(η) ,
η = α+ βX + γZ
and Y follows an exponential distribution, so that β is the treatment effect adjusted
for the covariate Z. Also consider an alternative GLM with linear predictor
η = α∗ + β∗X
so that β∗ is the unadjusted treatment effect.
Robinson et al. [5] first define several conditional probabilities as follows:
pi = pr(Y = 1|X = i) for i = 0, 1
pij = pr(Y = 1|X = i, Z = j) for i, j = 0, 1
cij = pr(Z = j|X = i) for i, j = 0, 1
(C.8)
By usual probability rules we then have the following relationships:
pi = ci0pi0 + ci1pi1 and ci0 + ci1 = 1 for i = 0, 1
X and Z are independent by randomisation, so we also have:
c0j = c1j for j = 0, 1
So let c = c01 = c11 = pr(Z = 1) and (1− c) = c00 = c10 = pr(Z = 0).
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Given the GLMs defined above, we can express the treatment effect parameters in
terms of conditional probabilities via the link function as follows:
β = g(p10)− g(p00) = g(p11)− g(p01)
β∗ = g(p1)− g(p0)
Also note that
p10 = g
−1(α+ β) and p11 = g−1(α+ β + γ) .
The asymptotic relative precision (ARP) of the adjusted estimate of treatment effect
to the unadjusted estimate of treatment effect is given by
ARP (βˆ to βˆ∗) =
var(βˆ|X)−1
var(βˆ∗|X)−1 =
var(βˆ∗|X)
var(βˆ|X) .
By standard likelihood theory results, we can express the asymptotic variances of the
unadjusted and adjusted treatment effect estimators in terms of the sample size in
each treatment arm, the conditional probabilities given in equations C.8 and the link
function:
var(βˆ|X) =
[{
1
N0c00k(p00)
+
1
N1c10k(p10)
}−1
+
{
1
N0c01k(p01)
+
1
N1c11k(p11)
}−1]−1
var(βˆ∗|X) = 1
N0k(p0)
+
1
N1k(p1)
(C.9)
where k(p) = [p(1−p){g′(p)}2]−1 and N0 and N1 are the sample sizes in each treatment
arm.
Robinson et al. [5] then show that for a linear or log link function the ARP of the
adjusted to unadjusted treatment effect estimators is greater than one. So when
using a GLM for a binary outcome and covariate with a linear or log link function,
the adjusted estimator always has smaller asymptotic variance than the unadjusted
estimator. The details of the method are given in Theorem C.10. The result is
achieved separately for the two forms of link function, by defining an appropriate
random variable and function of that variable and then using Jensen’s inequality.
Theorem C.10.
If the link function g is linear (g(p) = p) or log (g(p) = log(p)) then ARP (βˆ to βˆ∗) ≥ 1.
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Proof. If g(p) = p then k(p) = [p(1− p)]−1 and we have
var(βˆ|X) =
[{
p00(1− p00)
N0c00
+
p10(1− p10)
N1c10
}−1
+
{
p01(1− p01)
N0c01
+
p11(1− p11)
N1c11
}−1]−1
var(βˆ∗|X) =p0(1− p0)
N0
+
p1(1− p1)
N1
Define
f(W ) =
[
W (1−W )
N0
+
(W + β)[1− (W + β)]
N1
]−1
with W a random variable taking value p01 with probability c = c01 = c11 and value
p00 with probability (1− c) = c00 = c10, so
E(W ) = cp01 + (1− c)p00 = p0 .
Then we have
f(E(W )) = f(p0) = [var(βˆ
∗|X)]−1
and E(f(W )) = cf(p01) + (1− c)f(p00) = [var(βˆ|X)]−1 .
And so
ARP (βˆ to βˆ∗) =
E(f(W ))
f(E(W ))
.
Let f(W ) = [m(W )]−1. Then m(W ) is the sum of two concave functions and so it is
concave. Therefore f(W ) is a convex function so by Jensen’s inequality f(E(W )) ≤
E(f(W )) and
ARP (βˆ to βˆ∗) ≥ 1 .
If g(p) = log(p) then k(p) = p/(1− p). Now define
f(W ) =
[
1−W
N0W
+
1− rW
N1rW
]−1
with r = exp(β) and W a random variable taking value p01 with probability c = c01 =
c11 and value p00 with probability (1− c) = c00 = c10. Then again we have
f(E(W )) = f(p0) = [var(βˆ
∗|X)]−1
E(f(W )) = cf(p01) + (1− c)f(p00) = [var(βˆ|X)]−1
and ARP (βˆ to βˆ∗) =
E(f(W ))
f(E(W ))
.
Let f(W ) = [m(W )]−1. Then m(W ) is the sum of two concave functions and so it is
concave. Therefore f(W ) is a convex function so by Jensen’s inequality f(E(W )) ≤
E(f(W )) and
ARP (βˆ to βˆ∗) ≥ 1 .
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As in Theorem C.11, Robinson et al. [5] find a condition for the ARP to be less than
one. The method is similar to that used in the proof of Theorem C.10; by defining a
particular random variable and function, and using Jensen’s and Minkowski’s inequal-
ities. Finally, as in Corollary C.12, this condition is shown to apply for logit, probit,
complementary log-log and generalised logistic link functions. So when using a GLM
for a binary outcome and covariate with these link functions, the adjusted estimator
always has greater asymptotic variance than the unadjusted estimator.
Theorem C.11.
If the k(p) = [p(1− p){g′(p)}2]−1 is a concave function then ARP (βˆ to βˆ∗) ≤ 1.
Proof. Let aij = Micijk(pij), then
var(βˆ|X) =
{(
1
a00
+
1
a10
)−1
+
(
1
a01
+
1
a11
)−1}−1
.
Let W be a random variable taking value p01 with probability c = c01 = c11 and value
p00 with probability (1− c) = c00 = c10, so
E(W ) = cp01 + (1− c)p00 = p0 .
Then we have
k(E(W )) = k(p0)
and E(k(W )) = ck(p01) + (1− c)k(p00) .
If k(W ) is concave then k(E(W )) ≥ E(k(W )) by Jensen’s inequality and so
N0k(p0) ≥ N0(c00k(p00) + c01k(p01)) = a00 + a01 .
Similarly we can obtain
N1k(p1) ≥ N1(c10k(p10) + c11k(p11)) = a10 + a11 .
Therefore
var(βˆ∗|X) = 1
N0k(p0)
+
1
N1k(p1)
≤ 1
a00 + a01
+
1
a10 + a11
⇒
[
var(βˆ∗|X)
]−1 ≥ [ 1
a00 + a01
+
1
a10 + a11
]−1
.
By Minkowski’s inequality(
1
a00 + a01
)−1
+
(
1
a01 + a11
)−1
≤
(
1
a00 + a01
+
1
a10 + a11
)−1
⇒
[
var(βˆ|X)
]−1 ≤ [var(βˆ∗|X)]−1
⇒ ARP (βˆ to βˆ∗) ≤ 1 .
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Corollary C.12.
If the link function g is the logit, probit, log-log, complementary log-log or generalised
logistic (with 0 < θ ≤ 1) function then ARP (βˆ to βˆ∗) ≤ 1.
Proof. If g(p) = log (p/(1− p)) then g′(p) = [p(1−p)]−1 and so k(p) = p(1−p) which
is concave. Then, by Theorem C.11 ARP (βˆ to βˆ∗) ≤ 1.
It can be shown [5] that for probit, log-log, complementary log-log and generalised
logistic (with 0 < θ ≤ 1) link functions, k(p) is also concave and so by Theorem C.11
ARP (βˆ to βˆ∗) ≤ 1.
C.4 Approach of Robinson et al. for power with binary
outcomes and covariates
In this section I present details of the work of Robinson et al. [5] on power with binary
outcomes and covariates.
Let the GLMs and conditional probabilities be as defined in Section C.3, so that we
have unadjusted treatment effect parameter β∗ and adjusted treatment effect param-
eter β. Recall the following probabilities defined in equations C.8:
pi = pr(Y = 1|X = i) for i = 0, 1
pij = pr(Y = 1|X = i, Z = j) for i, j = 0, 1
cij = pr(Z = j|X = i) for i, j = 0, 1
Then, as before, by usual probability rules we have the following relationships:
pi = ci0pi0 + ci1pi1 and ci0 + ci1 = 1 for i = 0, 1
X and Z are independent by randomisation, so we also have:
c0j = c1j for j = 0, 1
So again let c = c01 = c11 = pr(Z = 1) and (1 − c) = c00 = c10 = pr(Z = 0). Given
the GLMs defined, we can again express the treatment effect parameters in terms of
conditional probabilities via the link function:
β = g(p10)− g(p00) = g(p11)− g(p01)
β∗ = g(p1)− g(p0)
Also note that
p10 = g
−1(α+ β) and p11 = g−1(α+ β + γ) .
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We can compare tests of no treatment effect by their asymptotic relative efficiency
(ARE). Suppose we have a parameter of interest θ and we wish to test θ = θ0. And
we have a statistic T that is a consistent estimator of µT (θ), a monotone function
(at least close to θ = θ0) of θ. A definition of ARE called the Pitman efficiency of
two such statistics T1 and T2 that are asymptotically normally distributed with mean
µT (θ) and variance σ
2
T (θ)is given by [28]:
ARE(T1 to T2 at θ = θ0) =
[
µ′T1(θ0)
µ′T2(θ0)
]2 [
σ2T2(θ0)
σ2T1(θ0)
]
(C.10)
We can test the null hypothesis β = 0 by the adjusted or unadjusted Wald test
statistics
βˆ√
var(βˆ)
or
βˆ∗√
var(βˆ∗)
which have asymptotic normal distributions with means β/
√
var(βˆ) and β∗/
√
var(βˆ∗)
and variances 1. Substituting the adjusted and unadjusted Wald test statistics into
the definition of ARE in equation C.10 we obtain the ARE of a test of no treatment
effect based on the adjusted estimator to a test based on the unadjusted estimator [5]:
ARE(βˆ to βˆ∗) =
[
lim
β→0
(
d
dβ
β
)(
d
dβ
β∗
)−1]2 [
lim
β→0
var(βˆ∗|X)
var(βˆ|X)
]
(C.11)
where we are considering β and β∗ as functions of β.
The following theorem details the method of Robinson et al. [5] for establishing that
the ARE of a test of no treatment effect based on the adjusted estimator to a test based
on the adjusted estimator is greater than one, for all link functions, if the covariate
is prognostic. If the covariate is independent of outcome (i.e. not prognostic) then
the ARE is one. The method of Robinson et al. [5] expresses each of the two factors
making up the ARE in terms of the link function and the probabilities defined above.
From the Cauchy-Schwarz inequality, an appropriately defined random variable and
Jensen’s inequality, this expression for the ARE is shown to be greater than or equal
to one.
Theorem C.13.
Given the defined GLMs, for any link function ARE(βˆ to βˆ∗) ≥ 1.
ARE(βˆ to βˆ∗) = 1 if and only if Z is independent of Y .
Proof. Firstly considering the first factor of the expression for ARE(βˆ to βˆ∗) as given
in equation C.11:
We have the trivial result ddββ = 1. Then noting that p0 is not a function of β, we
have
d
dβ
β∗ =
d
dβ
g(p1) = g
′(p1)
d
dβ
p1 .
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Recall that
p1 = (1− c)p10 + cp11 = (1− c)g−1(α+ β) + cg−1(α+ β + γ)
and so we have
d
dβ
β∗ = g′(p1)
(
1− c
g′(g−1(α+ β))
+
c
g′(g−1(α+ β + γ))
)
= g′(p1)
(
1− c
g′(p10)
+
c
g′(p11)
)
.
As β → 0, p10 → p00, p11 → p01 and p1 → p0, so
lim
β→0
d
dβ
β∗ = g′(p0)
(
1− c
g′(p00)
+
c
g′(p01)
)
.
So the first factor in the ARE is[
lim
β→0
(
d
dβ
β
)(
d
dβ
β∗
)−1]2
=
[
g′(p0)
(
1− c
g′(p00)
+
c
g′(p01)
)]−2
. (C.12)
Now considering the second factor of the expression for ARE(βˆ to βˆ∗) as given in
equation C.11:
Using the asymptotic variance formulae given in equations C.9, and that as β → 0,
p10 → p00, p11 → p01 and p1 → p0:
lim
β→0
var(βˆ∗|X) = lim
β→0
(
1
N0k(p0)
+
1
N1k(p1)
)
= {k(p0)}−1
(
1
N0
+
1
N1
)
and lim
β→0
var(βˆ|X) = {(1− c)k(p00) + ck(p01)}−1
(
1
N1
+
1
N0
)
∴ lim
β→0
var(βˆ∗|X)
var(βˆ|X) =
(1− c)k(p00) + ck(p01)
k(p0)
Now letting A = {g′(p00)}−1 and B = {g′(p01)}−1, by equations C.12 and we can
express the ARE in terms of the link function and defined probabilities:
ARE(βˆ to βˆ∗) =
p0(1− p0)
{
(1−c)A2
p00(1−p00) +
cB2
p01(1−p01)
}
{(1− c)A+ cB}2 (C.13)
To find an inequality involving the ARE, first note that it can by shown by the
Cauchy-Schwarz inequality:
{(1−c)A+cB}2 ≤
{
(1− c)A2
p00(1− p00) +
cB2
p01(1− p01)
}
{(1− c)p00(1− p00) + cp01(1− p01)}
Now consider a random variable W that takes value p01 with probability c and value
p00 with probability 1− c, then
E(W ) = p0 , p0(1− p0) = E(W )(1− E(W ))
and E(W (1−W )) = (1− c)p00(1− p00) + cp01(1− p01) .
271
Since W 2 is a strictly convex function of W , by Jensen’s inequality:
E(W 2) ≥ E(W )2
⇔ E(W )− E(W )2 ≥ E(W )− E(W 2)
⇔ E(W )(1− E(W )) ≥ E(W (1−W ))
⇔ p0(1− p0) ≥ (1− c)p00(1− p00) + cp01(1− p01)
So we have
{(1− c)A+ cB}2 ≤ p0(1− p0)
{
(1− c)A2
p00(1− p00) +
cB2
p01(1− p01)
}
which by equation C.13 gives our result
ARE(βˆ to βˆ∗) ≥ 1 .
Note that ARE(βˆ to βˆ∗) = 1 if and only if the variable W is constant, which is
equivalent to p00 = p01. So ARE(βˆ to βˆ
∗) = 1 if and only if Z is independent of
Y .
C.5 Approach of Neuhaus
In this section I present details of the work of Neuhaus [4].
Let Y be an outcome variable, X a binary variable identifying treatment arm (taking
value 1 with probability p = 12) and Z a covariate (here, we consider Z as one-
dimensional but the methods generalise to Z as a multi-dimensional vector). By
randomisation, X and Z are independent. Assume that E(Z) = µZ and var(Z) = σ
2
Z .
Consider the GLM that includes the covariate, defined by
E(Y |X,Z) = g−1(η) = h(η) ,
η = α+ βX + γZ
and Y follows a distribution in the exponential family. So β is the adjusted treatment
effect parameter. Assume the link function g is strictly monotone increasing and
differentiable. For convenience, define the covariate effect ψ = γZ so E(ψ) = γµZ
and var(ψ) = γ2σ2Z .
Also consider a GLM omitting the covariate Z, so we use the same GLM except with
linear predictor
η∗ = α∗ + β∗X
so that β∗ is the unadjusted treatment effect parameter.
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Recall the probability density function of Y is of the form [79]
fY (y; θ, φ) = exp
{
yθ − b(θ)
a(φ)
+ c(y, φ)
}
for specific functions a(.), b(.) and c(.). And the mean and variance of Y are
E(Y ) = µ = b′(θ) and var(Y ) = b′′(θ)a(φ) = V a(φ) .
The asymptotic relative efficiency (ARE) of a test of no treatment effect based on the
unadjusted estimator to a test based on the adjusted estimator is given by
ARE(βˆ∗ to βˆ) =
[
lim
β→0
(
d
dβ
β∗
)(
d
dβ
β
)−1]2 [
lim
β→0
var(βˆ|X)
var(βˆ∗|X)
]
(C.14)
where we are considering β and β∗ as functions of β. (Note that this ARE is the inverse
of that described in the previous section; unadjusted and adjusted are interchanged.
In both sections, the ARE considered is consistent with the source paper.)
Theorem C.14.
The asymptotic relative efficiency (ARE) of a test of no treatment effect based on the
unadjusted estimator to a test based on the adjusted estimator is less than or equal
to one: ARE(βˆ∗ to βˆ) ≤ 1.
Proof. Firstly, consider the first factor in the expression for the ARE. Neuhaus &
Jewell [7] show that
lim
β→0
∂β∗
∂β
= g′
(
E
[
g−1(α+ ψ)
])
E
[
1
g′ (g−1(α+ ψ))
]
= g′ (E[µ0])E
[
1
g′(µ0)
]
(C.15)
and we have the trivial result ddββ = 1. So the first factor of the ARE is given by[
lim
β→0
(
d
dβ
β∗
)(
d
dβ
β
)−1]2
= g′ (E[µ0])2E
[
1
g′(µ0)
]2
. (C.16)
To calculate the second factor of the ARE, we need to find the variances of the esti-
mators of the unadjusted and adjusted treatment effect parameters. Firstly, introduce
the following notation for the vector of parameters in the unadjusted model:
β∗ = (α∗, β∗)
And βˆ∗ is the maximum likelihood estimator of β∗. It has been shown by White [80]
that β∗ is asymptotically normally distributed with covariance matrix given by the
matrix product
var(βˆ∗) = A−1(βˆ∗)B(βˆ∗)A−1(βˆ∗) (C.17)
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where the matrices A and B are given by
Aij (β
∗) = EX,Z
[
EY |X,Z
[
∂2 logPF (Y = y|β∗, X)
∂β∗i ∂β
∗
j
]]
and Bij (β
∗) = EX,Z
[
EY |X,Z
[
∂ logPF (Y = y|β∗, X)
∂β∗i
× ∂ logPF (Y = y|β
∗, X)
∂β∗j
]]
.
Expectations in the above expressions are with respect to the adjusted model, while
PF are probabilities defined by the unadjusted model. Calculating the appropriate
derivatives, we obtain the following matrices for the vector of parameters of the un-
adjusted model:
A (β∗) = EX,Z
[
EY |X,Z
[
1
φ∗V ∗[g′(µ∗)]2
M(X)
]]
= EX,Z
1
φ∗V ∗[g′(Eµ0)]2
M(X)
B (β∗) = EX,Z
[
EY |X,Z
[
(Y − Eµ0)2
[φ∗V ∗g′(Eµ0)]2
M(X)
]]
= EX,Z
φV + (µ− Eµ0)2
[φ∗V ∗g′(Eµ0)]2
M(X)
where V ∗ and φ∗ are the variance function and scale factor under the unadjusted
model, V and φ are the variance function and scale factor under the adjusted model
and the matrix M(X) is
M(X) =
[
[c]1 X
X X2
]
.
Apply the result of White [80] given in equation C.17 and setting β = 0 obtains
var(βˆ∗|β = 0) = E[φV + (µ0 − Eµ0)
2][g′(Eµ0)]2
var(X)
.
From McCullagh & Nelder [79] we also obtain the following variance
var(βˆ|β = 0) = φ
var(X)
{
E
[
1
V [g′(µ0)]2
]}−1
.
Combining these two results for variance of estimators of treatment effect parameters,
we have the following expression for the second factor of the ARE:
var(βˆ|β = 0)
var(βˆ∗|β = 0) =
1
E[V + φ−1(µ0 − Eµ0)2] (g′(Eµ0))2E
[
1
V (g′(µ0))2
] (C.18)
Now by evaluating the product of equations C.16 and C.18 we obtain the following
expression for the ARE:
ARE(βˆ to βˆ∗) =
E
[
1
g′(µ0)
]2
E[V + φ−1(µ0 − Eµ0)2]E
[
1
V (g′(µ0))2
]
Note that φ−1(µ0 − Eµ0)2 ≥ 0 and so we have the inequality
ARE(βˆ to βˆ∗) ≤
E
[
1
g′(µ0)
]2
E[V ]E
[
1
V (g′(µ0))2
]
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Now let T 2 = 1
V (g′(µ0))2 and W
2 = V , so TW = 1g′(µ0) . Then by the Cauchy-Schwarz
inequality,
E[TW ]2 ≤ E[T 2]E[W 2]
⇒ E
[
1
g′(µ0)
]2
≤ E
[
1
V (g′(µ0))2
]
E[V ]
⇒ ARE(βˆ to βˆ∗) ≤ 1 .
So the ARE of a test of no treatment effect based on the unadjusted estimator to a
test based on the adjusted estimator is less than or equal to one.
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Appendix D
Numerical method
In Chapter 7 I have presented some equations that must be solved for an unknown.
Where these cannot be solved algebraically, we may employ a numerical method. In
general, we wish to find a numerical solution to
f(x) = 0
obtaining a value for x to some pre-determined precision. We must be able to calculate
f(x) for any given value of x.
I have chosen to use the bisection method. The basic steps of the bisection algorithm,
assuming f(x) is an increasing function of x, are:
1. Start with an interval [a, b], such that f(a) < 0 and f(b) > 0.
2. Calculate f(c), where c = a+b2 .
3. If f(c) = 0 then x = c, and stop.
4. If f(c) > 0, then x must lie between a and c, so set b = c and return to step 2.
If f(c) < 0, then x must lie between c and b, so set a = c and return to step 2.
5. Repeat steps 2 to 4 until b− a is less than a pre-determined value. Then x is in
the interval (a, b).
The following is Stata code for a program to find ICCY ∗ (given ICCY and Π0) where
ICCY =
Φ2
(
Φ−1(Π0),Φ−1(Π0), ICCY ∗
)−Π20
Π0(1−Π0) .
This program starts with the interval [0, 1]. The program returns the midpoint of the
interval (a, b) if it is the exact solution, or once b − a < 10−7. It will also stop after
100 steps, in case of any unforeseen error.
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program d e f i n e p r o b i t i c c , r c l a s s
syntax , ICC( r e a l ) PI ( r e a l )
l o c a l s t ep s=0
l o c a l a=0
l o c a l b=1
l o c a l prec =0.0000001
whi l e ‘ s teps ’ <100 {
l o c a l c = ( ‘ a ’+ ‘b ’ ) / 2 // midpoint
l o c a l f c = ( binormal ( invnormal ( ‘ pi ’ ) , invnormal ( ‘ pi ’ ) , ‘ c ’)− ‘ pi ’ ˆ 2 ) / ( ‘ pi ’∗(1− ‘ pi ’ ) )
l o c a l f a = ( binormal ( invnormal ( ‘ pi ’ ) , invnormal ( ‘ pi ’ ) , ‘ a ’)− ‘ pi ’ ˆ 2 ) / ( ‘ pi ’∗(1− ‘ pi ’ ) )
l o c a l fb = ( binormal ( invnormal ( ‘ pi ’ ) , invnormal ( ‘ pi ’ ) , ‘ b ’)− ‘ pi ’ ˆ 2 ) / ( ‘ pi ’∗(1− ‘ pi ’ ) )
i f ‘ f c ’==‘ i cc ’ | ( ‘ b’− ‘a ’ ) < ‘ prec ’ {
re turn s c a l a r i c c p r o b i t = ‘ c ’
continue , break
}
l o c a l s t ep s = ‘ steps ’ + 1
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i f s i gn ( ‘ i c c ’− ‘ fa ’)== s ign ( ‘ i c c ’− ‘ f c ’ ) {
l o c a l a = ‘ c ’
}
e l s e i f s i gn ( ‘ i c c ’− ‘ fb ’)== s ign ( ‘ i c c ’− ‘ f c ’ ) {
l o c a l b = ‘ c ’
}
i f ‘ s teps ’>99 {
di sp ”Couldn ’ t f i n d ICCprobit . ”
}
}
end
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Appendix E
Software
StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: Stata-
Corp LP.
Raudenbush SW et al. 2011. Optimal Design Software for Multi-level and Longitudinal
Research (Version 3.01). Available from www.wtgrantfoundation.org.
R Core Team (2014). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
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Appendix F
Review of the use of covariates
in cluster randomised trials:
paper in press
This appendix contains the Accepted Author Manuscript of the paper in press titled
“Adherence to recommendations on the use of covariates in the design, analysis, and
reporting of cluster randomised trials: a review of a sample of 300 trial reports” [60].
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 Abstract 
Objective 
Reviews of the handling of covariates in trials have explicitly excluded cluster randomised trials. In this study, we 
review the use of covariates in randomisation, the reporting of covariates, and adjusted analyses in cluster 
randomised trials (CRTs). 
Study Design and Setting 
We reviewed a random sample of 300 CRTs published between 2000 and 2008 across 150 English language journals. 
Results 
Fifty-eight per cent of trials used covariates in randomisation. Only 69 (23%) included tables of cluster and individual 
level covariates. 55% reported significance tests of baseline balance. Of 207 trials that reported baseline measures of 
the primary outcome, 155 (75%) subsequently adjusted for these in analyses. Of 174 trials that used covariates in 
randomisation, 30 (17%) included an analysis adjusting for all those covariates. Of 219 trial reports that included an 
adjusted analysis of the primary outcome, only 71 (32%) reported that covariates were chosen a priori. 
Conclusions 
There are some marked discrepancies between practice and guidance on the use of covariates in the design, 
analysis, and reporting of CRTs. It is essential that researchers follow guidelines on the use and reporting of 
covariates in CRTs, promoting the validity of trial conclusions and quality of trial reports. 
Key words: cluster randomised trials; covariates; restricted randomisation; CONSORT statement; adjusted analyses 
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What is new? 
Key findings 
 Restricted randomisation was used in around half of cluster randomised trials. 
 Few trial reports included tables summarising both cluster level and individual level baseline covariates, and 
over half of trials reported a significance test of baseline balance. 
 Adjusted analyses were common in cluster randomised trials, but authors often did not report whether 
covariates have been chosen before or after seeing the data. 
What this adds to what is known? 
 There are some marked discrepancies between practice and guidance in the use of covariates in cluster 
randomised trials. 
What is the implication and what should change now? 
 Researchers and editors should note existing guidelines on the use and reporting of covariates in cluster 
randomised trials. 
284
 Page 5 of 13 
 
1. Introduction 
In cluster randomised trials (CRTs), pre-existing groups (clusters) of individuals (for example, family practices, 
hospitals, communities, or schools) are randomised to intervention or control treatment arms. This is in 
contrast to individually randomised trials, where independent individuals are randomly allocated to 
treatment arms. A cluster randomised design may be used for one or more of several reasons, including 
logistical or administrative convenience; to avoid contamination; to improve compliance with treatment; to 
enable the use of routine data only available at the cluster level; or to evaluate an intervention that is 
applied at the cluster level.  Covariates are commonly used in the design and analysis of randomised trials to 
promote balance between treatment arms and to improve precision and power [1, 2]. Unlike in individually 
randomised trials, covariates in CRTs can exist at two levels: that of the cluster and that of the individual. A 
cluster level covariate describes an intrinsic characteristic of the cluster, and is fixed for all individuals in the 
same cluster. An individual level covariate describes something about an individual, and may vary across 
individuals in the same cluster. 
Specific recommendations are available with respect to the use of covariates in the design and analysis of 
randomised controlled trials. For example, the CONSORT guidelines [3] include recommendations for the 
reporting of covariates, and there is published guidance on adjusting for covariates in analyses [1, 4]. Austin 
et al. [5] and others [6, 7] have reviewed adherence to recommendations with respect to the handling of 
covariates in randomised trials, but reviews have excluded CRTs. A review of CRTs in primary care [8] 
included the use of matching or stratification, and reporting of baseline covariates. In this review we extend 
the work of Austin et al. [5] to CRTs, where the multi-level nature of CRTs introduces additional complexity in 
the handling of covariates.  
CRTs usually randomise a smaller number of units, so there is a greater risk of imbalance of covariates 
between treatment arms. The use of restricted randomisation, via stratification, matching, or minimisation, 
is therefore recommended to help balance both cluster level covariates and individual level covariates 
summarised at the cluster level, when available, between treatment arms [9]. Failure to do so may be a 
missed opportunity to improve validity and power by promoting balance in prognostic covariates [2, 9]. 
The CONSORT extension for CRTs [10] recommends reporting both cluster level and individual level 
covariates as applicable in tables comparing baseline characteristics between arms. Failure to report 
baseline distributions of covariates limits the extent to which a reader of a trial report can assess the validity 
of a trial’s findings and external relevance. There are clear recommendations against significance testing of 
balance of covariates between treatment arms [1, 11]. 
Including covariates that are strongly correlated with outcome in an analysis can improve analytic power and 
statistical precision [1, 12, 13]. A baseline measure of the outcome variable is often strongly correlated with 
outcome, and should be included in an adjusted analysis because it represents an opportunity to improve 
the statistical power of the analysis [14]. Covariates used in randomisation should also be adjusted for in an 
analysis [1, 4]. 
The effects of adjusting for covariates in CRTs are more complex than in individually randomised trials, as 
adjusting for covariates may affect both the cluster level and individual level residual variance of outcome. 
Only limited guidance for choosing covariates in the analysis of CRTs has been published [2, 14]. As for 
individually randomised trials, choosing covariates post hoc can invalidate conclusions, while failure to report 
the method and justification of choosing covariates prevents readers from assessing the validity of adjusted 
analyses [4, 11]. 
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In this paper, we review a random sample of published CRTs with respect to the use of covariates in 
randomisation, the reporting of covariates by treatment arm, and adjustment for covariates in analyses of 
the primary outcome. In particular, we assess whether: a) covariates were used in randomisation; b) tables 
of baseline cluster level and individual level covariates were presented; c) significance tests for baseline 
balance of covariates were avoided; d) an adjusted analysis of the primary outcome was reported; e) an 
analysis adjusting for baseline measure of the outcome (if available) was reported; f) an analysis adjusting 
for all covariates used in randomisation was reported; and g) all covariates were reported to have been 
chosen a priori. 
 
2. Methods 
2.1 Trial sample 
This review used a random sample of 300 CRTs previously identified using a published electronic search 
strategy [15] implemented in Medline. This sample has been used to assess the  impact of the CONSORT 
extension [10] on the reporting and methodological quality of CRTs [16]. The sample includes CRTs for which 
the main report was published between 2000 and 2008, across 150 English language journals. The journals 
include general medical journals (for example: the New England Journal of Medicine (NEJM); the Journal of 
the American Medical Association (JAMA); The Lancet; and the British Medical Journal (BMJ)), and various 
specialty journals (for example: the British Journal of Psychiatry; Diabetes Care; the International Journal of 
Cancer; and the Journal of Nutrition). 
2.2 Data abstraction 
Two reviewers (NW and NI) independently read and abstracted a defined list of items from each paper. Any 
discrepancies were resolved by consensus. The review method was piloted on fifteen papers, leading to 
clarifications to the abstraction strategy. Twenty five items were extracted from each trial report, relating to: 
sample size and primary outcome type (3 items); use of covariates in randomisation (4 items); reporting 
covariates at baseline (6 items); adjusting for covariates in an analysis of the primary outcome (8 items); and 
selection of covariates (2 items). Ten items related directly to recommendations made for handling 
covariates; others were abstracted to provide general background characteristics of the trial and information 
about the use of covariates. Definitions of variables abstracted and justification are described below. 
2.3 Data abstracted 
We describe each covariate as either a cluster or individual level variable. The level is that at which the 
covariate is most naturally measured. This may not always be the level at which it is reported or used in 
analysis. For example, in a trial where general practitioners are the clusters and their patients are the 
individuals, the number of years since registration as a general practitioner is a cluster level covariate, while 
the age of a patient is an individual level covariate. A covariate measured entirely or mostly on individuals 
not taking part in the trial, and used to describe some aspect of the cluster, would be counted as a cluster 
level covariate. For example, in a trial where the cluster is a general practice and only some patients in the 
practice are recruited to the trial, the average age of all patients in a general practice is a cluster level 
covariate. If a single covariate was summarised and reported in multiple ways (for example, mean age and 
proportion of patients above age 65), it was counted as one covariate. 
We limited abstraction to analyses of the primary outcome for each trial. The primary outcome was defined 
to be the first primary outcome identified by the author. If a primary outcome was not identified by the 
author, then it was identified as: the outcome used in the sample size calculation; the outcome identified by 
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the paper’s title; or the first reported outcome in the paper. To be included in this review, an analysis had to 
include an estimate of treatment effect plus a measure of uncertainty (such as a confidence interval or 
standard error), or a P-value of a significance test of no treatment effect. 
We characterised covariates used in analyses as one of the following: baseline measure of primary outcome; 
covariate used in randomisation (for example, stratification, minimization, or matching factors); and any 
other covariate.  When a study reported change from baseline as the primary outcome, we counted this as 
an attempt to adjust for the baseline measure of outcome, acknowledging that this is not the recommended 
approach [1]. We considered covariates used in randomisation separately from other covariates because 
these should be adjusted for in the analysis [1, 4], and to enable comparison with previous methodological 
reviews [5]. 
When considering analyses adjusted for covariates other than the baseline measure of outcome or 
covariates used in randomisation, only the analysis identified by the author as the main adjusted analysis (or 
the first reported if a main adjusted analysis was not identified) was evaluated. Subgroup analyses were not 
considered. Any reason given for selecting covariates for multivariable analysis was considered as 
justification given.  
The reported method for selecting covariates for adjusted analyses was considered post hoc if the paper 
described a method where covariates were chosen after observation of any trial data. For example, selecting 
covariates due to an observed imbalance between treatment groups, or using a covariate selection 
algorithm, were post hoc methods. If the paper reported that covariates were chosen before any data were 
observed, for example they were pre-specified in an analysis plan, then the reported method of choosing 
covariates is a priori. In all other cases, the method was considered unclear. 
 
3. Analysis 
Results are presented using descriptive statistics, and include two sets of results by subgroups which were 
chosen post hoc for further investigation. We explored whether the use of covariates in randomisation and 
adjusting for covariates at cluster and individual level varied according to the number of clusters in the trial. 
We explored whether reporting covariates in baseline tables, using statistical tests of baseline balance, and 
reporting choosing covariates a priori differed for trials published in high impact journals compared to other 
journals. 
In the first stratified analysis, three subgroups were defined by mean number of clusters per treatment arm. 
Subgroups were formed by the lower quartile, upper quartile, and remaining trials: 5 or fewer clusters per 
arm; from 5.5 to 23 clusters per arm; and more than 23 clusters per arm. These subgroups contained 75, 147 
and 71 trials, respectively. In this analysis, seven trials were excluded as the mean number of clusters per 
treatment arm could not be calculated, because either the total number of individuals or the number of 
clusters in the trial was not reported.  
In the second stratified analysis, two subgroups were defined by the impact factor of the publishing journal. 
Impact factors were obtained from journal citation reports (ISI Web of Science, 2009). We defined high 
impact journals as those with impact factor greater than ten, which in this sample are: the New England 
Journal of Medicine (NEJM); the Journal of the American Medical Association (JAMA); The Lancet; Annals of 
Internal Medicine; PLOS Medicine; and the British Medical Journal (BMJ). Fifty-one trial reports in the sample 
were published in these high impact journals. The remaining 249 trial reports were published in other 
journals.  
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4. Results 
4.1 Trial characteristics 
Characteristics of the 300 trial reports used in this review are summarised in Table 2 of Ivers et al. [16]. 
4.2 Randomisation 
Details with respect to the use of covariates in randomisation are presented in Table 1. In 174 (58.0%) of the 
300 trials, at least one covariate was used in randomisation. In 130 (43.3%) trials, at least one covariate 
other than cluster location and cluster size was used. In 118 (39.3%) trials, only cluster level covariates were 
used. 
In the 124 trials that used cluster level covariates in randomisation, 74 (59.7%) used one cluster level 
covariate, 24 (19.4%) used two, and 26 (21.0%) used between three and nine. Only 12 trials used individual 
level covariates in randomisation of which nine (75%) used only one individual level covariate.  
Of 277 trials that were conducted in more than one location, authors of 50 (18.1%) attempted to balance for 
cluster location in randomisation (three out of 277 were unclear). Of 285 trials with varying cluster sizes, 
authors of 51 (17.9%) attempted to balance cluster size in randomisation (four out of 285 were unclear). Of 
263 trials with multiple location and variable cluster size, authors of 12 (4.6%) attempted to balance both 
location and cluster size in randomisation. 
4.3 Reporting of baseline covariates 
Of 300 trial reports, 69 (23.0%) included tables reporting both cluster and individual level covariates by 
treatment arm, while 158 (52.7%) included a table of individual level covariates only. Further details are 
given in Table 1. The number of cluster level covariates described in a table or in the text ranged from 1 to 
19 (if non-zero), with a median of 3. The number of individual level covariates described in a table or in the 
text ranged from 1 to 28 (if non-zero), with a median of 7. 
Out of 300 trial reports, 207 (69%) reported a baseline measure of the primary outcome. A significance test 
of the balance of a covariate between treatment arms was reported or referred to in 166 (55.3%) trial 
reports. 
4.4 Adjusted analyses 
Out of 300 trial reports, 219 (73.0%) included at least one adjusted analysis of the primary outcome. Of 207 
trial reports that reported a baseline measure of the primary outcome, 155 (74.9%) included an analysis 
adjusting for a baseline measure of the outcome. Of 174 trials that used covariates (including cluster size and 
location) in randomisation, 30 (17.2%) included an analysis adjusting for all covariates used in 
randomisation. These results are summarised in Table 1. Seven trial reports did not include any unadjusted 
or adjusted analysis of the primary outcome, according to our criteria. 
There were 140 (46.7%) trials that included an analysis adjusting for covariates other than baseline measure 
of outcome or covariates used in randomisation. Of these 140 adjusted analyses, 7 (5.0%) included only 
cluster level covariates, while 100 (71.4%) adjusted for only individual level covariates. In 29 (20.7%) 
analyses both cluster and individual level covariates were included. In four (2.9%) of these trials it was 
unclear which level of covariates had been included. When included, the number of cluster level covariates 
ranged from 1 to 8, with a median of 1. Likewise, the number of individual level covariates included in an 
adjusted analysis ranged from 1 to 28, with a median of 3. 
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4.5 Choosing covariates 
Of the 219 (73.0%) trial reports that included an adjusted analysis of the primary outcome, in 71 (32.4%) 
authors reported choosing covariates a priori, but in 93 (42.4%) it was not reported when covariates 
adjusted for had been chosen. In 73 (33.3%) trial reports, authors gave some justification for the choice of 
covariates. 
4.6 Subgroup results – number of clusters 
The results from the subgroup analyses based on trial size are summarised in Table 2. At least one covariate 
other than cluster location and cluster size was used in randomisation in 22 out of 75 (29%) trials with five or 
fewer clusters per treatment arm. In trials with more than 23 clusters per treatment arm, 28 out of 71 (39%) 
balanced on covariates other than cluster location or cluster size. In the remaining 147 trials, 79 (53.7%) 
used other covariates in randomisation. 
Thirty-three (44%) of the 75 smallest trials included an analysis adjusting for covariates other than baseline 
measure of outcome and covariates used in randomisation. Five (15%) of those adjusted for cluster level 
covariates. Of the 71 largest trials (more than 23 clusters per arm), 34 (48%) reported an analysis adjusting 
for other covariates, and 10 (29%) of those analyses used cluster level covariates. Of the 147 remaining 
trials, 71 (48%) included an analysis adjusting for other covariates, with 21 (30%) using cluster level 
covariates. 
4.7 Subgroup results – journal impact factor 
The results described in this section are summarised in Table 3. Reports published in journals with high 
impact factors showed higher adherence to three guidelines assessed. In particular, tables reporting both 
cluster and individual level covariates were included in 24 out of 50 (48%) trial reports in high impact 
journals, compared with 45 out of 250 (18.0%) trial reports in other journals; a significance test of balance of 
a covariate between treatment arms was reported or referred to in 17 out of 50 (34%) trial reports in high 
impact journals, compared to 149 out of 250 (59.6%) trial reports in other journals; and 7 (21%) included an 
analysis adjusting for all covariates used in randomisation compared to 23 (16.3%) in other journals. 
Of 30 trial reports in high impact journals that reported a baseline measure of the primary outcome, twenty-
one (70%) included an analysis adjusting for a baseline measure of outcome, compared to 134 (75.7%) out of 
177 in other journals. In 19 (51.4%) high impact factor journal reports it was unclear when covariates 
adjusted for in the analysis had been chosen compared to 74 (40.7%) in other journals. 
 
5. Discussion 
In CRTs, baseline balance of covariates may be a greater concern than in individually randomised trials [9]. 
Despite recommendations to use restricted randomization, especially in smaller CRTs [9], over 40% of 
authors did not do so. This compares to 64% of authors not using restricted randomisation in a review of 
CRTs in primary care [8]. Furthermore, attempting to use restricted randomisation to achieve balance on 
individual level covariates was rare, in spite of the fact that balance of both cluster level and individual level 
covariates is important in a CRT [9]. 
While 80% of trials included at least one table reporting covariates by treatment group, less than 25% 
included tables for both cluster and individual level covariates at baseline, as recommended by CONSORT 
guidelines [10]. The proportion of trial reports including a table of individual level covariates by treatment 
arm at baseline was slightly higher in high impact journals (84%). This compares to 96.5% and 96% in the 
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individually randomised trials reviewed by Austin et al. [5] and Saquib et al. [17] respectively. Those reviews 
included only papers published in selections of journals with high impact factors. This suggests greater 
adherence in trial reports in high impact journals, rather than a difference in reporting between CRTs and 
individually randomised trials. 
More than half of sampled CRTs (55.3%) reported a significance test of baseline balance, despite clear 
recommendations against this practice [1, 11]. Although these recommendations strictly apply to individually 
randomised trials, the argument extends directly to not testing baseline balance of covariates that can only 
be imbalanced by chance. This practice appears less common in high impact journal reports (34%) and 
compares to 38.2% and 46% in the reviews of individually randomised trials by Austin et al. [5] and Saquib et 
al. [17] respectively. 
At least one adjusted analysis of the primary outcome was reported in 73% of CRT reports. Adjusted 
analyses of the primary outcome using the baseline measure of outcome (as recommended by Murray [14]) 
were conducted in 74.9% of trials which reported baseline values of the outcome.  An analysis adjusting for 
other covariates (not baseline measure of outcome, or covariates used in randomisation) was reported in 
almost half (46.7%) of trial reports. This compares to 34.2% of individually randomised trials in the review by 
Austin et al. [5] which included analyses adjusting for covariates other than baseline measure of outcome 
and covariates used in randomisation. 
In one quarter of adjusted analyses some or all covariates were reportedly chosen post hoc, defying 
guidance for choosing all covariates a priori [2]. In 93 (42.5%) cases it was not reported when the covariates 
adjusted for in the analysis had been chosen. This does not allow any assessment of the validity of selecting 
covariates, but is less common than in the individually randomised trials considered by Austin et al. [5] and 
Yu et al. [7] (67% and 75.6% of trial reports). Only a third of CRT reports gave any justification for covariate 
choice, compared to 41.7% and 73.6% of individually randomised trials in the reviews by Assman et al. [6] 
and Yu et al. [7] respectively. 
This review is limited by the age of the included trial reports, ranging from six to fourteen years old. It is 
plausible that more recently published CRTs could show different characteristics. In addition, we limited 
abstraction to one primary outcome and one adjusted analysis from each trial report. Therefore, the number 
of adjusted analyses actually conducted is almost certainly greater than we report. We did not carry out any 
hypothesis testing or inferential analysis, as we sought to describe practice and had no a priori hypotheses. 
Similarly, our results by subgroup were descriptive as we had no a priori hypotheses. Finally, no inferences 
were made with respect to the appropriateness of methods used for randomisation or adjusting for 
covariates in any trial as there is uncertainty regarding ideal strategies.  
In summary, there are some marked discrepancies between practice and guidance for CRTs with regard to 
using covariates in randomisation, reporting covariates, testing balance, and methods of choosing 
covariates. As with the reviews of individually randomised trials, there is inadequate adherence to clear 
guidance such as not using statistical tests of baseline balance of covariates, and choosing covariates to be 
used in an adjusted analysis a priori. There appears to be better adherence to some recommendations 
amongst CRTs published in high impact journals, compared to CRTs reported in other journals. 
Recommendations to use restricted randomisation and to report both cluster level and individual level 
covariates are not well followed. It is essential that researchers conducting CRTs follow existing guidelines on 
the use and reporting of covariates to ensure validity of trial conclusions and aid readers in assessing the 
quality and results of a trial. Readers should be aware of limitations in trials that do not adhere to such 
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guidelines. Further research is needed into the effects of adjusting for cluster and individual level covariates 
in the analysis of CRTs, and further guidance is needed for choosing covariates in CRTs. 
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Table 1: Use of covariates in randomisation, reporting of covariates, and use of covariates in analysis. 
 Number of trials / Relevant trials (%)   
Use of covariates in randomisation 
    
Covariates used in randomisation 174/300 (58.0%) (3/300 unclear) 
 
Types of covariates used in randomisation    
 Cluster location  50/277 (18.1%) (3/277 unclear) 
 Cluster size  51/285 (17.9%) (4/285 unclear) 
 Other:     
  Only cluster level covariates 118/300 (39.3%)  
  Only individual level covariates 6/300 (2.0%)  
  Both cluster and individual level covariates 6/300 (2.0%)  
  None 167/300 (55.7%)  
  Unclear 3/300 (1.0%)  
 
Reporting of covariates 
    
Trial report includes a table reporting:    
 Cluster level covariates only 13/300 (4.3%)  
 Individual level covariates only 158/300 (52.7%)  
 Cluster and individual level covariates 69/300 (23.0%)  
 None 60/300 (20.0%)  
    
Baseline measure of primary outcome reported 207/300 (69.0%)  
Significance test of balance of a covariate between treatment arms 166/300 (55.3%)  
 
Covariates used in analysis 
    
Trial report includes:    
 An unadjusted analysis of the primary outcome 130/300 (43.3%)  
 At least one adjusted analysis of the primary outcome 219/300 (73.0%)  
    
Trial report includes an analysis of the primary outcome adjusting for: 
 Baseline measure of outcome 155/207 (74.9%)  
 All covariates used in randomisation 30/174 (17.2%)  
 Other covariates 140/300 (46.7%)  
    
When covariates were reported to be chosen:    
 A priori 71/219 (32.4%)  
 Post hoc 37/219 (16.9%)  
 Both a priori and post hoc 18/219 (8.2%)  
 Not reported or unclear 93/219 (42.5%)  
    
Justification given for the selection of covariates 73/219 (33.3%)  
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Table 2: Covariates used in randomisation and covariates used in an adjusted analysis, by subgroup of mean number 
of clusters per treatment arm. 
 Mean number of clusters per treatment arm 
 1 to 5 5.5 to 23 23.5 to 3510.5 
Types of covariates used in randomisation (excluding cluster location and cluster size): 
Only cluster level 18/75 (24.0%) 73/147 (49.7%) 26/71 (36.6%) 
Only individual level 2/75 (2.7%) 3/147 (2.0%) 1/71 (1.4%) 
Both cluster and individual level 2/75 (2.7%) 3/147 (2.0%) 1/71 (1.4%) 
None 52/75 (69.3%) 66/147 (44.9%) 43/71 (60.6%) 
Unclear 1/75 (1.3%) 2/147 (1.4%) 0/71 (0.0%) 
       
Covariates (other than baseline measure of outcome and covariates used in randomisation) included in an 
adjusted analysis: 
Cluster only 0/33 (0.0%) 1/71 (1.4%) 6/34 (17.6%) 
Individual only 25/33 (75.8%) 50/71 (70.4%) 23/34 (67.6%) 
Both cluster and individual level 5/33 (15.2%) 20/71 (28.2%) 4/34 (11.8%) 
Unclear 3/33 (9.1%) 0/71 (0.0%) 1/34 (2.9%) 
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Table 3: Reporting of covariates and use of covariates in analysis, by subgroup defined by Journal Impact Factor. 
 High impact journals 
(Impact factor > 10) 
Other journals 
Reporting of covariates 
      
Trial report includes a table reporting:     
 Cluster level covariates only 2/50 (4.0%) 11/250 (4.4%) 
 Individual level covariates only 18/50 (36.0%) 140/250 (56.0%) 
 Cluster and individual level covariates 24/50 (48.0%) 45/250 (18.0%) 
 None 6/50 (12.0%) 54/250 (21.6%) 
      
Significance test of balance of a covariate 17/51 (34.0%) 149/250 (59.6%) 
      
Covariates used in analysis 
      
Trial report includes an adjusted analysis 
of the primary outcome 
37/50 (74.0%) 182/250 (72.8%) 
      
Trial report includes an analysis of the primary outcome adjusting for:   
 Baseline measure of outcome 21/30 (70.0%) 134/177 (75.7%) 
 All covariate used in randomisation 7/33 (21.2%) 23/141 (16.3%) 
 Other covariates 22/50 (44.0%) 118/250 (47.2%) 
      
When covariates were reported to be chosen:     
 A priori 12/37 (32.4%) 59/182 (32.4%) 
 Post hoc 5/37 (13.51%) 32/182 (17.6%) 
 Both a priori and post hoc 1/37 (2.7%) 17/182 (9.3%) 
 Unclear 19/37 (51.4%) 74/182 (40.7%) 
     
Justification given for the selection of covariates 12/37 (32.4%) 61/182 (33.5%) 
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